PT J
AU Chen, CT
   Lin, JG
   Huang, CP
   Lin, YW
AF Chen, Chao-Tsung
   Lin, Jaung-Geng
   Huang, Chun-Ping
   Lin, Yi-Wen
TI Electroacupuncture attenuates chronic fibromyalgia pain through the phosphorylated phosphoinositide 3-kinase signaling pathway in the mouse brain
SO IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Article
DE Dorsal root ganglion; Electroacupuncture; Fibromyalgia; Phosphatidylinositol; Somatosensory cortex; Thalamus; 3-kinase
ID neuropathic pain; beta-endorphin; ampa receptors; acupuncture; mechanisms; mediate; kinase; il-6
AB Objective(s): Fibromyalgia (FM) is a central nervous system disorder characterized by widespread mechanical hyperalgesia due to unknown mechanisms. Several inflammatory mediators, such as interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor, are increased in the serum of FM patients. Although medications including pregabalin, duloxetine, and milnacipran are used to treat FM, the results are unsatisfying. In the present study we assessed whether electroacupuncture (EA) can reduce chronic FM pain and then proposed an underlying mechanism for this effect. Materials and Methods: Chronic FM pain was induced in mice by dual acid saline injection lasting up to 4 weeks. Results: Chronic FM pain was treated by EA manipulation, but not in the sham operated group. Phosphorylated phosphatidylinositol 3-kinase (pPI3K), protein kinase B, mechanistic target of rapamycin, and nuclear factor kappa-light-chain-enhancer of activated B cells were unaltered in the mouse dorsal root ganglion (DRG) and spinal cord (SC) after inducing FM and administering EA treatment. The pPI3K-associated nociceptive signaling pathway was increased in the thalamus of FM mice, but reversed by EA. Similar results were observed in the mouse somatosensory cortex. Conclusion: These data suggest that EA has a significant effect on a signaling pathway in brain areas of FM mice. These findings suggest the value of EA for clinical practice.
C1 [Chen, Chao-Tsung] Chung Yuan Christian Univ, Ctr Gen Educ, Taoyuan 32023, Taiwan.
   [Lin, Jaung-Geng] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung 40402, Taiwan.
   [Huang, Chun-Ping; Lin, Yi-Wen] China Med Univ, Coll Chinese Med, Grad Inst Acupuncture Sci, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
C3 Chung Yuan Christian University; China Medical University Taiwan; China Medical University Taiwan
RP Lin, YW (corresponding author), China Med Univ, Coll Chinese Med, Grad Inst Acupuncture Sci, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.; Lin, YW (corresponding author), China Med Univ, Chinese Med Res Ctr, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
EM yiwenlin@mail.cmu.edu.tw
FU "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program within Ministry of Education (MOE) in Taiwan [CMRC-CENTER-0]; MOST [107-2320-B-039-033];  [CMU107-S-39]
CR ANDERSSON SA, 1973, LANCET, V2, P564
   Chang FC, 2004, J BIOMED SCI, V11, P179, DOI 10.1159/000076030
   Chen QJ, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00334
   Clauw DJ, 2014, JAMA-J AM MED ASSOC, V311, P1547, DOI 10.1001/jama.2014.3266
   CLEMENTJONES V, 1980, LANCET, V2, P946
   Dadabhoy D, 2008, ARTHRITIS RES THER, V10, P0, DOI 10.1186/ar2443
   del Pulgar TG, 2002, J BIOL CHEM, V277, P36527, DOI 10.1074/jbc.M205797200
   Deladeriere A, 2015, SCI SIGNAL, V8, P0, DOI 10.1126/scisignal.2005564
   English B, 2014, PAIN MANAG NURS, V15, P530, DOI 10.1016/j.pmn.2012.07.009
   Guo JR, 2017, ONCOTARGET, V8, P52923, DOI 10.18632/oncotarget.17629
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Jiang SP, 2016, EXP NEUROL, V275, P11, DOI 10.1016/j.expneurol.2015.11.001
   KISER RS, 1983, LANCET, V2, P1394
   Kwon M, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00079
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Liao HY, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/7498763
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42531
   Lin YW, 2010, J INTEGR NEUROSCI, V9, P269, DOI 10.1142/S0219635210002433
   Liu AF, 2018, EXP THER MED, V15, P2140, DOI 10.3892/etm.2017.5652
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Mendieta D, 2016, J NEUROIMMUNOL, V290, P22, DOI 10.1016/j.jneuroim.2015.11.011
   Ohgidani M, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-11506-4
   Ouyang ZH, 2017, ONCOTARGET, V8, P57870, DOI 10.18632/oncotarget.18628
   Panerai AE, 2002, CLIN J PAIN, V18, P270, DOI 10.1097/00002508-200207000-00008
   Pritchard RA, 2016, PAIN, V157, P137, DOI 10.1097/j.pain.0000000000000341
   Rubashkin MG, 2014, CANCER RES, V74, P4597, DOI 10.1158/0008-5472.CAN-13-3698
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Tsilioni I, 2016, J PHARMACOL EXP THER, V356, P664, DOI 10.1124/jpet.115.230060
   Wigerblad G, 2017, EXP NEUROL, V293, P144, DOI 10.1016/j.expneurol.2017.04.004
   Xie XJ, 2017, CELL PHYSIOL BIOCHEM, V41, P181, DOI 10.1159/000455987
   Yen LT, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep46663
NR 31
TC 6
Z9 6
U1 0
U2 1
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN
SN 2008-3866
EI 2008-3874
J9 IRAN J BASIC MED SCI
JI Iran. J. Basic Med. Sci.
PD SEP 15
PY 2019
VL 22
IS 9
BP 1085
EP 1090
DI 10.22038/ijbms.2019.35887.8547
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IM1ER
UT WOS:000477731900015
PM 31807253
DA 2026-01-16
ER

PT J
AU de, Matos NMP
   Pach, D
   Xing, JJ
   Barth, J
   Beyer, LE
   Shi, X
   Kern, A
   Lukic, N
   Ettlin, DA
   Brügger, M
   Witt, CM
AF de Matos, Nuno M P
   Pach, Daniel
   Xing, Jing Jing
   Barth, Jürgen
   Beyer, Lara Elena
   Shi, Xuemin
   Kern, Alexandra
   Lukic, Nenad
   Ettlin, Dominik A
   Brügger, Mike
   Witt, Claudia M
TI Evaluating the Effects of Acupuncture Using a Dental Pain Model in Healthy
SO The journal of pain
LA English
DT Journal Article
DE Acupuncture; Chinese traditional; Medicine; nociception; pain; toothache
AB Acupuncture is a complementary and nonpharmacological intervention that can be  effective for the management of chronic pain in addition to or instead of  medication. Various animal models for neuropathic pain, inflammatory pain,  cancer-related pain, and visceral pain already exist in acupuncture research. We  used a newly validated human pain model and examined whether acupuncture can  influence experimentally induced dental pain. For this study, we compared the  impact of manual acupuncture (real acupuncture), manual stimulation of a needle  inserted at nonacupuncture points (sham acupuncture) and no acupuncture on  experimentally induced dental pain in 35 healthy men who were randomized to  different sequences of all 3 interventions in a within-subject design. BORG CR10  pain ratings and autonomic responses (electrodermal activity and heart rate  variability) were investigated. An initial mixed model with repeated measures  included preintervention pain ratings and the trial sequence as covariates. The  results showed that acupuncture was effective in reducing pain intensity when  compared to no acupuncture (β = -.708, P = .002), corresponding to a medium  Cohen's d effect size of .56. The comparison to the sham acupuncture revealed no  statistically significant difference. No differences in autonomic responses  between real and sham acupuncture were found during the intervention procedures.  PERSPECTIVE: This study established a dental pain model for acupuncture research  and provided evidence that experimentally induced dental pain can be influenced  by either real acupuncture or manual stimulation of needles at nonacupuncture  points. The data do not support that acupoint specificity is a significant factor  in reducing experimental pain.
C1 Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland
   Clinic of Cranio-Maxillofacialand Oral Surgery, Center of Dental Medicine, University of Zurich, Zurich,Switzerland.
   Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland
   Charité - UniversitätsmedizinBerlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zuBerlin, and Berlin Institute of Health, Institute for Social Medicine,Epidemiology and Health Economics, Berlin, Germany. 
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
   Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
   Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
   Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
   Clinic of Cranio-Maxillofacial and Oral Surgery, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.
   Clinic of Cranio-Maxillofacial and Oral Surgery, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.
   Clinic of Cranio-Maxillofacial and Oral Surgery, Center of Dental Medicine, University of Zurich, Zurich, Switzerland
   Institute for Biomedical Engineering,ETH Zurich and University of Zurich, Zurich, Switzerland.
   Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland
   Charité - UniversitätsmedizinBerlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zuBerlin, and Berlin Institute of Health, Institute for Social Medicine,Epidemiology and Health Economics, Berlin, Germany
   Center for IntegrativeMedicine, University of Maryland School of Medicine Baltimore, Baltimore,Maryland.
EM aniel.pach@uzh.ch
NR 0
TC 0
SN 1528-844
EI 
J9 J Pain
PD SEP 16
PY 2019
VL 21
IS 3-4
BP 440
EP 454
DI 10.1016/j.jpain.2019.08.013
PG 14
WC Acupuncture Therapy; Adult; Cross-Over Studies; Galvanic Skin Response; physiology; Heart Rate; physiology; Humans; Male; Medicine, Chinese Traditional; Outcome Assessment, Health Care; Pain Measurement; Placebos; Toothache; therapy; Young Adult
UT PubMed:31521794
PM 31521794
DA 2019-09-16
ER

PT J
AU Fu, YB
   Li, B
   Sun, SF
   Liu, HL
   Wang, X
   Wang, SS
   Zhang, F
   Du, X
   Ge, DJ
   Shang, L
   Liang, RL
   Wang, LN
   Yuan, F
   Sun, JQ
   Chen, JW
AF Fu, Yuan-Bo
   Li, Bin
   Sun, San-Feng
   Liu, Hui-Lin
   Wang, Xin
   Wang, Shao-Song
   Zhang, Fan
   Du, Xin
   Ge, Du-Juan
   Shang, Lei
   Liang, Rui-Li
   Wang, Li-Na
   Yuan, Fang
   Sun, Jing-Qing
   Chen, Jun-Wei
TI Fire acupuncture for mild to moderate knee osteoarthritis: a protocol for a randomized controlled pilot trial
SO TRIALS
LA English
DT Article
DE Knee Osteoarthritis; Fire Acupuncture; Basic health management
ID outcm; arthritis; therapy; patient; hip
AB Background: Knee osteoarthritis (KOA) is one of the most common bone and joint diseases. As one of the main non-drug therapies, acupuncture is widely used to treat KOA, although the evidence for its efficacy is inconclusive. The objective of this pilot trial is to clarify the clinical efficacy and safety of fire acupuncture in the treatment of mild to moderate KOA and to provide high-quality data for further research. Methods/design: This study is a prospective randomized controlled pilot trial in which 120 patients with mild to moderate KOA will be randomly allocated in equal proportions to a fire acupuncture group or a general acupuncture group. They will receive acupuncture for six sessions over 2 weeks. The primary end point is success rate, which will be calculated based on the change from baseline of the pain and function scores in the Western Ontario and McMaster Universities Osteoarthritis Index at 4 weeks. Secondary end points include the proportion of patients achieving clinical improvement based on: (1) the OMERACT-OARSI responder criteria, (2) levels of matrix metalloproteinase 3, interleukin 1 beta, and tumor necrosis factor a in blood, and (3) a subjective efficacy evaluation from patients.
C1 [Fu, Yuan-Bo; Li, Bin; Liu, Hui-Lin; Wang, Xin; Wang, Shao-Song; Zhang, Fan; Du, Xin; Yuan, Fang; Sun, Jing-Qing; Chen, Jun-Wei] Capital Med Univ, Dept Acupuncture & Moxibust, Beijing Hosp Tradit Chinese Med, Beijing Key Lab Acupuncture Neuromodulat, 23 Meishuguanhou St, Beijing 100010, Peoples R China.
   [Fu, Yuan-Bo; Sun, San-Feng; Ge, Du-Juan; Shang, Lei; Liang, Rui-Li; Wang, Li-Na] Beijing Huairou Dist Hosp Tradit Chinese Med, 1 Houheng St, Beijing 101400, Peoples R China.
   [Chen, Jun-Wei] Beijing Univ Chinese Med, 11 Bei San Huan Dong Lu, Beijing 100029, Peoples R China.
C3 Capital Medical University; Beijing University of Chinese Medicine
RP Sun, JQ; Chen, JW (corresponding author), Capital Med Univ, Dept Acupuncture & Moxibust, Beijing Hosp Tradit Chinese Med, Beijing Key Lab Acupuncture Neuromodulat, 23 Meishuguanhou St, Beijing 100010, Peoples R China.; Chen, JW (corresponding author), Beijing Univ Chinese Med, 11 Bei San Huan Dong Lu, Beijing 100029, Peoples R China.
EM sjgdoctor@163.com; 847431304@qq.com
FU Beijing Huairou District Science and Technology Plan Project, Beijing Key Laboratory of Acupuncture Neuromodulation, Beijing, China [BZ0437, NY2019-6]; Beijing Municipal Hospital Research and Development Program [PZ2019019]
CR Aigner T, 2002, ARTHRITIS RHEUM-US, V46, P1986, DOI 10.1002/art.10554
   Unknown -, 2014, OST CAR MAN AD, V0, P0
   Unknown -, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/BMJ.C332
   Baker K, 2000, CURR OPIN RHEUMATOL, V12, P456, DOI 10.1097/00002281-200009000-00020
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Brown GA, 2013, J AM ACAD ORTHOP SUR, V21, P577, DOI 10.5435/JAAOS-21-09-577
   Gobbi A, 2015, KNEE SURG SPORT TR A, V23, P2170, DOI 10.1007/s00167-014-2987-4
   Goldring MB, 2007, J CELL PHYSIOL, V213, P626, DOI 10.1002/jcp.21258
   GOLDSMITH CH, 1993, J RHEUMATOL, V20, P561
   Higgs Rowan, 2010, NAT REV RHEUMATOL, V6, P616, DOI 10.1038/nrrheum.2010.165
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Liu CZ, 2014, PAIN MED, V15, P910, DOI 10.1111/pme.12392
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005
   ONeill TW, 2018, BEST PRACT RES CL RH, V32, P312, DOI 10.1016/j.berh.2018.10.007
   Wang YD, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1392627
   Wu J N, 1996, J ALTERN COMPLEMENT MED, V2, P19, DOI 10.1089/acm.1996.2.19
NR 19
TC 4
Z9 7
U1 1
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 4
PY 2019
VL 20
IS 1
BP 
EP 
DI 10.1186/s13063-019-3744-2
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA KC0NC
UT WOS:000506883300004
PM 31801600
DA 2026-01-16
ER

PT J
AU Liu, HP
   Ma, YB
   Liu, J
   Guo, ZX
   Yan, WJ
   Wen, SQ
   Zhao, Q
   Guo, XR
   Zhang, XY
   Sheng, Q
AF Liu, Haipeng
   Ma, Yabing
   Liu, Juan
   Guo, Zhaoxia
   Yan, Wenjun
   Wen, Shiqi
   Zhao, Qiong
   Guo, Xiaoru
   Zhang, Xiaoyan
   Sheng, Qing
TI Therapeutic effect of electroacupuncture on rats with neuropathic pain
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Acupuncture; neuropathic pain; CX3CRI protein
ID fractalkine receptor cx3cr1; dorsal-root ganglia; spinal-cord; up-regulation; mouse model; tnf-alpha; il-6; expression; drug
AB Objective: To study the therapeutic effect and possible mechanism of electroacupuncture on rats with neuropathic pain (NP). Methods: A total of 30 Sprague Dawley rats were randomized into three groups, group A (n=10), group B (n=10), and group C (n=10). In group A, a chronic constriction injury (CCI) model of NP was induced by loosely making four ligations at the mid-thigh level of the right sciatic nerve of rats with 4-0 chromic catgut, and electroacupuncture was used at day 1, day 4 and day 7 after surgery respectively as the treatment of NP. In group B, the CCI model was also induced and no treatment was given. In group C, the same surgery was made without tying the sciatic nerve. The thermal and mechanical pain thresholds of each rat before surgery and from day 1 to 7 after surgery were recorded and compared. The rats were sacrificed on day 8 after surgery and underwent perfusion-fixation for the removal of spinal cord. Western blot was used to detect the expression of CX3CR1 protein in the spinal cord. Enzyme-linked immunosorbent assay was used to measure the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin 6 (IL-6) in the spinal cord. Results: In group A, mechanical withdrawal thresholds (MWT) and paw withdrawal latency (PWL) of right hind paw on day 1-3 after surgery were significantly lower than those before surgery (P<0.05); MWT and PWL were significantly higher on day 4-7 after surgery than those on day 3 after surgery (P<0.05), but were still lower than the preoperative levels (P<0.05). In group B, MWT and PWL of right hind paw on day 1-7 after surgery were significantly lower than those before surgery (P<0.05). There were no significant differences in MWT and PWL of right hind paw between group A and group B on day 1-3 after surgery (P>0.05). MWT and PWL in group A were significantly higher than those in group B on day 4-7 after surgery (P<0.05). Compared with the preoperative levels, there were no significant differences in MWT and PWL in group C after surgery (P>0.05). Compared with those in group C, MWT and PWL of right hind paw in group A and group B declined significantly after surgery (all P<0.05); In group A and group B, no significant differences were found in MWT and PWL of left hind paw before and after surgery (all P>0.05). The expression of CX3CR1 protein was significantly increased in group A and group B compared with that in group C (all P<0.05), and the expression of CX3CR1 protein in group A was significantly lower than that in group B (P<0.05). The levels of TNF-alpha, IL-1 beta and IL-6 in group A and group B were significantly higher compared with those in group C (P<0.05). The levels of TNF-alpha, IL-1 beta and IL-6 in group A were significantly lower than those in group B (all P<0.05). Conclusion: The thermal and mechanical pain thresholds of CCI rats decrease significantly. Electroacupuncture can significantly relieve pain and increase pain threshold. The development of NP may be associated with the increase of the expression of CX3CR1 protein and the levels of inflammatory factors in the spinal cord, including TNF-alpha, IL-1 beta and IL-6. The mechanism of electroacupuncture as a treatment for NP may be related to the reduction of the expression of CX3CR1 protein and the levels of inflammatory factors.
C1 [Liu, Haipeng; Ma, Yabing; Guo, Xiaoru; Zhang, Xiaoyan; Sheng, Qing] Gansu Prov Hosp, Dept Pain, Lanzhou, Gansu, Peoples R China.
   [Liu, Juan] Gansu Prov Hosp, Dept Outpatient, Lanzhou, Gansu, Peoples R China.
   [Guo, Zhaoxia] Gansu Prov Hosp, Dept Cardiol, Lanzhou, Gansu, Peoples R China.
   [Yan, Wenjun] Gansu Prov Hosp, Dept Anesthesiol, Lanzhou, Gansu, Peoples R China.
   [Wen, Shiqi] Gansu Prov Hosp, Dept Vasc Surg, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.
   [Zhao, Qiong] Tianshui Combine Tradit Chinese & Western Med Hos, Dept Oral & Maxillofacial Surg, Tianshui, Gansu, Peoples R China.
RP Wen, SQ (corresponding author), Gansu Prov Hosp, Dept Vasc Surg, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.
EM wenshiqi73@163.com
FU Gansu Health Industry Research Program [GSWKY2017-52]
CR Al-Mazidi S, 2018, EUR J PAIN, V22, P810, DOI 10.1002/ejp.1169
   Unknown -, 2012, DRUG THER BULL, V50, P126, DOI 10.1136/dtb.2012.11.0139
   Baron R, 2017, PAIN, V158, P261, DOI 10.1097/j.pain.0000000000000753
   Barragán-Iglesias P, 2018, PHARMACOL REP, V70, P294, DOI 10.1016/j.pharep.2017.09.002
   BOUREAU F, 1978, ANN ANESTHESIOL FR, V19, P422
   Brázda V, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-42
   Bura AS, 2013, EUR J PAIN, V17, P832, DOI 10.1002/j.1532-2149.2012.00251.x
   Clark AK, 2014, FRONT CELL NEUROSCI, V8, P0, DOI 10.3389/fncel.2014.00121
   Dubovy P, 2010, NEURON GLIA BIOL, V6, P73, DOI 10.1017/S1740925X10000074
   Gopalsamy B, 2017, J PAIN RES, V10, P2605, DOI 10.2147/JPR.S143024
   Guo JR, 2017, ONCOTARGET, V8, P52923, DOI 10.18632/oncotarget.17629
   Huang PC, 2017, ANESTH ANALG, V124, P2038, DOI 10.1213/ANE.0000000000001600
   Laumet G, 2017, BRAIN BEHAV IMMUN, V66, P94, DOI 10.1016/j.bbi.2017.07.008
   Li Qiu-Yue, 2017, ZHONGGUO ZHONG YAO ZA ZHI, V42, P3709, DOI 10.19540/j.cnki.cjcmm.20170907.004
   Li WJ, 2012, NEUROCHEM INT, V61, P1397, DOI 10.1016/j.neuint.2012.10.002
   Lindia JA, 2005, J PAIN, V6, P434, DOI 10.1016/j.jpain.2005.02.001
   Liu HC, 2012, ARTIF CELL BLOOD SUB, V40, P331, DOI 10.3109/10731199.2012.659350
   Lu Bo, 2013, ZHONGHUA YI XUE ZA ZHI, V93, P1997
   Mah W, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-13561-3
   Notartomaso S, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917697009
   Pexton T, 2011, EXPERT OPIN INV DRUG, V20, P1277, DOI 10.1517/13543784.2011.600686
   Romundstad L, 2006, PAIN, V124, P92, DOI 10.1016/j.pain.2006.03.020
   Staniland AA, 2010, J NEUROCHEM, V114, P1143, DOI 10.1111/j.1471-4159.2010.06837.x
   Wang J, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917746564
   Wang XL, 2017, J PHARMACOL SCI, V135, P141, DOI 10.1016/j.jphs.2017.08.007
   Wei XH, 2013, EXP NEUROL, V241, P159, DOI 10.1016/j.expneurol.2012.12.007
   Zhao WX, 2017, MOL MED REP, V16, P1559, DOI 10.3892/mmr.2017.6723
   Zheng Jinwei, 2011, ZHONGGUO ZHONG YAO ZA ZHI, V36, P2552
   Zhu WJ, 2013, BIOMED RES INT, V2013, P0, DOI 10.1155/2013/480702
NR 29
TC 1
Z9 1
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
EI 
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PD JUN 15
PY 2019
VL 12
IS 7
BP 8531
EP 8539
DI 
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA IM4UR
UT WOS:000477991300063
DA 2026-01-16
ER

PT J
AU Aderibigbe, O
   Groft-MacFarlane, C
   Chu, EY
AF Aderibigbe, Oyinade
   Groft-MacFarlane, Caroline
   Chu, Emily Y
TI A Blue-Gray Macule on the Back: Answer.
SO The American Journal of dermatopathology
LA English
DT Review
C1 Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
   and.
   Dermatology Associates of Bryn Mawr Medical Specialists, Bryn Mawr, PA.
   Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
   and.
NR 0
TC 0
SN 1533-031
EI 
J9 Am J Dermatopathol
PD DEC 28
PY 2019
VL 42
IS 1
BP 65
EP 65
DI 10.1097/DAD.0000000000001267
PG 0
WC Acupuncture Therapy; methods; Biopsy, Needle; Diagnosis, Differential; Humans; Immunohistochemistry; Low Back Pain; diagnosis; Male; Middle Aged; Nevus, Blue; diagnosis; Ochronosis; diagnosis; Pigmentation Disorders; diagnosis; Rare Diseases
UT PubMed:31880637
PM 31880637
DA 2019-12-28
ER

PT J
AU Wu, GW
   Chen, J
   Huang, YM
   Pan, CB
   Chen, WL
   Zhang, SM
   Lin, W
   Liu, XX
   Wu, MX
AF Wu Guang-wen
   Chen Jun
   Huang Yun-mei
   Pan Cai-bin
   Chen Wen-lie
   Zhang Shi-mao
   Lin Wei
   Liu Xian-xiang
   Wu Ming-xia
TI Electroacupuncture Delays Cartilage Degeneration by Modulating Nuclear Factor-κB Signaling Pathway
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE osteoarthritis; electroacupuncture; synovial fluid; cartilage; cytokines; nuclear factor-kappa B signaling pathway
ID tumor-necrosis-factor; knee osteoarthritis; articular-cartilage; expression; alpha; pain; differentiation; pathogenesis; acupuncture; mechanisms
AB Objective To illustrate the molecular mechanisms underlying the therapeutic effects of electroacupuncture (EA) on knee osteoarthritis (OA). Methods Twenty-seven six-month-old New Zealand white rabbits were allocated into three groups in accordance with a random number table: normal group (no surgery-induced OA; without treatment), model group (surgery-induced OA; without treatment) and EA group [surgery-induced OA; received treatment with EA at acupoints Dubi (ST 35) and Neixiyan (EX-LE 5), 30 min twice a day]. After eight consecutive weeks of treatment, the histopathological alterations in cartilage were observed using optical microscopy and transmission electron microscopy, cartilage degeneration was evaluated by modified Mankin's score principles, the synovial fluid concentration of interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-3 (MMP-3) were evaluated by enzyme-linked immunosorbent assay, and the protein expression levels of IL-1 beta, IL-6, TNF-alpha, MMP-3, I kappa B kinase-beta (IKK-beta), nuclear factor of alpha light polypeptide gene enhancer in B-cells inhibitor alpha (I kappa B-alpha) and nuclear factor-kappa B (NF-kappa B) p65 were quantified by Western blot analysis. Results EA treatment significantly improved cartilage structure arrangement and reduced cellular degeneration. The IL-1 beta, IL-6, TNF-alpha and MMP-3 of synovial fluid in the EA-treated group were significantly decreased compared with the model group (all P<0.01). Compared with the model group, the IL-1 beta, IL-6, TNF-alpha, MMP-3, IKK-beta and NF-kappa B p65 protein expressions in cartilage of EA-treated group were significantly decreased (all P<0.01), whereas I kappa B-alpha expression was significantly up-regulated (P<0.01). Conclusion EA treatment may delay cartilage degeneration by down-regulating inflammatory factors through NF-kappa B signaling pathway, which may, in part, explain its clinical efficacy in the treatment of knee OA.
C1 [Wu Guang-wen; Chen Jun; Huang Yun-mei; Pan Cai-bin; Chen Wen-lie; Liu Xian-xiang] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China.
   [Zhang Shi-mao] Fujian Xiangxing Elect Technol Co Ltd, Ningde 352300, Fujian, Peoples R China.
   [Lin Wei] Fujian Prov Key Lab Integrat Med Geriatr, Fuzhou 350122, Fujian, Peoples R China.
   [Wu Ming-xia] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp 2, Dept Acupuncture, Fuzhou 350003, Fujian, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine
RP Wu, MX (corresponding author), Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp 2, Dept Acupuncture, Fuzhou 350003, Fujian, Peoples R China.
EM wumingxiafz@163.com
FU National Natural Science Foundation of China [81373719]; Project of Fujian Provincial Development and Reform Commission [2014-514]; Major Project of Fujian Provincial Department of Science and Technology Agency [2013Y4003]
CR Ahmed S, 2005, EVID-BASED COMPL ALT, V2, P301, DOI 10.1093/ecam/neh117
   Aigner T, 2007, NAT CLIN PRACT RHEUM, V3, P391, DOI 10.1038/ncprheum0534
   Unknown -, 2006, GUID SUGG CAR US LAB, V0, P0
   Aoki E, 2005, IN VIVO, V19, P495
   Berenbaum F, 2008, ARTHRITIS RES THER, V10, P0, DOI 10.1186/ar2462
   Botha-Scheepers S, 2008, ANN RHEUM DIS, V67, P1165, DOI 10.1136/ard.2007.084657
   Bowles RD, 2014, ARTHRITIS RHEUMATOL, V66, P637, DOI 10.1002/art.38279
   BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203
   Chen J, 2018, CHIN J INTEGR MED, V24, P803, DOI 10.1007/s11655-018-2929-3
   Chen N, 2017, AM J CHINESE MED, V45, P965, DOI 10.1142/S0192415X17500513
   Chen SN, 2016, MOL MED REP, V13, P419, DOI 10.3892/mmr.2015.4547
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749-6632.2009.05240.x
   Goldring SR, 2006, JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, V6, P376
   Huang YL, 2013, INT J MOL MED, V31, P1443, DOI 10.3892/ijmm.2013.1336
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kim J, 2010, OSTEOARTHR CARTILAGE, V18, P424, DOI 10.1016/j.joca.2009.09.008
   Kobayashi M, 2005, ARTHRITIS RHEUM-US, V52, P128, DOI 10.1002/art.20776
   Liu Xian-xiang, 2005, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V25, P1104
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009
   Marcu KB, 2010, CURR DRUG TARGETS, V11, P599, DOI 10.2174/138945010791011938
   Mendis E, 2008, BIOORGAN MED CHEM, V16, P8390, DOI 10.1016/j.bmc.2008.08.037
   Olivotto E, 2008, ARTHRITIS RHEUM-US, V58, P227, DOI 10.1002/art.23211
   Plaster R, 2014, ACUPUNCT MED, V32, P236, DOI 10.1136/acupmed-2013-010489
   Raman S, 2018, FRONT BIOENG BIOTECH, V6, P0, DOI 10.3389/fbioe.2018.00022
   Sakao K, 2008, J ORTHOP SCI, V13, P202, DOI 10.1007/s00776-008-1227-5
   Sundman EA, 2014, AM J SPORT MED, V42, P35, DOI 10.1177/0363546513507766
   Tong KM, 2008, CELL SIGNAL, V20, P1478, DOI 10.1016/j.cellsig.2008.04.003
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, P0, DOI 10.1155/2014/561459
   Wu GW, 2011, INT J MOL MED, V27, P79, DOI 10.3892/ijmm.2010.555
   Wu MX, 2010, CHIN J INTEGR MED, V16, P291, DOI 10.1007/s11655-010-0513-1
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Yu SM, 2012, BMB REP, V45, P317, DOI 10.5483/BMBRep.2012.45.5.317
   Zwerina J, 2007, P NATL ACAD SCI USA, V104, P11742, DOI 10.1073/pnas.0610812104
NR 35
TC 25
Z9 27
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD SEP 15
PY 2019
VL 25
IS 9
BP 677
EP 683
DI 10.1007/s11655-018-2916-8
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA JG9RI
UT WOS:000492413300006
PM 30656598
DA 2026-01-16
ER

PT J
AU Harvie, A
   Steel, A
   Wardle, J
AF Harvie, Alaia
   Steel, Arnie
   Wardle, Jon
TI Traditional Chinese Medicine Self-Care and Lifestyle Medicine Outside of Asia: A Systematic Literature Review
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
DE systematic review; Traditional Chinese Medicine; self-care; acupressure; acupuncture; lifestyle advice
ID cancer-related fatigue; chronic neck pain; controlled-trial; ear acupressure; clinical-trial; united-states; older-adults; acupuncture; complementary; nausea
AB Background: Chinese medicine, when applied as a whole system of care, traditionally incorporates self-care techniques and patient understanding as key aspects of patient recovery and health maintenance. Objectives: This review aims to explore the literature to date on Traditional Chinese Medicine (TCM) self-care in settings outside of Asia, beyond the sole application of t'ai chi or qigong, to consider simple self-care techniques as health care interventions that may be generalized to a wider population. Design: AMED, CINAHL, EMBASE, PubMed, and MEDLINE databases were searched for articles from inception to July 2018. Studies were included, which were undertaken in settings outside of Asia and/or Asian communities, and were excluded if they solely examined t'ai chi or qigong. Results: Findings of the included studies (n = 37) were categorized into four key areas in relation to the TCM self-care component evaluated: self-acupressure, self-acupuncture, self-moxibustion, and the adoption of prescribed lifestyle, diet, and exercise advice based on a TCM diagnosis. The studies included randomized clinical trials, case studies, hospital audits, and qualitative evaluations. The studies assessed TCM self-care in relation to a wide range of health conditions, with the majority of studies concluding positive findings. Conclusion: This review draws attention to the potential role of TCM self-care techniques, in settings outside of Asia, beyond the sole practices of t'ai chi and qigong, as an adjunct to health maintenance and recovery. Only tentative conclusions can be drawn from the existing research, however, due to variability across studies in reporting transparency and the overall low number of studies retrieved. Further research is warranted.
C1 [Harvie, Alaia; Steel, Arnie; Wardle, Jon] Univ Technol Sydney, Fac Hlth, Bldg 10,Level 7,235 Jones St, Sydney, NSW 2007, Australia.
   [Steel, Arnie; Wardle, Jon] Univ Technol Sydney, Fac Hlth, Australian Res Ctr Complementary & Integrat Med, Sydney, NSW, Australia.
C3 University of Technology Sydney; University of Technology Sydney
RP Harvie, A (corresponding author), Univ Technol Sydney, Fac Hlth, Bldg 10,Level 7,235 Jones St, Sydney, NSW 2007, Australia.
EM aharvie@protonmail.com
FU Australian Government Research Training Program (RTP) scholarship
CR Abbott R, 2015, J GEN INTERN MED, V30, P434, DOI 10.1007/s11606-014-3084-6
   Abedian Z, 2015, IRAN J MED SCI, V40, P328
   Unknown -, 2011, HUANG DI NEI JING SU, V0, P0
   Unknown -, 2016, AC PRACT UK, V0, P0
   Unknown -, 2018, INTERNATIONAL CLASSIFICATION OF DISEASES 11TH REVISION (ICD-11), V0, P0
   Armour M, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3467067
   Baccetti S, 2014, J ALTERN COMPLEM MED, V20, P550, DOI 10.1089/acm.2012.0499
   Bai ZG, 2015, AM J CHINESE MED, V43, P1525, DOI 10.1142/S0192415X15500871
   Bardy J, 2015, ACUPUNCT MED, V33, P210, DOI 10.1136/acupmed-2014-010708
   Behbahani BM, 2016, J RES MED SCI, V21, P0, DOI 10.4103/1735-1995.193176
   Bergmann N, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0097553
   Bishop FL, 2007, J HEALTH PSYCHOL, V12, P851, DOI 10.1177/1359105307082447
   Blödt S, 2018, AM J OBSTET GYNECOL, V218, P0, DOI 10.1016/j.ajog.2017.11.570
   Brown CA, 2014, J INTEGR MED-JIM, V12, P94, DOI 10.1016/S2095-4964(14)60010-8
   Burke A, 2006, J ALTERN COMPLEM MED, V12, P639, DOI 10.1089/acm.2006.12.639
   Cassidy CM, 1998, J ALTERN COMPLEM MED, V4, P17, DOI 10.1089/acm.1998.4.1-17
   Chen KW, 2013, J ALTERN COMPLEM MED, V19, P204, DOI 10.1089/acm.2011.0311
   Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1690, DOI 10.1002/cncr.27904
   Cramer H, 2014, INT J BEHAV MED, V21, P775, DOI 10.1007/s12529-013-9354-6
   Cui J, 2017, ACUPUNCT MED, V35, P200, DOI 10.1136/acupmed-2016-011106
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   Easthope G, 2000, COMPLEMENT THER MED, V8, P226, DOI 10.1054/ctim.2000.0398
   Enblom A, 2017, COMPLEMENT THER MED, V34, P141, DOI 10.1016/j.ctim.2017.08.003
   Ernst E, 2000, COMPLEMENT THER MED, V8, P32, DOI 10.1016/S0965-2299(00)90833-1
   Fagan Nigel, 2003, ACUPUNCT MED, V21, P28
   Filshie Jacqueline, 2005, ACUPUNCT MED, V23, P171
   Fonnebo V, 2007, BMC MED RES METHODOL, V7, P0, DOI 10.1186/1471-2288-7-7
   Ford I, 2016, NEW ENGL J MED, V375, P454, DOI 10.1056/NEJMra1510059
   Frank R, 2004, SOCIOL HEALTH ILL, V26, P351, DOI 10.1111/j.1467-9566.2004.00394.x
   Gadau M, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-136
   Guo B, 2001, LISTEN TO YOUR BODY: THE WISDOM OF THE DAO, V0, P0
   Guo R, 2007, POSTGRAD MED J, V83, P633, DOI 10.1136/pgmj.2007.060202
   Harris RE, 2005, J ALTERN COMPLEM MED, V11, P673, DOI 10.1089/acm.2005.11.673
   Hughes JG, 2015, EUR J INTEGR MED, V7, P623, DOI 10.1016/j.eujim.2015.08.003
   Ibanda HA, 2018, EUR J INTEGR MED, V20, P90, DOI 10.1016/j.eujim.2018.04.006
   Ijaz N, 2016, SOC SCI MED, V170, P97, DOI 10.1016/j.socscimed.2016.08.037
   Kaptchuk TJ, 2000, WEB HAS NO WEAVER, V0, P0
   Kelley GA, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0129181
   Kong HY, 2012, J IMMIGR MINOR HEALT, V14, P841, DOI 10.1007/s10903-011-9558-2
   Lee Jiyeon, 2010, ONCOL NURS FORUM, V37, PE419, DOI 10.1188/10.ONF.E419-E425
   Lee KC, 2012, ACUPUNCT MED, V30, P8, DOI 10.1136/acupmed-2011-010088
   Lee Myeong Soo, 2011, JRSM SHORT REP, V2, P7, DOI 10.1258/shorts.2010.010091
   Li LW, 2018, ARTHRIT CARE RES, V70, P221, DOI 10.1002/acr.23262
   Li LW, 2016, J ALTERN COMPLEM MED, V22, P396, DOI 10.1089/acm.2015.0231
   Lu CL, 2017, J IMMIGR MINOR HEALT, V19, P423, DOI 10.1007/s10903-016-0386-2
   Lu YX, 2015, HEALTH SOCIOL REV, V24, P15, DOI 10.1080/14461242.2015.1006656
   MacPherscon H, 2008, COMPLEMENT THER MED, V16, P101, DOI 10.1016/j.ctim.2008.02.010
   MacPherson H, 2006, COMPLEMENT THER MED, V14, P20, DOI 10.1016/j.ctim.2005.07.006
   MacPherson H, 2017, J ALTERN COMPLEM MED, V23, P180, DOI 10.1089/acm.2016.0303
   MacPherson H, 2015, ANN INTERN MED, V163, P653, DOI 10.7326/M15-0667
   McDonald J, 2017, THE ACUPUNCTURE EVIDENCE PROJECT: A COMPARATIVE LITERATURE REVIEW (REVISED EDITION), V0, P0
   McDonald-Miszczak L, 2005, J AGING HEALTH, V17, P836, DOI 10.1177/0898264305280984
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Mollart L, 2016, MIDWIFERY, V36, P21, DOI 10.1016/j.midw.2016.02.020
   Orpen Michele, 2004, ACUPUNCT MED, V22, P137
   Paterson C, 2012, PATIENT EDUC COUNS, V89, P467, DOI 10.1016/j.pec.2012.02.016
   Pavao TS, 2010, NEUROSCI LETT, V484, P47, DOI 10.1016/j.neulet.2010.08.016
   Pettersson PH, 2012, J CLIN NURS, V21, P1799, DOI 10.1111/j.1365-2702.2012.04114.x
   Pitchford Paul, 1993, HEALING WHOLE FOODS, V0, P0
   Qin ZS, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003095
   Riley DS, 2017, J CLIN EPIDEMIOL, V89, P218, DOI 10.1016/j.jclinepi.2017.04.026
   Sousa CM, 2015, J INTEGR MED-JIM, V13, P314, DOI 10.1016/S2095-4964(15)60194-7
   Sprague M, 2011, J ALTERN COMPLEM MED, V17, P67, DOI 10.1089/acm.2010.0088
   Teig Silje, 2006, ACUPUNCT MED, V24, P80
   Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Torkzahrani S, 2015, IRAN RED CRESCENT ME, V17, P0, DOI 10.5812/ircmj.28691
   VanderPloeg K, 2009, J ACUPUNCT MERIDIAN, V2, P26, DOI 10.1016/S2005-2901(09)60012-1
   Walter WA, 2013, ACUPUNCT MED, V31, P430, DOI 10.1136/acupmed-2013-010437
   Wang CW, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-8
   Wenham A, 2018, COMPLEMENT THER CLIN, V31, P308, DOI 10.1016/j.ctcp.2018.03.009
   WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, V0, P1
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Xu Y, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0186616
   Xue CCL, 2008, BMC PUBLIC HEALTH, V8, P0, DOI 10.1186/1471-2458-8-105
   Young M, 2012, THE MOON OVER MATSUSHIMA: INSIGHTS INTO MOXA AND MUGWORT, V0, P0
   Zhang CS, 2014, AM J RHINOL ALLERGY, V28, PE152, DOI 10.2500/ajra.2014.28.4081
   Zheng Z, 2014, INTEGR MED RES, V3, P103
   Zick SM, 2011, EVID BASED COMPLEMEN, V2011, P10
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/142913
NR 87
TC 12
Z9 14
U1 1
U2 42
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD AUG 1
PY 2019
VL 25
IS 8
BP 789
EP 808
DI 10.1089/acm.2018.0520
EA JUL 2019
PG 20
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA IR5PA
UT WOS:000474173700001
PM 31274332
DA 2026-01-16
ER

PT J
AU Molassiotis, A
   Suen, LKP
   Cheng, HL
   Mok, TSK
   Lee, SCY
   Wang, CH
   Lee, P
   Leung, H
   Chan, V
   Lau, TKH
   Yeo, W
AF Molassiotis, Alexander
   Suen, Lorna K P
   Cheng, Hui Lin
   Mok, T S K
   Lee, Sara C Y
   Wang, C H
   Lee, Paul
   Leung, Howan
   Chan, V
   Lau, T K H
   Yeo, Winnie
TI A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; cancer; chemotherapy-induced peripheral neuropathy; neurotoxicity; pain; quality of life
AB PURPOSE: Chemotherapy-induced peripheral neuropathy is a complex side effect with  few available treatment options. The aim of the study was to test the  effectiveness of an 8-week course of acupuncture in the management of  chemotherapy-induced peripheral neuropathy in cancer patients who were receiving  or had received neurotoxic chemotherapy. METHODS: Randomized assessor-blinded  controlled trial with 2 arms; one arm received acupuncture twice weekly for 8  weeks, while the other arm was a wait-list control group receiving only standard  care. Primary outcome was pain intensity and interference over the past week  using the Brief Pain Inventory at the end of the intervention. Secondary outcomes  included clinical assessment (CTCAE [Common Toxicity Criteria for Adverse Events]  grading and Total Neuropathy Score-Clinical Version) and nerve conduction  studies; and patient-reported outcome measures (Functional Assessment of Cancer  Therapy-Gynecologic Oncology Group-Neurotoxicity Quality of Life scale and  Symptom Distress Scale) assessed at baseline, end of treatment (8 weeks), week  14, and week 20 from the beginning of treatment. RESULTS: Eighty-seven patients  were randomized to the experimental arm (n = 44) and to the standard care  wait-list control arm (n = 43). Significant changes at 8 weeks were detected in  relation to primary outcome (pain), the clinical neurological assessment, quality  of life domains, and symptom distress (all P < .05). Improvements in pain  interference, neurotoxicity-related symptoms, and functional aspects of quality  of life were sustained in the 14-week assessment ( P < .05), as were physical and  functional well-being at the 20-week assessment ( P < .05). CONCLUSIONS:  Acupuncture is an effective intervention for treating chemotherapy-induced  peripheral neuropathy and improving patients' quality of life and experience with  neurotoxicity-related symptoms with longer term effects evident.
C1 1 The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.
   1 The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.
   1 The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.
   2 Prince of Wales Hospital, Sha Tin, Hong Kong SAR.
   1 The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.
   2 Prince of Wales Hospital, Sha Tin, Hong Kong SAR.
   1 The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.
   2 Prince of Wales Hospital, Sha Tin, Hong Kong SAR.
   2 Prince of Wales Hospital, Sha Tin, Hong Kong SAR.
   2 Prince of Wales Hospital, Sha Tin, Hong Kong SAR.
   2 Prince of Wales Hospital, Sha Tin, Hong Kong SAR.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD MAR 25
PY 2019
VL 18
IS 
BP 1534735419836501
EP 1534735419836501
DI 10.1177/1534735419836501
PG 1
WC Acupuncture; methods; Acupuncture Therapy; methods; Antineoplastic Agents; adverse effects; Female; Humans; Male; Middle Aged; Neoplasms; drug therapy; Pain; chemically induced; Peripheral Nervous System Diseases; chemically induced; Quality of Life; Surveys and Questionnaires
UT PubMed:30905173
PM 30905173
DA 2019-03-25
ER

PT J
AU Choi, HS
   Lee, SH
   Lee, YJ
   Ha, IH
AF Choi, Hee-Seung
   Lee, Sook-Hyun
   Lee, Yoon Jae
   Ha, In-Hyuk
TI Nonsurgical integrative Korean Medicine treatment of discal cyst: A case report
SO Medicine
LA English
DT Journal Article
AB RATIONALE: Discal cysts are rare lesions characterized by pain caused by  neurogenic compression with similar symptoms as those of disc herniation. This  study aims to report the spontaneous regression of discal cyst achieved through  nonsurgical integrative Korean Medicine treatment and the clinical  epidemiological features of discal cyst cases collected from 4 institutions.  PATIENT CONCERNS: A 31-year-old woman had low back pain and radiating pain  equivalent to a numeral rating scale (NRS) of 8 and had limitations in daily work  and activities. DIAGNOSES: The patient was diagnosed as having discal cysts that  compressed the left S1 based on findings of L-spine magnetic resonance imaging  (MRI) performed at our hospital. INTERVENTIONS: The patient received nonsurgical  Korean Medicine treatment and after 24 days of treatment in the hospital, she  underwent 16 additional treatments as an outpatient. OUTCOMES: Spontaneous  regression was confirmed in the L-spine MRI follow-up at 36 days and 99 days  after the initial test, and the patient underwent once-a-week follow up to  examine NRS, Oswestry Disability Index (ODI), EuroQol-5 Dimensions (EQ-5D), and  fear-avoidance beliefs questionnaire (FABQ) after 4 weeks, and 2, 3, and 6-month  follow-ups after that. The patient was discharged in a painless condition, and  she was able to carry on for 5 months without increased pain. LESSONS: Discal  cysts are more rapid progress than disc herniation, it seems valid to attempt  nonsurgical treatment. Epidemiologically, this is the first study to present the  clinical epidemiological characteristics of discal cysts, it would provide  valuable information to clinicians who treat and study discal cysts.
C1 Jaseng Hospital of Korean Medicine.
   Department of Medical Science of Meridian, Graduate School, Kyung Hee University.
   Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, Republic of Korea.
   Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, Republic of Korea.
   Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, Republic of Korea.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JUL 7
PY 2019
VL 98
IS 27
BP e16189
EP e16189
DI 10.1097/MD.0000000000016189
PG 1
WC Acupuncture Therapy; Adult; Cysts; therapy; Female; Humans; Integrative Medicine; Lumbar Vertebrae; diagnostic imaging; Magnetic Resonance Imaging; Male; Medicine, East Asian Traditional; methods; Middle Aged; Pain Measurement; Physical Therapy Modalities; Republic of Korea; Retrospective Studies; Treatment Outcome
UT PubMed:31277125
PM 31277125
DA 2019-07-07
ER

PT J
AU Lee, JE
   Shah, VK
   Lee, EJ
   Oh, MS
   Choi, JJ
AF Lee, Jae Eun
   Shah, Vikash Kumar
   Lee, Eun-Jung
   Oh, Min-Seok
   Choi, Jeong June
TI Melittin - A bee venom component - Enhances muscle regeneration factors expression in a mouse model of skeletal muscle contusion
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Melittin; Sweet bee venom; Muscle contusion; Muscle regeneration; Anti-inflammatory effects
ID monocyte chemoattractant protein-1; pain; acupuncture; inhibition; induction; recovery
AB Melittin is a major peptide component of sweet bee venom that possesses anti-allergic, anti-inflammatory, anti-arthritis, anti-cancer, and neuroprotective properties. However, the therapeutic effects of melittin on muscle injury have not been elucidated. We investigated the therapeutic effects of melittin on muscle injury in a mouse model of muscle contusion. The biceps femoris muscle of the mice was injured using drop mass method, and the animals were treated with melittin (4, 20, or 100 mu g/kg) for 7 days. Melittin significantly increased: locomotor activity in open field test, and treadmill running activity in a dose-dependent manner to level comparable to the positive control, diclofenac (30 mg/kg). Melittin treatment attenuated the pro-inflammatory cytokine MCP-1, TNF-alpha and IL-6. The expression of muscle regeneration biomarkers, including MyoD (muscle differentiation marker), myogenin, smooth muscle actin, and myosin heavy chain was markedly increased in the injured muscle tissue of melittin-treated mice, as determined by western blotting and quantitative real-time polymerase chain reaction. These results demonstrate that melittin inhibits inflammatory response and improves muscle damage by regenerating muscles in a mouse model of muscle contusion. Taken together, the results of present study suggest that melittin is a promising candidate for the muscle injury treatment. (C) 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
C1 [Lee, Jae Eun] Daejeon Univ, Cheonan Korean Med Hosp, Dept Korean Rehabil Med, Cheonan 31099, South Korea.
   [Shah, Vikash Kumar; Choi, Jeong June] Daejeon Univ, Coll Korean Med, Lab Mol Med, 62 Daehak Ro, Daejeon 34520, South Korea.
   [Lee, Eun-Jung; Oh, Min-Seok] Daejeon Univ, Coll Korean Med, Dept Korean Rehabil Med, 1136 Dunsan Dong, Daejeon 34520, South Korea.
C3 Daejeon University; Daejeon University; Daejeon University
RP Choi, JJ (corresponding author), Daejeon Univ, Coll Korean Med, Lab Mol Med, 62 Daehak Ro, Daejeon 34520, South Korea.; Oh, MS (corresponding author), Daejeon Univ, Coll Korean Med, Dept Korean Rehabil Med, 1136 Dunsan Dong, Daejeon 34520, South Korea.
EM ohmin@dju.ac.kr; c27022@dju.ac.kr
FU Daejeon University fund
CR Alvarez P, 2014, PAIN, V155, P1161, DOI 10.1016/j.pain.2014.03.004
   Bryant AE, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0172486
   Ceafalan LC, 2014, BIOMED RES INT, V2014, P0, DOI 10.1155/2014/957014
   Delos D, 2013, SPORTS HEALTH, V5, P346, DOI 10.1177/1941738113480934
   Jarvinen TA, 2014, MUSCLES LIGAMENTS TE, V3, P337
   Jo M, 2012, TOXICOL APPL PHARM, V258, P72, DOI 10.1016/j.taap.2011.10.009
   Kang H, 2014, J PHARMACOPUNCT, V17, P73
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Kim YJ, 2009, J PHARMACOPUNCT, V12, P5, DOI 10.3831/KPI.2009.12.4.005
   Launay T, 2001, J HISTOCHEM CYTOCHEM, V49, P887, DOI 10.1177/002215540104900709
   Lee JA, 2014, BMJ OPEN, V4, P0
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Mann CJ, 2011, SKELET MUSCLE, V1, P0, DOI 10.1186/2044-5040-1-21
   Morelli KM, 2018, AM J SPORT MED, V46, P224, DOI 10.1177/0363546517697957
   Park JH, 2012, APOPTOSIS, V17, P61, DOI 10.1007/s10495-011-0659-0
   Plackett TP, 2015, ADV WOUND CARE, V4, P92, DOI 10.1089/wound.2014.0597
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4
   Vignaud A, 2005, EXP PHYSIOL, V90, P487, DOI 10.1113/expphysiol.2005.029835
   Volans G, 2015, IBUPROFEN: DISCOVERY, V0, P498
   Wolfe RR, 2006, AM J CLIN NUTR, V84, P475, DOI 10.1093/ajcn/84.3.475
   Zádor E, 2002, BBA-MOL CELL RES, V1590, P52, DOI 10.1016/S0167-4889(02)00198-2
NR 24
TC 18
Z9 20
U1 2
U2 9
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAY 15
PY 2019
VL 140
IS 1
BP 26
EP 32
DI 10.1016/j.jphs.2019.03.009
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ID7SN
UT WOS:000471882900005
PM 31113730
DA 2026-01-16
ER

PT J
AU Herrera-Peco, I
   Moran, JM
   Santillan-Garcia, A
AF Herrera-Peco, Ivan
   Moran, Jose-María
   Santillan-Garcia, Azucena
TI Commentary on Transcutaneous Acupoint Interferential Current Stimulation for
SO Integrative cancer therapies
LA English
DT Letter
C1 1 Universidad Alfonso X El Sabio, Madrid, Spain.
   2 Universidad Extremadura, Cáceres, Spain.
   3 Hospital Universitario de Burgos, Burgos, Spain.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD APR 25
PY 2019
VL 18
IS 
BP 1534735419845141
EP 1534735419845141
DI 10.1177/1534735419845141
PG 1
WC Acupuncture Points; Analgesics, Opioid; Cancer Pain; Constipation; Humans; Neoplasms; Prospective Studies; Transcutaneous Electric Nerve Stimulation
UT PubMed:31014121
PM 31014121
DA 2019-04-25
ER

PT J
AU Anand, K
   Niravath, P
AF Anand, Kartik
   Niravath, Polly
TI Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced
SO Current oncology reports
LA English
DT Review
DE Acupuncture; Aromatase inhibitor; Arthralgia; Breast cancer; Breast cancer survivors; Quality of life; Vitamin D
AB PURPOSE OF REVIEW: Aromatase inhibitor-induced arthralgia (AIA) is a very common  syndrome which significantly affects breast cancer survivors' quality of life,  and it often leads to non-compliance with aromatase inhibitor (AI) therapy.  However, the treatment of AIA remains a clinical challenge. Here, we will review  the current data for acupuncture and vitamin D in the management of AIA. RECENT  FINDINGS: Acupuncture has been shown to improve AIA symptoms, but it has not  consistently been proven to offer significantly more clinical benefit than sham  acupuncture. Similarly, while some vitamin D trials have shown benefit, the  studies have not consistently shown improvement in AIA symptoms. Neither  acupuncture nor vitamin D can be touted as standard treatments for AIA. However,  many patients do experience subjective improvement of their symptoms with these  therapies. When other treatments, such as exercise and duloxetine, are not  feasible or not effective, it is reasonable to offer a trial of acupuncture or  vitamin D to patients who are suffering from AIA, as the potential harms are very  few, and they do offer possible relief from AIA symptoms.
C1 Houston Methodist Cancer Center/Weill Cornell Medicine, Outpatient Tower, Floor 24, 6445 Main Street, Houston, TX, 77030, USA.
   Houston Methodist Cancer Center/Weill Cornell Medicine, Outpatient Tower, Floor 24, 6445 Main Street, Houston, TX, 77030, USA. paniravath@houstonmethodist.org.
NR 0
TC 0
SN 1534-626
EI 
J9 Curr Oncol Rep
PD APR 19
PY 2019
VL 21
IS 6
BP 51
EP 51
DI 10.1007/s11912-019-0795-1
PG 0
WC Acupuncture Therapy; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Cancer Survivors; Female; Humans; Quality of Life; Treatment Outcome; Vitamin D; therapeutic use
UT PubMed:30997616
PM 30997616
DA 2019-04-19
ER

PT J
AU Deng, G
   Giralt, S
   Chung, DJ
   Landau, H
   Siman, J
   Li, QS
   Lapen, K
   Mao, JJ
AF Deng, Gary
   Giralt, Sergio
   Chung, David J
   Landau, Heather
   Siman, Jonathan
   Li, Qing S
   Lapen, Kaitlyn
   Mao, Jun J
TI Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem
SO Pain medicine (Malden, Mass.)
LA English
DT Journal Article
DE Acupuncture; Cancer Pain; Opioids; Pain Management
AB OBJECTIVE: To evaluate acupuncture as a nonpharmacologic intervention for pain  management in patients undergoing hematopoietic stem cell transplantation (HSCT).  METHODS: Adult patients with multiple myeloma undergoing high-dose melphalan  chemotherapy and autologous peripheral blood HSCT were randomized to receive  either true (TA) or sham acupuncture (SA) once daily for five days starting on  the day after chemotherapy. Use of pain medications and pain scores were assessed  at baseline and at days 5, 15, and 30 after transplantation. RESULTS: Among 60  evaluable subjects, the SA group (vs TA) had greater than five times odds of  increasing pain medication use from baseline. Among patients who were opioid  nonusers at baseline, all 15 patients in the TA group remained free from opioid  use at the end of the study. In contrast, 20% of those in the SA group (four of  the 20 patients) started to use opioids after chemotherapy and stem cell infusion  (day 5) and 40% (eight of the 20) had become opioid users by day 30 after HSCT  (Fisher exact test P = 0.006). Among patients who were taking opioids at  baseline, 14% in the TA group vs 10% in the SA group increased opioid intake at  day 5, and 21% (TA) vs 30% (SA) at day 30 (P = 0.86). CONCLUSIONS: Acupuncture  appears to significantly reduce the need for pain medications during HSCT and the  number of post-HSCT opioid users among baseline opioid nonusers. It warrants  further studies as an opioid-sparing intervention for pain in HSCT patients.
C1 Integrative Medicine Service.
   Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.
   Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.
   Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.
   Seattle Cancer Care Alliance, Seattle, Washington.
   Integrative Medicine Service.
   Medical School, University of Illinois at Chicago, Chicago, Illinois.
   Integrative Medicine Service.
NR 0
TC 0
SN 1526-463
EI 1526-237
J9 Pain Med
PD SEP 10
PY 2019
VL 21
IS 3
BP 636
EP 642
DI 10.1093/pm/pnz190
PG 6
WC Acupuncture Therapy; methods; Adult; Analgesics, Opioid; therapeutic use; Cancer Pain; therapy; Female; Hematopoietic Stem Cell Transplantation; adverse effects; Humans; Male; Middle Aged; Multiple Myeloma; therapy; Pain Management; methods; Pilot Projects
UT PubMed:31498394
PM 31498394
DA 2019-09-10
ER

PT J
AU Liou, KT
   Hung, TKW
   Meghani, SH
   Epstein, AS
   Li, QSS
   Romero, SAD
   Cohen, RB
   Mao, JJ
AF Liou, Kevin T.
   Hung, Tony K. W.
   Meghani, Salimah H.
   Epstein, Andrew S.
   Li, Q. Susan
   Romero, Sally A. D.
   Cohen, Roger B.
   Mao, Jun J.
TI What if Acupuncture Were Covered by Insurance for Pain Management? A Cross-Sectional Study of Cancer Patients at One Academic Center and 11 Community Hospitals
SO PAIN MEDICINE
LA English
DT Article
DE Acupuncture; Pain; Cancer; Insurance; Disparities; Health Beliefs; Access
ID alternative medicine use; persistent opioid use; planned behavior; breast-cancer; complementary; attitudes; disparity; prevalence; guideline; survivors
AB Objective. In response to the national opioid crisis, governmental and medical organizations have called for broader insurance coverage of acupuncture to improve access to nonpharmacologic pain therapies, especially in cancer populations, where undertreatment of pain is prevalent. We evaluated whether cancer patients would be willing to use insurance-covered acupuncture for pain. Design and Setting. We conducted a cross-sectional survey of cancer patients with pain at one academic center and 11 community hospitals. Methods. We used logistic regression models to examine factors associated with willingness to use insurance-covered acupuncture for pain. Results. Among 634 cancer patients, 304 (47.9%) reported willingness to use insurance-covered acupuncture for pain. In univariate analyses, patients were more likely to report willingness if they had severe pain (odds ratio [OR] = 1.59, 95% confidence interval [CI] = 1.03-2.45) but were less likely if they were nonwhite (OR = 0.59, 95% CI = 0.39-0.90) or had only received high school education or less (OR = 0.46, 95% CI = 0.32-0.65). After adjusting for attitudes and beliefs in multivariable analyses, willingness was no longer significantly associated with education (adjusted OR [aOR] = 0.78, 95% CI = 0.50-1.21) and was more negatively associated with nonwhite race (aOR = 0.49, 95% CI = 0.29-0.84). Conclusions. Approximately one in two cancer patients was willing to use insurance-covered acupuncture for pain. Willingness was influenced by patients' attitudes and beliefs, which are potentially modifiable through counseling and education. Further research on racial disparities is needed to close the gap in utilization as acupuncture is integrated into insurance plans in response to the opioid crisis.
C1 [Liou, Kevin T.; Li, Q. Susan; Romero, Sally A. D.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, 1429 First Ave, New York, NY 10021 USA.
   [Hung, Tony K. W.] Olive View UCLA Med Ctr, Dept Hematol Oncol, 14445 Olive View Dr, Sylmar, CA 91342 USA.
   [Meghani, Salimah H.] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA.
   [Epstein, Andrew S.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
   [Epstein, Andrew S.; Mao, Jun J.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
   [Cohen, Roger B.] Univ Penn, Div Hematol Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 Memorial Sloan Kettering Cancer Center; University of California System; University of California Los Angeles; University of Pennsylvania; Memorial Sloan Kettering Cancer Center; Cornell University; Weill Cornell Medicine; University of Pennsylvania
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, 1429 First Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU National Cancer Institute [2P30CA016520-40, 3P30CA008748-50]; Byrne Fund; Translational Research and Integrative Medicine Fund at Memorial Sloan Kettering Cancer Center; National Cancer Institute [P30CA016520, P30CA008748] Funding Source: NIH RePORTER
CR Ajzen I, 2011, PSYCHOL HEALTH, V26, P1113, DOI 10.1080/08870446.2011.613995
   American Association of Acupuncture and Oriental Medicine (AAAOM), 2009, POS STAT SUPP DES AC, V0, P0
   Austin Shamly, 2015, HEALTH MARK Q, V32, P113, DOI 10.1080/07359683.2015.1033929
   Ballantyne JC, 2015, JAMA-J AM MED ASSOC, V313, P1059, DOI 10.1001/jama.2015.0521
   Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Barclay JS, 2014, SUPPORT CARE CANCER, V22, P1883, DOI 10.1007/s00520-014-2167-6
   Bauml JM, 2015, CANCER-AM CANCER SOC, V121, P2431, DOI 10.1002/cncr.29173
   Bennett Mike, 2017, AM SOC CLIN ONCOL EDUC BOOK, V37, P705, DOI 10.1200/edbk_180469
   Bishop FL, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-102
   Bishop FL, 2011, BMC HEALTH SERV RES, V11, P0, DOI 10.1186/1472-6963-11-129
   Bonafede M, 2008, MED CARE, V46, P41, DOI 10.1097/MLR.0b013e3181589b7d
   Breuer B, 2011, J CLIN ONCOL, V29, P4769, DOI 10.1200/JCO.2011.35.0561
   Brummett CM, 2017, JAMA SURG, V152, P0, DOI 10.1001/jamasurg.2017.0504
   Chuang E, 2018, J ALTERN COMPLEM MED, V24, P336, DOI 10.1089/acm.2017.0262
   Clarke Hance, 2014, BMJ, V348, Pg1251, DOI 10.1136/bmj.g1251
   Davis RT, 2018, GLOB ADV HLTH MED, V7, P1
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Enblom A, 2017, ACUPUNCT MED, V35, P251, DOI 10.1136/acupmed-2015-011007
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Frankel E, 2014, EUR J INTEGR MED, V6, P532, DOI 10.1016/j.eujim.2014.06.007
   Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761
   Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hirai K, 2008, ANN ONCOL, V19, P49, DOI 10.1093/annonc/mdm494
   Hopton A, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0056806
   Jabbour MJ, 2009, AM ACUPUNCT, V49, P1
   Judson PL, 2017, INTEGR CANCER THER, V16, P96, DOI 10.1177/1534735416660384
   Kim SY, 2012, ACUPUNCT MED, V30, P273, DOI 10.1136/acupmed-2012-010178
   Kligler B, 2015, J ALTERN COMPLEM MED, V21, P713, DOI 10.1089/acm.2014.0376
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lafferty WE, 2006, AM J MANAG CARE, V12, P397
   Lee JSJ, 2017, J CLIN ONCOL, V35, P4042, DOI 10.1200/JCO.2017.74.1363
   Lino S, 2014, COMPLEMENT THER MED, V22, P400, DOI 10.1016/j.ctim.2014.03.002
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Mao JJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/798098
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   McKee MD, 2013, J AM BOARD FAM MED, V26, P692, DOI 10.3122/jabfm.2013.06.130003
   Mckee MD, 2012, J ALTERN COMPLEM MED, V18, P839, DOI 10.1089/acm.2011.0193
   Meghani SH, 2014, J CLIN ONCOL, V32, P2773, DOI 10.1200/JCO.2013.54.7992
   Meghani SH, 2012, PAIN MED, V13, P150, DOI 10.1111/j.1526-4637.2011.01310.x
   Nahin Richard L, 2016, NCHS DATA BRIEF, V0, P1
   Oh B, 2017, ACUPUNCT MED, V35, P107, DOI 10.1136/acupmed-2016-011115
   Paice JA, 2016, J ONCOL PRACT, V12, P757, DOI 10.1200/JOP.2016.014837
   Prochaska JO, 2008, HLTH BEHAV HLTH ED T, V4th, P97
   Schwehr NA, 2018, ACUPUNCT MED, V36, P88, DOI 10.1136/acupmed-2016-011341
   Sohn H, 2017, POPUL RES POLICY REV, V36, P181, DOI 10.1007/s11113-016-9416-y
   Soneji N, 2016, JAMA SURG, V151, P1083, DOI 10.1001/jamasurg.2016.1681
   Tanco K, 2014, PALLIAT SUPPORT CARE, V12, P515, DOI 10.1017/S1478951514000091
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Weeks J, 2016, J ALTERN COMPLEM MED, V22, P947, DOI 10.1089/acm.2016.29016.jjw
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/710750
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 56
TC 23
Z9 24
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD OCT 15
PY 2019
VL 20
IS 10
BP 2060
EP 2068
DI 10.1093/pm/pnz087
PG 9
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA JP1SN
UT WOS:000498052000022
PM 31329938
DA 2026-01-16
ER

PT J
AU Jeong, YJ
   Park, YY
   Park, KK
   Choi, YH
   Kim, CH
   Chang, YC
AF Jeong, Yun-Jeong
   Park, Yoon-Yub
   Park, Kwan-Kyu
   Choi, Yung Hyun
   Kim, Cheorl-Ho
   Chang, Young-Chae
TI Bee Venom Suppresses EGF-Induced Epithelial-Mesenchymal Transition and Tumor Invasion in Lung Cancer Cells
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Bee Venom; Epithelial-Mesenchymal Transition; Invasion; Melittin; Apamin
ID down-regulation; metastasis; growth; promotes; emt; activation; acupuncture; sensitivity; expression; receptors
AB Bee venom of Apis mellifera is a traditional medicine in Asia. It has been used with promoting results for the treatment of pain, rheumatoid, and cancer disease. The purpose of this study was to investigate the effects of bee venom on epidermal growth factor (EGF)-induced epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) and determine possible signaling pathway affected in EGF-induced EMT in A549 cells. Bee venom inhibited EGF-induced F-actin reorganization and cell invasion, and suppressed EGF-induced EMT, processes associated with tumor metastasis in NSCLC. Bee venom enhanced the upregulation of E-cadherin and the downregulation of vimentin and inhibited EGF-induced ERK, JNK, FAK, and mTOR phosphorylation in A549 cells. However, the inhibition of JNK phosphorylation by bee venom was not related to the inhibitory effects of EMT. Furthermore, we found that bee venom suppressed the EMT-related transcription factors ZEB2 and Slug by blocking EGF-induced ERK, FAK and mTOR phosphorylation. Bee venom inhibits EGF-induced EMT by blocking the phosphorylation of ERK, FAK, and mTOR, resulting in the suppression of ZEB2 and Slug. These data suggest bee venom as a potential antimetastatic agent for NSCLC.
C1 [Jeong, Yun-Jeong; Park, Yoon-Yub; Park, Kwan-Kyu; Chang, Young-Chae] Catholic Univ, Res Inst Biomed Engn, Daegu Sch Med, Daegu 42472, South Korea.
   [Jeong, Yun-Jeong; Park, Yoon-Yub; Park, Kwan-Kyu; Chang, Young-Chae] Catholic Univ, Dept Med, Daegu Sch Med, Daegu 42472, South Korea.
   [Choi, Yung Hyun] Dong Eui Univ, Dept Biochem, Coll Korean Med, Busan 47227, South Korea.
   [Kim, Cheorl-Ho] Sungkyunkwan Univ, Dept Biol Sci, Suwon 16419, Kyunggi Do, South Korea.
C3 Catholic University of Daegu; Catholic University of Daegu; Dong-Eui University; Sungkyunkwan University (SKKU)
RP Chang, YC (corresponding author), Catholic Univ, Daegu Sch Med, Dept Cell Biol, 3056-6,Daemyung 4 Dong, Daegu 42472, South Korea.
EM ycchang@cu.ac.kr
FU National Research Foundation of Korea (NRF) - Korean government (MSIT) [NRF-2017R1A2B4005937, NRF-2018R1C1B6008908]
CR Al Dayel Fouad, 2012, J INFECT PUBLIC HEALTH, V5 Suppl 1, PS31, DOI 10.1016/j.jiph.2012.09.008
   Alqutub AN, 2011, WORLD J HEPATOL, V3, P268, DOI 10.4254/wjh.v3.i10.268
   BILLINGHAM ME, 1973, NATURE, V245, P163, DOI 10.1038/245163a0
   Buonato JM, 2014, CANCER RES, V74, P309, DOI 10.1158/0008-5472.CAN-12-4721
   Cheng JC, 2012, J CLIN ENDOCR METAB, V97, PE1380, DOI 10.1210/jc.2011-2751
   Cho HJ, 2010, J ETHNOPHARMACOL, V127, P662, DOI 10.1016/j.jep.2009.12.007
   Cho SY, 2018, J ALTERN COMPLEM MED, V24, P25, DOI 10.1089/acm.2016.0250
   Constanzo JD, 2016, NEOPLASIA, V18, P282, DOI 10.1016/j.neo.2016.03.003
   Gu H, 2018, MOL MED REP, V0, P0
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Han SM, 2012, TOX RESEARCH, V28, P99, DOI 10.5487/TR.2012.28.2.099
   Herbst RS, 2003, CLIN CANCER RES, V9, P5813
   Jeong JH, 2010, MOL CANCER THER, V9, P2102, DOI 10.1158/1535-7163.MCT-09-1159
   Jeong YJ, 2014, FOOD CHEM TOXICOL, V68, P218, DOI 10.1016/j.fct.2014.03.022
   Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kim GT, 2014, INT J ONCOL, V45, P1673, DOI 10.3892/ijo.2014.2546
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Lee SH, 2003, JOURNAL OF ACUPUNCTURE RESEARCH, V20, P80
   Lee WR, 2015, TOXINS, V7, P4758, DOI 10.3390/toxins7114758
   Lee WR, 2014, BIOCHEM BIOPH RES CO, V450, P195, DOI 10.1016/j.bbrc.2014.05.089
   Li YR, 2017, BIOMED PHARMACOTHER, V92, P140, DOI 10.1016/j.biopha.2017.05.058
   Li YW, 2016, CANCER BIOL THER, V17, P272, DOI 10.1080/15384047.2016.1139242
   Liu CC, 2016, CANCER CHEMOTH PHARM, V78, P1113, DOI 10.1007/s00280-016-3160-1
   Liu F, 2017, EUR J PHARMACOL, V811, P180, DOI 10.1016/j.ejphar.2017.05.040
   Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x
   Park J, 2018, ANN DERMATOL, V30, P202, DOI 10.5021/ad.2018.30.2.202
   Park JY, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9100319
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Saintigny P, 2012, DISCOV MED, V13, P287
   Shi ZM, 2017, ONCOGENE, V36, P2577, DOI 10.1038/onc.2016.414
   Shin SH, 2018, MOL MED REP, V17, P6632, DOI 10.3892/mmr.2018.8720
   Shintani Y, 2011, ANN THORAC SURG, V92, P1794, DOI 10.1016/j.athoracsur.2011.07.032
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Tang J, 2003, BIOCHEM BIOPH RES CO, V312, P930, DOI 10.1016/j.bbrc.2003.11.016
   Tashiro E, 2016, BIOCHEM BIOPH RES CO, V477, P801, DOI 10.1016/j.bbrc.2016.06.138
   VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104
   Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1
   Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377
   Xu QL, 2017, ONCOTARGET, V8, P9557, DOI 10.18632/oncotarget.13771
   Zheng J, 2015, ONCOTARGET, V6, P44437, DOI 10.18632/oncotarget.6295
NR 43
TC 20
Z9 26
U1 1
U2 23
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2019
VL 47
IS 8
BP 1869
EP 1883
DI 10.1142/S0192415X19500952
PG 15
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA JW4GJ
UT WOS:000503011400011
PM 31786944
DA 2026-01-16
ER

PT J
AU Tang, Y
   Yin, HY
   Lu, J
   Rubini, P
   Illes, P
AF Tang, Yong
   Yin, Hai-yan
   Lu, Juan
   Rubini, Patrizia
   Illes, Peter
TI P2X receptors and acupuncture analgesia
SO BRAIN RESEARCH BULLETIN
LA English
DT Review
DE Acupuncture analgesia; Purinergic signaling; ATP; P2X receptors
ID dorsal-root ganglia; neuropathic pain; spinal microglia; purinergic receptors; inflammatory pain; sham acupuncture; pore formation; up-regulation; cancer pain; electroacupuncture
AB Purinergic signaling has recently been suggested to constitute the cellular mechanism underlying acupuncture-induced analgesia (AA). By extending the original hypothesis on endogenous opioids being released during AA, Geoffrey Bumstock and Maiken Nedergaard supplied evidence for the involvement of purinoceptors (P2 and P1/A1 receptors) in the beneficial effects of AA. In view of certain pain states (e.g. neuropathic pain) which respond only poorly to therapy with standard analgesics, as well as with respect to the numerous unwanted effects of opioids and non-steroidal anti-inflammatory drugs, it is of great significance to search for alternative therapeutic options. Because clinical studies on AA yielded sometimes heterogeneous results, it is of eminent importance to relay on experiments carried out on laboratory animals, by evaluating the data with stringent statistical methods including comparison with a sufficient number of control groups. In this review, we summarize the state of the art situation with respect to the participation of P2 receptors in AA and try to forecast how the field is likely to move forward in the future.
C1 [Tang, Yong] Chengdu Univ, Med & Nursing Sch, Chengdu 610106, Sichuan, Peoples R China.
   [Rubini, Patrizia; Illes, Peter] Univ Leipzig, Rudolf Boehm Inst Pharmakol & Toxikol, Haertelstr 16-18, D-04107 Leipzig, Germany.
   [Tang, Yong; Yin, Hai-yan; Lu, Juan; Illes, Peter] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 610075, Sichuan, Peoples R China.
C3 Chengdu University; Leipzig University; Chengdu University of Traditional Chinese Medicine
RP Illes, P (corresponding author), Univ Leipzig, Rudolf Boehm Inst Pharmakol & Toxikol, Haertelstr 16-18, D-04107 Leipzig, Germany.; Tang, Y (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 610075, Sichuan, Peoples R China.
EM tangyong@cdutcm.edu.cn; Peter.Illes@medizin.uni-leipzig.de
FU Deutsche Forschungsgemeinschaft [IL 20/21-1]; Sino-German Centre [GZ919]; Sichuan Provincial Administration of Foreign Affairs [SZD201846, SZD201731]; Science &Technology Department of Sichuan Province [2018HH0123]; National Natural Science Foundation of China [81373735, 81774437, 81704190, 81873240]; Innovative Research Team in University of Sichuan Province [16TD0015]
CR Anderson M, 2018, NEUROSCI BULL, V34, P194, DOI 10.1007/s12264-017-0139-9
   Andó RD, 2010, BRIT J PHARMACOL, V159, P1106, DOI 10.1111/j.1476-5381.2009.00596.x
   Barragán-Iglesias P, 2016, BRAIN RES, V1636, P43, DOI 10.1016/j.brainres.2016.01.042
   Barragán-Iglesias P, 2015, PHARMACOL BIOCHEM BE, V128, P23, DOI 10.1016/j.pbb.2014.11.001
   Barragán-Iglesias P, 2014, MOL PAIN, V10, P0, DOI 10.1186/1744-8069-10-29
   Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114
   Bernier LP, 2018, BRIT J PHARMACOL, V175, P2219, DOI 10.1111/bph.13957
   BURNSTOCK G, 1972, PHARMACOL REV, V24, P509
   Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3
   Burnstock G, 1978, CELL MEMBRAIN RECEPT, V0, P107
   Burnstock G, 2006, PHARMACOL THERAPEUT, V110, P433, DOI 10.1016/j.pharmthera.2005.08.013
   Burnstock G, 2018, BIOCHEM PHARMACOL, V151, P157, DOI 10.1016/j.bcp.2017.07.016
   Burnstock G, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00661
   Burnstock G, 2016, ADV PHARMACOL, V75, P91, DOI 10.1016/bs.apha.2015.09.001
   Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006
   Burnstock G, 2009, MED HYPOTHESES, V73, P470, DOI 10.1016/j.mehy.2009.05.031
   Burnstock G, 2009, CURR PHARM DESIGN, V15, P1717, DOI 10.2174/138161209788186335
   Carroll WA, 2009, PURINERG SIGNAL, V5, P63, DOI 10.1007/s11302-008-9110-6
   CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0
   Chen XM, 2015, BRIT J ANAESTH, V114, P150, DOI 10.1093/bja/aeu199
   Cheng Ke, 2009, ZHONGGUO ZHEN JIU, V29, P478
   Cheng RD, 2013, CHIN J INTEGR MED, V19, P374, DOI 10.1007/s11655-013-1447-1
   Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002
   Chizh BA, 2001, PHARMACOL REV, V53, P553
   Costa HM, 2011, PURINERG SIGNAL, V7, P7, DOI 10.1007/s11302-011-9215-1
   Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223
   Deng G, 2018, ONCOLOGY-NY, V32, P310
   Donnelly-Roberts D, 2008, J PHARMACOL EXP THER, V324, P409, DOI 10.1124/jpet.106.105890
   Falk S, 2015, NEUROSCIENCE, V291, P93, DOI 10.1016/j.neuroscience.2015.02.011
   Fang JQ, 2018, LIFE SCI, V200, P69, DOI 10.1016/j.lfs.2018.03.028
   Ford AP, 2012, PURINERG SIGNAL, V8, PS3, DOI 10.1007/s11302-011-9271-6
   Gao YH, 2017, PURINERG SIGNAL, V13, P215, DOI 10.1007/s11302-016-9552-1
   Gerevich Z, 2007, BRIT J PHARMACOL, V151, P226, DOI 10.1038/sj.bjp.0707217
   Gerevich Zoltan, 2004, PURINERGIC SIGNAL, V1, P3, DOI 10.1007/s11302-004-4740-9
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Grace PM, 2018, EXP NEUROL, V304, P125, DOI 10.1016/j.expneurol.2018.03.005
   Guo XX, 2013, NEURAL REGEN RES, V8, P2069, DOI 10.3969/j.issn.1673-5374.2013.22.006
   Hansen RR, 2012, EUR J PHARMACOL, V688, P27, DOI 10.1016/j.ejphar.2012.05.008
   Hayashida Masakazu, 2005, J ANESTH, V19, P225, DOI 10.1007/s00540-005-0310-8
   He XF, 2017, J ZHEJIANG UNIV-SC B, V18, P239, DOI 10.1631/jzus.B1600247
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559
   Hurt JK, 2012, MOL PAIN, V8, P0, DOI 10.1186/1744-8069-8-28
   Ide S, 2014, MOL PAIN, V10, P0, DOI 10.1186/1744-8069-10-75
   Inoue K, 2007, PURINERG SIGNAL, V3, P311, DOI 10.1007/s11302-007-9071-1
   Kennedy C, 2003, J PHYSIOL-LONDON, V553, P683, DOI 10.1113/jphysiol.2003.049114
   Köles L, 2007, CURR PHARM DESIGN, V13, P2368
   Köles L, 2008, N-S ARCH PHARMACOL, V377, P1, DOI 10.1007/s00210-007-0222-2
   Latremoliere A, 2018, NEUROSCI BULL, V34, P143, DOI 10.1007/s12264-017-0152-z
   Lazarowski ER, 2012, PURINERG SIGNAL, V8, P359, DOI 10.1007/s11302-012-9304-9
   LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0
   Li CL, 2018, NEUROSCI BULL, V34, P200, DOI 10.1007/s12264-017-0147-9
   Li J, 2017, PURINERG SIGNAL, V13, P13, DOI 10.1007/s11302-016-9537-0
   Liu C, 1994, ZHEN CI YAN JIU, V19, P59
   Liu CY, 2017, MEDIAT INFLAMM, V2017, P1, DOI 10.1155/2017/6361479
   Liu SM, 2015, PURINERG SIGNAL, V11, P161, DOI 10.1007/s11302-014-9439-y
   Locovei S, 2007, FEBS LETT, V581, P483, DOI 10.1016/j.febslet.2006.12.056
   Madsen MV, 2009, BMJ-BRIT MED J, V338, P0, DOI 10.1136/bmj.a3115
   Mansoor SE, 2016, NATURE, V538, P66, DOI 10.1038/nature19367
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Moutal A, 2017, PAIN, V158, P2301, DOI 10.1097/j.pain.0000000000001002
   Murasaki K, 2013, J DENT RES, V92, P260, DOI 10.1177/0022034512474668
   Nagaoka S, 2016, ACUPUNCT MED, V34, P229, DOI 10.1136/acupmed-2015-010959
   Nelson DW, 2006, J MED CHEM, V49, P3659, DOI 10.1021/jm051202e
   Park JH, 2017, EXPERT OPIN THER PAT, V27, P257, DOI 10.1080/13543776.2017.1246538
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   Prado FC, 2013, NEUROPHARMACOLOGY, V67, P252, DOI 10.1016/j.neuropharm.2012.11.011
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   Schiavuzzo JG, 2015, NEUROSCIENCE, V285, P24, DOI 10.1016/j.neuroscience.2014.11.020
   Shi Y, 2011, WORLD J GASTROENTERO, V17, P3733, DOI 10.3748/wjg.v17.i32.3733
   Sorge RE, 2012, NAT MED, V18, P595, DOI 10.1038/nm.2710
   Sperlagh B, 2006, PROG NEUROBIOL, V78, P327, DOI 10.1016/j.pneurobio.2006.03.007
   Sperlágh B, 2014, TRENDS PHARMACOL SCI, V35, P537, DOI 10.1016/j.tips.2014.08.002
   Stephan G, 2018, NAT COMMUN, V9, P0, DOI 10.1038/s41467-018-03728-5
   Sumitani M, 2018, PAIN MED, V19, P348, DOI 10.1093/pm/pnx102
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Takano T, 2012, J PAIN, V13, P1215, DOI 10.1016/j.jpain.2012.09.012
   Tang Y, 2016, NEUROSCIENTIST, V22, P563, DOI 10.1177/1073858416654453
   Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009
   Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160
   Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786
   Tsuda M, 2013, FRONT CELL NEUROSCI, V7, P0, DOI 10.3389/fncel.2013.00191
   Tsuda M, 2009, MOL PAIN, V5, P0, DOI 10.1186/1744-8069-5-28
   Tu WZ, 2012, NEUROCHEM INT, V60, P379, DOI 10.1016/j.neuint.2012.01.006
   Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008
   Villa G, 2010, NEURON GLIA BIOL, V6, P31, DOI 10.1017/S1740925X10000086
   Wang WS, 2014, J NEUROSCI RES, V92, P1703, DOI 10.1002/jnr.23451
   Weng ZJ, 2015, PURINERG SIGNAL, V11, P321, DOI 10.1007/s11302-015-9447-6
   Weng ZJ, 2013, NEURAL REGEN RES, V8, P802, DOI 10.3969/j.issn.1673-5374.2013.09.004
   Wirkner K, 2007, MOL NEUROBIOL, V36, P165, DOI 10.1007/s12035-007-0033-y
   Wu B, 2017, BRAIN RES BULL, V135, P25, DOI 10.1016/j.brainresbull.2017.09.006
   Xiao Z, 2010, BRAIN RES, V1330, P31, DOI 10.1016/j.brainres.2010.03.030
   Xie YF, 2018, EXP NEUROL, V306, P117, DOI 10.1016/j.expneurol.2018.05.003
   Xing S, 2016, FRONT PHYSIOL, V7, P0, DOI 10.3389/fphys.2016.00294
   Xu J, 2016, ANESTH ANALG, V122, P882, DOI 10.1213/ANE.0000000000001097
   Yegutkin GG, 2008, BBA-MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024
   Ying YL, 2014, EXP NEUROL, V261, P836, DOI 10.1016/j.expneurol.2014.09.007
   Yu JB, 2013, ANESTH ANALG, V116, P239, DOI 10.1213/ANE.0b013e31826f0a4a
   Zhang D, 2008, EXPLORE-NY, V4, P170, DOI 10.1016/j.explore.2008.02.002
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
NR 100
TC 43
Z9 50
U1 1
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD SEP 15
PY 2019
VL 151
IS 
BP 144
EP 152
DI 10.1016/j.brainresbull.2018.10.015
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA IW3IG
UT WOS:000484873100016
PM 30458249
DA 2026-01-16
ER

PT J
AU Choi, S
   Chae, HK
   Heo, H
   Hahm, DH
   Kim, W
   Kim, SK
AF Choi, Seunghwan
   Chae, Hyeon Kyeong
   Heo, Ho
   Hahm, Dae-Hyun
   Kim, Woojin
   Kim, Sun Kwang
TI Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral Neuropathy in Rats
SO TOXINS
LA English
DT Article
DE chemotherapy; cold allodynia; mechanical allodynia; melittin; neuropathic pain; oxaliplatin
ID diluted bee venom; acupoint stimulation; cold allodynia; pain; electroacupuncture; model; mechanisms; fluorouracil; leucovorin; receptors
AB Oxaliplatin is a chemotherapeutic agent used for metastatic colon and other advanced cancers. Most common side effect of oxaliplatin is peripheral neuropathy, manifested in mechanical and cold allodynia. Although the analgesic effect of bee venom has been proven to be effective against oxaliplatin-induced peripheral neuropathy, the effect of its major component; melittin has not been studied yet. Thus, in this study, we investigated whether melittin has an analgesic effect on oxaliplatin-induced allodynia. Intraperitoneal single injection of oxaliplatin (6 mg /kg) induced mechanical and cold allodynia, resulting in increased withdrawal behavior in response to von Frey filaments and acetone drop on hind paw. Subcutaneous melittin injection on acupoint ST36 (0.5 mg /kg) alleviated oxaliplatin-induced mechanical and cold allodynia. In electrophysiological study, using spinal in vivo extracellular recording, it was shown that oxaliplatin-induced hyperexcitation of spinal wide dynamic range neurons in response to peripheral stimuli, and melittin administration inhibited this neuronal activity. In behavioral assessment, analgesic effect of melittin was blocked by intrathecal alpha(1)- and alpha(2)-adrenergic receptor antagonists administration. Based on these results, we suggest that melittin could be used as an analgesic on oxaliplatin-induced peripheral neuropathy, and that its effect is mediated by activating the spinal alpha(1)-and alpha(2)-adrenergic receptors.
C1 [Choi, Seunghwan; Kim, Woojin; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02447, South Korea.
   [Chae, Hyeon Kyeong; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02447, South Korea.
   [Heo, Ho] Anapn Korean Tradit Med Clin, 11 Seongnae Ro, Seoul 05392, South Korea.
   [Hahm, Dae-Hyun] Kyung Hee Univ, Sch Med, Dept Physiol, Seoul 02447, South Korea.
   [Kim, Woojin; Kim, Sun Kwang] Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Kim, W; Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02447, South Korea.; Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02447, South Korea.; Kim, W; Kim, SK (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 02447, South Korea.
EM wjkim@khu.ac.kr; skkim77@khu.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government [NRF-2017M3A9E4057926]; Immune and Pain Society
CR Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Argyriou AA, 2015, TOXICS, V3, P187, DOI 10.3390/toxics3020187
   Chae HK, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11020432
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen HS, 2010, BRAIN RES, V1355, P61, DOI 10.1016/j.brainres.2010.08.002
   Chen J, 2016, NEUROSCI BULL, V32, P265, DOI 10.1007/s12264-016-0024-y
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi S, 2017, J PHYSIOL SCI, V67, P431, DOI 10.1007/s12576-016-0505-9
   CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304-3959(94)90023-X
   Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149
   Dault R, 2016, CURR ONCOL, V23, PE65, DOI 10.3747/co.23.2780
   de Medeiros MA, 2003, BRAIN RES, V973, P196, DOI 10.1016/S0006-8993(03)02479-X
   DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X
   DIXON WJ, 1965, J AM STAT ASSOC, V60, P967, DOI 10.2307/2283398
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Fradkin M, 2019, CURR MED CHEM, V0, P0
   Graham J, 2004, NAT REV DRUG DISCOV, V3, P11, DOI 10.1038/nrd1287
   Huh JE, 2018, ALTERN THER HEALTH M, V24, P28
   Kidwell KM, 2012, CANCER-AM CANCER SOC, V118, P5614, DOI 10.1002/cncr.27593
   Kim W, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18122626
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Lee C, 2017, ONCOTARGET, V8, P54951, DOI 10.18632/oncotarget.18627
   LEE G, 2016, MOLECULES BASEL SWIT, V21, P0, DOI 10.3390/MOLECULES21050616
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-471
   Li D, 2015, TOXINS, V7, P2422, DOI 10.3390/toxins7072422
   Li JH, 2010, AM J CHINESE MED, V38, P1039, DOI 10.1142/S0192415X10008457
   Li KC, 2004, NEUROSCIENCE, V126, P753, DOI 10.1016/j.neuroscience.2004.03.050
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/369324
   LIU X, 1986, PAIN, V24, P383, DOI 10.1016/0304-3959(86)90124-7
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Pachman DR, 2015, J CLIN ONCOL, V33, P3416, DOI 10.1200/JCO.2014.58.8533
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   Park JH, 2009, J PHYSIOL SCI, V59, P291, DOI 10.1007/s12576-009-0035-9
   Park SB, 2011, ONCOLOGIST, V16, P708, DOI 10.1634/theoncologist.2010-0248
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   Ryu HK, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/191347
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Suker M, 2016, LANCET ONCOL, V17, P801, DOI 10.1016/S1470-2045(16)00172-8
   Yang J, 2006, BRAIN RES BULL, V68, P453, DOI 10.1016/j.brainresbull.2005.10.002
   Yeo JH, 2016, J PAIN, V17, P298, DOI 10.1016/j.jpain.2015.10.018
   Yoon H, 2015, BIOL PHARM BULL, V38, P710, DOI 10.1248/bpb.b14-00797
   Yoon SY, 2009, J PAIN, V10, P253, DOI 10.1016/j.jpain.2008.09.002
   Yoshimura M, 2006, J PHARMACOL SCI, V101, P107, DOI 10.1254/jphs.CRJ06008X
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 45
TC 31
Z9 33
U1 1
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6651
J9 TOXINS
JI Toxins
PD JUL 15
PY 2019
VL 11
IS 7
BP 
EP 
DI 10.3390/toxins11070396
PG 10
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA IS4FW
UT WOS:000482110000026
PM 31288453
DA 2026-01-16
ER

PT J
AU Santillan-Garcia, A
   Moran, JM
AF Santillan-Garcia, Azucena
   Moran, J. M.
TI Statistical Concerns About Acupressure on Pain in Cancer Patients With Bone Metastasis Trial
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Letter
C1 [Santillan-Garcia, Azucena] Hosp Univ Burgos, Avd Islas Baleares S-N, Burgos 09006, Spain.
   [Moran, J. M.] Univ Extremadura, Caceres, Spain.
C3 Universidad de Extremadura
RP Santillan-Garcia, A (corresponding author), Hosp Univ Burgos, Avd Islas Baleares S-N, Burgos 09006, Spain.
EM ebevidencia@gmail.com
CR Heavey E, 2014, STATISTICS FOR NURSING: A PRACTICAL APPROACH, V0, P0
   Serçe S, 2018, INTEGR CANCER THER, V17, P728, DOI 10.1177/1534735418769153
NR 3
TC 2
Z9 2
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JAN 29
PY 2019
VL 18
IS 
BP 
EP 
DI 10.1177/1534735419827087
PG 2
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA HJ8AI
UT WOS:000457418300001
PM 30791737
DA 2026-01-16
ER

PT J
AU Miller, KR
   Patel, JN
   Symanowski, JT
   Edelen, CA
   Walsh, D
AF Miller, Katherine R.
   Patel, Jai N.
   Symanowski, James T.
   Edelen, Connie A.
   Walsh, Declan
TI Acupuncture for Cancer Pain and Symptom Management in a Palliative Medicine Clinic
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE acupuncture; cancer; pain; palliative; symptom; supportive care
ID fatigue; trial
AB Objective: Studies suggest acupuncture improves cancer-related symptoms; however, it is unclear whether patient characteristics predict pain response. This study determined acupuncture's effect on cancer-related pain and identified variables associated with pain response. Methods: A retrospective chart review included adult patients with cancer referred to palliative medicine and received acupuncture for pain management. Paired t tests compared differences in pain scores from pre- to postacupuncture. Clinically meaningful pain improvement was defined as >= 2-point reduction in pain score. Logistic regression was used to evaluate associations between patient characteristics and pain improvement. Results: One hundred seventy acupuncture treatments from 68 individual patients were studied. Significant reductions in mean pain scores were observed after the first treatment (-1.9 +/- 1.8; P < .001) and across all treatments (-1.7 +/- 1.9; P < .001). Multivariable analysis demonstrated clinically meaningful pain improvement with higher baseline pain scores (odds ratio [OR]: 1.79, 95% confidence interval [CI]: 1.44-2.22; P < .001) and stage III/IV disease (OR: 3.23, 95% CI: 1.11-9.40; P < .001). There were significant improvements in anxiety, depression, drowsiness, dyspnea, fatigue, nausea, and well-being after the first treatment and across all treatments (P < .001). Conclusions: Acupuncture improved cancer-related pain and other symptoms. Those with higher baseline pain scores and advanced disease were more likely to achieve significant pain reduction. Improved depression and fatigue were closely related to pain reduction. Further studies are needed to confirm pain response variables, establish durability, and develop a personalized approach to acupuncture.
C1 [Miller, Katherine R.; Patel, Jai N.] Atrium Hlth, Levine Canc Inst, Dept Canc Pharmacol, 1021 Morehead Med Dr,Suite 3100, Charlotte, NC 28204 USA.
   [Patel, Jai N.; Edelen, Connie A.; Walsh, Declan] Atrium Hlth, Dept Support Oncol, Sect Palliat Med, Charlotte, NC USA.
   [Symanowski, James T.] Atrium Hlth, Levine Canc Inst, Dept Biostat, Charlotte, NC USA.
RP Patel, JN (corresponding author), Atrium Hlth, Levine Canc Inst, Dept Canc Pharmacol, 1021 Morehead Med Dr,Suite 3100, Charlotte, NC 28204 USA.
EM jai.patel@atriumhealth.org
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Argyriou AA, 2012, CRIT REV ONCOL HEMAT, V82, P51, DOI 10.1016/j.critrevonc.2011.04.012
   Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114
   Carlsson Christer, 2002, ACUPUNCT MED, V20, P82
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Dobscha SK, 2016, J PAIN, V17, P824, DOI 10.1016/j.jpain.2016.03.006
   Dong ST, 2014, J PAIN SYMPTOM MANAG, V48, P411, DOI 10.1016/j.jpainsymman.2013.10.027
   Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Glick RM, 2015, MED ACUPUNCT, V27, P188, DOI 10.1089/acu.2015.1100
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   He XR, 2013, ASIAN PAC J CANCER P, V14, P3067, DOI 10.7314/APJCP.2013.14.5.3067
   Hershman DL, 2018, CANCER RES, V78, P0
   Laird BJA, 2011, J PAIN SYMPTOM MANAG, V42, P1, DOI 10.1016/j.jpainsymman.2010.10.261
   Leung AY, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-18
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paley CA, 2015, COCHRANE DB SYST REV, V1, P0
   Romeo MJ, 2015, EXPLORE-NY, V11, P357, DOI 10.1016/j.explore.2015.06.001
   Thompson SJ, 2018, PAIN, V159, P1856, DOI 10.1097/j.pain.0000000000001282
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Xu M, 2004, J NEUROSCI, V24, P4576, DOI 10.1523/JNEUROSCI.5552-03.2004
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
   Zhao FM, 2014, J CLIN ONCOL, V32, P312, DOI 10.1200/JCO.2013.50.6071
NR 27
TC 35
Z9 42
U1 0
U2 43
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
EI 1938-2715
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD APR 15
PY 2019
VL 36
IS 4
BP 326
EP 332
DI 10.1177/1049909118804464
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA HM5KN
UT WOS:000459514700009
PM 30286611
DA 2026-01-16
ER

PT J
AU Hou, W
   Pei, L
   Song, Y
   Wu, J
   Geng, H
   Chen, L
   Wang, Y
   Hu, Y
   Zhou, J
   Sun, J
AF Hou, Wenzhen
   Pei, Lixia
   Song, Yafang
   Wu, Jian
   Geng, Hao
   Chen, Lu
   Wang, Yuhang
   Hu, Yao
   Zhou, Jinyong
   Sun, Jianhua
TI Acupuncture therapy for breast cancer-related lymphedema: A systematic review and
SO The journal of obstetrics and gynaecology research
LA English
DT Journal Article
DE acupuncture therapy; breast cancer-related lymphedema; meta-analysis
AB This study aimed to conduct a comprehensive analysis of clinical studies on  acupuncture treatment for breast cancer-related lymphedema (BCRL), so as to  explore the efficacy and safety of acupuncture treatment and provide evidence for  the clinical decision-making. Public databases, mainly including China Academic  Journals Full-text Database, Database of Chinese Sci-Tech Journal, Wanfang,  PubMed, Embase and the Cochrane Library, from the establishment of databases to  December 2018 were searched for randomized controlled trials (RCT) of acupuncture  for BCRL. Clinical RCT on the treatment of BCRL with acupuncture combined with  drugs or functional exercise were enrolled for the analysis. Bias risk and  quality were assessed by two investigators according to the Cochrane Handbook  5.1.0 standard, and the Revman 5.3 software was used for meta-analysis. A total  of 13 studies were enrolled, comprising 747 patients (377 in the treatment group  and 370 in the control group). The results of meta-analysis showed that  acupuncture intervention could improve the total effective rate for the treatment  of BCRL (odds ratio = 4.62; 95% confidence interval 2.61-8.17). Recent studies  suggest that acupuncture therapy can alleviate the upper limb swelling and  improve the subjective pain and discomfort in patients with BCRL, regardless of  the control intervention used. However, the number of high-quality RCT is low.  Moreover, most of the studies adopted inconsistent efficacy indicators. Hence,  additional blinded, large-sample, randomized, well-controlled studies with  objective and uniform efficacy indicators are needed, especially in China, to  confirm the findings.
C1 Department of Acupuncture, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Acupuncture, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Acupuncture and Manipulation, Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Central Laboratory, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Acupuncture, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Acupuncture, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Acupuncture and Manipulation, Nanjing University of Chinese Medicine, Nanjing, China.
   Department of TCM, WUXI Higher Health Vocational Technology School, Wuxi, China.
   Department of Central Laboratory, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Acupuncture, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
NR 0
TC 0
SN 1447-075
EI 
J9 J Obstet Gynaecol Res
PD OCT 15
PY 2019
VL 45
IS 12
BP 2307
EP 2317
DI 10.1111/jog.14122
PG 10
WC Acupuncture Therapy; adverse effects; Breast Neoplasms; complications; Female; Humans; Lymphedema; therapy; Quality Assurance, Health Care; Randomized Controlled Trials as Topic
UT PubMed:31608558
PM 31608558
DA 2019-10-15
ER

PT J
AU Li, Y
   Yin, C
   Li, X
   Liu, B
   Wang, J
   Zheng, X
   Shao, X
   Liang, Y
   Du, J
   Fang, J
   Liu, B
AF Li, Yuanyuan
   Yin, Chengyu
   Li, Xiaojie
   Liu, Boyu
   Wang, Jie
   Zheng, Xiaoli
   Shao, Xiaomei
   Liang, Yi
   Du, Junying
   Fang, Jianqiao
   Liu, Boyi
TI Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in
SO International journal of molecular sciences
LA English
DT Journal Article
DE Paclitaxel; TLR4; TRPV1; acupuncture; dorsal root ganglion; glial cell; peripheral neuropathy
AB Paclitaxel-induced peripheral neuropathy is a common adverse effect during  paclitaxel treatment resulting in sensory abnormalities and neuropathic pain  during chemotherapy and in cancer survivors. Conventional therapies are usually  ineffective and possess adverse effects. Here, we examined the effects of  electroacupuncture (EA) on a rat model of paclitaxel-induced neuropathic pain and  related mechanisms. EA robustly and persistently alleviated paclitaxel-induced  pain hypersensitivities. Mechanistically, TLR4 (Toll-Like Receptor 4) and  downstream signaling MyD88 (Myeloid Differentiation Primary Response 88) and  TRPV1 (Transient Receptor Potential Vallinoid 1) were upregulated in dorsal root  ganglion (DRGs) of paclitaxel-treated rats, whereas EA reduced their  overexpression. Ca(2+) imaging further indicated that TRPV1 channel activity was  enhanced in DRG neurons of paclitaxel-treated rats whereas EA suppressed the  enhanced TRPV1 channel activity. Pharmacological blocking of TRPV1 mimics the  analgesic effects of EA on the pain hypersensitivities, whereas capsaicin  reversed EA's effect. Spinal astrocytes and microglia were activated in  paclitaxel-treated rats, whereas EA reduced the activation. These results  demonstrated that EA alleviates paclitaxel-induced peripheral neuropathic pain  via mechanisms possibly involving suppressing TLR4 signaling and TRPV1  upregulation in DRG neurons, which further result in reduced spinal glia  activation. Our work supports EA as a potential alternative therapy for  paclitaxel-induced neuropathic pain.
C1 Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou 310053, China.
NR 0
TC 0
SN 1422-006
EI 
J9 Int J Mol Sci
PD NOV 30
PY 2019
VL 20
IS 23
BP 
EP 
DI 10.3390/ijms20235917
PG 0
WC Animals; Antineoplastic Agents, Phytogenic; toxicity; Electroacupuncture; methods; Gene Expression Regulation; Male; Myeloid Differentiation Factor 88; antagonists & inhibitors; Neuralgia; chemically induced; Paclitaxel; toxicity; Peripheral Nervous System Diseases; chemically ; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; drug effects; TRPV Cation Channels; antagonists & inhibitors; Toll-Like Receptor 4; antagonists & inhibitors
UT PubMed:31775332
PM 31775332
DA 2019-11-30
ER

PT J
AU He, Y
   Guo, X
   May, BH
   Zhang, AL
   Liu, Y
   Lu, C
   Mao, JJ
   Xue, CC
   Zhang, H
AF He, Yihan
   Guo, Xinfeng
   May, Brian H
   Zhang, Anthony Lin
   Liu, Yihong
   Lu, Chuanjian
   Mao, Jun J
   Xue, Charlie Changli
   Zhang, Haibo
TI Clinical Evidence for Association of Acupuncture and Acupressure With Improved
SO JAMA oncology
LA English
DT Journal Article
AB IMPORTANCE: Research into acupuncture and acupressure and their application for  cancer pain has been growing, but the findings have been inconsistent. OBJECTIVE:  To evaluate the existing randomized clinical trials (RCTs) for evidence of the  association of acupuncture and acupressure with reduction in cancer pain. DATA  SOURCES: Three English-language databases (PubMed, Embase, and CINAHL) and 4  Chinese-language biomedical databases (Chinese Biomedical Literature Database,  VIP Database for Chinese Technical Periodicals, China National Knowledge  Infrastructure, and Wanfang) were searched for RCTs published from database  inception through March 31, 2019. STUDY SELECTION: Randomized clinical trials  that compared acupuncture and acupressure with a sham control, analgesic therapy,  or usual care for managing cancer pain were included. DATA EXTRACTION AND  SYNTHESIS: Data were screened and extracted independently using predesigned  forms. The quality of RCTs was appraised with the Cochrane Collaboration risk of  bias tool. Random-effects modeling was used to calculate the effect sizes of  included RCTs. The quality of evidence was evaluated with the Grading of  Recommendations Assessment, Development and Evaluation approach. MAIN OUTCOMES  AND MEASURES: The primary outcome was pain intensity measured by the Brief Pain  Inventory, Numerical Rating Scale, Visual Analog Scale, or Verbal Rating Scale.  RESULTS: A total of 17 RCTs (with 1111 patients) were included in the systematic  review, and data from 14 RCTs (with 920 patients) were used in the meta-analysis.  Seven sham-controlled RCTs (35%) were notable for their high quality, being  judged to have a low risk of bias for all of their domains, and showed that real  (compared with sham) acupuncture was associated with reduced pain intensity (mean  difference [MD], -1.38 points; 95% CI, -2.13 to -0.64 points; I2 = 81%). A  favorable association was also seen when acupuncture and acupressure were  combined with analgesic therapy in 6 RCTs for reducing pain intensity (MD, -1.44  points; 95% CI, -1.98 to -0.89; I2 = 92%) and in 2 RCTs for reducing opioid dose  (MD, -30.00 mg morphine equivalent daily dose; 95% CI, -37.5 mg to -22.5 mg). The  evidence grade was moderate because of the substantial heterogeneity among  studies. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis  found that acupuncture and/or acupressure was significantly associated with  reduced cancer pain and decreased use of analgesics, although the evidence level  was moderate. This finding suggests that more rigorous trials are needed to  identify the association of acupuncture and acupressure with specific types of  cancer pain and to integrate such evidence into clinical care to reduce opioid  use.
C1 Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy ofChinese Medical Sciences, Guangzhou, Guangdong Province, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy ofChinese Medical Sciences, Guangzhou, Guangdong Province, China.
   China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
   China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy ofChinese Medical Sciences, Guangzhou, Guangdong Province, China.
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy ofChinese Medical Sciences, Guangzhou, Guangdong Province, China.
   Integrative Medicine Department, Memorial Sloan Kettering Cancer Center, New York, New York.
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy ofChinese Medical Sciences, Guangzhou, Guangdong Province, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy ofChinese Medical Sciences, Guangzhou, Guangdong Province, China.
NR 0
TC 0
SN 2374-244
EI 2374-243
J9 JAMA Oncol
PD DEC 20
PY 2019
VL 6
IS 2
BP 271
EP 278
DI 10.1001/jamaoncol.2019.5233
PG 7
WC Acupressure; adverse effects; Acupuncture Therapy; adverse effects; Cancer Pain; therapy; Humans; Randomized Controlled Trials as Topic
UT PubMed:31855257
PM 31855257
DA 2019-12-20
ER

PT J
AU Calcagni, N
   Gana, K
   Quintard, B
AF Calcagni, Nicolas
   Gana, Kamel
   Quintard, Bruno
TI A systematic review of complementary and alternative medicine in oncology: Psychological and physical effects of manipulative and body-based practices
SO PLOS ONE
LA English
DT Review
ID randomized controlled-trial; quality-of-life; breast-cancer; aromatherapy massage; supportive care; delivered reflexology; symptom-management; clinical-trial; pain; acupressure
AB Background Complementary and Alternative Medicines (CAM) are widely used by cancer patients, despite limited evidence of efficacy. Manipulative and body-based practices are some of the most commonly used CAM. This systematic review evaluates their benefits in oncology. Method A systematic literature review was carried out with no restriction of language, time, cancer location or type. PubMed, CENTRAL, PsycArticle, Psychlnfo, Psychology and Behavioral Sciences Collection and SOCindex were queried. Inclusion criteria were adult cancer patients and randomized controlled trials (RCT) assessing manipulative and body-based complementary practices on psychological and symptom outcomes. Effect size was calculated when applicable. Results Of 1624 articles retrieved, 41 articles were included: massage (24), reflexology (11), acu-pressure (6). Overall, 25 studies showed positive and significant effects on symptom outcomes (versus 9 that did not), especially pain and fatigue. Mixed outcomes were found for quality of life (8 papers finding a significant effect vs. 10 which did not) and mood (14 papers vs. 13). In most studies, there was a high risk of bias with a mean Jadad score of 2, making interpretation of results difficult. Conclusion These results seem to indicate that manipulative CAM may be effective on symptom management in cancer. However, more robust methodologies are needed. The methodological requirements of randomized controlled trials are challenging, and more informative results may be provided by more pragmatic study design.
C1 [Calcagni, Nicolas; Quintard, Bruno] INSERM, UMR 1219, Team Handicap Act Cognit Hlth HACH, Lab EA 4136, Bordeaux, France.
   [Calcagni, Nicolas; Gana, Kamel; Quintard, Bruno] Univ Bordeaux, Bordeaux, France.
C3 Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bordeaux
RP Calcagni, N (corresponding author), INSERM, UMR 1219, Team Handicap Act Cognit Hlth HACH, Lab EA 4136, Bordeaux, France.; Calcagni, N (corresponding author), Univ Bordeaux, Bordeaux, France.
EM nicolas.calcagni@u-bordeaux.fr
FU French 'Site de Recherche Integree sur le Cancer Bordeaux Recherche Integree en Oncologie' (SIRIC -BRIO)
CR Unknown -, 1900, DOI 10.1186/2046-4053-4-1, V0, P0
   Unknown -, 2018, COMPL ALT INT HLTH W, V0, P0
   Avci HS, 2016, HOLIST NURS PRACT, V30, P257, DOI 10.1097/HNP.0000000000000161
   Ayik C, 2018, COMPLEMENT THER MED, V36, P93, DOI 10.1016/j.ctim.2017.12.002
   Beikmoradi A, 2015, IRAN RED CRESCENT ME, V17, P0, DOI 10.5812/ircmj.25919
   Berger VW, 2006, J RHEUMATOL, V33, P1710
   Billhult A, 2008, AUTON NEUROSCI-BASIC, V140, P88, DOI 10.1016/j.autneu.2008.03.006
   Billhult A, 2007, J ALTERN COMPLEM MED, V13, P53, DOI 10.1089/acm.2006.6049
   Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775
   Buchanan DR, 2005, J CLIN ONCOL, V23, P6682, DOI 10.1200/JCO.2005.10.728
   Buzyn A, 2014, EDITIONSPRESSES DE SCIENCES PO PUBLICATIONS, V43, P53
   Campeau Marie-Pierre, 2007, J SOC INTEGR ONCOL, V5, P133, DOI 10.2310/7200.2007.018
   Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4
   Cumming G, 2017, INTRO NEW STAT ESTIM, V0, P0, DOI DOI 10.4324/9781315708607
   Darabpour S, 2016, IRAN RED CRESCENT ME, V18, P0, DOI 10.5812/ircmj.25461
   Donoyama N, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0196638
   Ernst E, 2011, MATURITAS, V68, P116, DOI 10.1016/j.maturitas.2010.10.011
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Fernández-Lao C, 2012, EUR J CANCER CARE, V21, P233, DOI 10.1111/j.1365-2354.2011.01306.x
   Giordano J, 2002, J ALTERN COMPLEM MED, V8, P897, DOI 10.1089/10755530260511892
   Harrison S, 2017, RES SYNTH METHODS, V8, P281, DOI 10.1002/jrsm.1239
   Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2
   2011, 1900, V343, V0, PPD5928, DOI 10.1136/BMJ.D5928
   Hodgson H, 2000, NURS STAND, V14, P33
   Hsiung WT, 2015, COMPLEMENT THER MED, V23, P339, DOI 10.1016/j.ctim.2015.03.010
   Jackson C, 2015, HOLIST NURS PRACT, V29, P178, DOI 10.1097/HNP.0000000000000088
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jane SW, 2011, PAIN, V152, P2432, DOI 10.1016/j.pain.2011.06.021
   Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487
   Kashani Fahimeh, 2014, IRAN J NURS MIDWIFERY RES, V19, P113
   Kim JI, 2010, INTEGR CANCER THER, V9, P326, DOI 10.1177/1534735410387423
   Kotronoulas G, 2017, EUR J ONCOL NURS, V29, P60, DOI 10.1016/j.ejon.2017.05.004
   Krohn M, 2011, SUPPORT CARE CANCER, V19, P1303, DOI 10.1007/s00520-010-0946-2
   Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Lai T K T, 2011, COMPLEMENT THER CLIN PRACT, V17, P37, DOI 10.1016/j.ctcp.2010.02.004
   Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592
   Listing M, 2010, ARCH WOMEN MENT HLTH, V13, P165, DOI 10.1007/s00737-009-0143-9
   Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508
   Loquai C, 2017, EUR J CANCER, V71, P70, DOI 10.1016/j.ejca.2016.10.029
   Massingill Jeanne, 2018, INT J THER MASSAGE BODYWORK, V11, P4
   McVicar A, 2016, J ALTERN COMPLEM MED, V22, P739, DOI 10.1089/acm.2016.0015
   Miladinia M, 2017, CANCER NURS, V40, P31, DOI 10.1097/NCC.0000000000000353
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Özdelikara A, 2017, COMPLEMENT THER CLIN, V29, P122, DOI 10.1016/j.ctcp.2017.09.004
   Pan YQ, 2014, INT J CLIN ONCOL, V19, P829, DOI 10.1007/s10147-013-0635-5
   Price David, 2014, ANN AM THORAC SOC, V11 Suppl 2, PS92, DOI 10.1513/AnnalsATS.201308-276RM
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002
   Robinson N, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-88
   Ross CSK, 2002, PALLIATIVE MED, V16, P544, DOI 10.1191/0269216302pm597xx
   Scott E, 2019, CANCER NURSING PRACTICE, V18, P35, DOI 10.7748/cnp.2019.e1566
   Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006
   Sikorskii A, 2009, NURS RES, V58, P444, DOI 10.1097/NNR.0b013e3181bf15fe
   Simon L, 2007, B CANCER, V94, P483
   Smith JD, 2012, PSYCHOL METHODS, V17, P510, DOI 10.1037/a0029312
   Soden K, 2004, PALLIATIVE MED, V18, P87, DOI 10.1191/0269216304pm874oa
   Stephenson N, 2003, APPL NURS RES, V16, P284, DOI 10.1016/j.apnr.2003.08.003
   Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132
   Toth M, 2013, J ALTERN COMPLEM MED, V19, P650, DOI 10.1089/acm.2012.0466
   Tsay SL, 2008, CANCER NURS, V31, P109, DOI 10.1097/01.NCC.0000305694.74754.7b
   Uysal N, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12532
   Wang T, 2018, BMC PALLIAT CARE, V17, P0, DOI 10.1186/s12904-018-0346-9
   Weinrich S P, 1990, APPL NURS RES, V3, P140, DOI 10.1016/S0897-1897(05)80135-1
   Wilcock A, 2004, PALLIATIVE MED, V18, P287, DOI 10.1191/0269216304pm895oa
   Wilkie D J, 2000, HOSP J, V15, P31
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wilkinson SM, 2007, J CLIN ONCOL, V25, P532, DOI 10.1200/JCO.2006.08.9987
   Wyatt G, 2017, J PAIN SYMPTOM MANAG, V54, P670, DOI 10.1016/j.jpainsymman.2017.07.037
   Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577
   Zhang B, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000007750
NR 82
TC 28
Z9 34
U1 2
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2019
VL 14
IS 10
BP 
EP 
DI 10.1371/journal.pone.0223564
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LM9KP
UT WOS:000532567300028
PM 31622362
DA 2026-01-16
ER

PT J
AU Maschio, M
   Mengarelli, A
   Zarabla, A
   Giannarelli, D
   Maialetti, A
   Gumenyuk, S
   Renzi, D
   Palombi, F
   Pisani, F
   Romano, A
   Spadea, A
   Galiè, E
   Marchesi, F
AF Maschio, Marta
   Mengarelli, Andrea
   Zarabla, Alessia
   Giannarelli, Diana
   Maialetti, Andrea
   Gumenyuk, Svetlana
   Renzi, Daniela
   Palombi, Francesca
   Pisani, Francesco
   Romano, Atelda
   Spadea, Antonio
   Galie, Edvina
   Marchesi, Francesco
TI Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study
SO CLINICAL NEUROPHARMACOLOGY
LA English
DT Review
DE polyneuropathy; multiple myeloma; pregabalin; neurophysiological data; chemotherapy; bortezomib
ID induced peripheral neuropathy; bortezomib; management; prevention; neurotoxicity; acupuncture; guidelines; consensus; system
AB Objectives Polyneuropathy (PN) is a frequent and significant clinical manifestation of multiple myeloma that may be observed at onset of disease or induced during treatment as a therapy-related complication. Polyneuropathy may be a relevant issue in myeloma patients owing to its significant impact on the quality of life, considering that it may lead to dose reduction or treatment discontinuation. The present retrospective study intended to evaluate efficacy of pregabalin (PGB) in treatment of PN in multiple myeloma patients. Materials and Methods Medical charts of 108 consecutive PN myeloma patients were reviewed. Data regarding the tumor history and therapy as well as the clinical and neurophysiological examinations 6 months before and after initiation of PGB therapy were collected. Results Thirty-eight medical charts had all the requested information. All patients (n = 38) underwent bortezomib-based treatment; 19 were previously treated and 19 were treatment naive. At first neurologic visit, all patients had PN symptoms (grade 2 of National Cancer Institute-Common Toxicity Criteria) without relevant pain. Neurophysiological evaluation showed a significant decrease in sensory nerve action potential amplitude (P = 0.006), conduction velocity (P = 0.006), and distal latency (P = 0.03) of sensory nerves between the first and the last neurological examination, in all patient population. Similar results were observed in treatment-naive patients, when the study cohort was stratified according to previous treatment. On the contrary, no significant differences were found between the first and the last neurophysiological follow-up evaluation in previously treated patients. Six months after PGB treatment, all patients reported disappearance of neurological symptoms (grade 0 National Cancer Institute-Common Toxicity Criteria). Conclusions In this retrospective study, improvement in neurological symptoms during PGB therapy was observed in the total population, despite the presence of a distal, sensory axonal neuropathy, as evidenced by neurophysiological examination.
C1 [Maschio, Marta; Zarabla, Alessia; Maialetti, Andrea] IRCCS Regina Elena Natl Canc Inst, UOSD Neurol, Ctr Tumor Related Epilepsy, Via Elio Chianesi 55, I-00144 Rome, Italy.
   [Mengarelli, Andrea; Gumenyuk, Svetlana; Renzi, Daniela; Palombi, Francesca; Pisani, Francesco; Romano, Atelda; Spadea, Antonio; Marchesi, Francesco] IRCCS Regina Elena Natl Canc Inst, Hematol & Stem Cell Transplantat Unit, Rome, Italy.
   [Giannarelli, Diana] IRCCS Regina Elena Natl Canc Inst, Biostat Unit, Rome, Italy.
   [Galie, Edvina] IRCCS Regina Elena Natl Canc Inst, UOSD Neurol, Rome, Italy.
RP Maschio, M (corresponding author), IRCCS Regina Elena Natl Canc Inst, UOSD Neurol, Ctr Tumor Related Epilepsy, Via Elio Chianesi 55, I-00144 Rome, Italy.
EM marta.maschio@ifo.gov.it
CR Unknown -, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007076.pub2
   Antoine JC, 2007, LANCET NEUROL, V6, P75, DOI 10.1016/S1474-4422(06)70679-2
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Beijers AJM, 2016, SUPPORT CARE CANCER, V24, P2411, DOI 10.1007/s00520-015-3032-y
   Beijers AJM, 2012, NETH J MED, V70, P18
   Bilinska M, 2013, WSPOLCZESNA ONKOL, V17, P421, DOI 10.5114/wo.2013.37214
   Callander N, 2014, CANCER CHEMOTH PHARM, V74, P875, DOI 10.1007/s00280-014-2550-5
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Delforge M, 2010, LANCET ONCOL, V11, P1086, DOI 10.1016/S1470-2045(10)70068-1
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Javed Saad, 2015, REV DIABET STUD, V12, P63, DOI 10.1900/rds.2015.12.63
   Koeppen S, 2014, ONCOL RES TREAT, V37, P506, DOI 10.1159/000365534
   Lanzani F, 2008, J PERIPHER NERV SYST, V13, P267, DOI 10.1111/j.1529-8027.2008.00192.x
   Leone C, 2016, NEUROL SCI, V37, P1141, DOI 10.1007/s10072-016-2542-9
   Mallick-Searle T, 2016, J MULTIDISCIP HEALTH, V9, P0, DOI 10.2147/JMDH.S106340
   Maschio M, 2018, INTEGR CANCER THER, V17, P1115, DOI 10.1177/1534735418803758
   Mohty B, 2010, HAEMATOL-HEMATOL J, V95, P311, DOI 10.3324/haematol.2009.012674
   Morawska M, 2015, HEMATOL ONCOL, V33, P113, DOI 10.1002/hon.2149
   Moulin DE, 2014, PAIN RES MANAG, V19, P328
   Nagahara Hisashi, 2013, GAN TO KAGAKU RYOHO, V40, P1181
   Nasu S, 2014, CLIN NEUROPHYSIOL, V125, P381, DOI 10.1016/j.clinph.2013.07.014
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Postma TJ, 2000, ANN ONCOL, V11, P509, DOI 10.1023/A:1008345613594
   Richardson PG, 2012, LEUKEMIA, V26, P595, DOI 10.1038/leu.2011.346
   Saif MW, 2010, ANTICANCER RES, V30, P2927
   SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shinde SS, 2016, SUPPORT CARE CANCER, V24, P547, DOI 10.1007/s00520-015-2807-5
   Snowden JA, 2011, BRIT J HAEMATOL, V154, P76, DOI 10.1111/j.1365-2141.2011.08574.x
   Sonneveld P, 2010, HEMATOL-AM SOC HEMAT, V0, PP423, DOI 10.1182/asheducation-2010.1.423
   Terpos E, 2015, HAEMATOLOGICA, V100, P1254, DOI 10.3324/haematol.2014.117176
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Zhang Li-Li, 2017, ZHONGGUO SHI YAN XUE YE XUE ZA ZHI, V25, P480, DOI 10.7534/j.issn.1009-2137.2017.02.031
NR 37
TC 2
Z9 3
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-5664
EI 1537-162X
J9 CLIN NEUROPHARMACOL
JI Clin. Neuropharmacol.
PD SEP-OCT 15
PY 2019
VL 42
IS 5
BP 167
EP 171
DI 10.1097/WNF.0000000000000360
PG 5
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA KA3VD
UT WOS:000505725500004
PM 31361668
DA 2026-01-16
ER

PT J
AU Serçe, S
   Ovayolu, Ö
   Pirbudak, L
   Ovayolu, N
AF Serce, Sibel
   Ovayolu, Ozlem
   Pirbudak, Luetfiye
   Ovayolu, Nimet
TI Response to "Statistical Concerns About Acupressure on Pain in Cancer Patients With Bone Metastasis Trial"
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Letter
C1 [Serce, Sibel] Gaziantep Univ Hosp, Gaziantep, Turkey.
   [Ovayolu, Ozlem; Pirbudak, Luetfiye; Ovayolu, Nimet] Gaziantep Univ, Gaziantep, Turkey.
C3 Gaziantep University; Gaziantep University
RP Ovayolu, Ö (corresponding author), Gaziantep Univ, Dept Nursing, Fac Hlth Sci, TR-27310 Gaziantep, Turkey.
EM oucan@gantep.edu.tr
CR Santillan-Garcia A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419827087
   Serçe S, 2018, INTEGR CANCER THER, V17, P728, DOI 10.1177/1534735418769153
NR 2
TC 0
Z9 0
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD MAR 18
PY 2019
VL 18
IS 
BP 
EP 
DI 10.1177/1534735419834355
PG 1
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA HP4HG
UT WOS:000461636400001
PM 30879342
DA 2026-01-16
ER

PT J
AU Yeh, CH
   Lukkahatai, N
   Campbell, C
   Sair, H
   Zhang, FZ
   Mensah, S
   Garry, C
   Zeng, J
   Chen, CY
   Pinedo, M
   Khoshnoodi, M
   Smith, TJ
   Saligan, LN
AF Yeh, Chao Hsing
   Lukkahatai, Nada
   Campbell, Claudia
   Sair, Haris
   Zhang, Fengzhi
   Mensah, Sylvanus
   Garry, Courtney
   Zeng, Jing
   Chen, Changying
   Pinedo, Mariela
   Khoshnoodi, Mohammad
   Smith, Thomas J.
   Saligan, Leorey N.
TI Preliminary Effectiveness of Auricular Point Acupressure on Chemotherapy-Induced Neuropathy: Part 1 Self-Reported Outcomes
SO PAIN MANAGEMENT NURSING
LA English
DT Article
ID induced peripheral neuropathy; inhibitor-induced arthralgia; breast-cancer survivors; quality-of-life; chronic-pain; psychological distress; american-society; risk-factors; health; management
AB Purpose: To reduce chemotherapy-induced neuropathy (CIN)-a significant challenge among cancer patients following chemotherapy-we explored the effects of auricular point acupressure (APA), which involves needleless, acupuncture-like stimulation on specific ear points. Design/Method: This pilot study examined the effects of a 4-week APA intervention in the management of CIN. Descriptive analysis was used to examine the changes in study outcomes. Results: Fifteen participants were enrolled. Two participants dropped out because they developed new medical conditions. Thirteen participants completed the study (87% retention rate). Study participants had more severe symptoms in their lower extremities (i.e., toes, feet, soles) than in their upper extremities (i.e., fingers, wrists, elbows). After the 4-week APA intervention, the mean percentage change scores ranged from 38% (tingling) to 49% (numbness); compared to pre-intervention, the therapeutic effects of APA were sustained at the 1-month follow-up. Function in both upper and lower extremities improved after the APA intervention (>= 28%) and continued to improve at the 1-month follow-up (>= 36%). Conclusions: Preliminary results from this small sample provide initial evidence of the effectiveness of APA on CIN. Future studies should confirm these results using a larger sample, a comparative sham control, and an examination of the underlying physiological mechanisms of the anti-CIN effects of APA. Clinical Implications: APA may provide an inexpensive and effective complementary approach for the self-management of CIN. Once the seeds have been taped to the patient's ear by the provider, patients are empowered to self-manage their CIN in their own environment. (C) 2019 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights reserved.
C1 [Yeh, Chao Hsing; Lukkahatai, Nada; Mensah, Sylvanus; Garry, Courtney; Pinedo, Mariela] Johns Hopkins Univ, Sch Nursing, 525 N Wolfe St,Room 421, Baltimore, MD 21205 USA.
   [Campbell, Claudia] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
   [Sair, Haris] Johns Hopkins Univ, Sch Med, Dept Radiol, 600 N Wolfe St,Phipps 455, Baltimore, MD 21205 USA.
   [Zhang, Fengzhi] Zhengzhou Univ, Affiliated Hosp 3, Dept Gynecol, Zhengzhou, Henan, Peoples R China.
   [Zeng, Jing] Chengdu Med Coll, Sch Nursing, Chengdu, Sichuan, Peoples R China.
   [Chen, Changying] Zhengzhou Univ, Nursing Coll, 100 Sci Ave, Zhengzhou, Henan, Peoples R China.
   [Khoshnoodi, Mohammad] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Smith, Thomas J.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   [Saligan, Leorey N.] NINR, NIH, Bethesda, MD 20892 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Zhengzhou University; Chengdu Medical College; Zhengzhou University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Nursing Research (NINR)
RP Yeh, CH (corresponding author), Johns Hopkins Univ, Sch Nursing, 525 N Wolfe St,Room 421, Baltimore, MD 21205 USA.
EM cyeh13@jhu.edu
FU Johns Hopkins Discovery Award
CR Alimi D, 2002, MED ACUPUNCT, V13, P18
   Unknown -, 1997, MANUAL FUNCTIONAL AS, V0, P0
   Unknown -, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Unknown -, 1991, WHO TECHNICAL WORKING GROUP REPORT, V0, P0
   Unknown -, 2005, AURICULAR MEDICINE: A COMPLETE MANUAL OF AURICULAR DIAGNOSIS AND TREATMENT, V0, P0
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Beaton DE, 2005, J BONE JOINT SURG AM, V87A, P1038, DOI 10.2106/JBJS.D.02060
   Bellamy N, 2002, WOMAC OSTEOARTHRITIS INDEX USER GUIDE, V0, P0
   Bellingham GA, 2010, REGION ANESTH PAIN M, V35, P294, DOI 10.1097/AAP.0b013e3181df2645
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Brier MJ, 2015, CANCER-AM CANCER SOC, V121, P2808, DOI 10.1002/cncr.29407
   Campbell CM, 2009, TRANSL RES, V153, P97, DOI 10.1016/j.trsl.2008.12.002
   Candiotti KA, 2010, CURR MED RES OPIN, V26, P1677, DOI 10.1185/03007995.2010.483941
   Carullo Veronica, 2015, J PAIN PALLIAT CARE PHARMACOTHER, V29, P378, DOI 10.3109/15360288.2015.1082006
   Cashion AK, 2015, NURS OUTLOOK, V63, P484, DOI 10.1016/j.outlook.2015.03.001
   CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5
   Chen Lucy, 2014, J OPIOID MANAG, V10, P383, DOI 10.5055/jom.2014.0235
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Desai K, 2013, SUPPORT CARE CANCER, V21, P43, DOI 10.1007/s00520-012-1490-z
   Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Dublin S, 2015, J AM GERIATR SOC, V63, P1519, DOI 10.1111/jgs.13562
   Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581
   Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580
   Gilron I, 2015, PAIN, V156, P1440, DOI 10.1097/j.pain.0000000000000149
   Hays RD, 2018, QUAL LIFE RES, V27, P1885, DOI 10.1007/s11136-018-1842-3
   Hays RD, 2016, PHARMACOECONOMICS, V34, P1015, DOI 10.1007/s40273-016-0408-x
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Huang L, 2007, HANDBOOK OF AURICULAR TREATMENT PRESCRIPTIONS & FORMULAR ORLANDO FL, V0, P0
   Hurst H, 2004, J MANIP PHYSIOL THER, V27, P26, DOI 10.1016/j.jmpt.2003.11.003
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Kennedy CA, 2013, QUAL LIFE RES, V22, P2509, DOI 10.1007/s11136-013-0362-4
   Kleckner IR, 2018, SUPPORT CARE CANCER, V26, P1019, DOI 10.1007/s00520-017-4013-0
   Laroche F, 2014, J PAIN, V15, P293, DOI 10.1016/j.jpain.2013.11.004
   Lumley MA, 2011, J CLIN PSYCHOL, V67, P942, DOI 10.1002/jclp.20816
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Maixner W, 2016, J PAIN, V17, PT93, DOI 10.1016/j.jpain.2016.06.002
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Markovitz LC, 2017, PSYCHO-ONCOLOGY, V26, P2294, DOI 10.1002/pon.4362
   Miaskowski C, 2017, J PAIN SYMPTOM MANAG, V54, P204, DOI 10.1016/j.jpainsymman.2016.12.342
   Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071
   Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036
   National Center for Complementary and Integrative Health, 2015, CHRONIC PAIN, V0, P0
   Nogier P, 1987, POINTS REFLEXES AURI, V0, P0
   Nogier P, 1981, HDB AURICULOTHERAPY, V0, P0
   Nogier R, 2014, MED ACUPUNCT, V26, P76, DOI 10.1089/acu.2014.1035
   Otte JL, 2010, J PAIN SYMPTOM MANAG, V39, P535, DOI 10.1016/j.jpainsymman.2009.07.004
   Pergolizzi Joseph, 2008, PAIN PRACT, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x
   Pike CT, 2012, CHEMOTHERAPY RES PRA, V0, P12
   Pinsker E, 2015, FOOT ANKLE INT, V36, P617, DOI 10.1177/1071100714566624
   Poulsen JL, 2015, THER ADV GASTROENTER, V8, P360, DOI 10.1177/1756283X15589526
   Romoli M, 2014, NEUROL SCI, V35, PS189, DOI 10.1007/s10072-014-1768-7
   Rosenquist RW, 2010, ANESTHESIOLOGY, V112, P810, DOI 10.1097/ALN.0b013e3181c43103
   Schapira MM, 2014, SUPPORT CARE CANCER, V22, P1207, DOI 10.1007/s00520-013-2073-3
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shah A, 2018, J NEUROL NEUROSUR PS, V89, P636, DOI 10.1136/jnnp-2017-317215
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Takei H, 2012, BREAST CANCER RES TR, V133, P227, DOI 10.1007/s10549-011-1943-y
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Yeh CH, 2017, ONCOL NURS FORUM, V44, P476, DOI 10.1188/17.ONF.476-487
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2015, PAIN MED, V16, P1857, DOI 10.1111/pme.12789
   Yeh CH, 2015, PAIN MANAG NURS, V16, P285, DOI 10.1016/j.pmn.2014.08.005
   Yeh CH, 2013, MED ACUPUNCT, V25, P423, DOI 10.1089/acu.2013.1006
   Yeh CH, 2014, MED ACUPUNCT, V26, P148, DOI 10.1089/acu.2014.1026
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/934670
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/375173
   Yeh CH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/196978
   Yeh CH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/383257
NR 72
TC 16
Z9 18
U1 2
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1524-9042
EI 1532-8635
J9 PAIN MANAG NURS
JI Pain Manag. Nurs.
PD DEC 15
PY 2019
VL 20
IS 6
BP 614
EP 622
DI 10.1016/j.pmn.2019.04.005
PG 9
WC Nursing
SC Nursing
GA JT1CH
UT WOS:000500735600014
PM 31155279
DA 2026-01-16
ER

PT J
AU Badel, T
   Zadravec, D
   Bašić, Kes V
   Smoljan, M
   Kocijan, Lovko S
   Zavoreo, I
   Krapac, L
   Anić, Milošević S
AF Badel, Tomislav
   Zadravec, Dijana
   Bašić Kes, Vanja
   Smoljan, Mia
   Kocijan Lovko, Sandra
   Zavoreo, Iris
   Krapac, Ladislav
   Anić Milošević, Sandra
TI OROFACIAL PAIN - DIAGNOSTIC AND THERAPEUTIC CHALLENGES.
SO Acta clinica Croatica
LA English
DT Journal Article
DE anxiety; orofacial pain; temporomandibular joint; trigeminal neuralgia
AB The concept of diagnostics and therapy of musculoskeletal and neuropathic  diseases of the stomatognathic system, which are the subject of this paper, has  been developing for decades. It can be said that in order to avoid  misunderstanding, the orofacial pain as a clinical problem, in the narrower  sense, involves non-odontogenic and non-malignant causes of orofacial region. In  this study, the results of clinical diagnosis of the population of 557  consecutive patients with orofacial pain based on multidisciplinary diagnostics  were evaluated. 15.6% of patients have given up on the participation in the  study. It has been shown that the patients who dropped out of the study were  significantly older (p=0.0411) than those who agreed to participate, but there  was no difference in gender ratio (p=0.185) since the proportion of female  patients prevailed. In an analysis of 84.4% of patients participating in the  study, the elevated anxiety values were established (mean value on STAI 1 was  39.2 and STAI 2 was 41.1) and statistical significance was found in correlation  between elevated anxiety and intensity of pain as shown on visual analogue scale  on open mouth (p<0.0001). Compared to the age, the statistical significance was  for STAI 1 (p=0.0097) but not for STAI 2 (p=0.5599). The most common form of  therapy is Michigan stabilization splint: for disc displacement of  temporomandibular joint (TMJ) in 38.9% of patients and in combination with  physiotherapy in 18.7% of patients; for osteoarthritis of TMJ in 28.4% and in  combination with physiotherapy in 26.4% of patients. The treatment with  anticonvulsant drugs for trigeminal neuralgia predominates in 54.3% of patients,  which is combined with acupuncture in 25.7% of patients and only acupuncture in  17.1% of patients. In this study, a multidisciplinary co-operation in initial  diagnostics and differential was designed to develop subspecialist knowledge on  orofacial pain.
C1 1Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
   2Department of Diagnostic and Interventional Radiology,Sestre milosrdnice University Hospital Center, University of Zagreb, Zagreb,Croatia
   3Department of Neurology, Sestre milosrdnice University Hospital Center,University of Zagreb, Zagreb, Croatia
   4Psychiatry Hospital "Sv Ivan", Zagreb,Croatia
   5Academy of Medical Sciences of Croatia, Department of Public Health,Zagreb, Croatia
   6Department of Orthodontics, School of Dental Medicine,University of Zagreb, Zagreb, Croatia.
   1Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
   2Department of Diagnostic and Interventional Radiology,Sestre milosrdnice University Hospital Center, University of Zagreb, Zagreb,Croatia
   3Department of Neurology, Sestre milosrdnice University Hospital Center,University of Zagreb, Zagreb, Croatia
   4Psychiatry Hospital "Sv Ivan", Zagreb,Croatia
   5Academy of Medical Sciences of Croatia, Department of Public Health,Zagreb, Croatia
   6Department of Orthodontics, School of Dental Medicine,University of Zagreb, Zagreb, Croatia.
   1Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
   2Department of Diagnostic and Interventional Radiology,Sestre milosrdnice University Hospital Center, University of Zagreb, Zagreb,Croatia
   3Department of Neurology, Sestre milosrdnice University Hospital Center,University of Zagreb, Zagreb, Croatia
   4Psychiatry Hospital "Sv Ivan", Zagreb,Croatia
   5Academy of Medical Sciences of Croatia, Department of Public Health,Zagreb, Croatia
   6Department of Orthodontics, School of Dental Medicine,University of Zagreb, Zagreb, Croatia.
   1Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
   2Department of Diagnostic and Interventional Radiology,Sestre milosrdnice University Hospital Center, University of Zagreb, Zagreb,Croatia
   3Department of Neurology, Sestre milosrdnice University Hospital Center,University of Zagreb, Zagreb, Croatia
   4Psychiatry Hospital "Sv Ivan", Zagreb,Croatia
   5Academy of Medical Sciences of Croatia, Department of Public Health,Zagreb, Croatia
   6Department of Orthodontics, School of Dental Medicine,University of Zagreb, Zagreb, Croatia.
   1Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
   2Department of Diagnostic and Interventional Radiology,Sestre milosrdnice University Hospital Center, University of Zagreb, Zagreb,Croatia
   3Department of Neurology, Sestre milosrdnice University Hospital Center,University of Zagreb, Zagreb, Croatia
   4Psychiatry Hospital "Sv Ivan", Zagreb,Croatia
   5Academy of Medical Sciences of Croatia, Department of Public Health,Zagreb, Croatia
   6Department of Orthodontics, School of Dental Medicine,University of Zagreb, Zagreb, Croatia.
   1Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
   2Department of Diagnostic and Interventional Radiology,Sestre milosrdnice University Hospital Center, University of Zagreb, Zagreb,Croatia
   3Department of Neurology, Sestre milosrdnice University Hospital Center,University of Zagreb, Zagreb, Croatia
   4Psychiatry Hospital "Sv Ivan", Zagreb,Croatia
   5Academy of Medical Sciences of Croatia, Department of Public Health,Zagreb, Croatia
   6Department of Orthodontics, School of Dental Medicine,University of Zagreb, Zagreb, Croatia.
   1Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
   2Department of Diagnostic and Interventional Radiology,Sestre milosrdnice University Hospital Center, University of Zagreb, Zagreb,Croatia
   3Department of Neurology, Sestre milosrdnice University Hospital Center,University of Zagreb, Zagreb, Croatia
   4Psychiatry Hospital "Sv Ivan", Zagreb,Croatia
   5Academy of Medical Sciences of Croatia, Department of Public Health,Zagreb, Croatia
   6Department of Orthodontics, School of Dental Medicine,University of Zagreb, Zagreb, Croatia.
   1Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
   2Department of Diagnostic and Interventional Radiology,Sestre milosrdnice University Hospital Center, University of Zagreb, Zagreb,Croatia
   3Department of Neurology, Sestre milosrdnice University Hospital Center,University of Zagreb, Zagreb, Croatia
   4Psychiatry Hospital "Sv Ivan", Zagreb,Croatia
   5Academy of Medical Sciences of Croatia, Department of Public Health,Zagreb, Croatia
   6Department of Orthodontics, School of Dental Medicine,University of Zagreb, Zagreb, Croatia.
NR 0
TC 0
SN 1333-945
EI 0353-946
J9 Acta Clin Croat
PD NOV 20
PY 2019
VL 58
IS Suppl 1
BP 82
EP 89
DI 10.20471/acc.2019.58.s1.12
PG 7
WC Acupuncture Therapy; Adolescent; Adult; Aged; Aged, 80 and over; Anxiety; etiology; Child; Facial Pain; etiology; Female; Humans; Male; Middle Aged; Osteoarthritis; complications; Pain Measurement; Physical Therapy Modalities; Temporomandibular Joint; Temporomandibular Joint Disorders; complications; Trigeminal Neuralgia; complications; Young Adult
UT PubMed:31741564
PM 31741564
DA 2019-11-20
ER

PT J
AU Shin, S
   Jang, BH
   Park, SH
   Lee, JW
   Chae, MS
   Kim, N
   Suh, HS
   Han, S
   Min, SY
   Baek, SK
   Lim, YJ
   Hwang, DS
AF Shin, Seungwon
   Jang, Bo-Hyoung
   Park, Seung-Hyeok
   Lee, Jin-Wook
   Chae, Min Soo
   Kim, Namhoon
   Suh, Hae Sun
   Han, Sola
   Min, Sun Young
   Baek, Sun Kyung
   Lim, Yu Jin
   Hwang, Deok-Sang
TI Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy
SO Medicine
LA English
DT Journal Article
AB INTRODUCTION: This study is a prospective, assessor-blinded, parallel-group,  randomized controlled pilot trial to explore the effectiveness of 12-week  adjuvant moxibustion therapy for arthralgia in menopausal females at stage I to  III breast cancer on aromatase inhibitor (AI) administration, compared with those  receiving usual care. METHODS/DESIGN: Forty-six menopausal female patients with  breast cancer who completed cancer therapy will be randomly allocated to either  adjuvant moxibustion or usual care groups with a 1:1 allocation ratio. The  intervention group will undergo 24 sessions of adjuvant moxibustion therapy with  usual care for 12 weeks, whereas the control group will receive only usual care  during the same period. The usual care consists of acetaminophen administration  on demand and self-directed exercise education to manage AI-related joint pain.  The primary outcome is the mean change of the worst pain level according to the  Brief Pain Inventory-Short Form between the initial visit and the endpoint. The  mean changes in depression, fatigue, and quality of life will also be compared  between groups. Safety and pharmacoeconomic evaluations will also be included.  DISCUSSION: Continuous variables will be compared by an independent t test or  Wilcoxon rank-sum test between the adjuvant moxibustion and usual care groups.  Adverse events will be analyzed using the chi-square or Fisher exact test. The  statistical analysis will be performed by a 2-tailed test at a significance level  of .05.
C1 Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University.
   Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University.
   Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul.
   Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul.
   Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul.
   Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul.
   Pharmaceutical Economics, Outcomes Research and Policy, Pusan National University, Busan.
   College of Pharmacy, Pusan National University, Busan.
   Department of Surgery, College of Medicine, Kyung Hee University.
   Department of Internal Medicine, College of Medicine, Kyung Hee University.
   Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine.
   Department of Korean Obstetrics & Gynecology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD OCT 1
PY 2019
VL 98
IS 38
BP e17260
EP e17260
DI 10.1097/MD.0000000000017260
PG 1
WC Aged; Female; Humans; Middle Aged; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Cost-Benefit Analysis; Health Care Costs; Moxibustion; adverse effects; Pilot Projects; Postmenopause; Treatment Outcome; Randomized Controlled Trials as Topic
UT PubMed:31568000
PM 31568000
DA 2019-10-01
ER

PT J
AU Chen, Y
   Li, LQ
   Wang, MH
   Li, WQ
   Zhang, Q
   Zhang, HF
   Ge, YL
AF Chen, Yi
   Li, Li Q
   Wang, Meng H
   Li, Wen Q
   Zhang, Qian
   Zhang, Hai F
   Ge, Yan L
TI Elevated D-Dimer Combined with Persistent Acupuncture-like Chest Pain in An
SO Clinical laboratory
LA English
DT Review
AB BACKGROUND: Pulmonary hamartoma is one of the most common benign tumors of the  lung, the symptoms are often atypical, so its diagnosis is not so easy. We  presented an elderly man with elevated D-dimer combined persistent  acupuncture-like chest pain misdiagnosed as pulmonary embolism finally proved as  lung hamartoma with secondary lung infection by bronchoscopy biopsy. METHODS:  Appropriate laboratory tests were carried out. The chest computed tomography (CT)  scan and bronchoscopy were performed for diagnosis. RESULTS: Laboratory tests  showed D-dimer was 2,615.88 ng/mL, the chest CT scan showed the right lung portal  occupying lesions accompanied by obstructive changes in the middle of the right  lung and mediastinal lymphade-nopathy with partial calcification. Bronchoscopy  showed the new spherical neoplasm in the middle of the right lung completely  blocked the opening of the bronchus, the surface of the neoplasm was smooth and  blood vessels were abundant, pathological result was lung hamartoma. CONCLUSIONS:  Elevated D-dimer is not a specific index of pulmonary embolism. When a patient's  D-dimer rise combined with severe chest pain, the physician should be wary of  pulmonary embolism, myocardial infarction, aortic dissection, and other  emergencies, and should also take into account serious infections, tumors, and  other diseases. Diagnosis needs further related examination. Chest CT scan has  guidance function, and when the chest CT scan suggests the occupying lesion, the  pathology examination is the key to identify the benign tumor.
NR 0
TC 0
SN 
EI 1433-651
J9 Clin Lab
PD SEP 19
PY 2019
VL 65
IS 9
BP 
EP 
DI 10.7754/Clin.Lab.2019.190306
PG 0
WC Aged; Bronchoscopy; Chest Pain; diagnosis; Diagnosis, Differential; Diagnostic Errors; Fibrin Fibrinogen Degradation Products; metabolism; Hamartoma; diagnosis; Humans; Lung Neoplasms; diagnosis; Male; Pulmonary Embolism; diagnosis; Respiratory Tract Infections; diagnosis
UT PubMed:31532091
PM 31532091
DA 2019-09-19
ER

PT J
AU Ren, ZQ
   Wang, Y
   Zhu, WH
   Dou, HM
   Cao, XH
   Hong, H
   Azhen,
AF Ren Zhenqing
   Wang Yan
   Zhu Weihua
   Dou Hongmei
   Cao Xiuhong
   Hong Hua
   Yuan Azhen
TI Efficacy of acupoint massage combined with acupoint application on arterial blood gas in patients undergoing laparoscopic cholecystectomy
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Acupoint massage; acupoint application; blood gas; laparoscopic cholecystectomy The NCT number of original study was NCT02096835
ID postoperative nausea; lung-cancer; surgery
AB To explore efficacy of acupoint massage combined with acupoint application on arterial blood gas and postoperative complications for patients undergoing laparoscopic cholecystectomy. Patients undergoing laparoscopic cholecystectomy (LC) in general anesthesia condition were randomly enrolled from local hospital into control group and experimental group. Four acupuncture points were prepared for acupoint massage and acupoint application, including bilateral Hegu acupoint (LI4), Neiguan Point (PC6), Zusanli Point (ST36) and Tanzhong acupoint (CV17). All patients in experimental group were treated with point acupressure treatment combined with acupoint application before LC, while control group directly receive LC surgery. The peak inspiratory pressure (PIP), end-tidal CO2 pressure (PETCO2), oxygen saturation (SpO(2)) and pH were examined at multiple time points during LC surgery. Related postoperative complications were documented for further analysis. All data were analyzed to assess efficacy of acupoint massage combined with acupoint application on arterial blood gas. There is no difference in baseline condition between experimental group and control group. Compared with control group, PetCO(2) and SpO(2) in experimental group were significantly increased while PIP was decreased. PH in experimental group ranged in a more stable domain. Hypercapnia and deep venous thrombosis were mitigated in experimental group compared with control group. Moreover, multiple pneumoperitoneum-related complications were alleviated after combined treatment, including pain and frequency of nausea and vomiting. Acupoint massage combined with acupoint application ameliorated related postoperative complications, and reduced side events of LC surgery via improving carbon dioxide metabolism.
C1 [Ren Zhenqing; Wang Yan; Zhu Weihua; Dou Hongmei; Cao Xiuhong; Hong Hua] Taizhou Peoples Hosp, Operat Dept, Taizhou, Peoples R China.
   [Yuan Azhen] Taizhou Peoples Hosp, Nursing Dept, Taizhou, Peoples R China.
RP Azhen, (corresponding author), Taizhou Peoples Hosp, Nursing Dept, Taizhou, Peoples R China.
EM yuanazhendr@163.com
FU Medical Clinical Science and Technology Development Funding of Jiangsu University, China
CR Akbarzade Marzieh, 2016, J REPROD INFERTIL, V17, P39
   Akbarzadeh Marzieh, 2014, INT J COMMUNITY BASED NURS MIDWIFERY, V2, P112
   Antor MA, 2014, FRONT PHARMACOL, V5, P0, DOI 10.3389/fphar.2014.00055
   Braga ELC, 2019, EUR J ANAESTH, V36, P241, DOI 10.1097/EJA.0000000000000932
   Fathy M, 2019, OBES SURG, V29, P1614, DOI 10.1007/s11695-019-03762-2
   Giménez ME, 2018, ABCD-ARQ BRAS CIR DI, V31, P0, DOI 10.1590/0102-672020180001e1380
   Grillo CM, 2014, J ACUPUNCT MERIDIAN, V7, P65, DOI 10.1016/j.jams.2013.03.005
   Kim HJ, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000014339
   Li Y, 2017, J CANCER RES THER, V13, P844, DOI 10.4103/jcrt.JCRT_709_17
   Liu BY, 2018, CHIN J INTEGR MED, V24, P260, DOI 10.1007/s11655-018-2798-4
   Lu Chao, 2019, ZHONGGUO ZHEN JIU, V39, P9, DOI 10.13703/j.0255-2930.2019.01.002
   Luo J, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0676-6
   Mayberry John F, 2018, MED LEG J, V86, P23, DOI 10.1177/0025817217734482
   Mehta Piyush, 2015, J TRADIT COMPLEMENT MED, V5, P127, DOI 10.1016/j.jtcme.2014.11.036
   Meng Xin-liang, 2016, ZHEN CI YAN JIU, V41, P74
   Ng JY, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1410-8
   Niemtzow R, 2018, MIL MED, V183, PE486, DOI 10.1093/milmed/usy028
   Rozenfeld E, 2016, J BODYW MOV THER, V20, P173, DOI 10.1016/j.jbmt.2015.11.009
   Shu Q, 2016, FORSCH KOMPLEMENTMED, V23, P336, DOI 10.1159/000448207
   Wang Q, 2015, INT J CARDIOL, V194, P28, DOI 10.1016/j.ijcard.2015.05.043
   Wildes TS, 2019, JAMA-J AM MED ASSOC, V321, P473, DOI 10.1001/jama.2018.22005
   Yao L, 2017, SURG LAPARO ENDO PER, V27, P346, DOI 10.1097/SLE.0000000000000463
   Yeoh AH, 2016, TURK J MED SCI, V46, P620, DOI 10.3906/sag-1502-56
   Youssef N, 2014, ANESTH ANALG, V119, P965, DOI 10.1213/ANE.0000000000000377
   Zhang LL, 2016, J PAIN SYMPTOM MANAG, V51, P504, DOI 10.1016/j.jpainsymman.2015.11.020
NR 25
TC 4
Z9 5
U1 1
U2 24
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011-601X
EI 
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD MAY 15
PY 2019
VL 32
IS 3
BP 1375
EP 1380
DI 
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA IF7GI
UT WOS:000473249100015
PM 31551218
DA 2026-01-16
ER

PT J
AU Chen, Y
   Li, LQ
   Wang, MH
   Li, WQ
   Zhang, Q
   Zhang, HF
   Ge, YL
AF Chen, Yi
   Li, Li Q.
   Wang, Meng H.
   Li, Wen Q.
   Zhang, Qian
   Zhang, Hai F.
   Ge, Yan L.
TI Elevated D-Dimer Combined with Persistent Acupuncture-like Chest Pain in An Elderly Patient Misdiagnosed as Pulmonary Embolism Finally Proved as Lung Hamartoma with Secondary Lung Infection by Bronchoscopy Biopsy: a Case Report and Literature Review
SO CLINICAL LABORATORY
LA English
DT Review
DE pulmonary embolism; D-dimer; pulmonary hamartoma; bronchoscopy; pathology; treatment
ID endobronchial hamartoma; diagnosis
AB Background: Pulmonary hamartoma is one of the most common benign tumors of the lung, the symptoms are often atypical, so its diagnosis is not so easy. We presented an elderly man with elevated D-dimer combined persistent acupuncture-like chest pain misdiagnosed as pulmonary embolism finally proved as lung hamartoma with secondary lung infection by bronchoscopy biopsy. Methods: Appropriate laboratory tests were carried out. The chest computed tomography (CT) scan and bronchoscopy were performed for diagnosis. Results: Laboratory tests showed D-dimer was 2,615.88 ng/mL, the chest CT scan showed the right lung portal occupying lesions accompanied by obstructive changes in the middle of the right lung and mediastinal lymphadenopathy with partial calcification. Bronchoscopy showed the new spherical neoplasm in the middle of the right lung completely blocked the opening of the bronchus, the surface of the neoplasm was smooth and blood vessels were abundant, pathological result was lung hamartoma. Conclusions: Elevated D-dimer is not a specific index of pulmonary embolism. When a patient's D-dimer rise combined with severe chest pain, the physician should be wary of pulmonary embolism, myocardial infarction, aortic dissection, and other emergencies, and should also take into account serious infections, tumors, and other diseases. Diagnosis needs further related examination. Chest CT scan has guidance function, and when the chest CT scan suggests the occupying lesion, the pathology examination is the key to identify the benign tumor.
C1 [Chen, Yi; Li, Li Q.; Li, Wen Q.; Zhang, Qian; Zhang, Hai F.; Ge, Yan L.] North China Univ Sci & Technol, Affiliated Hosp, Dept Resp Med, Jianshe Rd 73, Tangshan 063000, Hebei, Peoples R China.
   [Wang, Meng H.] North China Univ Sci & Technol, Affiliated Hosp, Dept Hosp Informat Management, Tangshan, Hebei, Peoples R China.
C3 North China University of Science & Technology; North China University of Science & Technology
RP Ge, YL (corresponding author), North China Univ Sci & Technol, Affiliated Hosp, Dept Resp Med, Jianshe Rd 73, Tangshan 063000, Hebei, Peoples R China.
EM geyanlei1983@qq.com
FU Hebei Province Science Development Program [20180768]
CR Ahmed S, 2017, RESPIR MED CASE REP, V22, P224, DOI 10.1016/j.rmcr.2017.08.019
   Aktas Z, 2018, TUBERK TORAK, V66, P312, DOI 10.5578/tt.67434
   Bhargavan M, 2010, AM J ROENTGENOL, V194, P1018, DOI 10.2214/AJR.09.3215
   Boda Zoltan, 2002, ORVOSI HETILAP, V143, P2717
   Cosío BG, 2002, CHEST, V122, P202, DOI 10.1378/chest.122.1.202
   Cosmi Benilde, 2003, SEMIN VASC MED, V3, P303
   Dimitrakakis G, 2014, J BUON, V19, P60
   Doherty S, 2017, AUST FAM PHYSICIAN, V46, P816
   Jiang L, 2018, ONCOL LETT, V16, P660, DOI 10.3892/ol.2018.8660
   Kline JA, 2002, ANN EMERG MED, V39, P144, DOI 10.1067/mem.2002.121398
   Liu C, 2017, THER ADV RESPIR DIS, V11, P435, DOI 10.1177/1753465817736745
   Lucassen W, 2011, ANN INTERN MED, V155, P448, DOI 10.7326/0003-4819-155-7-201110040-00007
   Matsuda Eisuke, 2010, KYOBU GEKA, V63, P875
   Miranda-Bacallado J, 2019, J MED CASE REP, V13, P0, DOI 10.1186/s13256-019-1994-y
   Miyaoka Masashi, 2018, TOKAI J EXP CLIN MED, V43, P1
   Nazerian P, 2017, ACAD EMERG MED, V24, P270, DOI 10.1111/acem.13130
   Oshima Yutaka, 2018, KYOBU GEKA, V71, P142
   Uhlén N, 2016, CLIN NUCL MED, V41, P263, DOI 10.1097/RLU.0000000000001114
   Weiss CR, 2006, ACAD RADIOL, V13, P434, DOI 10.1016/j.acra.2006.01.002
   Wu JI, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-018-37443-4
NR 20
TC 1
Z9 1
U1 0
U2 6
PU CLIN LAB PUBL
PI HEIDELBERG
PA IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY
SN 1433-6510
EI 
J9 CLIN LAB
JI Clin. Lab.
PD JUN 15
PY 2019
VL 65
IS 9
BP 1763
EP 1766
DI 10.7754/Clin.Lab.2019.190306
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA IY4TZ
UT WOS:000486387200025
PM 31532091
DA 2026-01-16
ER

PT J
AU Lu, J
   Zhang, Z
AF Lu, Jing
   Zhang, Zhaohui
TI [Review and prospect of clinical application of ear-acupuncture treating
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Review
DE anxiety-depression; breast cancer; ear-acupuncture; joint pain; nausea and vomiting; review; sleep disorders
AB To analyze the application of ear-acupuncture for post-operative syndromes of  breast cancer so as to provide method and evidence for the syndromes. The related  clinical literature was retrieved from CNKI, WANFANG and VIP databases from the  database establishment time to August 30, 2017. We found ear-acupuncture are  mainly used in treating nausea and vomiting caused by radiation and chemotherapy  (shenmen (TF(4)), jiaogan (AH(6a)), wei (CO(4)), pi (CO(13)), etc), insomnia in  the rehabilitation period (xin (CO(15)), pizhixia (AT(4)), shenmen (TF(4)), etc),  depression and anxiety (pizhixia (AT(4)), shenmen (TF(4)), pi (CO(13)), wei  (CO(4)), xin (CO(15)), gan (CO(12)), etc), and joint pain (pain point), etc.
C1 Departmeng of Acupuncture and Moxibustion, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
   Departmeng of Acupuncture and Moxibustion, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JAN 24
PY 2019
VL 38
IS 11
BP 1249
EP 54
DI 10.13703/j.0255-2930.2018.11.031
PG -1195
WC Acupuncture Points; Acupuncture, Ear; Breast Neoplasms; Humans; Postoperative Period; Syndrome
UT PubMed:30672210
PM 30672210
DA 2019-01-24
ER

PT J
AU Zhao, XM
   Liu, L
   Wang, YK
   Wang, G
   Zhao, YK
   Zhang, Y
AF Zhao, Xiaoming
   Liu, Li
   Wang, Yuku
   Wang, Gang
   Zhao, Yingkai
   Zhang, Yao
TI Electroacupuncture Enhances Antioxidative Signal Pathway and Attenuates Neuropathic Pain Induced by Chemotherapeutic Paclitaxel
SO PHYSIOLOGICAL RESEARCH
LA English
DT Article
DE Electroacupuncture; Paclitaxel; Neuropathic pain; Nrf2-ARE; SOD; Oxidative stress
ID rat model; hyperalgesia; modulation; allodynia; responses; roles
AB One of the significant limiting complications of paclitaxel is painful peripheral neuropathy during its therapy for several types of cancers. Our recent study showed that impairment of Nrf2-antioxidant response element (Nrf2-ARE) and upregulation of oxidative signals in the dorsal root ganglion (DRG) of rats with treatment of paclitaxel result in neuropathic pain. The purpose of this study was to examine the beneficial role played by electroacupuncture (EA) in modifying neuropathic pain evoked by paclitaxel via Nrf2-ARE and oxidative mechanisms. Behavioral test was performed to determine mechanical and thermal sensitivity in rats. Western Blot analysis and ELISA were used to examine expression of Nrf2-ARE and superoxide dismutases (SOD); and the levels of products of oxidative stress in the DRG. Our data showed that paclitaxel increased mechanical and thermal sensitivity and this was accompanied with impaired Nrf2-ARE and SOD in the DRG and amplified products of oxidative stress (i.e. 8-isoprostaglandin Fla and 8-hydroxy-2'-deoxyguanosine). EA treatment largely restored the levels of Nrf2-ARE/SOD and inhibited products of oxidative stress and thereby attenuated mechanical and thermal hypersensitivity induced by paclitaxel. In conclusion, we revealed specific signaling pathways leading to paclitaxel-evoked neuropathic pain, including impairment of Nrf2-ARE and heightened oxidative signals. We further provided evidence for the role of EA in alleviating paclitaxel-neuropathic pain via these molecular mediators.
C1 [Zhao, Xiaoming; Liu, Li] Jilin Univ, Hosp 1, Tumor Ctr, Changchun, Jilin, Peoples R China.
   [Wang, Yuku] Jilin Heart Dis Hosp, Changchun, Jilin, Peoples R China.
   [Wang, Gang] Jilin Univ, Hosp 1, Div Operat, Changchun, Jilin, Peoples R China.
   [Zhao, Yingkai] Jilin Univ, Hosp 1, Dept Gerontol, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China.
   [Zhang, Yao] Jilin Univ, Hosp 1, Dept Thorac Surg, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Jilin University
RP Zhao, YK (corresponding author), Jilin Univ, Hosp 1, Dept Gerontol, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China.; Zhang, Y (corresponding author), Jilin Univ, Hosp 1, Dept Thorac Surg, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China.
EM ykz9798@163.com
CR Altenhöfer S, 2012, CELL MOL LIFE SCI, V69, P2327, DOI 10.1007/s00018-012-1010-9
   Unknown -, 2017, COCHRANE DATABASE SY, V0, P0
   Cata JP, 2008, BRAIN RES, V1229, P100, DOI 10.1016/j.brainres.2008.07.001
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen Y, 2011, NEUROSCIENCE, V193, P440, DOI 10.1016/j.neuroscience.2011.06.085
   Choi EM, 2012, CHIN MED-UK, V7, P0, DOI 10.1186/1749-8546-7-4
   DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5
   Dougherty PM, 2004, PAIN, V109, P132, DOI 10.1016/j.pain.2004.01.021
   Duggett NA, 2016, NEUROSCIENCE, V333, P13, DOI 10.1016/j.neuroscience.2016.06.050
   Fidanboylu M, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0025212
   Gavazzi G, 2006, FEBS LETT, V580, P497, DOI 10.1016/j.febslet.2005.12.049
   Ghersi D, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003366.pub3
   Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287
   Griffiths LA, 2015, J PAIN, V16, P981, DOI 10.1016/j.jpain.2015.06.008
   Hanna M, 2013, CANCER PAIN, V0, P0
   Hoskin PJ, 2008, CLINICAL PAIN MANAGEMENT: CANCER PAIN, V2nd, P251, DOI 10.1201/b13440-19
   Janes K, 2013, PAIN, V154, P2432, DOI 10.1016/j.pain.2013.07.032
   Kallenborn-Gerhardt W, 2012, J NEUROSCI, V32, P10136, DOI 10.1523/JNEUROSCI.6227-11.2012
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892
   Kim HK, 2017, FRONT PHARMACOL, V7, P0, DOI 10.3389/fphar.2016.00532
   Kim HK, 2016, PAIN PHYSICIAN, V19, PE589, DOI 10.36076/ppj/2019.19.e589
   Kim JH, 2015, GYNECOL ONCOL, V136, P453, DOI 10.1016/j.ygyno.2015.01.524
   Kim SK, 2005, EXP NEUROL, V195, P430, DOI 10.1016/j.expneurol.2005.06.018
   Lam GY, 2010, SEMIN IMMUNOPATHOL, V32, P415, DOI 10.1007/s00281-010-0221-0
   Lee MS, 2011, CHIN J INTEGR MED, V17, P187, DOI 10.1007/s11655-011-0665-7
   Li P, 2006, AM J PHYSIOL-HEART C, V290, PH2535, DOI 10.1152/ajpheart.00972.2005
   Lujan HL, 2007, AM J PHYSIOL-HEART C, V292, PH2550, DOI 10.1152/ajpheart.00979.2006
   McDonald JL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/591796
   Miao H, 2019, PHYSIOL RES, V68, P491, DOI 10.33549/physiolres.933939
   Miller Richard J, 2009, HANDB EXP PHARMACOL, V0, PP417, DOI 10.1007/978-3-540-79090-7_12
   MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926
   Pasetto LM, 2006, CRIT REV ONCOL HEMAT, V59, P159, DOI 10.1016/j.critrevonc.2006.01.001
   Pittler MH, 2008, CLIN J PAIN, V24, P731, DOI 10.1097/AJP.0b013e3181759231
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Salvemini D, 2011, FREE RADICAL BIO MED, V51, P951, DOI 10.1016/j.freeradbiomed.2011.01.026
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Smith SB, 2004, LIFE SCI, V74, P2593, DOI 10.1016/j.lfs.2004.01.002
   Suzuki Y, 2012, SCI REP-UK, V2, P0, DOI 10.1038/srep00896
   Tanabe Y, 2013, INT J CLIN ONCOL, V18, P132, DOI 10.1007/s10147-011-0352-x
   WORTHLEY EG, 1969, TOXICOL APPL PHARM, V15, P275, DOI 10.1016/0041-008X(69)90027-1
   Zhou W, 2006, J APPL PHYSIOL, V100, P926, DOI 10.1152/japplphysiol.01130.2005
NR 42
TC 38
Z9 44
U1 2
U2 13
PU ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY
PI PRAGUE 4
PA VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC
SN 0862-8408
EI 1802-9973
J9 PHYSIOL RES
JI Physiol. Res.
PD JUN 15
PY 2019
VL 68
IS 3
BP 501
EP 510
DI 10.33549/physiolres.934084
PG 10
WC Physiology
SC Physiology
GA IK8FT
UT WOS:000476830200015
PM 30904013
DA 2026-01-16
ER

PT J
AU Gouveia, DN
   Guimaraes, AG
   Santos, WBD
   Quintans, LJ
AF Gouveia, Daniele Nascimento
   Guimaraes, Adriana Gibara
   da Rocha Santos, Wagner Barbosa
   Quintans-Junior, Lucindo Jose
TI Natural products as a perspective for cancer pain management: A systematic review
SO PHYTOMEDICINE
LA English
DT Review
DE Natural products; Cancer pain; Pain
ID tetracyclic triterpene euphol; tanshinone-iia; neuropathic pain; alpha-terpineol; essential oil; p-cymene; oxidative stress; in-vitro; beta-cyclodextrin; antitumor-activity
AB Background: Cancer is the leading cause of death in the world and one of the main symptoms affecting these individuals is chronic pain, which must be evaluated and treated in its various components. Several drugs are currently used, but beyond the high cost, they have harmful side effects to patients or are transitorily effective. Ergo, there is a need to look for new options for cancer pain relief. Natural products (NPs) present themselves as strong candidates for the development of new drugs for the treatment of chronic pain, such as cancer pain. Purpose: This systematic review aimed to summarize current knowledge about the analgesic profile of NPs in cancer pain. Methods: The search included PubMed, Scopus and Web of Science (from inception to June 2018) sought to summarize the articles studying new proposals with NPs for the management of oncological pain. Two independent reviewers extracted data on study characteristics, methods and outcomes. Results: After an extensive survey, 21 articles were selected, which described the analgesic potential of 15 natural compounds to relieve cancer pain. After analyzing the data, it can be suggested that these NPs, which have targets in central and peripheral mechanisms, are interesting candidates for the treatment of cancer pain for addressing different pharmacological mechanisms (even innovative), but ensuring the safety of these compounds is still a challenge. Likewise, the cannabinoids compounds leave the front as the most promising compounds for direct applicability due to the clinical studies that have already been developed and the background already established about these effects on chronic pain. Conclusion: Regarding these findings, it can be concluded that the variability of possible biological sites of action is strategic for new perspectives in the development of therapeutic proposals different from those available in the current market.
C1 [Gouveia, Daniele Nascimento; da Rocha Santos, Wagner Barbosa; Quintans-Junior, Lucindo Jose] Univ Fed Sergipe, Lab Neurociencias & Ensaios Farmacol LANEF, Dept Fisiol, Sao Cristovao, Sergipe, Brazil.
   [Guimaraes, Adriana Gibara] Univ Fed Sergipe, Dept Educ Saude, Av Governador Marcelo Deda 13, Lagarto, Sergipe, Brazil.
C3 Universidade Federal de Sergipe; Universidade Federal de Sergipe
RP Guimaraes, AG (corresponding author), Univ Fed Sergipe, Dept Educ Saude, Av Governador Marcelo Deda 13, Lagarto, Sergipe, Brazil.
EM adrianagibara@pq.cnpq.br
FU Foundation for Research and Technological Innovation Support of the State of Sergipe (Fundacao de Apoio a Pesquisa e Inovacao Tecnologica do Estado de Sergipe - FAPITEC/SE); National Council of Technological and Scientific Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq/Brazil); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES/Brazil)
CR Anjaneyulu M, 2003, PROG NEURO-PSYCHOPH, V27, P1001, DOI 10.1016/S0278-5846(03)00160-X
   Unknown -, 2012, BASIC CLIN PHARMACOL, V0, P0, DOI DOI 10.1111/J.1742-7843.2012.00875.X
   Araújo HG, 2017, NEUROSCIENCE, V358, P158, DOI 10.1016/j.neuroscience.2017.06.037
   Araújo HG, 2016, NEUROCHEM RES, V41, P647, DOI 10.1007/s11064-015-1771-2
   Bachewal P, 2018, BIOFACTORS, V44, P109, DOI 10.1002/biof.1397
   Betancur-Galvis LA, 2002, MEM I OSWALDO CRUZ, V97, P541, DOI 10.1590/S0074-02762002000400017
   Blake A, 2017, ANN PALLIAT MED, V6, PS215, DOI 10.21037/apm.2017.08.05
   Bonjardim LR, 2012, Z NATURFORSCH C, V67, P15, DOI 10.5560/ZNC.2012.67c0015
   Booz GW, 2011, FREE RADICAL BIO MED, V51, P1054, DOI 10.1016/j.freeradbiomed.2011.01.007
   Borghi SM, 2018, J NUTR BIOCHEM, V53, P81, DOI 10.1016/j.jnutbio.2017.10.010
   Brawley OW, 2009, CA-CANCER J CLIN, V59, P285, DOI 10.3322/caac.20030
   Brito RG, 2015, EXPERT OPIN DRUG DEL, V12, P1677, DOI 10.1517/17425247.2015.1046835
   Brown DC, 2015, PAIN, V156, P1018, DOI 10.1097/j.pain.0000000000000115
   Brown MRD, 2018, EUR J INTERN MED, V49, P30, DOI 10.1016/j.ejim.2018.01.020
   Bueno-Durán AY, 2014, J ESSENT OIL RES, V26, P153, DOI 10.1080/10412905.2013.840808
   Calgarotto AK, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-21516-5
   Calixto-Campos C, 2015, ANAL CELL PATHOL, V2015, P0, DOI 10.1155/2015/285708
   Campbell FA, 2001, BMJ-BRIT MED J, V323, P13, DOI 10.1136/bmj.323.7303.13
   Campos AC, 2012, PHILOS T R SOC B, V367, P3364, DOI 10.1098/rstb.2011.0389
   Cao FL, 2015, PHARMACOL BIOCHEM BE, V128, P1, DOI 10.1016/j.pbb.2014.11.004
   Cascella M, 2017, INFECT AGENTS CANCER, V12, P0, DOI 10.1186/s13027-017-0145-6
   Choi JI, 2012, NEUROSCI LETT, V510, P53, DOI 10.1016/j.neulet.2011.12.070
   Dagne E, 2000, J ESSENT OIL RES, V12, P467, DOI 10.1080/10412905.2000.9699567
   Dai WL, 2017, INT J CANCER, V141, P805, DOI 10.1002/ijc.30780
   de Oliveira MGB, 2015, EXPERT OPIN THER PAT, V25, P897, DOI 10.1517/13543776.2015.1045412
   de Santana MF, 2015, PHARM BIOL, V53, P1583, DOI 10.3109/13880209.2014.993040
   Souza MTD, 2017, BIOMED PHARMACOTHER, V96, P313, DOI 10.1016/j.biopha.2017.10.017
   Souza MTD, 2014, BASIC CLIN PHARMACOL, V115, P244, DOI 10.1111/bcpt.12221
   Dias DA, 2012, METABOLITES, V2, P0, DOI 10.3390/metabo2020303
   Ding XQ, 2021, NAT PROD RES, V35, P815, DOI 10.1080/14786419.2019.1598991
   Dutra RC, 2015, NEUROSCIENCE, V303, P126, DOI 10.1016/j.neuroscience.2015.06.051
   Dutra RC, 2012, NEUROPHARMACOLOGY, V63, P593, DOI 10.1016/j.neuropharm.2012.05.008
   Fallon MT, 2017, BRIT J PAIN, V11, P119, DOI 10.1177/2049463717710042
   Farfariello V, 2014, CHEM-BIOL INTERACT, V224, P128, DOI 10.1016/j.cbi.2014.10.020
   Farrell KE, 2014, INFLAMM BOWEL DIS, V20, P176, DOI 10.1097/01.MIB.0000437499.52922.b1
   Fu JJ, 2007, EUR J PHARMACOL, V568, P213, DOI 10.1016/j.ejphar.2007.04.031
   Gan LG, 2017, ONCOL LETT, V14, P6314, DOI 10.3892/ol.2017.6980
   Geraets L, 2007, J NUTR, V137, P2190, DOI 10.1093/jn/137.10.2190
   Gouveia DN, 2018, BIOMED PHARMACOTHER, V105, P652, DOI 10.1016/j.biopha.2018.06.027
   Grotenhermen F, 2012, DTSCH ARZTEBL INT, V109, P495, DOI 10.3238/arztebl.2012.0495
   Guimaraes AG, 2014, LIFE SCI, V116, P8, DOI 10.1016/j.lfs.2014.08.020
   Guimaraes AG, 2014, EXPERT OPIN THER PAT, V24, P243, DOI 10.1517/13543776.2014.870154
   Guimaraes AG, 2013, PHYTOTHER RES, V27, P1, DOI 10.1002/ptr.4686
   Guimaraes AG, 2015, CHEM-BIOL INTERACT, V227, P69, DOI 10.1016/j.cbi.2014.12.020
   Gunasekaran Thirumurugan, 2014, ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE, V4, PS1, DOI 10.12980/APJTB.4.2014C980
   Gupta SC, 2013, BIOCHEM PHARMACOL, V85, P898, DOI 10.1016/j.bcp.2012.12.018
   Hang LH, 2014, BASIC CLIN PHARMACOL, V115, P477, DOI 10.1111/bcpt.12265
   Hao W, 2016, PAIN PHYSICIAN, V19, P465
   Hashimotodani Y, 2007, NEUROSCIENTIST, V13, P127, DOI 10.1177/1073858406296716
   Hassan SB, 2010, ANTICANCER RES, V30, P1911
   Held S, 2007, J AGR FOOD CHEM, V55, P8040, DOI 10.1021/jf071691m
   Hill AJ, 2012, PHARMACOL THERAPEUT, V133, P79, DOI 10.1016/j.pharmthera.2011.09.002
   Hill KP, 2017, CANNABIS CANNABINOID, V2, P96, DOI 10.1089/can.2017.0017
   Hoyle GW, 2010, AM J PHYSIOL-LUNG C, V298, PL830, DOI 10.1152/ajplung.00014.2010
   Hsieh YL, 2018, EXP NEUROL, V300, P87, DOI 10.1016/j.expneurol.2017.10.026
   Hu XF, 2017, J NEUROINFLAMM, V14, P0, DOI 10.1186/s12974-017-0988-1
   Hu YH, 2017, MOLECULES, V22, P0, DOI 10.3390/molecules22060937
   Huang JQ, 2012, J PHARM PHARMACOL, V64, P1119, DOI 10.1111/j.2042-7158.2012.01504.x
   Huang Q, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0696-2
   Iffland K, 2017, CANNABIS CANNABINOID, V2, P139, DOI 10.1089/can.2016.0034
   Izzo AA, 2009, TRENDS PHARMACOL SCI, V30, P515, DOI 10.1016/j.tips.2009.07.006
   Jansen DJ, 2014, FUTURE MED CHEM, V6, P1127, DOI 10.4155/fmc.14.71
   Jha RN, 2009, NAT PROD RES, V23, P250, DOI 10.1080/14786410801996390
   Jia LJ, 2018, LIFE SCI, V208, P123, DOI 10.1016/j.lfs.2018.07.027
   Jiang W, 2017, PHYTOTHER RES, V31, P1298, DOI 10.1002/ptr.5849
   Jin H, 2014, INT J ONCOL, V45, P1629, DOI 10.3892/ijo.2014.2535
   Kawata J, 2008, J NAT MED-TOKYO, V62, P239, DOI 10.1007/s11418-007-0221-0
   Khalil Z, 2004, J INVEST DERMATOL, V123, P683, DOI 10.1111/j.0022-202X.2004.23407.x
   Khan I, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-017-18644-9
   Kim JM, 2010, FREE RADICAL RES, V44, P454, DOI 10.3109/10715761003610737
   Klein AH, 2015, CHEMOSENS PERCEPT, V8, P96, DOI 10.1007/s12078-015-9176-9
   Komirishetty P, 2016, NEUROCHEM RES, V41, P2029, DOI 10.1007/s11064-016-1914-0
   Kuang X, 2012, EUR J PHARMACOL, V676, P51, DOI 10.1016/j.ejphar.2011.11.037
   Kumar SP, 2011, INDIAN J PALLIAT CAR, V17, P116, DOI 10.4103/0973-1075.84532
   Kwak TW, 2017, ONCOTARGETS THER, V10, P137, DOI 10.2147/OTT.S112364
   Lara CO, 2016, BRIT J PHARMACOL, V173, P2263, DOI 10.1111/bph.13507
   Laverdet B, 2017, BURNS, V43, P562, DOI 10.1016/j.burns.2016.09.016
   Li HB, 2017, BEHAV NEUROL, V2017, P0, DOI 10.1155/2017/2182843
   Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243
   Li J, 2018, DRUG DES DEV THER, V12, P121, DOI 10.2147/DDDT.S151860
   Li J, 2013, BRAIN RES BULL, V97, P81, DOI 10.1016/j.brainresbull.2013.05.015
   Li QS, 2015, INT IMMUNOPHARMACOL, V29, P818, DOI 10.1016/j.intimp.2015.08.037
   Li W, 2015, INT IMMUNOPHARMACOL, V28, P382, DOI 10.1016/j.intimp.2015.06.032
   Lima MD, 2013, EUR J PHARMACOL, V699, P112, DOI 10.1016/j.ejphar.2012.11.040
   Lima PSS, 2016, CARBOHYD POLYM, V151, P965, DOI 10.1016/j.carbpol.2016.06.040
   Liu L, 2017, ONCOL LETT, V14, P4391, DOI 10.3892/ol.2017.6712
   Liu QY, 2011, INT IMMUNOPHARMACOL, V11, P377, DOI 10.1016/j.intimp.2011.01.012
   Lozano-Ondoua AN, 2013, NEUROSCI LETT, V557, P52, DOI 10.1016/j.neulet.2013.08.003
   Luger NM, 2005, J PAIN SYMPTOM MANAG, V29, PS32, DOI 10.1016/j.jpainsymman.2005.01.008
   Martín-Banderas L, 2015, INT J PHARMACEUT, V487, P205, DOI 10.1016/j.ijpharm.2015.04.054
   McAllister SD, 2015, J NEUROIMMUNE PHARM, V10, P255, DOI 10.1007/s11481-015-9608-y
   Menédez L, 2006, NEUROSCI LETT, V393, P70, DOI 10.1016/j.neulet.2005.09.046
   Neubert JK, 2003, PAIN, V104, P219, DOI 10.1016/S0304-3959(03)00009-5
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Noshy PA, 2018, NEUROTOXICOLOGY, V67, P141, DOI 10.1016/j.neuro.2018.05.005
   NOYES R, 1975, CLIN PHARMACOL THER, V18, P84
   Ohtsubo S, 2015, PHARMACOL RES PERSPE, V3, P0, DOI 10.1002/prp2.127
   Oliveira MGB, 2016, CHEM-BIOL INTERACT, V254, P54, DOI 10.1016/j.cbi.2016.05.029
   Oliveira MA, 2017, EXPERT OPIN THER PAT, V27, P1147, DOI 10.1080/13543776.2017.1349105
   Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766
   Oz HS, 2013, FRONT IMMUNOL, V4, P0, DOI 10.3389/fimmu.2013.00132
   Park Ji Young, 2013, J CANCER PREV, V18, P249
   Park SH, 2018, CANCERS, V10, P0, DOI 10.3390/cancers10050141
   Passos GF, 2013, EUR J PHARMACOL, V698, P413, DOI 10.1016/j.ejphar.2012.10.019
   Patridge E, 2016, DRUG DISCOV TODAY, V21, P204, DOI 10.1016/j.drudis.2015.01.009
   Pertwee RG, 2000, ADDICT BIOL, V5, P37, DOI 10.1080/13556210071252
   Pina LTS, 2019, NAT PROD RES, V33, P1773, DOI 10.1080/14786419.2018.1434634
   Pina LTS, 2017, EXPERT OPIN THER PAT, V27, P787, DOI 10.1080/13543776.2017.1297425
   Portenoy RK, 2012, J PAIN, V13, P438, DOI 10.1016/j.jpain.2012.01.003
   Quintans LJ, 2018, MOL NEUROBIOL, V55, P1665, DOI 10.1007/s12035-017-0438-1
   Quintans LJ, 2011, PHARM BIOL, V49, P583, DOI 10.3109/13880209.2010.529616
   Raisinghani M, 2005, J PHYSIOL-LONDON, V567, P771, DOI 10.1113/jphysiol.2005.087874
   Ren BX, 2015, GENET MOL RES, V14, P2133, DOI 10.4238/2015.March.20.24
   Ren W, 2012, AFR J TRADIT COMPLEM, V9, P574, DOI 10.4314/ajtcam.v9i4.15
   Ribeiro TP, 2010, CLIN EXP PHARMACOL P, V37, P811, DOI 10.1111/j.1440-1681.2010.05383.x
   Campos-Esparza MR, 2009, CELL CALCIUM, V45, P358, DOI 10.1016/j.ceca.2008.12.007
   Sabino Mary Ann C, 2005, J SUPPORT ONCOL, V3, P15
   Salaritabar A, 2017, WORLD J GASTROENTERO, V23, P5097, DOI 10.3748/wjg.v23.i28.5097
   Santos PL, 2018, MOL NEUROBIOL, V55, P4560, DOI 10.1007/s12035-017-0658-4
   Schmidt BL, 2015, J ORAL MAXIL SURG, V73, PS132, DOI 10.1016/j.joms.2015.04.045
   Selvaraj M, 2002, J MOL CATAL A-CHEM, V186, P173, DOI 10.1016/S1381-1169(02)00134-6
   Shen Y, 2010, HELV CHIM ACTA, V93, P863, DOI 10.1002/hlca.200900297
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Singh NA, 2018, J BIOMED NANOTECHNOL, V14, P1147, DOI 10.1166/jbn.2018.2552
   Quintans JDS, 2013, PHYTOMEDICINE, V20, P436, DOI 10.1016/j.phymed.2012.12.009
   Stefanakis MK, 2013, FOOD CONTROL, V34, P539, DOI 10.1016/j.foodcont.2013.05.024
   Sun SB, 2018, GENE, V664, P50, DOI 10.1016/j.gene.2018.04.045
   Sun SK, 2012, BRAIN RES BULL, V88, P581, DOI 10.1016/j.brainresbull.2012.06.002
   SZALLASI A, 1989, NEUROSCIENCE, V30, P515, DOI 10.1016/0306-4522(89)90269-8
   Tai SY, 2016, BMC PALLIAT CARE, V15, P0, DOI 10.1186/s12904-016-0105-8
   Thomas A, 2007, BRIT J PHARMACOL, V150, P613, DOI 10.1038/sj.bjp.0707133
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vignoletti F, 2012, CLIN ORAL IMPLAN RES, V23, P22, DOI 10.1111/j.1600-0501.2011.02331.x
   Vogt-Eisele AK, 2007, BRIT J PHARMACOL, V151, P530, DOI 10.1038/sj.bjp.0707245
   WAGNER H, 1986, PLANTA MED, V0, PP184, DOI 10.1055/s-2007-969117
   Wang J, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917746564
   Wang L, 2013, MOL MED REP, V8, P1279, DOI 10.3892/mmr.2013.1650
   Wang W, 2012, PAIN PHYSICIAN, V15, P0
   Wesolowska A, 2015, J ESSENT OIL BEAR PL, V18, P215, DOI 10.1080/0972060X.2014.895177
   Wu YE, 2015, ACTA PHARMACOL SIN, V36, P1308, DOI 10.1038/aps.2015.86
   Xia YM, 2017, ANESTH ANALG, V124, P1244, DOI 10.1213/ANE.0000000000001942
   Xie GH, 2012, MOLECULES, V17, P8159, DOI 10.3390/molecules17078159
   Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692
   Yang CS, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21121679
   Yen JH, 2018, CELL DEATH DIS, V9, P0, DOI 10.1038/s41419-018-1016-9
   Yousefzadi M, 2012, TOXICOL ENVIRON CHEM, V94, P1735, DOI 10.1080/02772248.2012.728606
   Yu HL, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0033584
   Zhang JY, 2013, PAIN, V154, P2452, DOI 10.1016/j.pain.2013.07.027
   Zhang Y, 2017, THORAC CANCER, V8, P296, DOI 10.1111/1759-7714.12441
   Zhang Y, 2011, BIOL PHARM BULL, V34, P1052, DOI 10.1248/bpb.34.1052
   Zhao QC, 2010, J ASIAN NAT PROD RES, V12, P731, DOI 10.1080/10286020.2010.492951
   Zorzi GK, 2015, REV BRAS FARMACOGN, V25, P426
   Zubair H, 2017, MOLECULES, V22, P0, DOI 10.3390/molecules22030395
NR 160
TC 28
Z9 33
U1 0
U2 41
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD MAY 15
PY 2019
VL 58
IS 
BP 
EP 
DI 10.1016/j.phymed.2018.11.026
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA IF4JH
UT WOS:000473047100009
PM 31005719
DA 2026-01-16
ER

PT J
AU Gao, J
   Yuan, YS
   Liu, T
   Lv, HR
   Xu, HL
AF Gao, Jie
   Yuan, Yu-Song
   Liu, Ting
   Lv, Hao-Run
   Xu, Hai-Lin
TI Synovial sarcoma in the plantar region: A case report and literature review.
SO World journal of clinical cases
LA English
DT Journal Article
DE Case report; Imaging examination; Pathological examination; Plantar; Synovial sarcoma
AB BACKGROUND: Synovial sarcoma (SS), a rare malignant soft tissue tumor whose  histological origin is still unknown, often occurs in limbs in young people and  is easily misdiagnosed. CASE SUMMARY: We report a 24-year-old man who sought  treatment for plantar pain thought to be caused by a foot injury that occurred 4  years prior. Currently, he had been seen at another hospital for a 1-wk history  of unexplained pain in the left plantar region and was treated with acupuncture,  a kind of therapy of Chinese medicine, which partly relieved the pain. Because of  this, the final diagnosis of biphasic SS was made after two subsequent treatments  by pathological evaluation after the last operation. SS is rarely seen in the  plantar area, and his history of a left plantar injury confused the original  diagnosis. CONCLUSION: This study shows that pathological and imaging  examinations may play a vital role in the early diagnosis and treatment of SS.
C1 Pingxiang Health Vocational College, Pingxiang Medical School, Pingxiang 337000, Jiangxi Province, China.
   Department of Trauma and Orthopedics, Peking University People's Hospital, Beijing 100044, China.
   Pingxiang Health Vocational College, Pingxiang Medical School, Pingxiang 337000, Jiangxi Province, China.
   Department of Trauma and Orthopedics, Peking University People's Hospital, Beijing 100044, China.
   Department of Trauma and Orthopedics, Peking University People's Hospital, Beijing 100044, China.
NR 0
TC 0
SN 2307-896
EI 2307-896
J9 World J Clin Cases
PD SEP 29
PY 2019
VL 7
IS 17
BP 2549
EP 2555
DI 10.12998/wjcc.v7.i17.2549
PG 6
UT PubMed:31559291
PM 31559291
DA 2019-09-29
ER

PT J
AU Maindet, C
   Burnod, A
   Minello, C
   George, B
   Allano, G
   Lemaire, A
AF Maindet, Caroline
   Burnod, Alexis
   Minello, Christian
   George, Brigitte
   Allano, Gilles
   Lemaire, Antoine
TI Strategies of complementary and integrative therapies in cancer-related
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Review
DE Cancer pain; Complementary therapies; Mind-body therapy; Multimorphic pain; Pain management; Personalized management
AB PURPOSE: Complementary integrative therapies (CITs) correspond to growing demand  in patients with cancer-related pain. This demand needs to be considered  alongside pharmaceutical and/or interventional therapies. CITs can be used to  cover certain specific pain-related characteristics. The objective of this review  is to present the options for CITs that could be used within dynamic,  multidisciplinary, and personalized management, leading to an integrative  oncology approach. METHODS: Critical reflection based on literature analysis and  clinical practice. RESULTS: Most CITs only showed trends in efficacy as cancer  pain was mainly a secondary endpoint, or populations were restricted. Physical  therapy has demonstrated efficacy in motion and pain, in some specific cancers  (head and neck or breast cancers) or in treatments sequelae (lymphedema). In  cancer survivors, higher levels of physical activity decrease pain intensity. Due  to the multimorphism of cancer pain, certain mind-body therapies acting on  anxiety, stress, depression, or mood disturbances (such as massage, acupuncture,  healing touch, hypnosis, and music therapy) are efficient on cancer pain. Other  mind-body therapies have shown trends in reducing the severity of cancer pain and  improving other parameters, and they include education (with coping skills  training), yoga, tai chi/qigong, guided imagery, virtual reality, and  cognitive-behavioral therapy alone or combined. The outcome sustainability of  most CITs is still questioned. CONCLUSIONS: High-quality clinical trials should  be conducted with CITs, as their efficacy on pain is mainly based on efficacy  trends in pain severity, professional judgment, and patient preferences. Finally,  the implementation of CITs requires an interdisciplinary team approach to offer  optimal, personalized, cancer pain management.
C1 Pain management centre, Grenoble-Alpes University Hospital, Grenoble, France.
   Department of supportive care, Institut Curie, PSL Research University, Paris, France.
   Anaesthesia-intensive care department, Cancer Centre Georges François Leclerc, Dijon, France.
   Pain management unit, Saint-Louis Hospital, Paris, France.
   Pain management unit, Mutualist Clinic of la Porte-de-l'Orient, Lorient, France.
   Oncology and medical specialties department, Valenciennes General Hospital, Valenciennes, France. lemaire-a@ch-valenciennes.fr.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD MAY 12
PY 2019
VL 27
IS 8
BP 3119
EP 3132
DI 10.1007/s00520-019-04829-7
PG 13
WC Acupuncture Therapy; methods; Cancer Pain; psychology; Complementary Therapies; methods; Humans; Massage; methods; Music Therapy; Neoplasms; therapy; Pain Management; methods; Randomized Controlled Trials as Topic
UT PubMed:31076901
PM 31076901
DA 2019-05-12
ER

PT J
AU Lee, SM
   Choi, HC
   Hyun, MK
AF Lee, Seong Min
   Choi, Ho Cheol
   Hyun, Min Kyung
TI An Overview of Systematic Reviews: Complementary Therapies for Cancer Patients.
SO Integrative cancer therapies
LA English
DT Journal Article
DE AMSTAR2; Assessing the Methodological Quality of Systematic Reviews 2; Complementary therapies; cancer
AB Introduction: This article critically examines the systematic reviews (SR) and  meta-analysis (MA) of complementary therapies for cancer patients to appraise the  evidence level, and offers suggestions for future research and practice. Methods:  The Cochrane Library and MEDLINE were searched from their inception to January  2018, to identify SR and MA of complementary therapies available for cancer  patients. Final selected SR and MA were methodologically evaluated for their  quality by applying the Assessing the Methodological Quality of Systematic  Reviews 2 (AMSTAR2) instrument. Data extraction and risk of quality assessments  were performed by 2 independent reviewers. Results: A total of 104 studies were  included in the analysis. The majority of the individual clinical trials included  in the SR and MA were performed in China (48%) and the United States (26.9%).  Breast cancer was the most studied cancer type (25%), and acupuncture was the  most studied intervention (21%). Side effects of cancer such as pain, depression,  and fatigue were effectively managed with complementary therapies. The  methodologically problematic items included not listing the excluded studies and  lack of protocol or protocol registration. Conclusions: With increasing interest  in research, complementary therapies appear to be beneficial in reducing side  effects and raising the quality of life of cancer patients. Complementary  therapies have generally been studied for all cancers, with acupuncture being the  most researched, regardless of the cancer type. Since AMSTAR2 is a stricter  assessment tool than before, future studies need to consider the risk of  methodological bias with caution and discuss appropriate overall quality  assessment tools.
C1 College of Korean Medicine, Dongguk University, Gyeongju, Republic of Korea.
   College of Korean Medicine, Dongguk University, Gyeongju, Republic of Korea.
   Department of Preventive Medicine, College of Korean Medicine, Dongguk University, Gyeongju, Republic of Korea.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD DEC 27
PY 2019
VL 18
IS 
BP 1534735419890029
EP 1534735419890029
DI 10.1177/1534735419890029
PG 1
WC China; Complementary Therapies; methods; Humans; Neoplasms; therapy; Quality of Life
UT PubMed:31876212
PM 31876212
DA 2019-12-27
ER

PT J
AU Garland, SN
   Xie, SX
   DuHamel, K
   Bao, T
   Li, Q
   Barg, FK
   Song, S
   Kantoff, P
   Gehrman, P
   Mao, JJ
AF Garland, Sheila N
   Xie, Sharon X
   DuHamel, Kate
   Bao, Ting
   Li, Qing
   Barg, Frances K
   Song, Sarah
   Kantoff, Philip
   Gehrman, Philip
   Mao, Jun J
TI Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors:
SO Journal of the National Cancer Institute
LA English
DT Journal Article
AB BACKGROUND: Insomnia is a common and debilitating disorder experienced by cancer  survivors. Although cancer survivors express a preference for using  nonpharmacological treatment to manage insomnia, the comparative effectiveness  between acupuncture and Cognitive Behavioral Therapy for Insomnia (CBT-I) for  this disorder is unknown. METHODS: This randomized trial compared 8 weeks of  acupuncture (n = 80) and CBT-I (n = 80) in cancer survivors. Acupuncture involved  stimulating specific points on the body with needles. CBT-I included sleep  restriction, stimulus control, cognitive restructuring, relaxation training, and  education. We measured insomnia severity (primary outcome), pain, fatigue, mood,  and quality of life posttreatment (8 weeks) with follow-up until 20 weeks. We  used linear mixed-effects models for analyses. All statistical tests were  two-sided. RESULTS: The mean age was 61.5 years and 56.9% were women. CBT-I was  more effective than acupuncture posttreatment (P < .001); however, both  acupuncture and CBT-I produced clinically meaningful reductions in insomnia  severity (acupuncture: -8.31 points, 95% confidence interval = -9.36 to -7.26;  CBT-I: -10.91 points, 95% confidence interval = -11.97 to -9.85) and maintained  improvements up to 20 weeks. Acupuncture was more effective for pain at the end  of treatment; both groups had similar improvements in fatigue, mood, and quality  of life and reduced prescription hypnotic medication use. CBT-I was more  effective for those who were male (P < .001), white (P = .003), highly educated  (P < .001), and had no pain at baseline (P < .001). CONCLUSIONS: Although both  treatments produced meaningful and durable improvements, CBT-I was more effective  and should be the first line of therapy. The relative differences in the  comparative effectiveness between the two interventions for specific groups  should be confirmed in future adequately powered trials to guide more tailored  interventions for insomnia.
NR 0
TC 0
SN 1460-210
EI 0027-887
J9 J Natl Cancer Inst
PD MAY 14
PY 2019
VL 111
IS 12
BP 1323
EP 1331
DI 10.1093/jnci/djz050
PG 8
WC Acupuncture Therapy; adverse effects; Affect; Cancer Survivors; Cognitive Behavioral Therapy; statistics & numerical data; Confidence Intervals; Fatigue; therapy; Female; Humans; Male; Middle Aged; Neoplasms; complications; Quality of Life; Sleep Initiation and Maintenance Disorders; psychology; Socioeconomic Factors; Treatment Outcome
UT PubMed:31081899
PM 31081899
DA 2019-05-14
ER

PT J
AU Mokaberinejad, R
   Rampisheh, Z
   Aliasl, J
   Akhtari, E
AF Mokaberinejad, Roshanak
   Rampisheh, Zahra
   Aliasl, Jale
   Akhtari, Elham
TI The comparison of fennel infusion plus dry cupping versus metformin in management
SO Journal of obstetrics and gynaecology : the journal of the Institute of
LA English
DT Journal Article
DE Fennel; PCOS; dry cupping; menstruation; metformin; oligomenorrhoea
AB Oligomenorrhoea treatment with hormone therapy and Metformin is not usually well  tolerated and is associated with a broad range of side effects. In Persian  medicine, the management of oligomenorrhoea can be done with fennel and dry  cupping. A clinical trial was conducted on 61 patients with oligomenorrhoea. The  patients randomly received treatment for 6 months in two groups: fennel infusion  plus dry cupping (Group A); versus treatment with Metformin (Group B). On the  days between the two periods, the patients' BMI, pain levels and side effects  were assessed. Thirty-one patients (mean age: 26.68) in Group A, and 30 patients  (mean age: 28.90) in Group B were enrolled. The mean numbers of days between the  two periods after 3 and 6 months in Group A was, respectively, 32.59 and 30.69,  versus 40.66 and 431.22 in Group B. The mean pain severity dropped significantly  in Group A. Fennel seed infusion plus a dry cupping uses a safe and effective  therapeutic intervention in the management of oligomenorrhoea. IMPACT STATEMENT  What is already known on this subject? Polycystic ovary syndrome (PCOS) is a  common endocrine disorder in women. Some common clinical manifestations of this  syndrome include menstrual disorders such as oligomenorrhoea and amenorrhoea. The  recommended therapeutic interventions include oral intervention, as well as  metformin, which are associated with an increased risk of vascular  thromboembolism, digestive complications such as nausea, and dizziness, and  vitamin B12 deficiency. Therefore, the use of complementary medicine in  controlling and treating PCOS is considered a valuable intervention in  conventional medicine. In Persian traditional medicine, medicinal fennel (with  the scientific name of Foeniculum Vulgare Mill) is commonly used in this regard.  The practice of dry cupping during the monthly period that ends with ovulation is  also recommended. What do the results of this study add? The present study  concludes that fennel seed infusion plus a dry cupping therapy is effective and  safe in reducing the days between two menstrual periods and manages  oligomenorrhoea. What are the implications of these findings for clinical  practice and/or further research? A clinical study is suggested for assessing the  effect of fennel seed infusion plus dry cupping on oligomenorrhoea, with a large  sample size and a longer follow up time.
C1 a Department of Traditional Medicine , School of Traditional Medicine Shahid Beheshti University of Medical Sciences , Iran.
   b Preventive Medicine and Public Health Research Center , Iran University of Medical Sciences , Tehran , Iran.
   c Community Medicine Department, School of Medicine , Iran University of Medical 
   d Traditional Medicine Clinical Trial Research Center , Shahed University , Tehran , Iran.
   e Research Institute for Islamic and Complementary Medicine, School of Iranian Traditional Medicine , Iran University of Medical Sciences , Tehran , Iran.
NR 0
TC 0
SN 1364-689
EI 
J9 J Obstet Gynaecol
PD MAR 12
PY 2019
VL 39
IS 5
BP 652
EP 658
DI 10.1080/01443615.2018.1541232
PG 6
WC Acupuncture Therapy; Adult; Body Mass Index; Cupping Therapy; Dysmenorrhea; therapy; Female; Foeniculum; chemistry; Humans; Iran; Medicine, Traditional; Metformin; therapeutic use; Oligomenorrhea; therapy; Phytotherapy; Plant Extracts; administration & dosage; Polycystic Ovary Syndrome; complications; Seeds; chemistry
UT PubMed:30856025
PM 30856025
DA 2019-03-12
ER

PT J
AU Chien, TJ
   Liu, CY
   Fang, CJ
   Kuo, CY
AF Chien, Tsai-Ju
   Liu, Chia-Yu
   Fang, Ching-Ju
   Kuo, Chun-Yu
TI The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE acupuncture; cancer; chemotherapy; neuropathy; systematic review
ID multiple-myeloma; cancer pain; neurotoxicity; electroacupuncture; vincristine; prevention; glutamine; quality
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) has no cure, but acupuncture may provide relief through its known neuromodulation or neuroendocrine adjustment. This review aimed to assess the efficacy of acupuncture in treating CIPN. Method: A literature review following the PRISMA Statement was performed, searching 7 databases from inception through August 2019. All studies were clinical trials of the effect of acupuncture on CIPN. The methodological quality of these trials was assessed using Cochrane criteria; meta-analysis software (RevMan 5.2) was used to analyze the data. Data Sources: The databases searched were the following: MEDLINE (Ovid), Embase, Cochrane CENTRAL, Scopus, World Health Organization International Clinical Trials Registry Platform, CNKI (China National Knowledge Infrastructure), and Wanfang Med Online. Results: We examined 386 cancer patients from 6 randomized control trials, which had high quality, based on the modified Jadad scale. Meta-analysis showed that acupuncture led to significant improvements in pain scores (-1.21, 95% confidence interval [CI] = -1.61 to -0.82, P < .00001) and nervous system symptoms based on Functional Assessment of Cancer Therapy/Neurotoxicity questionnaire scores (-2.02, 95% CI = -2.21 to -1.84, P < .00001). No significant change was noted in nerve conduction velocity (1.58, 95% CI = -2.67 to 5.83, P = .47). Conclusion: Acupuncture can effectively relieve CIPN pain and functional limitation. The limited number of subjects warrants a larger scale study.
C1 [Chien, Tsai-Ju] Taipei City Hosp, Taipei, Taiwan.
   [Chien, Tsai-Ju; Liu, Chia-Yu; Kuo, Chun-Yu] Natl Yang Ming Univ, Taipei, Taiwan.
   [Liu, Chia-Yu] Chang Gung Univ, Taoyuan, Taiwan.
   [Liu, Chia-Yu] China Med Univ, Taichung, Taiwan.
   [Liu, Chia-Yu] Flourish Tradit Chinese Med Clin, Taipei, Taiwan.
   [Fang, Ching-Ju] Natl Cheng Kung Univ, Tainan, Taiwan.
   [Fang, Ching-Ju] Natl Cheng Kung Univ Hosp, Tainan, Taiwan.
C3 Taipei City Hospital; National Yang Ming Chiao Tung University; Chang Gung University; China Medical University Taiwan; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital
RP Chien, TJ (corresponding author), Taipei City Hosp, Dept Internal Med, Div Hematooncol, Branch Zhong Zhou & Jen Ai, 87 Tong De Rd, Taipei 11556, Taiwan.
EM silence021@gmail.com
FU Ministry of Science and Technology [108-2320-B-532-001-MY3]
CR Al-Mazidi S, 2018, EUR J PAIN, V22, P810, DOI 10.1002/ejp.1169
   Unknown -, 2010, SURGERY, V0, P0, DOI DOI 10.1016/J.SURG.2009.06.030
   Argyriou AA, 2010, J BUON, V15, P435
   Baeumler PI, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0113731
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Brown JJ, 2017, J DIABETES RES, V2017, P0, DOI 10.1155/2017/1467213
   Butkovic D, 2017, COMPLEMENT THER MED, V35, P53, DOI 10.1016/j.ctim.2017.09.006
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Cavaletti G, 2007, EXP NEUROL, V204, P317, DOI 10.1016/j.expneurol.2006.11.010
   Cavaletti G, 2011, LANCET ONCOL, V12, P1151, DOI 10.1016/S1470-2045(11)70131-0
   Chen LH, 2015, MOL CANCER THER, V14, P2206, DOI 10.1158/1535-7163.MCT-15-0268
   Chen LY, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0175568
   Chien TJ, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180918
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chu SH, 2015, J KOREAN ACAD NURS, V45, P783, DOI 10.4040/jkan.2015.45.6.783
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Dimitrova A, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3094-5
   Dimitrova A, 2017, MED ACUPUNCT, V29, P352, DOI 10.1089/acu.2017.1242
   Driessen CML, 2012, SUPPORT CARE CANCER, V20, P877, DOI 10.1007/s00520-011-1336-0
   Enblom A, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/5806351
   Flatters SJL, 2006, PAIN, V122, P245, DOI 10.1016/j.pain.2006.01.037
   Gao Z, 2013, J TRADIT CHIN MED, V33, P1
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Guo L, 2017, TOXICOL SCI, V156, P275, DOI 10.1093/toxsci/kfw254
   Hadianfard M, 2015, J ACUPUNCT MERIDIAN, V8, P229, DOI 10.1016/j.jams.2014.11.005
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Johnson DC, 2011, J CLIN ONCOL, V29, P797, DOI 10.1200/JCO.2010.28.0792
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Langjahr M, 2018, J NEUROL, V265, P618, DOI 10.1007/s00415-018-8748-4
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-471
   Liang FX, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/792793
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Liberati Alessandro, 2009, BMJ-BRIT MED J, V339, Pb2700, DOI 10.1136/bmj.b2700
   Litscher Gerhard, 2007, CRITICAL REVIEWS IN BIOMEDICAL ENGINEERING, V35, P1, DOI 10.1615/CritRevBiomedEng.v35.i1-2.10
   Lobert S, 1996, BIOCHEMISTRY-US, V35, P6806, DOI 10.1021/bi953037i
   Long Xing-xing, 2011, ZHONGHUA XUE YE XUE ZA ZHI, V32, P633
   Lu W, 2017, CANCER RES, V77, P0, DOI 10.1158/1538-7445.SABCS16-PD4-01
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Lu ZX, 2017, J ALTERN COMPLEM MED, V23, P964, DOI 10.1089/acm.2017.0052
   McKeage MJ, 2001, BRIT J CANCER, V85, P1219, DOI 10.1054/bjoc.2001.2024
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Nian JY, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2015-010787
   Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI 10.1136/bmjspcare-2011-000022
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Plasmati R, 2007, NEUROLOGY, V69, P573, DOI 10.1212/01.wnl.0000267271.18475.fe
   Poupon L, 2015, EXPERT OPIN DRUG SAF, V14, P1269, DOI 10.1517/14740338.2015.1056777
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Sands S, 2017, SUPPORT CARE CANCER, V25, P701, DOI 10.1007/s00520-016-3441-6
   Schiff D, 2009, NAT REV CLIN ONCOL, V6, P596, DOI 10.1038/nrclinonc.2009.128
   Schloss J, 2017, CURR ONCOL REP, V19, P0, DOI 10.1007/s11912-017-0636-z
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Visovsky Constance, 2012, J ADV PRACT ONCOL, V3, P178
   Wang WS, 2007, ONCOLOGIST, V12, P312, DOI 10.1634/theoncologist.12-3-312
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Xiao WH, 2011, NEUROSCIENCE, V199, P461, DOI 10.1016/j.neuroscience.2011.10.010
   Yang Xiaolin, 2013, EVID BASED COMPLEMENT ALTERNAT MED, V2013, P926928, DOI 10.1155/2013/926928
   Zhang C, 2010, J TRADIT CHIN MED, V30, P13, DOI 10.1016/S0254-6272(10)60003-9
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zhong Huan, 2017, ZHONGGUO ZHEN JIU, V37, P199, DOI 10.13703/j.0255-2930.2017.02.027
   Zhou YH, 2009, AM J CLIN ONCOL-CANC, V32, P319, DOI 10.1097/COC.0b013e318173a520
NR 65
TC 43
Z9 51
U1 4
U2 27
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD DEC 15
PY 2019
VL 18
IS 
BP 
EP 
DI 10.1177/1534735419886662
PG 10
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA JW0KL
UT WOS:000502748200001
PM 31833790
DA 2026-01-16
ER

PT J
AU Mao, HJ
   Mao, JJ
   Chen, JC
   Li, Q
   Chen, XF
   Shen, XB
   Zhao, L
   Wei, JZ
   Shen, XY
AF Mao, Huijuan
   Mao, Jun J.
   Chen, Junchao
   Li, Qing
   Chen, Xuefen
   Shen, Xubo
   Zhao, Ling
   Wei, Jianzi
   Shen, Xueyong
TI Effects of infrared laser moxibustion on cancer-related fatigue in breast cancer survivors Study protocol for a randomized controlled trial
SO MEDICINE
LA English
DT Article
DE acupuncture; breast cancer; cancer survivor; cancer-related fatigue; infrared laser; moxibustion
ID quality-of-life; chinese version; telomere length; depression scale; hospital anxiety; risk-factors; brief pain; acupuncture; validation; stress
AB Background: Cancer-related fatigue (CRF) is the most common and distressing symptom associated with cancer treatment that breast cancer survivors (BCS) experience. We previously found that laser moxibustion may be efficacious for CRF. The primary aim of this study is to determine the specific efficacy of 10.6mm infrared laser moxibustion on CRF. The secondary aim is to evaluate the effect of infrared laser moxibustion on co-existing symptoms that BCS experience. Methods: We will conduct a randomized, sham-controlled, three-arm trial of infrared laser moxibustion (ILM) against sham ILM (SILM) and waitlist control (WLC) among BCS with moderate to severe fatigue. The two intervention groups will receive either real or sham infrared laser moxibustion on four acupoints (i.e., ST36 [bilateral], CV4, and CV6) for 20 minutes each session for 6 weeks (twice per week). The primary endpoint is the change in fatigue score from Baseline to Week 6 as measured by the Chinese version of the Brief Fatigue Inventory (BFI-C). Our secondary aim is to compare the severity of co-morbidities (e. g., depression, insomnia, and pain) among the 3 groups. Discussion: The results of our trial will establish evidence for the efficacy of infrared laser moxibustion for CRF, a very common and challenging symptom.
C1 [Mao, Huijuan; Zhao, Ling; Wei, Jianzi; Shen, Xueyong] Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, 1200 Cailun Rd, Shanghai 201203, Peoples R China.
   [Mao, Jun J.; Li, Qing] Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Chen, Junchao] Shanghai Univ Tradit Chinese Med, Inst Disciplinary Sci, Shanghai, Peoples R China.
   [Chen, Xuefen] Shanghai Univ Tradit Chinese Med, Sch Publ Hlth, Shanghai, Peoples R China.
   [Shen, Xubo] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai, Peoples R China.
   [Shen, Xueyong] Shanghai Res Ctr Acupuncture & Meridian, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Memorial Sloan Kettering Cancer Center; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Shen, XY (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, 1200 Cailun Rd, Shanghai 201203, Peoples R China.
EM snowysh@hotmail.com
FU National Natural Science Foundation of China [81603703]; Shanghai Municipal Commission of Health and Family Planning [201840171]; National Institutes of Health/National Cancer Institute Cancer Center grant [P30 CA008748]; MSK Translational Research and Integrative Medicine Fund; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Unknown -, 2010, ACUPUNCTURE RELATED, V0, P0
   Bendix Laila, 2014, J AGING RES, V2014, P403253, DOI 10.1155/2014/403253
   Berger AM, 2015, J NATL COMPR CANC NE, V13, P1012, DOI 10.6004/jnccn.2015.0122
   Biegler KA, 2012, CANCER PREV RES, V5, P1173, DOI 10.1158/1940-6207.CAPR-12-0008
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Bower JE, 2006, CANCER-AM CANCER SOC, V106, P751, DOI 10.1002/cncr.21671
   Brouilette S, 2003, ARTERIOSCL THROM VAS, V23, P842, DOI 10.1161/01.ATV.0000067426.96344.32
   Bruera E, 2010, J CLIN ONCOL, V28, P3671, DOI 10.1200/JCO.2010.29.8984
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Carlson LE, 2015, CANCER-AM CANCER SOC, V121, P476, DOI 10.1002/cncr.29063
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   Curt GA, 2000, SEMIN HEMATOL, V37, P14, DOI 10.1053/shem.2000.18119
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   Epel ES, 2009, HORM-INT J ENDOCRINO, V8, P7, DOI 10.14310/horm.2002.1217
   Groenvold M, 2007, BREAST CANCER RES TR, V105, P209, DOI 10.1007/s10549-006-9447-x
   Ho RTH, 2014, SLEEP MED, V15, P565, DOI 10.1016/j.sleep.2013.10.019
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lawrence D, 2004, J NATL CANC INSTITUE, V32, P40, DOI 10.1093/JNCIMONOGRAPHS/LGH027
   Lee EH, 2012, ASIAN NURS RES, V6, P121, DOI 10.1016/j.anr.2012.08.004
   Lee S, 2014, SUPPORT CARE CANCER, V22, P1429, DOI 10.1007/s00520-014-2161-z
   Li QP, 2016, EUR J ONCOL NURS, V25, P16, DOI 10.1016/j.ejon.2016.09.004
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   Mao HJ, 2018, EUR J CANCER, V101, P47, DOI 10.1016/j.ejca.2018.06.009
   Mao HJ, 2016, CANCER-AM CANCER SOC, V122, P3667, DOI 10.1002/cncr.30189
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-7
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Montazeri A, 2008, J EXP CLIN CANC RES, V27, P0, DOI 10.1186/1756-9966-27-32
   Mustian KM, 2017, JAMA ONCOL, V3, P961, DOI 10.1001/jamaoncol.2016.6914
   Nguyen Jasmine, 2015, J COMP EFF RES, V4, P157, DOI 10.2217/cer.14.76
   ODonovan A, 2012, BRAIN BEHAV IMMUN, V26, P573, DOI 10.1016/j.bbi.2012.01.007
   Pellatt AJ, 2013, GENE CHROMOSOME CANC, V52, P595, DOI 10.1002/gcc.22056
   Romero SAD, 2018, J CANCER SURVIV, V12, P744, DOI 10.1007/s11764-018-0711-y
   Scott K, 2017, HOLIST NURS PRACT, V31, P66, DOI 10.1097/HNP.0000000000000194
   Servaes P, 2002, EUR J CANCER, V38, P27, DOI 10.1016/S0959-8049(01)00332-X
   Shen XY, 2006, COMPLEMENT THER MED, V14, P213, DOI 10.1016/j.ctim.2005.09.003
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Viscuse PV, 2017, CURR OPIN ONCOL, V29, P235, DOI 10.1097/CCO.0000000000000376
   Wan CH, 2007, BREAST CANCER RES TR, V106, P413, DOI 10.1007/s10549-007-9511-1
   Wang XS, 1996, PAIN, V67, P407, DOI 10.1016/0304-3959(96)03147-8
   Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P322, DOI 10.1016/j.jpainsymman.2003.09.008
   White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485
   Woodward M, 2005, EPIDEMIOLOGY STUDY D, V2nd, P0
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
NR 56
TC 9
Z9 10
U1 0
U2 30
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG 15
PY 2019
VL 98
IS 34
BP 
EP 
DI 10.1097/MD.0000000000016882
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA IY4SJ
UT WOS:000486383000028
PM 31441863
DA 2026-01-16
ER

PT J
AU Lam, WC
   Zhong, LD
   Liu, YQ
   Shi, NN
   Ng, B
   Ziea, E
   Bian, ZX
   Lu, AP
AF Lam, Wai Ching
   Zhong, Linda
   Liu, Yuqi
   Shi, Nannan
   Ng, Bacon
   Ziea, Eric
   Bian, Zhaoxiang
   Lu, Aiping
TI Hong Kong Chinese Medicine Clinical Practice Guideline for Cancer Palliative Care: Pain, Constipation, and Insomnia
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
AB It is common for patients with cancers in Hong Kong seeking Chinese Medicine (CM) therapies as supportive care during cancer treatment and to manage treatment-related side effects. This article provides clinical practice guideline (CPG) on the use of CM for specific clinical indications caused by cancer and during cancer treatment, including pain, constipation, and insomnia, and aims to guide local licensed CM practitioners and provide beneficial reference for social medical decision makers and patients. In this manuscript, we summarize the clinical manifestation, CM pattern classification, and CM intervention including herbal treatment, acupuncture treatment, regulating, and nursing based on pattern differentiation.
C1 [Lam, Wai Ching; Zhong, Linda; Bian, Zhaoxiang; Lu, Aiping] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong Chinese Med Clin Study Ctr, Kowloon, Hong Kong 999077, Peoples R China.
   [Liu, Yuqi; Shi, Nannan] China Acad Chinese Med Sci, Beijing 100700, Peoples R China.
   [Ng, Bacon; Ziea, Eric] Hong Kong Hosp Author, Dept Chinese Med, Kowloon, Hong Kong 999077, Peoples R China.
C3 Hong Kong Baptist University; China Academy of Chinese Medical Sciences
RP Lu, AP (corresponding author), Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong Chinese Med Clin Study Ctr, Kowloon, Hong Kong 999077, Peoples R China.
EM aipinglu@hkbu.edu.hk
FU Hong Kong Hospital Authority Research Fund [HA 33-14-110-542-130]
CR Unknown -, 2011, EVIDENCE BASED GUIDE, V0, P0
   Unknown -, 2013, J LIAONING U TCM, V0, P0
   Bao Y, 2014, EVID-BASED COMPL ALT, V2014, P9, DOI 10.1155/2014/
   BERGER A, 2002, JOURNAL OF PAIN AND, V33, P398
   Berger Ann M, 2010, ONCOL NURS FORUM, V37, PE359, DOI 10.1188/10.ONF.E359-E369
   Burton AW, 2014, CURR OPIN SUPPORT PA, V8, P112, DOI 10.1097/SPC.0000000000000047
   Cai P, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000012888
   Carmady B, 2011, CHIN MED-UK, V6, P0, DOI 10.1186/1749-8546-6-22
   CHEN C, 2002, CHINESE JOURNAL OF I, V20, P496
   CHENG C, 2002, SUPPORTIVE CARE IN C, V21, P149
   CHENG CW, 2012, EVID BASED COMPL ALT, V0, P0
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chung VCH, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002793
   Cramer H, 2016, MEDICINE, V95, P2901
   Curtis E B, 1991, J PALLIAT CARE, V7, P25
   Davidson JR, 2002, SOC SCI MED, V54, P1309, DOI 10.1016/S0277-9536(01)00043-0
   DEANDREA S, 2002, JOURNAL OF PAIN AND, V47, P57
   Duan K-N, 2009, W CHINA MED J, V24, P9
   Fallon MT, 1999, EUROPEAN JOURNAL OF PAIN, V3, P3, DOI 10.1016/S1090-3801(99)90169-6
   Fan D, 2014, JOURNAL OF PRACTICAL, V1, P109
   Feng J, 2011, LIAONING J TRADITION, V38, P1612
   Feng Y, 2011, J TRADIT CHIN MED, V31, P199, DOI 10.1016/S0254-6272(11)60042-3
   Gao H, 2007, LIAONING J TRADITION, V34, P612
   GOUDAS L, 2002, CANCER INVEST, V23, P182
   HADDAD N, 2002, INTEGR CANCER THER, V13, P371
   Hu HJ, 2014, J CHENGDU U TRADITIO, V37, P85
   Hu H-J, 2014, J CHENGDU U TRADITIO, V37, P76
   Jianhong H, 2013, GUANGMING J CHINESE, V28, P2073
   Kang F, 2013, J HUNAN UNIV TRADIT CHIN MED, V33, P31
   Kim W, 2015, COMPLEMENT THER MED, V23, P626, DOI 10.1016/j.ctim.2015.03.011
   Koopman Cheryl, 2002, BREAST J, V8, P362, DOI 10.1046/j.1524-4741.2002.08606.x
   Larkin PJ, 2008, PALLIATIVE MED, V22, P796, DOI 10.1177/0269216308096908
   LAUGSAND E, 2002, MANAGEMENT, V5, P11
   Le Guen Y, 2007, LUNG CANCER, V58, P139, DOI 10.1016/j.lungcan.2007.05.021
   Li H, 2010, MED RECAPITULATE, V16, P2531
   Li J-Y, 2013, J TRADITIONAL CHINES, V33, P76
   Li K, 2013, JILIN J TRADITIONAL, V33, P1029
   Liu Jian-Ping, 2007, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V27, P1061
   LU W, 2002, CURRENT PAIN AND HEA, V17, P321
   MERCADANTE S, 2002, SUPPORTIVE CARE IN C, V12, P355
   Ning N, 2014, J CIRCUIT SYST COMP, V23, P0, DOI 10.1142/S0218126614500066
   Palesh OG, 2010, J CLIN ONCOL, V28, P292, DOI 10.1200/JCO.2009.22.5011
   PALEY C, 2002, COCHRANE DB SYST REV, V19, P1
   Pan G, 2014, HENAN TRADITIONAL CH, V34, P1332
   PENG H, 2002, CHINESE, V8, P501, DOI 10.3736/JCIM20100601
   PORTENOY R, 2000, LANCET, V377, P2236
   Potter J, 2003, PALLIATIVE MED, V17, P310, DOI 10.1191/0269216303pm760oa
   Qiao X, 2012, GUANGMING J CHINESE, V27, P2016
   Rao SSC, 2016, NAT REV GASTRO HEPAT, V13, P295, DOI 10.1038/nrgastro.2016.53
   ROMITO F, 2002, EUROPEAN JOURNAL OF, V23, P385
   Savard J, 2001, SLEEP, V24, P583, DOI 10.1093/sleep/24.5.583
   SAVARD J, 2002, JCO, V19, P895
   Savard J, 2011, J CLIN ONCOL, V29, P3580, DOI 10.1200/JCO.2010.33.2247
   SELA R, 2002, PALLIAT SUPPORT CARE, V3, P23
   SHAM M, 2002, J PAIN PALLIATIVE CA, V17, P65
   Shi NN, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/482706
   SMITH M, 2002, SEMINARS ONCOLOGY NU, V28, P64
   Tan GS, 2012, WORLD J INTEGR MED, V7, P147
   Tao WW, 2015, ONCOTARGET, V6, P39725, DOI 10.18632/oncotarget.5388
   The Hospital Authority, 2018, HOSP AUTH LAUNCH INT, V0, P0
   Tsai JS, 2006, PALLIATIVE MED, V20, P617, DOI 10.1177/0269216306071065
   Vinjamury SP, 2013, CHIN MED-UK, V8, P0, DOI 10.1186/1749-8546-8-15
   Wang Ju-yong, 2011, ZHONG XI YI JIE HE XUE BAO, V9, P129, DOI 10.3736/jcim20110202
   Wang M, 2013, J PRACT TRADITIONAL, V27, P79, DOI 10.3969/j.issn.1671-7813.2013.06(x).40
   XIANGYONG Y, 2002, SUPPORT CARE CANCER, V24, P11
   XU L, 2002, INTEGR CANCER THER, V6, P208
   Yu Chien-Tai, 2010, HU LI ZA ZHI, V57, P100
   ZHANG L, 2009, XINJIANG JOURNAL OF, V6, P6
   Zhao W, 2006, MODERN ONCOL, V14, P1286
   Zheng G, 2011, BIODATA MIN, V4, P0, DOI 10.1186/1756-0381-4-18
   Zhenxiong H, 2007, J PRACTICAL TRADITIO, V23, P213
   Zhu Shi-jie, 2011, ZHONG XI YI JIE HE XUE BAO, V9, P11
   1998, 1900, V280, V0, PP1518, DOI 10.1001/JAMA.280.17.1518
NR 74
TC 19
Z9 25
U1 1
U2 27
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2019
VL 2019
IS 
BP 
EP 
DI 10.1155/2019/1038206
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA HV9VT
UT WOS:000466331000001
PM 30805017
DA 2026-01-16
ER

PT J
AU Schlaeger, J
   Cai, HY
   Steffen, AD
   Angulo, V
   Shroff, AR
   Briller, JE
   Hoppensteadt, D
   Uwizeye, G
   Pauls, HA
   Takayama, M
   Yajima, H
   Takakura, N
   DeVon, HA
AF Schlaeger, Judith
   Cai, Hui Yan
   Steffen, Alana D
   Angulo, Veronica
   Shroff, Adhir R
   Briller, Joan E
   Hoppensteadt, Debra
   Uwizeye, Glorieuse
   Pauls, Heather A
   Takayama, Miho
   Yajima, Hiroyoshi
   Takakura, Nobuari
   DeVon, Holli A
TI Acupuncture to Improve Symptoms for Stable Angina: Protocol for a Randomized
SO JMIR research protocols
LA English
DT Journal Article
DE acupuncture; complementary medicine; ischemic heart disease; stable angina
AB BACKGROUND: Acupuncture has demonstrated physiologic analgesic effects in Chinese  patients with stable angina. One proposed mechanism of action for these analgesic  effects is the downregulation of M1 macrophages, interleukin 1 beta,  interleukin-6, interleukin-18, and tumor necrosis factor alpha. OBJECTIVE: This  study aims to test a 10-session, 5-week acupuncture treatment protocol as a  complementary therapy for symptoms of stable angina for American patients, who  vary from Chinese patients in health care systems and other salient variables.  METHODS: We are conducting a randomized controlled trial (RCT) of 69 adults (35  assigned to initial acupuncture and 34 to an attention control condition) with a  medically confirmed diagnosis of stable angina, whose pain and associated  symptoms have not been controlled to their satisfaction with guideline-directed  medical management. Participants in the experimental group will receive a  standardized traditional Chinese medicine point prescription. The attention  control group will view non-pain-related health education videos over 5 weeks  equal to the 10 hours of treatment for the acupuncture group. Participants will  complete the McGill Pain Questionnaire and the Seattle Angina Questionnaire-7, as  well as have inflammatory cytokines measured at baseline and study completion.  The primary outcomes are anginal pain and quality of life. RESULTS: This study  has been funded over 2 years by the National Institutes of Health, National  Institute for Nursing Research. We are currently recruiting and expect to have  initial results by December 2020. CONCLUSIONS: We will generate data on  feasibility, acceptability, effect sizes, and protocol revisions for a future  fully powered RCT of the protocol. Findings will help determine if patients with  persistent ischemic symptoms experience a proinflammatory state and hyperalgesia  caused by multiple neural and immune processes not always relieved with  medication. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):  DERR1-10.2196/14705.
C1 Department of Women, Children and Family Health Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, United States.
   Department of Acupuncture and Oriental Medicine, National University of Health Sciences, Lagrange, IL, United States.
   Department of Health Systems Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, United States.
   Department of Women, Children and Family Health Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, United States.
   Department of Cardiology, College of Medicine, University of Illinois at Chicago, Chicago, IL, United States.
   Department of Cardiology, College of Medicine, University of Illinois at Chicago, Chicago, IL, United States.
   Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL, United States.
   Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, United States.
   Office of Research Facilitation, College of Nursing, University of Illinois at Chicago, Chicago, IL, United States.
   Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan.
   Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan.
   Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan.
   Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, United States.
NR 0
TC 0
SN 1929-074
EI 1929-074
J9 JMIR Res Protoc
PD JUL 31
PY 2019
VL 8
IS 7
BP e14705
EP e14705
DI 10.2196/14705
PG 1
UT PubMed:31359872
PM 31359872
DA 2019-07-31
ER

PT J
AU Liang, Y
   Bao, GA
   Gong, LY
   Zhou, J
   Kong, XM
   Ran, R
   Shao, XM
   Jiang, YL
   Zhang, WP
   Liu, BY
   Du, JY
   Fang, JF
   Nie, N
   Ji, CH
   Fang, JQ
AF Liang, Yi
   Bao, Guanai
   Gong, Liyan
   Zhou, Jie
   Kong, Xiangming
   Ran, Ran
   Shao, Xiaomei
   Jiang, Yongliang
   Zhang, Weiping
   Liu, Boyi
   Du, Junying
   Fang, Junfan
   Nie, Na
   Ji, Conghua
   Fang, Jianqiao
TI Evaluating the analgesic effect and advantage of transcutaneous electrical acupoint stimulation combined with opioid drugs for moderate to severe cancer-related pain: a study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Study protocol; Randomized controlled trial; TEAS; Cancer-related pain
ID nerve-stimulation; acupuncture; prevalence; relief; morphine; surgery; labor; tens
AB BackgroundTranscutaneous electrical acupoint stimulation (TEAS), which is also known as acupuncture-like transcutaneous electrical nerve stimulation (TENS), has been widely used in acute or chronic pain. However, previous research has not demonstrated that TEAS is effective for cancer-related pain. Opioid drugs are strongly recommended for treating cancer-related pain, but opioid-induced immunosuppression is still the most intractable drug-induced medical problem. Evaluating the efficacy and potential advantage of TEAS combined with opioid drugs in moderate and severe cancer-related pain in China is important because such studies are lacking.Methods/DesignThis trial is a multicenter, prospective randomized controlled clinical trial. In total, 160 patients who were enrolled from two hospitals in the Zhejiang Province (China) will be randomly allocated into two groups: a TEAS group and sham TEAS group without acupoint electrical stimulation. Both groups will receive a 21-day interval of chemotherapy and conventional cancer pain therapy. Fifteen treatment sessions will be performed over a three-week period. The primary outcomes will be measured by changes in the Numerical Rating Scale (NRS) scores and equivalent dosage of morphine at baseline, three weeks of treatment and one two-week follow-up. The secondary outcome measures include cellular immunity function, life quality assessment, opioids side effects assessment, and safety and compliance evaluation.DiscussionThis trial is expected to clarify whether TEAS is effective for cancer-related pain. These results demonstrate the advantage of TEAS combined with opioid drugs on improving immune function and decreasing opioid induced side effects.Trial registrationChinese Clinical Trial Registry, ChiCTR-13003803. Registered on 27 August 2013.
C1 [Liang, Yi; Zhou, Jie; Ran, Ran; Shao, Xiaomei; Jiang, Yongliang; Zhang, Weiping; Du, Junying; Fang, Junfan; Nie, Na; Fang, Jianqiao] Zhejiang Chinese Med Univ, Dept Acupuncture, Affiliated Hosp 3, 219 Moganshan Rd, Hangzhou 310005, Zhejiang, Peoples R China.
   [Liang, Yi; Shao, Xiaomei; Jiang, Yongliang; Liu, Boyi; Du, Junying; Fang, Junfan; Fang, Jianqiao] Zhejiang Chinese Med Univ, Clin Med Coll 3, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   [Bao, Guanai; Gong, Liyan; Kong, Xiangming] Zhejiang Canc Hosp, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China.
   [Ji, Conghua] Zhejiang Prov Hosp TCM, Clin Res Inst, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Cancer Hospital; Zhejiang Chinese Medical University
RP Fang, JQ (corresponding author), Zhejiang Chinese Med Univ, Dept Acupuncture, Affiliated Hosp 3, 219 Moganshan Rd, Hangzhou 310005, Zhejiang, Peoples R China.; Fang, JQ (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 3, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
EM fangjianqiao7532@163.com
FU National Natural Science Foundation of China [81102643, 81674061]; Foundation of the Zhejiang Health Committee [2014KYA162]
CR Unknown -, 2016, EVID-BASED COMPL ALT, V0, P0, DOI DOI 10.1155/2016/1720239
   Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552
   Chao AS, 2007, PAIN, V127, P214, DOI 10.1016/j.pain.2006.08.016
   Chesterton LS, 2009, BMC MUSCULOSKEL DIS, V10, P0, DOI 10.1186/1471-2474-10-156
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Colson J, 2011, PAIN PHYSICIAN, V14, P0
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Gavronsky S, 2012, PAIN MANAG NURS, V13, P150, DOI 10.1016/j.pmn.2009.08.001
   Houghtling RA, 2000, ANN NY ACAD SCI, V917, P771
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Johnson MI, 2011, EXPERT REV NEUROTHER, V11, P735, DOI 10.1586/ern.11.48
   Lan F, 2012, MINERVA ANESTESIOL, V78, P887
   MELZACK R, 1984, POSTGRAD MED J, V60, P893, DOI 10.1136/pgmj.60.710.893
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Page G G, 1997, SEMIN ONCOL NURS, V13, P10, DOI 10.1016/S0749-2081(97)80044-7
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Peng T, 2010, CHIN J INTEGR MED, V16, P234, DOI 10.1007/s11655-010-0234-9
   Robb K, 2009, J PAIN SYMPTOM MANAG, V37, P746, DOI 10.1016/j.jpainsymman.2008.03.022
   Sacerdote P, 2006, PALLIATIVE MED, V20, PS9, DOI 10.1191/0269216306pm1124oa
   Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028
   Searle RD, 2009, J PAIN SYMPTOM MANAG, V37, P424, DOI 10.1016/j.jpainsymman.2008.03.017
   Singhal P, 2001, ADV EXP MED BIOL, V493, P127
   Sun K, 2017, CLIN J PAIN, V33, P340, DOI 10.1097/AJP.0000000000000400
   Wei G, 2003, BIOCHEM PHARMACOL, V65, P1761, DOI 10.1016/S0006-2952(03)00085-6
   Wu HX, 2016, EXP THER MED, V11, P495, DOI 10.3892/etm.2015.2913
NR 27
TC 14
Z9 16
U1 3
U2 31
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1745-6215
EI 
J9 TRIALS
JI Trials
PD JAN 11
PY 2019
VL 20
IS 
BP 
EP 
DI 10.1186/s13063-018-3145-y
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA HH2EI
UT WOS:000455531100004
PM 30635007
DA 2026-01-16
ER

PT J
AU Kwan, YH
   Fong, W
   Ang, XL
   Tan, CS
   Tai, BC
   Huang, Y
   Bilger, M
   Phang, JK
   Tan, HC
   Lee, JV
   Sun, L
   Tan, CT
   Dong, BQ
   Koh, HL
   Leung, YY
   Lui, NL
   Yeo, SI
   Ng, SC
   Fong, KY
   Thumboo, J
   Østbye, T
AF Kwan, Yu Heng
   Fong, Warren
   Ang, Xiang Ling
   Tan, Chuen Seng
   Tai, Bee Choo
   Huang, Youyi
   Bilger, Marcel
   Phang, Jie Kie
   Tan, Hui Chin
   Lee, Jia Ven
   Sun, Limin
   Tan, Choy Tip
   Dong, Bao Qiang
   Koh, Hwee Ling
   Leung, Ying Ying
   Lui, Nai Lee
   Yeo, Siaw Ing
   Ng, Swee Cheng
   Fong, Kok Yong
   Thumboo, Julian
   Østbye, Truls
TI Traditional Chinese medicine (TCM) collaborative care for patients with axial
SO Trials
LA English
DT Journal Article
AB BACKGROUND: Axial spondyloarthritis (AxSpA) is a chronic disease which results in  fatigue, pain, and reduced quality of life (QoL). Traditional Chinese medicine  (TCM), especially acupuncture, has shown promise in managing pain. Although a TCM  collaborative model of care (TCMCMC) has been studied in cancer, there are no  randomized controlled trials investigating TCM in AxSpA. Therefore, we will  conduct a pragmatic trial to determine the clinical effectiveness, safety, and  cost-effectiveness of TCMCMC for patients with AxSpA. We define TCMCMC as  standard TCM history taking and physical examination, acupuncture, and TCM  non-pharmacological advice and communications with rheumatologists in addition to  usual rheumatologic care. The purpose of this paper is to describe the rationale  for and methodology of this trial. METHODS/DESIGN: This pragmatic randomized  controlled trial will recruit 160 patients who are diagnosed with AxSpA and have  inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs). Simple  randomization to usual rheumatologic care or the intervention (TCMCMC) with a 1:1  allocation ratio will be used. Ten 30-min acupuncture sessions will be provided  to patients assigned to the TCMCMC arm. All participants will continue to receive  usual rheumatologic care. The primary endpoint - spinal pain - will be evaluated  at week 6. Secondary endpoints include clinical, quality of life, and economic  outcome measures. Patients will be followed up for up to 52 weeks, and adverse  events will be documented. DISCUSSION: This trial may provide evidence regarding  the clinical effectiveness, safety, and cost-effectiveness of a TCMCMC for  patients with AxSpA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03420404 .  Registered on 14 February 2018.
C1 Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.
   Department of Rheumatology and Immunology, Singapore General Hospital, Academia Building, Level 4, 20 College Road, Singapore, 169856, Singapore.
   Duke-NUS Medical School, Singapore, Singapore.
   Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
   Singapore Thong Chai Medical Institution, Singapore, Singapore.
   Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
   Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
   Internal Medicine Residency, SingHealth, Singapore, Singapore.
   Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.
   Department of Rheumatology and Immunology, Singapore General Hospital, Academia Building, Level 4, 20 College Road, Singapore, 169856, Singapore.
   Singapore Thong Chai Medical Institution, Singapore, Singapore.
   Singapore Thong Chai Medical Institution, Singapore, Singapore.
   Singapore Thong Chai Medical Institution, Singapore, Singapore.
   Singapore Thong Chai Medical Institution, Singapore, Singapore.
   Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, People's Republic of China.
   Department of Pharmacy, National University of Singapore, Singapore, Singapore.
   Department of Rheumatology and Immunology, Singapore General Hospital, Academia Building, Level 4, 20 College Road, Singapore, 169856, Singapore.
   Duke-NUS Medical School, Singapore, Singapore.
   Department of Rheumatology and Immunology, Singapore General Hospital, Academia Building, Level 4, 20 College Road, Singapore, 169856, Singapore.
   Department of Rheumatology and Immunology, Singapore General Hospital, Academia Building, Level 4, 20 College Road, Singapore, 169856, Singapore.
   Department of Rheumatology and Immunology, Singapore General Hospital, Academia Building, Level 4, 20 College Road, Singapore, 169856, Singapore.
   Department of Rheumatology and Immunology, Singapore General Hospital, Academia Building, Level 4, 20 College Road, Singapore, 169856, Singapore.
   Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore. julian.thumboo@singhealth.com.sg.
   Department of Rheumatology and Immunology, Singapore General Hospital, Academia 
   Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.
NR 0
TC 0
SN 1745-621
EI 
J9 Trials
PD JAN 16
PY 2019
VL 20
IS 1
BP 46
EP 46
DI 10.1186/s13063-018-3117-2
PG 0
WC Acupuncture Therapy; Back Pain; diagnosis; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Interdisciplinary Communication; Male; Medical History Taking; Medicine, Chinese Traditional; adverse effects; Patient Care Team; Physical Examination; Pragmatic Clinical Trials as Topic; Rheumatologists; economics; Singapore; Spondylarthropathies; diagnosis; Time Factors; Treatment Outcome
UT PubMed:30642381
PM 30642381
DA 2019-01-16
ER

PT J
AU He, Y
   May, BH
   Zhang, AL
   Guo, X
   Liu, Y
   Qu, Y
   Chang, X
   Lu, CJ
   Xue, CC
   Zhang, H
AF He, Yihan
   May, Brian H
   Zhang, Anthony Lin
   Guo, Xinfeng
   Liu, Yihong
   Qu, Yanchun
   Chang, Xuesong
   Lu, Chuan-Jian
   Xue, Charlie Changli
   Zhang, Haibo
TI Acupuncture for cancer pain: protocol for a pilot pragmatic randomised controlled
SO BMJ open
LA English
DT Journal Article
DE acupuncture; cancer pain; pilot; pragmatic randomised controlled trial; protocol
AB INTRODUCTION: Although acupuncture has been recommended for alleviating cancer  pain by clinical guidelines, the level of the supporting evidence needs to be  improved. A pragmatic randomised controlled trial (pRCT) in a hospital setting  would provide real-world assessments of the overall clinical effects of  acupuncture. This pilot trial aims to explore the feasibility and provide data  for sample size calculations for a pRCT evaluating the effectiveness of  acupuncture as an adjunctive therapy to routine medical care for cancer pain.  METHODS AND ANALYSIS: Thirty patients with cancer admitted to the oncology  department with moderate or severe pain will be recruited. Participants will be  randomised at a ratio of 1:1 to the adjunctive acupuncture group or a control  group which receives routine pain management without acupuncture. The  standardised section of the acupuncture protocol will be developed based on the  results of reviews of the literature, recommendations in clinical guidelines and  interviews with clinical experts. The acupuncturist will be allowed to tailor the  protocol according to the individual situation of each participant. Primary  outcomes relevant to the feasibility of conducting a fully powered trial include:  numbers and proportions of participants recruited, screened, consented and  randomised; numbers and reasons for withdrawals and dropouts; numbers and types  of adverse events; feasibility of implementing the trial procedures; evaluation  of the comprehensiveness and ease-of-use of the case report form. Secondary  outcomes are clinical measurements of the effectiveness of the treatment that are  intended for use in the full-scale trial. Analysis of feasibility will be  descriptive and pain intensity measures will be analysed using mixed-effects  regression. ETHICS AND DISSEMINATION: Ethics approval was obtained from the  Institutional Ethics Committee of Guangdong Provincial Hospital of Chinese  Medicine (approval no: Z2017-184-01) and RMIT University Human Research Ethics  Committee (reference no: 21361). Results will be disseminated in a peer-reviewed  journal, and trial participants will be informed via email and/or phone calls.  TRIAL REGISTRATION NUMBER: ChiCTR1800017023.
C1 Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy ofChinese Medical Science, Guangzhou, Guangdong, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
   China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy ofChinese Medical Science, Guangzhou, Guangdong, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy ofChinese Medical Science, Guangzhou, Guangdong, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy ofChinese Medical Science, Guangzhou, Guangdong, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy ofChinese Medical Science, Guangzhou, Guangdong, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy ofChinese Medical Science, Guangzhou, Guangdong, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy ofChinese Medical Science, Guangzhou, Guangdong, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD JUL 11
PY 2019
VL 9
IS 7
BP e025564
EP e025564
DI 10.1136/bmjopen-2018-025564
PG 1
WC Acupuncture Therapy; Adult; Cancer Pain; psychology; Female; Humans; Male; Pain Management; methods; Pain Measurement; Pilot Projects; Pragmatic Clinical Trials as Topic; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:31289059
PM 31289059
DA 2019-07-11
ER

PT J
AU Wang, PM
   Hsu, CW
   Liu, CT
   Lai, TY
   Tzeng, FL
   Huang, CF
AF Wang, Pei-Ming
   Hsu, Ching-Wen
   Liu, Chun-Ting
   Lai, Ting-Yu
   Tzeng, Fe-Ling
   Huang, Chih-Fang
TI Effect of acupressure on constipation in patients with advanced cancer
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Advanced cancer; Constipation; Acupressure; Complementary medicine
ID opioid-induced constipation; symptom management; self-acupressure; acupuncture; efficacy; pain; therapy; trials
AB PurposeConstipation is a common and distressing symptom for patients with advanced cancer. Few reports have focused on the symptoms of constipation in patients with advanced cancer. The aim of this study was to investigate the effect of a short-term acupressure intervention on patients with advanced cancer.MethodsThis study used a non-randomized, pre-post study design to assess the effect of acupressure intervention. A total of 30 patients with advanced cancer were recruited from the hospice unit of a medical center in southern Taiwan. In addition to routine care, patients in the intervention group received an 8-min acupressure treatment daily for 3 consecutive days. Three acupoints were used in this study: Zhongwan (CV12), Guanyuan (CV4), and Tianshu (ST25). Analysis of covariance was used to compare the differences in symptoms of constipation between the two groups, adjusted for baseline values. Effect sizes were calculated using partial eta squared (eta(2)).ResultsSignificant improvements in symptoms of constipation (partial eta(2)=0.40, p<0.001 for straining during defecation; partial eta(2)=0.30, p=0.002 for hard stools; partial eta(2)=0.42, p<0.001 for sensation of incomplete evacuation; and partial eta(2)=0.29, p=0.002 for sensation of anorectal obstruction), Bristol stool form scale scores (partial eta(2)=0.40, p<0.001), comfort levels during defecation (partial eta(2)=0.82, p<0.001), and colonic motility (partial eta(2)=0.85, p<0.001) were observed in patients receiving acupressure intervention compared with the controls.ConclusionsFindings from this study indicated that short-term acupressure was effective in alleviating symptoms of constipation among patients with advanced cancer. Further, randomized controlled trials are warranted to confirm the results.
C1 [Wang, Pei-Ming; Huang, Chih-Fang] Kaohsiung Chang Gung Mem Hosp, Dept Family Med, 123 Dapi Rd, Kaohsiung 83301, Taiwan.
   [Hsu, Ching-Wen; Lai, Ting-Yu; Tzeng, Fe-Ling] Kaohsiung Chang Gung Mem Hosp, Dept Nursing, Kaohsiung, Taiwan.
   [Liu, Chun-Ting] Kaohsiung Chang Gung Mem Hosp, Dept Chinese Med, Kaohsiung, Taiwan.
   [Huang, Chih-Fang] Chung Hwa Univ Med Technol, Dept Long Term Care, Tainan, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chung Hua University
RP Huang, CF (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Family Med, 123 Dapi Rd, Kaohsiung 83301, Taiwan.; Huang, CF (corresponding author), Chung Hwa Univ Med Technol, Dept Long Term Care, Tainan, Taiwan.
EM pauline.chifang@gmail.com
CR Abbott R, 2015, J GEN INTERN MED, V30, P434, DOI 10.1007/s11606-014-3084-6
   Abramowitz L, 2013, J MED ECON, V16, P1423, DOI 10.3111/13696998.2013.851082
   Unknown -, 2016, PHARMACOL, V0, P0
   Chang CM, 2011, CHANG GUNG NURSING, V22, P311
   Chen YW, 2014, PAIN MANAG NURS, V15, P539, DOI 10.1016/j.pmn.2012.12.005
   Dhingra L, 2013, PALLIATIVE MED, V27, P447, DOI 10.1177/0269216312450358
   Ford AC, 2013, AM J GASTROENTEROL, V108, P1566, DOI 10.1038/ajg.2013.169
   Hrobjartsson A, 2014, INT J EPIDEMIOL, V43, P1272, DOI 10.1093/ije/dyu115
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee EJ, 2011, J PAIN SYMPTOM MANAG, V42, P589, DOI 10.1016/j.jpainsymman.2011.01.007
   Lee Myeong Soo, 2010, BMC RES NOTES, V3, P284, DOI 10.1186/1756-0500-3-284
   Lee Myeong Soo, 2010, CHIN MED, V5, P28, DOI 10.1186/1749-8546-5-5
   Lembo AJ, 2011, NEW ENGL J MED, V365, P527, DOI 10.1056/NEJMoa1010863
   Levett KM, 2014, COMPLEMENT THER MED, V22, P523, DOI 10.1016/j.ctim.2014.03.011
   Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203
   Li MK, 2010, J ALTERN COMPLEM MED, V16, P435, DOI 10.1089/acm.2009.0348
   Lin SF, 2011, J. NURS. HEALTHC. RES., V7, P175, DOI 10.6225/JNHR.7.3.175
   Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   Luo D, 2008, DIGEST DIS SCI, V53, P689, DOI 10.1007/s10620-007-9929-7
   Mehta Piyush, 2017, J TRADIT COMPLEMENT MED, V7, P251, DOI 10.1016/j.jtcme.2016.06.004
   Patsopoulos Nikolaos A, 2011, DIALOGUES CLIN NEUROSCI, V13, P217
   Perdue Colin, 2005, NURS TIMES, V101, P36
   Rhondali W, 2013, J PAIN SYMPTOM MANAG, V45, P23, DOI 10.1016/j.jpainsymman.2012.01.009
   Sbahi Hani, 2015, CURR GASTROENTEROL REP, V17, P47, DOI 10.1007/s11894-015-0471-z
   Shin HS, 2007, J ADV NURS, V59, P510, DOI 10.1111/j.1365-2648.2007.04342.x
   Shin J, 2018, WESTERN J NURS RES, V40, P67, DOI 10.1177/0193945916680362
   Sinclair M, 2011, J BODYW MOV THER, V15, P436, DOI 10.1016/j.jbmt.2010.07.007
   Song HJ, 2015, COMPLEMENT THER MED, V23, P68, DOI 10.1016/j.ctim.2014.11.002
   Sykes Nigel P, 2006, J SUPPORT ONCOL, V4, P213
   Walsh D, 2000, SUPPORT CARE CANCER, V8, P175, DOI 10.1007/s005200050281
   Wang XJ, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/396396
   Woodward S, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008486.pub2
   World Health Organization, 2008, WHO STANDARD ACUPUNCTURE POINT LOCATIONS IN THE WESTERN PACIFIC REGION, V1st ed., P0
   Yin JY, 2010, AUTON NEUROSCI-BASIC, V157, P31, DOI 10.1016/j.autneu.2010.03.007
   Zhang T, 2013, AM J CHINESE MED, V41, P717, DOI 10.1142/S0192415X13500493
NR 36
TC 18
Z9 22
U1 1
U2 34
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD SEP 15
PY 2019
VL 27
IS 9
BP 3473
EP 3478
DI 10.1007/s00520-019-4655-1
PG 6
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA IL9QJ
UT WOS:000477618900032
PM 30675666
DA 2026-01-16
ER

PT J
AU Asmussen, S
   Przkora, R
   Maybauer, DM
   Fraser, JF
   Sanfilippo, F
   Jennings, K
   Adamzik, M
   Maybauer, MO
AF Asmussen, Sven
   Przkora, Rene
   Maybauer, Dirk M.
   Fraser, John F.
   Sanfilippo, Filippo
   Jennings, Kristofer
   Adamzik, Michael
   Maybauer, Marc O.
TI Meta-Analysis of Electroacupuncture in Cardiac Anesthesia and Intensive Care
SO JOURNAL OF INTENSIVE CARE MEDICINE
LA English
DT Article
DE systematic review; transcutaneous electrical acupoint stimulation; anesthetic drugs; cytokines; immune response
ID electrical-stimulation; auricular acupuncture; postoperative nausea; acupoint; release; surgery; rats; cardioprotection; pretreatment; reperfusion
AB Background: Acupuncture treatment has been employed in China for over 2500 years and it is used worldwide as analgesia in acute and chronic pain. Acupuncture is also used in general anesthesia (GA). The aim of this systematic review and meta-analysis was to assess the efficacy of electroacupuncture (EA) in addition to GA in patients undergoing cardiac surgery. Methods: We searched 3 databases (Pubmed, Cochrane Library, and Web of Science-from 1965 until January 31, 2017) for randomized controlled trials (RCTs) including patients undergoing cardiac surgery and receiving GA alone or GA + EA. As primary outcomes, we investigated the association between GA + EA approach and the dosage of intraoperative anesthetic drugs administered, the duration of mechanical ventilation (MV), the postoperative dose of vasoactive drugs, the length of intensive care unit (ICU) and hospital stay, and the levels of troponin I and cytokines. Results: The initial search yielded 477 citations, but only 7 prospective RCTs enrolling a total of 321 patients were included. The use of GA + EA reduced the dosage of intraoperative anesthetic drugs (P < .05), leading to shorter MV time (P < .01) and ICU stay (P < .05) as well as reduced postoperative dose of vasoactive drugs (P < .001). In addition, significantly lower levels of troponin I (P < .01) and tumor necrosis factor alpha (P < .01) were observed. Conclusion: The complementary use of EA for open-heart surgery reduces the duration of MV and ICU stay, blunts the inflammatory response, and might have protective effects on the heart. Our findings stimulate future RCT to provide definitive recommendations.
C1 [Asmussen, Sven; Adamzik, Michael] Ruhr Univ Bochum, Univ Hosp Knappschaftskrankenhaus, Dept Anaesthesiol Intens Care & Pain Med, Schornau 23-25, D-44892 Bochum, Germany.
   [Asmussen, Sven; Przkora, Rene; Maybauer, Dirk M.; Jennings, Kristofer; Maybauer, Marc O.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA.
   [Asmussen, Sven; Przkora, Rene; Maybauer, Dirk M.; Jennings, Kristofer; Maybauer, Marc O.] Univ Texas Med Branch, Dept Epidemiol & Biostat, Galveston, TX 77555 USA.
   [Asmussen, Sven; Fraser, John F.; Maybauer, Marc O.] Univ Queensland, Prince Charles Hosp, Crit Care Res Grp, Brisbane, Qld, Australia.
   [Przkora, Rene] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL USA.
   [Maybauer, Dirk M.; Maybauer, Marc O.] St George Hosp, Dept Cardiothorac Anaesthesia & Crit Care, London, England.
   [Sanfilippo, Filippo] ISMETT, IRCCS, Ist Mediterraneo Trapianti & Terapie Alta Special, Dept Anesthesia & Intens Care, Palermo, Italy.
   [Sanfilippo, Filippo] Philipps Univ, Dept Anaesthesiol & Intens Care, Marburg, Germany.
   [Maybauer, Marc O.] Univ Manchester, Manchester Royal Infirm, Cent Manchester Univ Hosp NHS Fdn Trust, Cardiothorac Anaesthesia & Intens Care, Manchester, Lancs, England.
C3 Ruhr University Bochum; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Prince Charles Hospital; University of Queensland; State University System of Florida; University of Florida; City St Georges, University of London; IRCCS Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT); Philipps University Marburg; University of Manchester
RP Asmussen, S (corresponding author), Ruhr Univ Bochum, Univ Hosp Knappschaftskrankenhaus, Dept Anaesthesiol Intens Care & Pain Med, Schornau 23-25, D-44892 Bochum, Germany.
EM sven.asmussen@kk-bochum.de
FU Queensland Health OHMR; NHMRC [1010939]; National Health and Medical Research Council (NHMRC) [1010939] Funding Source: National Health and Medical Research Council (NHMRC)
CR An Li-xin, 2011, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V31, P1181
   An Li-xin, 2010, ZHONGGUO ZHEN JIU, V30, P669
   An Li-Xin, 2010, ZHEN CI YAN JIU, V35, P368
   Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Unknown -, 1996, CHIN J PAIN MED, V0, P0
   Arnberger M, 2007, ANESTHESIOLOGY, V107, P903, DOI 10.1097/01.anes.0000290617.98058.d9
   Bause GS, 2009, ANESTHESIOLOGY, V111, P924, DOI 10.1097/01.anes.0000350856.35701.cb
   CHENG RSS, 1980, LIFE SCI, V26, P631, DOI 10.1016/0024-3205(80)90239-8
   Collaboration TC, 2011, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V0, P0
   Cooke M, 2014, BMJ OPEN, V4, P0, DOI 10.1136/bmjopen-2014-006179
   Gao JH, 2006, J PHYSIOL SCI, V56, P275, DOI 10.2170/physiolsci.RP006606
   Gemma M, 2015, J INTEGR MED-JIM, V13, P99, DOI 10.1016/S2095-4964(15)60159-5
   Greif R, 2002, ANESTHESIOLOGY, V96, P306, DOI 10.1097/00000542-200202000-00014
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Howick J, 2011, THE 2011 OXFORD CEBM EVIDENCE LEVELS OF EVIDENCE (INTRODUCTORY DOCUMENT), V0, P0
   Hunter RF, 2012, CLIN J PAIN, V28, P259, DOI 10.1097/AJP.0b013e3182274018
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   Lee S, 2013, CHIN J INTEGR MED, V19, P277, DOI 10.1007/s11655-013-1425-7
   Lu Jian-Qin, 2013, ZHEN CI YAN JIU, V38, P245
   Ma Fuguo, 2015, ZHONGGUO ZHEN JIU, V35, P707
   Ma LY, 2014, AM J PHYSIOL-HEART C, V306, P0, DOI 10.1152/ajpheart.00889.2013
   Ni XL, 2012, PEDIATR ANESTH, V22, P805, DOI 10.1111/j.1460-9592.2012.03822.x
   Pettersson PH, 2012, J CLIN NURS, V21, P1799, DOI 10.1111/j.1365-2702.2012.04114.x
   Redington KL, 2013, J PHYSIOL SCI, V63, P219, DOI 10.1007/s12576-013-0259-6
   Ren XJ, 2012, CHINESE MED J-PEKING, V125, P1627, DOI 10.3760/cma.j.issn.0366-6999.2012.09.019
   Shan Jiang-Gui, 2010, ZHONGGUO ZHEN JIU, V30, P585
   Shankar Nilima, 2011, INDIAN J PHYSIOL PHARMACOL, V55, P25
   Song Q, 2014, AFR J TRADIT COMPLEM, V11, P469, DOI 10.4314/ajtcam.v11i2.35
   Syuu Y, 2001, JPN J PHYSIOL, V51, P231, DOI 10.2170/jjphysiol.51.231
   Tsou MT, 2004, AM J CHINESE MED, V32, P951, DOI 10.1142/S0192415X04002557
   Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004
   Wang B G, 1994, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V14, P10
   Wang J L, 2001, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V21, P180
   Wang LP, 2012, PAIN MED, V13, P623, DOI 10.1111/j.1526-4637.2012.01376.x
   Wu Yan-Chun, 2007, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V27, P1070
   Yang LF, 2010, ANN THORAC SURG, V89, P781, DOI 10.1016/j.athoracsur.2009.12.003
   Yang Q G, 2001, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V21, P729
   Yang Qing-guo, 2003, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V23, P887
   [杨庆国 Yang Qingguo], 2006, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V26, P503
   Yu Hui-jie, 2016, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V36, P289
   Zhang HH, 2012, BRAIN RES BULL, V89, P71, DOI 10.1016/j.brainresbull.2012.06.008
   Zhang LX, 1997, BRAIN RES, V745, P158, DOI 10.1016/S0006-8993(96)01095-5
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang RX, 2005, J ALTERN COMPLEM MED, V11, P135, DOI 10.1089/acm.2005.11.135
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou W, 2012, AM J PHYSIOL-HEART C, V302, PH1818, DOI 10.1152/ajpheart.00030.2012
NR 48
TC 25
Z9 28
U1 1
U2 46
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0885-0666
EI 1525-1489
J9 J INTENSIVE CARE MED
JI J. Intensive Care Med.
PD AUG 15
PY 2019
VL 34
IS 8
BP 652
EP 661
DI 10.1177/0885066617708558
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA IF6JP
UT WOS:000473187300008
PM 28569130
DA 2026-01-16
ER

PT J
AU So, TH
   Chan, SK
   Lee, VHF
   Chen, BZ
   Kong, FM
   Lao, LX
AF So, T-H
   Chan, S-K
   Lee, V. H-F
   Chen, B-Z
   Kong, F-M
   Lao, L-X
TI Chinese Medicine in Cancer Treatment - How is it Practised in the East and the West?
SO CLINICAL ONCOLOGY
LA English
DT Article
DE Cancer management; Chinese medicine; herbal medicine; traditional Chinese medicine
ID cell lung-cancer; chemotherapy-induced nausea; breast-cancer; controlled-trial; hot flashes; acupuncture; multicenter; management; fatigue; pain
AB Chinese medicine therapies in cancer treatment are very common in the East. Although it is usually classified as a form of complementary and alternative therapy in the West, Chinese medicine is an independent medical profession in Hong Kong and mainland China. It has a different perspective in understanding health and diseases compared with Western medicine. In oncology practice, whereas Western medicine focuses on direct tumour eradication by surgery, radiation therapy and systemic therapies, Chinese medicine focuses on restoring body balance and enhancing the body's defences (immunity), in addition to some cytotoxic herbal therapies. Most often patients, especially those in the East, receive both treatments. Chinese medicine is also commonly used to reduce side-effects from chemotherapy or radiation therapy, to aid recovery after an operation, to palliate symptoms and to address survivorship issues. However, this raises concerns of drug-herb interactions and toxicity in combination therapies. Commonly used Chinese medicine treatment modalities include acupuncture, moxibustion, diet therapy, prescribed Chinese medicine herbal decoction, single Chinese medicine herbs or supplements and tai chi. Although there is an increasing trend of Chinese medicine use in cancer patients in both the East and the West, the scientific evidence of safety and efficacy is often questioned by oncologists. This article reviews the current evidence in different Chinese medicine therapies in cancer management in both the East and the West. (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [So, T-H; Chan, S-K; Lee, V. H-F; Kong, F-M] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Lee, V. H-F; Kong, F-M] Univ Hong Kong, Shenzhen Hosp, Clin Oncol Ctr, Shenzhen, Peoples R China.
   [Chen, B-Z] Chinese Univ Hong Kong, Hong Kong Inst Integrat Med, Hong Kong, Peoples R China.
   [Lao, L-X] Univ Hong Kong, Li Ka Shing Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
   [Lao, L-X] Univ Hong Kong, Shenzhen Hosp, Dept Chinese Med, Shenzhen, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; University of Hong Kong
RP So, TH (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China.
EM sth495@hku.hk
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2018, TRADITIONAL CHINESE, V0, P0
   Unknown -, 2019, NCCN CLIN PRACTICE G, V0, P0
   Unknown -, 2005, COCHRANE DB SYST REV, V0, P0
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Chen BZ, 2012, DIAGNOSIS CHINESE ME, V0, P0
   Chen CM, 2014, CHIN J INTEGR MED, V20, P496, DOI 10.1007/s11655-014-1864-9
   Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Fai CK, 2011, RECENT PATENTS INFLA, V5, P169, DOI 10.2174/187221311795399237
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8
   Fu HW, 2015, J ACUPUNCT MERIDIAN, V8, P122, DOI 10.1016/j.jams.2014.09.003
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Jiang Y, 2016, COMPLEMENT THER MED, V24, P55, DOI 10.1016/j.ctim.2015.12.006
   Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487
   Johnson SB, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx145
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Kann BH, 2017, J CLIN ONCOL, V35, P0, DOI 10.1200/JCO.2017.35.15_suppl.e15162
   Khan M A, 2010, THE OPEN NUTRACEUTICAL JOURNAL, V3, P179, DOI 10.2174/18763960010030100179
   Komoroski BJ, 2004, DRUG METAB DISPOS, V32, P512, DOI 10.1124/dmd.32.5.512
   Lam WC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1038206
   Lam W, 2018, CANCER RES, V78, P0, DOI 10.1158/1538-7445.AM2018-2724
   Lam W, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep09384
   Lam Yuen-chi, 2009, CHIN MED, V4, P25, DOI 10.1186/1749-8546-4-25
   Leung G, 2019, EFFECT PUERARIN HEAR, V0, P0
   LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6
   Liu JP, 2015, COMPLEMENT THER MED, V23, P751, DOI 10.1016/j.ctim.2015.08.001
   Liu J, 2017, CHIN J INTEGR MED, V23, P733, DOI 10.1007/s11655-016-2737-1
   Liu J, 2015, THORAC CANCER, V6, P561, DOI 10.1111/1759-7714.12270
   Lu AP, 2004, WORLD J GASTROENTERO, V10, P1854
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Lu WD, 2009, J ALTERN COMPLEM MED, V15, P745, DOI 10.1089/acm.2008.0589
   Ma M, 2015, INT J RADIAT ONCOL, V93, PE511, DOI 10.1016/j.ijrobp.2015.07.1856
   Ma MW, 2018, NUTR CANCER, V70, P1166, DOI 10.1080/01635581.2018.1504091
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao Jun James, 2009, J SOC INTEGR ONCOL, V7, P52
   McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Morelli MP, 2015, ANN ONCOL, V26, P731, DOI 10.1093/annonc/mdv005
   Nakamura K, 2015, J PHARMACOL SCI, V127, P53, DOI 10.1016/j.jphs.2014.09.001
   Panel on Health Services, 2018, LIST OUTST IT DISC D, V0, P0
   Patil S, 2016, CURR PAIN HEADACHE R, V20, P0, DOI 10.1007/s11916-016-0552-1
   Podoltsev NA, 2009, J CLIN ONCOL, V27, P0
   Qi GD, 2008, RECENT PATENTS INFLA, V2, P123, DOI 10.2174/187221308784543700
   Reindl TK, 2006, SUPPORT CARE CANCER, V14, P172, DOI 10.1007/s00520-005-0846-z
   Saif MW, 2014, CANCER CHEMOTH PHARM, V73, P373, DOI 10.1007/s00280-013-2359-7
   Sato T, 2018, J NAT MED-TOKYO, V72, P211, DOI 10.1007/s11418-017-1135-0
   Shen T, 2019, GASTROENTEROLOGY, V156, P2230, DOI 10.1053/j.gastro.2019.02.002
   Shi ZF, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-04351-y
   Sliva Daniel, 2003, INTEGR CANCER THER, V2, P358, DOI 10.1177/1534735403259066
   Teschke R, 2015, ANN HEPATOL, V14, P7, DOI 10.1016/S1665-2681(19)30796-3
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   VINCENT C, 1995, J ROY SOC MED, V88, P199
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wong W, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419828836
   Yuen MFL, 2016, HEPATOL INT, V10, P0
   Yung T, 2016, CHINESE MED CM SAFET, V0, P0
NR 65
TC 71
Z9 77
U1 2
U2 101
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0936-6555
EI 1433-2981
J9 CLIN ONCOL-UK
JI Clin. Oncol.
PD AUG 15
PY 2019
VL 31
IS 8
BP 578
EP 588
DI 10.1016/j.clon.2019.05.016
PG 11
WC Oncology
SC Oncology
GA IG2EP
UT WOS:000473609300012
PM 31178347
DA 2026-01-16
ER

PT J
AU Fu, YB
   Li, B
   Sun, SF
   Liu, HL
   Wang, X
   Wang, SS
   Zhang, F
   Du, X
   Ge, DJ
   Shang, L
   Liang, RL
   Wang, LN
   Yuan, F
   Sun, JQ
   Chen, JW
AF Fu, Yuan-Bo
   Li, Bin
   Sun, San-Feng
   Liu, Hui-Lin
   Wang, Xin
   Wang, Shao-Song
   Zhang, Fan
   Du, Xin
   Ge, Du-Juan
   Shang, Lei
   Liang, Rui-Li
   Wang, Li-Na
   Yuan, Fang
   Sun, Jing-Qing
   Chen, Jun-Wei
TI Fire acupuncture for mild to moderate knee osteoarthritis: a protocol for a
SO Trials
LA English
DT Journal Article
DE Basic health management; Fire Acupuncture; Knee Osteoarthritis
AB BACKGROUND: Knee osteoarthritis (KOA) is one of the most common bone and joint  diseases. As one of the main non-drug therapies, acupuncture is widely used to  treat KOA, although the evidence for its efficacy is inconclusive. The objective  of this pilot trial is to clarify the clinical efficacy and safety of fire  acupuncture in the treatment of mild to moderate KOA and to provide high-quality  data for further research. METHODS/DESIGN: This study is a prospective randomized  controlled pilot trial in which 120 patients with mild to moderate KOA will be  randomly allocated in equal proportions to a fire acupuncture group or a general  acupuncture group. They will receive acupuncture for six sessions over 2 weeks.  The primary end point is success rate, which will be calculated based on the  change from baseline of the pain and function scores in the Western Ontario and  McMaster Universities Osteoarthritis Index at 4 weeks. Secondary end points  include the proportion of patients achieving clinical improvement based on: (1)  the OMERACT-OARSI responder criteria, (2) levels of matrix metalloproteinase 3,  interleukin 1β, and tumor necrosis factor α in blood, and (3) a subjective  efficacy evaluation from patients. TRIAL REGISTRATION: Chinese Clinical Trial  Registry, ChiCTR1800019162. Registered on 29 October 2018.
C1 The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China.
   Beijing Huairou District Hospital of Traditional Chinese Medicine, No. 1 Houheng 
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China.
   Beijing Huairou District Hospital of Traditional Chinese Medicine, No. 1 Houheng Street, Huairou District, Beijing, 101400, China.
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China.
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China.
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China.
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China.
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China.
   Beijing Huairou District Hospital of Traditional Chinese Medicine, No. 1 Houheng Street, Huairou District, Beijing, 101400, China.
   Beijing Huairou District Hospital of Traditional Chinese Medicine, No. 1 Houheng Street, Huairou District, Beijing, 101400, China.
   Beijing Huairou District Hospital of Traditional Chinese Medicine, No. 1 Houheng Street, Huairou District, Beijing, 101400, China.
   Beijing Huairou District Hospital of Traditional Chinese Medicine, No. 1 Houheng Street, Huairou District, Beijing, 101400, China.
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China.
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China. sjqdoctor@163.com.
   The Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory ofAcupuncture Neuromodulation, No. 23 Meishuguanhou Street, Dongcheng District,Beijing, 100010, China. 847431304@qq.com.
   Beijing University of Chinese Medicine, No. 11, Bei San Huan Dong Lu, Chaoyang
NR 0
TC 0
SN 1745-621
EI 
J9 Trials
PD DEC 6
PY 2019
VL 20
IS 1
BP 673
EP 673
DI 10.1186/s13063-019-3744-2
PG 0
WC Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Acupuncture Therapy; methods; Osteoarthritis, Knee; therapy; Pilot Projects; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Multicenter Studies as Topic
UT PubMed:31801600
PM 31801600
DA 2019-12-06
ER

PT J
AU Piedalue, KAL
   Reed, EN
   Oberoi, D
   Carlson, LE
   Landmann, J
AF Piedalue, Katherine-Ann L.
   Reed, Erica N.
   Oberoi, Devesh
   Carlson, Linda E.
   Landmann, Jessa
TI GROUP VERSUS INDIVIDUAL ACUPUNCTURE FOR THE TREATMENT OF CANCER PAIN
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
C1 [Piedalue, Katherine-Ann L.] Univ Calgary, Psychosocial Oncol, Calgary, AB, Canada.
   [Reed, Erica N.] Univ Calgary, Cummings Sch Med, Calgary, AB, Canada.
   [Oberoi, Devesh; Carlson, Linda E.; Landmann, Jessa] Univ Calgary, Cummings Sch Med, Psychosocial Oncol, Naturopath Med, Calgary, AB, Canada.
C3 University of Calgary; University of Calgary; University of Calgary
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD MAY 15
PY 2019
VL 81
IS 4
BP A37
EP A37
DI 
PG 1
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA HX7CG
UT WOS:000467560700105
DA 2026-01-16
ER

PT J
AU Kim, TH
   Kang, JW
AF Kim, Tae-Hun
   Kang, Jung Won
TI Acupuncture for symptoms management in Korean breast cancer survivors: a prospective pilot study
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE acupuncture; aromatase inhibitor-related arthralgia; breast cancer survivor; hot flushes; insomnia; Korea; post-mastectomy pain; sexual dysfunction
ID quality-of-life; hot flashes; unmet needs; reliability; arthralgia; prevalence; version; statistics; validation; depression
AB Background: There is an unmet need for effective treatment of the various treatment-related symptoms experienced by breast cancer survivors. These symptoms could be alleviated by acupuncture. Although several lines of evidence in Western countries suggest that acupuncture has a beneficial effect on symptoms in breast cancer survivors, few relevant studies have been conducted in Korean patients. This pilot study assessed the feasibility of acupuncture for a variety of treatment-related symptoms in Korean breast cancer survivors. Method: From October 2015 to March 2016, we recruited patients who had undergone treatment for breast cancer and subsequently reported symptoms, including aromatase inhibitor-related knee pain, vasomotor symptoms, insomnia, sexual dysfunction and post-mastectomy pain in the chest wall or shoulder. The women received 4 weeks of symptom-specific acupuncture followed by a further 4 weeks of follow-up to evaluate the feasibility of acupuncture for this indication, and its impact on common and symptom-specific outcome variables. Results: Eight study participants were recruited over a period of 6 months, six of whom completed the planned acupuncture treatment and follow-up assessments. A total of 78 acupuncture sessions were performed. We found that acupuncture was feasible, with only six minor self-limiting acupuncture-related adverse events. Most of the women felt that they had benefitted from participation in the study. The preliminary analysis indicated improvement in common symptom-specific outcomes. Conclusion: Our findings suggest that acupuncture is feasible, but low recruitment rates should be considered when considering future acupuncture research in Korean breast cancer survivors. Rigorous evaluation of this symptomatic treatment strategy is now needed in the Korean population.
C1 [Kim, Tae-Hun] Kyung Hee Univ, Korean Med Hosp, Korean Med Clin Trial Ctr, 23 Kyung Hee Dae Ro, Seoul 02447, South Korea.
   [Kang, Jung Won] Kyung Hee Univ, Coll Korean Med, Dept Acupuncture & Moxibust, Seoul, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Kim, TH (corresponding author), Kyung Hee Univ, Korean Med Hosp, Korean Med Clin Trial Ctr, 23 Kyung Hee Dae Ro, Seoul 02447, South Korea.
EM rockandmineral@gmail.com
FU Kyung Hee University
CR Unknown -, 2009, WHO GUIDELINES ON HAND HYGIENE IN HEALTH CARE: FIRST GLOBAL PATIENT SAFETY CHALLENGE CLEAN CARE IS SAFER CARE, V0, P30
   Aronson JK, 2003, BRIT MED J, V326, P1346, DOI 10.1136/bmj.326.7403.1346
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bae SC, 2001, OSTEOARTHR CARTILAGE, V9, P746, DOI 10.1053/joca.2001.0471
   Bauml J, 2014, ACUPUNCT MED, V32, P183, DOI 10.1136/acupmed-2013-010459
   Blaes AH, 2011, SEMIN ONCOL, V38, P394, DOI 10.1053/j.seminoncol.2011.03.009
   Burg MA, 2015, CANCER-AM CANCER SOC, V121, P623, DOI 10.1002/cncr.28951
   Cheng KKF, 2016, SUPPORT CARE CANCER, V24, P2025, DOI 10.1007/s00520-015-2994-0
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659
   Derogatis LR, 2015, CURR SEX HEALTH REP, V7, P151, DOI 10.1007/s11930-015-0052-z
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Han Changsu, 2004, THE WORLD JOURNAL OF MENS HEALTH, V22, P68
   Hervik JB, 2016, BREAST CANCER RES TR, V160, P223, DOI 10.1007/s10549-016-4002-x
   Hewitt M, 2005, CANC PATIENT CANC SU, V0, P0
   HWANG JH, 2015, EVID-BASED COMPL ALT, V2015, P0
   Janz NK, 2007, J WOMENS HEALTH, V16, P1348, DOI 10.1089/jwh.2006.0255
   Jeong YJ, 2013, J ALTERN COMPLEM MED, V19, P690, DOI 10.1089/acm.2012.0347
   Jung KW, 2015, CANCER RES TREAT, V47, P127, DOI 10.4143/crt.2015.060
   Kang E, 2012, SUPPORT CARE CANCER, V20, P461, DOI 10.1007/s00520-011-1094-z
   Kim HY, 2002, KOR. J. ANDROL., V20, P50
   Lawani MA, 2017, SYST REV-LONDON, V6, P0, DOI 10.1186/s13643-017-0446-2
   Levine DW, 2003, PSYCHOL ASSESSMENT, V15, P137, DOI 10.1037/1040-3590.15.2.137
   Li XB, 2018, PHARMACOPSYCHIATRY, V51, P100, DOI 10.1055/s-0043-114670
   Lim JW, 2016, J CANCER EDUC, V31, P108, DOI 10.1007/s13187-015-0790-7
   Maass SWMC, 2015, MATURITAS, V82, P100, DOI 10.1016/j.maturitas.2015.04.010
   Mallory MJ, 2015, AM J CHINESE MED, V43, P45, DOI 10.1142/S0192415X15500032
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   McGahuey CA, 2000, J SEX MARITAL THER, V26, P25, DOI 10.1080/009262300278623
   North Amer Menopause Soc, 2013, MENOPAUSE, V20, P888, DOI 10.1097/gme.0b013e3182a122c2
   Paterson C, 1996, BRIT MED J, V312, P1016
   Pereira S, 2015, BREAST, V24, P582, DOI 10.1016/j.breast.2015.05.006
   Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280
   Sohn SI, 2012, SLEEP BREATH, V16, P803, DOI 10.1007/s11325-011-0579-9
   Spilker B, 1991, GUIDE CLIN TRIALS, V0, P198
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang MH, 2016, GENOME MED, V8, P0, DOI 10.1186/s13073-016-0355-3
   Yun YH, 2004, ONCOLOGY-BASEL, V66, P439, DOI 10.1159/000079497
   Yun YH, 2004, SUPPORT CARE CANCER, V12, P441, DOI 10.1007/s00520-004-0632-3
NR 40
TC 5
Z9 10
U1 0
U2 19
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD JUN 15
PY 2019
VL 37
IS 3
BP 164
EP 174
DI 10.1177/0964528419832610
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA IW9LF
UT WOS:000485314300003
PM 30896247
DA 2026-01-16
ER

PT J
AU Sasaki, Y
   Cheon, C
   Motoo, Y
   Jang, S
   Park, S
   Ko, SG
   Jang, BH
   Hwang, DS
AF Sasaki, Yui
   Cheon, Chunhoo
   Motoo, Yoshiharu
   Jang, Soobin
   Park, Sunju
   Ko, Seong-Gyu
   Jang, Bo-Hyoung
   Hwang, Deok-Sang
TI Complementary and Alternative Medicine for Breast Cancer Patients: An Overview of Systematic Reviews
SO YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
LA Japanese
DT Review
DE complementary and alternative medicine; breast cancer; overview; systematic review
ID quality-of-life; tai-chi; yoga interventions; adjunctive therapy; stress reduction; herbal medicine; hot flashes; acupuncture; survivors; women
AB The application of systematic review (SR) has been increased rapidly in the field of cancer treatment. Complementary and alternative medicine (CAM) for cancer is no exception. The aim of this review is to evaluate and summarize systematic reviews on the CAM use in breast cancer patients. Search sources were Centre for Reviews and Dissemination (CRD), Cochrane Database of Systematic Reviews (CDSR), and PubMed. In addition, we assessed the quality of SR with the Assessing the Methodological Quality of Systematic Reviews (AMSTAR). This review did not consider control groups and outcomes. Thirty-four SRs met a set of criteria. According to interventions, there were twenty SRs which included yoga, acupuncture, and herbal medicines. Meta-analysis of 19 out of 34 reviews showed the followings: (1) acupuncture had a beneficial effect on the frequency of hot flushes, (2) yoga had a beneficial effect on depression and health-related QOL, (3) mindfulness-based stress reduction (MBSR) had a beneficial effect on anxiety and depression, (4) combination of herbal medicine and chemotherapy synergistically improved clinical outcomes, (5) acupuncture did not show significant effect on the severity of hot flushes and cancer-related pain, (6) yoga was unable to be confirmed as having an effect on cancer-related pain and physical well-being. Given the results of AMSTAR, 9 out of 34 reviews were of high quality and 3 reviews were deemed to be of low quality. In conclusion, since most SRs were at moderate or high quality levels, CAM could be helpful for treating specific symptoms related to breast cancer.
C1 [Sasaki, Yui] Kyung Hee Univ, Grad Sch, Dept Appl Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Cheon, Chunhoo; Ko, Seong-Gyu; Jang, Bo-Hyoung] Kyung Hee Univ, Coll Korean Med, Dept Prevent Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Motoo, Yoshiharu] Kanazawa Med Univ, Dept Med Oncol, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan.
   [Jang, Soobin] Korea Inst Oriental Med, Clin Med Div, 1672 Yuseong Daero, Daejeon 34054, South Korea.
   [Park, Sunju] Daejeon Univ, Coll Korean Med, Dept Prevent Med, 62 Daehak Ro, Daejeon 34520, South Korea.
   [Hwang, Deok-Sang] Kyung Hee Univ, Coll Korean Med, Dept Korean Gynecol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kanazawa Medical University; Korea Institute of Oriental Medicine (KIOM); Daejeon University; Kyung Hee University
RP Hwang, DS (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Korean Gynecol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM soulhus@gmail.com
CR Buffart LM, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-559
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Chen YP, 2016, J CANCER RES THER, V12, P535, DOI 10.4103/0973-1482.172716
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chiu HY, 2016, CANCER NURS, V39, P228, DOI 10.1097/NCC.0000000000000278
   Cramer H, 2012, CURR ONCOL, V19, PE343, DOI 10.3747/co.19.1016
   Cramer H, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010802.pub2
   Cramer H, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-412
   De Groef A, 2015, ARCH PHYS MED REHAB, V96, P1140, DOI 10.1016/j.apmr.2015.01.006
   Fritz H, 2014, INTEGR CANCER THER, V13, P12, DOI 10.1177/1534735413477191
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Harder H, 2012, SUPPORT CARE CANCER, V20, P3055, DOI 10.1007/s00520-012-1611-8
   Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126
   Japanese Breast Cancer Society, 2018, JAP BREAST CANC SOC, V0, P0
   Japanese Society for Palliative Medicine, 2016, CLIN EV COMPL ALT TH, V0, P0
   Johannsen M, 2013, BREAST CANCER RES TR, V138, P675, DOI 10.1007/s10549-013-2503-4
   Johns C, 2016, BREAST CANCER RES TR, V156, P415, DOI 10.1007/s10549-016-3765-4
   Kassab S, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004845.pub2
   Kim JI, 2010, INTEGR CANCER THER, V9, P326, DOI 10.1177/1534735410387423
   Kim W, 2015, COMPLEMENT THER MED, V23, P626, DOI 10.1016/j.ctim.2015.03.011
   Lee MS, 2007, SUPPORT CARE CANCER, V15, P597, DOI 10.1007/s00520-007-0221-3
   Lee MS, 2010, BREAST CANCER RES TR, V120, P309, DOI 10.1007/s10549-010-0741-2
   Lee MS, 2009, BREAST CANCER RES TR, V115, P497, DOI 10.1007/s10549-008-0230-z
   Lin KY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/659876
   Ohno S, 2016, JOURNAL FOR THE INTEGRATED STUDY OF DIETARY HABITS, V27, P3, DOI 10.2740/jisdh.27.3
   Pan YQ, 2014, INT J CLIN ONCOL, V19, P829, DOI 10.1007/s10147-013-0635-5
   Pan YQ, 2017, ASIA-PAC J CLIN ONCO, V13, PE79, DOI 10.1111/ajco.12329
   Sadja J, 2013, EXPLORE-NY, V9, P232, DOI 10.1016/j.explore.2013.04.005
   Santos SD, 2010, MED ACUPUNCT, V22, P81
   Seely Dugald, 2005, INTEGR CANCER THER, V4, P144, DOI 10.1177/1534735405276420
   Sharma M, 2016, J CANCER RES CLIN, V142, P2523, DOI 10.1007/s00432-016-2269-2
   Shin ES, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009873.pub3
   Silva V, 2015, SAO PAULO MED J, V133, P206, DOI 10.1590/1516-3180.2013.8150015
   Silva V, 2012, SAO PAULO MED J, V130, P398, DOI 10.1590/S1516-31802012000600007
   Stuiver MM, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009765.pub2
   Suzuki K, 2017, PALLIATIVE CARE RESEARCH, V12, P731, DOI 10.2512/jspm.12.731
   Wang W, 2015, CELL BIOCHEM BIOPHYS, V71, P1299, DOI 10.1007/s12013-014-0348-z
   Yan JH, 2014, ASIAN PAC J CANCER P, V15, P3715, DOI 10.7314/APJCP.2014.15.8.3715
   Zainal NZ, 2013, PSYCHO-ONCOLOGY, V22, P1457, DOI 10.1002/pon.3171
   Zhang J, 2012, J ALTERN COMPLEM MED, V18, P994, DOI 10.1089/acm.2011.0514
   Zhang M, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004921.pub2
   Zhu LB, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/9469276
NR 52
TC 12
Z9 14
U1 2
U2 24
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0031-6903
EI 
J9 YAKUGAKU ZASSHI
JI Yakugaku Zasshi-J. Pharm. Soc. Jpn.
PD JUL 15
PY 2019
VL 139
IS 7
BP 1027
EP 1046
DI 10.1248/yakushi.18-00215
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA IG1PD
UT WOS:000473562600011
PM 31257250
DA 2026-01-16
ER

PT J
AU Chen, LS
   Li, YY
   Chen, H
   Liu, BW
   Wang, DW
   Zhao, YH
AF Chen, Li-Shu
   Li, Yue-Ying
   Chen, Hao
   Liu, Bo-Wen
   Wang, Da-Wei
   Zhao, Yong-Hua
TI Polyglycolic acid sutures embedded in abdominal acupoints for treatment of simple
SO Chinese medicine
LA English
DT Journal Article
DE Polyglycolic acid sutures embedding therapy; Regulation of inflammatory response; Simple obesity; Therapeutic effects
AB BACKGROUND: Acupoint catgut embedding therapy characterized by acupoint, needle  and catgut are superior to traditional acupuncture, due to exerting more  comprehensive therapeutic efficacy. However, it is still deficient in clinical  evidence for polyglycolic acid sutures, a novel biodegradable material instead of  catgut, embedded for the treatment of simple obesity. In our study, we  investigate the efficacy and related mechanism of polyglycolic acid sutures  embedded in abdominal acupoints on simple obese persons by a randomized control  trial. METHODS: A total of 51 eligible participators were randomly allocated to a  polyglycolic acid sutures embedding therapy (PASET) group (n = 28) or control  group (n = 23). Participators in PASET group received polyglycolic acid sutures  alternatively embedded in abdominal I group and II group acupoints in odd and  even number therapeutic courses, and participators in control group were required  to perform lifestyle modification. The duration of the study was 10 weeks.  RESULTS: It suggested that PASET significantly reduced weight, body mass index,  hip circumference, waist circumference, waist/hip ratio, waist-to-height ratio  and thickness of abdominal subcutaneous fat tissue compared with those before  treatment (p < 0.01), but lifestyle modification only illustrated downward trend  of weight (p < 0.05). Moreover, PASET group also improved the evaluated scores in  aspects of physical function, self-esteem, public distress and sexual life, as  well as decreased blood pressure, glycemia, low density lipoprotein, uric acid  and the levels of tumor necrosis factor-alpha, interleukin-1β, and increased high  density lipoprotein in comparison with those before treatment (p < 0.05), whose  efficacies are superior to control group. Additionally, our results also indicate  PASET is relative safe and its pain and discomfort can be tolerable. CONCLUSIONS:  PASET distinctly ameliorates anthropometric data and quality of life in obese  population, which associates with improvements of metabolic profile and  inflammatory response. Based on the advantageous actions, we think PASET is an  effective therapeutic approach to simple obesity treatment.Trial registration  ChiCTR, ChiCTR1800015591. Registered 10 April 2018,  http://www.chictr.org.cn/showproj.aspx?proj=23258.
C1 1Ningbo College of Health Sciences, Ningbo, 315100 China. ISNI: 0000 0004 1760 1080. GRID: grid.496809.a
   Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin'sClinical Research Center for Cancer, Tianjin, 300060 China.
   3Nanjing University of Chinese Medicine, Nanjing, 210046 China. ISNI: 0000 0004 1765 1045. GRID: grid.410745.3
   4Department of Neurology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine,Nanjing, 210008 China. ISNI: 0000 0004 1765 1045. GRID: grid.410745.3
   Shunde Hospital of Guangzhou University of Chinese Medicine, Shunde, 528333 China.
   State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, 999078 Macao SARChina.
NR 0
TC 0
SN 1749-854
EI 1749-854
J9 Chin Med
PD SEP 25
PY 2019
VL 14
IS 
BP 32
EP 32
DI 10.1186/s13020-019-0258-5
PG 0
UT PubMed:31548850
PM 31548850
DA 2019-09-25
ER

PT J
AU He, YH
   May, BH
   Zhang, AL
   Guo, XF
   Liu, YH
   Qu, YC
   Chang, XS
   Lu, CJ
   Xue, CC
   Zhang, HB
AF He, Yihan
   May, Brian H.
   Zhang, Anthony Lin
   Guo, Xinfeng
   Liu, Yihong
   Qu, Yanchun
   Chang, Xuesong
   Lu, Chuan-jian
   Xue, Charlie Changli
   Zhang, Haibo
TI Acupuncture for cancer pain: protocol for a pilot pragmatic randomised controlled trial
SO BMJ OPEN
LA English
DT Article
ID inhibitor-related arthralgia; breast-cancer; sample-size; management; real; validation; expectancy; allocation; sham; electroacupuncture
AB Introduction Although acupuncture has been recommended for alleviating cancer pain by clinical guidelines, the level of the supporting evidence needs to be improved. A pragmatic randomised controlled trial (pRCT) in a hospital setting would provide real-world assessments of the overall clinical effects of acupuncture. This pilot trial aims to explore the feasibility and provide data for sample size calculations for a pRCT evaluating the effectiveness of acupuncture as an adjunctive therapy to routine medical care for cancer pain. Methods and analysis Thirty patients with cancer admitted to the oncology department with moderate or severe pain will be recruited. Participants will be randomised at a ratio of 1:1 to the adjunctive acupuncture group or a control group which receives routine pain management without acupuncture. The standardised section of the acupuncture protocol will be developed based on the results of reviews of the literature, recommendations in clinical guidelines and interviews with clinical experts. The acupuncturist will be allowed to tailor the protocol according to the individual situation of each participant. Primary outcomes relevant to the feasibility of conducting a fully powered trial include: numbers and proportions of participants recruited, screened, consented and randomised; numbers and reasons for withdrawals and dropouts; numbers and types of adverse events; feasibility of implementing the trial procedures; evaluation of the comprehensiveness and ease-of-use of the case report form. Secondary outcomes are clinical measurements of the effectiveness of the treatment that are intended for use in the full-scale trial. Analysis of feasibility will be descriptive and pain intensity measures will be analysed using mixed-effects regression. Ethics and dissemination Ethics approval was obtained from the Institutional Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (approval no: Z2017-184-01) and RMIT University Human Research Ethics Committee (reference no: 21361). Results will be disseminated in a peer-reviewed journal, and trial participants will be informed via email and/or phone calls.
C1 [He, Yihan; Guo, Xinfeng; Liu, Yihong; Qu, Yanchun; Lu, Chuan-jian; Xue, Charlie Changli; Zhang, Haibo] Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Affiliated Hosp 2, Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [He, Yihan; May, Brian H.; Zhang, Anthony Lin; Guo, Xinfeng; Liu, Yihong; Qu, Yanchun; Lu, Chuan-jian; Xue, Charlie Changli; Zhang, Haibo] RMIT Univ, China Australia Int Res Ctr Chinese Med, Sch Hlth & Biomed Sci, Melbourne, Vic, Australia.
   [He, Yihan; Guo, Xinfeng; Liu, Yihong; Qu, Yanchun; Chang, Xuesong; Lu, Chuan-jian; Xue, Charlie Changli; Zhang, Haibo] Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Royal Melbourne Institute of Technology (RMIT); Guangzhou University of Chinese Medicine
RP Xue, CC; Zhang, HB (corresponding author), Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Affiliated Hosp 2, Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China.; Xue, CC; Zhang, HB (corresponding author), RMIT Univ, China Australia Int Res Ctr Chinese Med, Sch Hlth & Biomed Sci, Melbourne, Vic, Australia.; Xue, CC; Zhang, HB (corresponding author), Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Guangdong, Peoples R China.
EM charlie.xue@rmit.edu.au; haibozh@aliyun.com
FU Guangdong Provincial Academy of Chinese Medical Sciences, China; RMIT University through the China-Australia International Research Centre for Chinese Medicine; School of Health and Biomedical Sciences, RMIT University; Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine (2018) [YN2018QL04]; Research Project of Traditional Chinese Medicine Bureau of Guangdong Province (2019) [20191126]
CR Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843
   Unknown -, 2018, BMJ OPEN, V0, P0, DOI DOI 10.1136/bmjopen-2018-021999
   Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Beebe, 1994, NURSING STANDARD, V9, P55, DOI 10.7748/ns.9.11.55.s69.
   Bennett Mike, 2017, AM SOC CLIN ONCOL EDUC BOOK, V37, P705, DOI 10.1200/edbk_180469
   Berger VW, 2010, CONTEMP CLIN TRIALS, V31, P406, DOI 10.1016/j.cct.2010.05.001
   Brady B, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2018-021999
   Chalkidou K, 2012, CLIN TRIALS, V9, P436, DOI 10.1177/1740774512450097
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Craig P, 2008, BMJ-BRIT MED J, V337, P0, DOI 10.1136/bmj.a1655
   Dionne CE, 2012, PAIN, V153, P1338, DOI 10.1016/j.pain.2012.05.001
   Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Ford I, 2016, NEW ENGL J MED, V375, P454, DOI 10.1056/NEJMra1510059
   Franconi G, 2013, EVID BASED COMPLEMEN, V2013, P1
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   Greenlee H, 2015, J ACUPUNCT MERIDIAN, V8, P152, DOI 10.1016/j.jams.2015.03.006
   Hagino A, 2004, CONTROL CLIN TRIALS, V25, P572, DOI 10.1016/j.cct.2004.08.004
   He YH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2017-018494
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P2270, DOI 10.1001/jama.2018.16744
   Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Huang MI, 2006, FERTIL STERIL, V86, P700, DOI 10.1016/j.fertnstert.2006.02.100
   Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185
   Kaptchuk TJ, 2010, CHIN J INTEGR MED, V16, P197, DOI 10.1007/s11655-010-0197-x
   Kim YC, 2015, CANCER MED-US, V4, P1196, DOI 10.1002/cam4.471
   Knaul FM, 2018, LANCET, V391, P0
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lund Irene, 2009, CHIN MED, V4, P1, DOI 10.1186/1749-8546-4-1
   Lundeberg T, 2008, ACUPUNCT MED, V26, P239, DOI 10.1136/aim.26.4.239
   Luo J, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0676-6
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Marcus DA, 2011, CURR PAIN HEADACHE R, V15, P231, DOI 10.1007/s11916-011-0208-0
   May BH, 2014, J ALTERN COMPLEM MED, V20, P937, DOI 10.1089/acm.2013.0372
   Moskovitz Bruce L, 2011, J OPIOID MANAG, V7, P277
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Niemtzow RC, 2006, J ALTERN COMPLEM MED, V12, P597, DOI 10.1089/acm.2006.597
   Nir Y, 2007, MATURITAS, V56, P383, DOI 10.1016/j.maturitas.2006.11.001
   Paley CA, 2017, PAIN MANAG, V7, P345, DOI 10.2217/pmt-2017-0018
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Patsopoulos Nikolaos A, 2011, DIALOGUES CLIN NEUROSCI, V13, P217
   Porzsolt F, 2013, J PUBLIC HEALTH-HEID, V21, P307, DOI 10.1007/s10389-012-0544-5
   Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233
   Schnyer RN, 2008, J ALTERN COMPLEM MED, V14, P515, DOI 10.1089/acm.2007.0826
   Sox HC, 2016, JAMA-J AM MED ASSOC, V316, P1205, DOI 10.1001/jama.2016.11409
   Swarm R, 2010, J NATL COMPR CANC NE, V8, P1046, DOI 10.6004/jnccn.2010.0076
   Taves DR, 2011, CONTEMP CLIN TRIALS, V32, P323, DOI 10.1016/j.cct.2010.12.010
   Thabane L, 2010, BMC MED RES METHODOL, V10, P0, DOI 10.1186/1471-2288-10-1
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   VENTAFRIDDA V, 1987, CANCER-AM CANCER SOC, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1
   VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Witt CM, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-148
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Worsley SD, 2017, J CLIN EPIDEMIOL, V88, P14, DOI 10.1016/j.jclinepi.2017.05.003
   Xiao L, 2013, J MED INTERNET RES, V15, P279, DOI 10.2196/jmir.2392
   Xu ZZ, 2016, STAT MED, V35, P2315, DOI 10.1002/sim.6874
   Yang GS, 2017, CANCER NURS, V40, PE26, DOI 10.1097/NCC.0000000000000409
NR 62
TC 7
Z9 9
U1 1
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD AUG 15
PY 2019
VL 9
IS 7
BP 
EP 
DI 10.1136/bmjopen-2018-025564
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA IW8US
UT WOS:000485269700318
PM 31289059
DA 2026-01-16
ER

PT J
AU Jiang, X
   Tian, Y
   Xu, L
   Zhang, Q
   Wan, Y
   Qi, X
   Li, B
   Guo, J
   Sun, W
   Luo, A
   Huang, J
   Gu, X
AF Jiang, Xin
   Tian, Yehong
   Xu, Lin
   Zhang, Qiaoli
   Wan, Yuxiang
   Qi, Xuewei
   Li, Bo
   Guo, Jing
   Sun, Weiliang
   Luo, Aiping
   Huang, Jinchang
   Gu, Xiaohong
TI Inhibition of Triple-Negative Breast Cancer Tumor Growth by Electroacupuncture
SO International journal of medical sciences
LA English
DT Journal Article
DE Electroacupuncture; Encircled needling; Mechanisms; Triple-negative breast cancer; Tumor inhibition
AB Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast  cancer without effective targeted drugs. While breast cancer patients often use  acupuncture for the relief of cancer-induced pain or the side effects of chemo-  or radiation therapy, little information is known regarding the direct effects of  electroacupuncture on TNBC tumor and its potential mechanisms. Here, we created a  mice model of TNBC and electroacupuncture with encircled needling around the  tumors was given to the animals daily for 3 weeks at 15-20 Hz (3 min, each time).  For sham electroacupuncture control, the skin was punctured to a depth of 5 mm  and then the needle was quickly withdrawn without electrical stimulation or  manual needle manipulation. We found that electroacupuncture significantly  inhibited TNBC tumor growth and the inhibitory rate increased gradually overtime.  Mechanistic analysis showed that electroacupuncture inhibited tumor angiogenesis  by reducing the expression of vascular endothelial growth factor A (VEGF-A), its  receptor VEGF-R and neuropilin 1 (NRP-1). Electroacupuncture also led to a  significant decrease of matrix metalloproteinase-2 (MMP-2) expression and an  increase of tissue inhibitor of MMP (TIMP-2) expression. Additionally, the  expression of semaphorin 3A (Sema3A) and nerve growth factor receptor (NGFR) p75  in TNBC tissue was significantly upregulated in response to electroacupuncture.  Furthermore, tumor necrosis factor (TNF)-alpha level in the serum was  dramatically reduced after electroacupuncture. These results showed that  electroacupuncture could directly inhibit TNBC tumor growth through the  inhibition of proteins related to tumor angiogenesis and extracellular matrix,  the suppression of TNBC-induced inflammation and the upregulation of nerve growth  factor receptors.
C1 Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China.
   School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, 
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China.
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China.
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China.
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China.
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China.
   Department of Traditional Chinese Medicine, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
   Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing 100029, China.
   Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing 100029, China.
   State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing 100021, China.
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China.
   School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
NR 0
TC 0
SN 1449-190
EI 
J9 Int J Med Sci
PD DEC 17
PY 2019
VL 16
IS 12
BP 1642
EP 1651
DI 10.7150/ijms.38521
PG 9
WC Animals; Cell Line, Tumor; Cell Movement; genetics; Cell Proliferation; genetics; Disease Models, Animal; Electroacupuncture; Female; Gene Expression Regulation, Neoplastic; genetics; Humans; Matrix Metalloproteinase 2; genetics; Mice; Neovascularization, Pathologic; genetics; Semaphorin-3A; genetics; Tissue Inhibitor of Metalloproteinase-2; genetics; Triple Negative Breast Neoplasms; therapy; Tumor Necrosis Factor-alpha; genetics; Vascular Endothelial Growth Factor A; genetics; Xenograft Model Antitumor Assays
UT PubMed:31839752
PM 31839752
DA 2019-12-17
ER

PT J
AU Thottungal, A
   Kumar, P
   Bhaskar, A
AF Thottungal, Athmaja
   Kumar, Pranab
   Bhaskar, Arun
TI Interventions for myofascial pain syndrome in cancer pain: recent advances: why,
SO Current opinion in supportive and palliative care
LA English
DT Review
AB PURPOSE OF REVIEW: Pain is one of the most feared and most common symptoms of  cancer, experienced by 38-85% of patients. Pain in terminally ill cancer patients  is a multidimensional experience caused by a diverse array of factors - cancer  itself, its treatment or other causes. Studies have shown a high incidence of  myofascial pain syndrome (MPS) in patients with cancer and the knowledge of  myofascial trigger points (MTrPs) is important to address and manage existing  pain, and to prevent the recurrence of pain. This review aims to summarize recent  advances in interventions for managing MPS in patients with cancer. RECENT  FINDINGS: Database searches were conducted on MEDLINE, CINAHL, and Google Scholar  to locate all studies published from inception until April 2019 using the  keywords cancer pain, myofascial pain, TrPs with emphasis of any methodological  quality that included interventions for MPS. MPS in advanced cancer patients are  more commonly observed along with other cancer pains rather than independently  with a prevalence of 11.9-48% in those patients diagnosed with cancer of head and  neck and breast cancer. SUMMARY: Interventional therapies employing ultrasound  guided injection of the MTrPs is gaining popularity in the management of MPS in  cancer pain and may be a better alternative than the use of opioid analgesics in  the multidisciplinary management.
C1 Department of Anesthesia and Pain Management, East Kent University Hospitals, Kent, United Kingdom.
   Department of Anesthesia and Pain Management, University Health Network-Toronto Western Hospital, Ontario, Canada.
   Department of Anesthesia and Pain Management, Charing Cross University Hospital, London, United Kingdom.
NR 0
TC 0
SN 1751-426
EI 
J9 Curr Opin Support Palliat Care
PD JUL 28
PY 2019
VL 13
IS 3
BP 262
EP 269
DI 10.1097/SPC.0000000000000446
PG 7
WC Acupuncture Therapy; methods; Analgesics; therapeutic use; Anesthetics, Local; therapeutic use; Humans; Myofascial Pain Syndromes; etiology; Neoplasms; complications; Nerve Block; methods; Therapy, Soft Tissue; methods; Trigger Points
UT PubMed:31348012
PM 31348012
DA 2019-07-28
ER

PT J
AU Liang, Y
   Bao, G
   Gong, L
   Zhou, J
   Kong, X
   Ran, R
   Shao, X
   Jiang, Y
   Zhang, W
   Liu, B
   Du, J
   Fang, J
   Nie, N
   Ji, C
   Fang, J
AF Liang, Yi
   Bao, Guanai
   Gong, Liyan
   Zhou, Jie
   Kong, Xiangming
   Ran, Ran
   Shao, Xiaomei
   Jiang, Yongliang
   Zhang, Weiping
   Liu, Boyi
   Du, Junying
   Fang, Junfan
   Nie, Na
   Ji, Conghua
   Fang, Jianqiao
TI Evaluating the analgesic effect and advantage of transcutaneous electrical
SO Trials
LA English
DT Journal Article
DE Cancer-related pain; Randomized controlled trial; Study protocol; TEAS
AB BACKGROUND: Transcutaneous electrical acupoint stimulation (TEAS), which is also  known as acupuncture-like transcutaneous electrical nerve stimulation (TENS), has  been widely used in acute or chronic pain. However, previous research has not  demonstrated that TEAS is effective for cancer-related pain. Opioid drugs are  strongly recommended for treating cancer-related pain, but opioid-induced  immunosuppression is still the most intractable drug-induced medical problem.  Evaluating the efficacy and potential advantage of TEAS combined with opioid  drugs in moderate and severe cancer-related pain in China is important because  such studies are lacking. METHODS/DESIGN: This trial is a multicenter,  prospective randomized controlled clinical trial. In total, 160 patients who were  enrolled from two hospitals in the Zhejiang Province (China) will be randomly  allocated into two groups: a TEAS group and sham TEAS group without acupoint  electrical stimulation. Both groups will receive a 21-day interval of  chemotherapy and conventional cancer pain therapy. Fifteen treatment sessions  will be performed over a three-week period. The primary outcomes will be measured  by changes in the Numerical Rating Scale (NRS) scores and equivalent dosage of  morphine at baseline, three weeks of treatment and one two-week follow-up. The  secondary outcome measures include cellular immunity function, life quality  assessment, opioids side effects assessment, and safety and compliance  evaluation. DISCUSSION: This trial is expected to clarify whether TEAS is  effective for cancer-related pain. These results demonstrate the advantage of  TEAS combined with opioid drugs on improving immune function and decreasing  opioid induced side effects. TRIAL REGISTRATION: Chinese Clinical Trial Registry,  ChiCTR-13003803 . Registered on 27 August 2013.
C1 Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, No. 
   The Zhejiang Cancer Hospital, No. 1 Banshan East Road, Gongshu District, Hangzhou, 310022, Zhejiang Province, China.
   The Zhejiang Cancer Hospital, No. 1 Banshan East Road, Gongshu District, Hangzhou, 310022, Zhejiang Province, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   The Zhejiang Cancer Hospital, No. 1 Banshan East Road, Gongshu District, Hangzhou, 310022, Zhejiang Province, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, No. 
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, No. 
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang Province, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, No. 
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, No. 
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China.
   The Clinical Research Institute of Zhejiang Provincial Hospital of TCM, No.54 Youdian Road, Xihu District, Hangzhou, 310006, Zhejiang Province, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, XiHu District, Hangzhou, 310005,Zhejiang Province, China. fangjianqiao7532@163.com.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, No.
NR 0
TC 0
SN 1745-621
EI 
J9 Trials
PD JAN 13
PY 2019
VL 20
IS 1
BP 40
EP 40
DI 10.1186/s13063-018-3145-y
PG 0
WC Acupuncture Points; Adolescent; Adult; Aged; Analgesics, Opioid; adverse effects; Cancer Pain; diagnosis; China; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pain Measurement; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Transcutaneous Electric Nerve Stimulation; adverse effects; Treatment Outcome; Young Adult
UT PubMed:30635007
PM 30635007
DA 2019-01-13
ER

PT J
AU Li, YY
   Yin, CY
   Li, XJ
   Liu, BY
   Wang, J
   Zheng, XL
   Shao, XM
   Liang, Y
   Du, JY
   Fang, JQ
   Liu, BY
AF Li, Yuanyuan
   Yin, Chengyu
   Li, Xiaojie
   Liu, Boyu
   Wang, Jie
   Zheng, Xiaoli
   Shao, Xiaomei
   Liang, Yi
   Du, Junying
   Fang, Jianqiao
   Liu, Boyi
TI Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Paclitaxel; acupuncture; dorsal root ganglion; peripheral neuropathy; TRPV1; glial cell; TLR4
ID potential vanilloid 1; chemotherapy; receptor; activation; mechanisms; responses; acupuncture; contributes; astrocytes; roles
AB Paclitaxel-induced peripheral neuropathy is a common adverse effect during paclitaxel treatment resulting in sensory abnormalities and neuropathic pain during chemotherapy and in cancer survivors. Conventional therapies are usually ineffective and possess adverse effects. Here, we examined the effects of electroacupuncture (EA) on a rat model of paclitaxel-induced neuropathic pain and related mechanisms. EA robustly and persistently alleviated paclitaxel-induced pain hypersensitivities. Mechanistically, TLR4 (Toll-Like Receptor 4) and downstream signaling MyD88 (Myeloid Differentiation Primary Response 88) and TRPV1 (Transient Receptor Potential Vallinoid 1) were upregulated in dorsal root ganglion (DRGs) of paclitaxel-treated rats, whereas EA reduced their overexpression. Ca2+ imaging further indicated that TRPV1 channel activity was enhanced in DRG neurons of paclitaxel-treated rats whereas EA suppressed the enhanced TRPV1 channel activity. Pharmacological blocking of TRPV1 mimics the analgesic effects of EA on the pain hypersensitivities, whereas capsaicin reversed EA's effect. Spinal astrocytes and microglia were activated in paclitaxel-treated rats, whereas EA reduced the activation. These results demonstrated that EA alleviates paclitaxel-induced peripheral neuropathic pain via mechanisms possibly involving suppressing TLR4 signaling and TRPV1 upregulation in DRG neurons, which further result in reduced spinal glia activation. Our work supports EA as a potential alternative therapy for paclitaxel-induced neuropathic pain.
C1 [Li, Yuanyuan; Yin, Chengyu; Li, Xiaojie; Liu, Boyu; Wang, Jie; Zheng, Xiaoli; Shao, Xiaomei; Liang, Yi; Du, Junying; Fang, Jianqiao; Liu, Boyi] Zhejiang Chinese Med Univ, Key Lab Acupuncture & Neurol Zhejiang Prov, Dept Neurobiol & Acupuncture Res, Clin Med Coll 3, Hangzhou 310053, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Fang, JQ; Liu, BY (corresponding author), Zhejiang Chinese Med Univ, Key Lab Acupuncture & Neurol Zhejiang Prov, Dept Neurobiol & Acupuncture Res, Clin Med Coll 3, Hangzhou 310053, Zhejiang, Peoples R China.
EM yuanyuanlizy@163.com; chengyu.yin@hotmail.com; 18300670930@163.com; lby_0731@163.com; bemyhalo@163.com; zxl861260876@163.com; 13185097375@163.com; liangyiwww@126.com; dujunying0706@163.com; fangjianqiao7532@163.com; boyi.liu@foxmail.com
FU National Natural Science Foundation of China [81873365, 81603676]; Zhejiang Provincial Natural Science Funds for Distinguished Young Scholars [LR17H270001]; Zhejiang Chinese Medical University [Q2019J01, 2018ZY37, 2018ZY19]
CR Ba XY, 2018, BIOMED PHARMACOTHER, V108, P76, DOI 10.1016/j.biopha.2018.09.018
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Brewer JR, 2016, GYNECOL ONCOL, V140, P176, DOI 10.1016/j.ygyno.2015.11.011
   Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Chai WX, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2598975
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Diogenes A, 2011, J DENT RES, V90, P759, DOI 10.1177/0022034511400225
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Ebbinghaus M, 2012, ARTHRITIS RHEUM-US, V64, P3897, DOI 10.1002/art.34675
   Fang D, 2015, PAIN, V156, P1124, DOI 10.1097/j.pain.0000000000000158
   Fang JQ, 2018, LIFE SCI, V200, P69, DOI 10.1016/j.lfs.2018.03.028
   Fang JQ, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-13
   Fehrenbacher JC, 2015, PROG MOL BIOL TRANSL, V131, P471, DOI 10.1016/bs.pmbts.2014.12.002
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Fojo T, 2007, ANN ONCOL, V18, PV3, DOI 10.1093/annonc/mdm172
   Gao W, 2016, ACTA PHARMACOL SIN, V37, P1166, DOI 10.1038/aps.2016.58
   Gavva NR, 2005, J PHARMACOL EXP THER, V313, P474, DOI 10.1124/jpet.104.079855
   Hagiwara Hiroki, 2004, BREAST CANCER, V11, P82, DOI 10.1007/BF02968008
   Hara T, 2013, PAIN, V154, P882, DOI 10.1016/j.pain.2013.02.023
   Hou TF, 2019, PURINERG SIGNAL, V15, P193, DOI 10.1007/s11302-019-09655-4
   Hu QM, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.00453
   Ji RR, 2019, NAT REV NEUROSCI, V20, P667, DOI 10.1038/s41583-019-0218-1
   Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924
   Li Y, 2015, J NEUROSCI, V35, P13487, DOI 10.1523/JNEUROSCI.1956-15.2015
   Li Y, 2014, J PAIN, V15, P712, DOI 10.1016/j.jpain.2014.04.001
   Liu BY, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0165200
   Liu BY, 2016, P NATL ACAD SCI USA, V113, PE7572, DOI 10.1073/pnas.1606608113
   Liu BY, 2013, FASEB J, V27, P3549, DOI 10.1096/fj.13-229948
   Liu BY, 2010, J CLIN INVEST, V120, P1240, DOI 10.1172/JCI41084
   Liu CC, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-76
   Liu T, 2012, NEUROSCI BULL, V28, P131, DOI 10.1007/s12264-012-1219-5
   Liu XJ, 2014, CELL RES, V24, P1374, DOI 10.1038/cr.2014.106
   Luo JL, 2018, J NEUROSCI, V38, P474, DOI 10.1523/JNEUROSCI.1816-17.2017
   Meng J, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.00365
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Min H, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918812636
   Mody MD, 2016, JAMA OTOLARYNGOL, V142, P898, DOI 10.1001/jamaoto.2016.1238
   ONeill LA, 2008, NAT CLIN PRACT RHEUM, V4, P319, DOI 10.1038/ncprheum0802
   Patwardhan AM, 2010, J CLIN INVEST, V120, P1617, DOI 10.1172/JCI41678
   Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3
   Rossato MF, 2018, EUR J PHARMACOL, V828, P42, DOI 10.1016/j.ejphar.2018.03.033
   ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507
   Shim JW, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3485875
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Starobova H, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00174
   Su M, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918754612
   Tai Y, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-07651-5
   Willis DN, 2011, FASEB J, V25, P4434, DOI 10.1096/fj.11-188383
   Wu YW, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919830018
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Xu YM, 2016, ACTA BIOCH BIOPH SIN, V48, P902, DOI 10.1093/abbs/gmw083
   Yen CM, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20184471
   Yin CY, 2019, J PAIN RES, V12, P1201, DOI 10.2147/JPR.S188758
   Zhang HJ, 2012, J PAIN, V13, P293, DOI 10.1016/j.jpain.2011.12.002
   Zhang HM, 2016, J PAIN, V17, P775, DOI 10.1016/j.jpain.2016.02.011
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zheng XL, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919842473
NR 61
TC 126
Z9 146
U1 4
U2 38
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC 15
PY 2019
VL 20
IS 23
BP 
EP 
DI 10.3390/ijms20235917
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA JY5AR
UT WOS:000504428300099
PM 31775332
DA 2026-01-16
ER

PT J
AU Benson, S
   Hagen, S
   Hoffmann, O
   Pasler, A
   Bingel, U
   Schedlowski, M
   Peters, J
   Elsenbruch, S
   Frey, UH
AF Benson, Sven
   Hagen, Susanne
   Hoffmann, Oliver
   Pasler, Annika
   Bingel, Ulrike
   Schedlowski, Manfred
   Peters, Juergen
   Elsenbruch, Sigrid
   Frey, Ulrich H.
TI Can a brief psychological expectancy intervention improve postoperative pain? A randomized, controlled trial in patients with breast cancer
SO PAIN
LA English
DT Article
DE Postoperative pain; Placebo analgesia; Psychological intervention; Positive expectations; Sham acupuncture; Patient-controlled intravenous analgesia
ID placebo analgesia; risk-factors; postsurgical pain; nocebo responses; persistent pain; surgery; expectations; acupuncture; mechanisms; relief
AB Pain after surgery remains a major health problem, calling for optimized treatment regimens to maximize the efficacy of pharmacological interventions. In this randomized controlled trial, we tested in a routine surgical treatment setting whether postoperative pain can be reduced by a brief preoperative intervention, ie, positive verbal suggestions in combination with sham acupuncture, designed to optimize treatment expectations. We hypothesized that the expectancy intervention as add-on to patient-controlled intravenous analgesia with morphine reduces patient-reported postoperative pain and improves satisfaction with analgesia. Ninety-six women undergoing breast cancer surgery were randomized at 2 stages: Before surgery, anesthesiologists delivered either positive or neutral verbal suggestions regarding the benefits of acupuncture needling on postoperative pain ("information condition"). Patients were then randomized to receive sham acupuncture or no sham acupuncture during postoperative care ("sham acupuncture condition"). Average pain during the 24-hour observation period after surgery as primary and satisfaction with analgesia as secondary outcome was assessed with standardized measures and analyzed with analysis of covariance accounting for morphine dose, surgery-related, and psychological parameters. Postoperative pain ratings were significantly reduced in patients who received positive treatment-related suggestions (F = 4.45, P = 0.038, main effect of information). Moreover, patients who received an intervention aimed at optimized treatment expectations reported significantly greater satisfaction with analgesia (F = 4.89, P = 0.030, interaction effect). Together, our proof-of-concept data support that optimizing treatment expectations through verbal suggestions may offer a promising approach to improve patient-reported outcomes. Future translational and clinical studies are needed to test such psychological strategies in different surgical interventions, patient groups, and pharmacological treatment regimens.
C1 [Benson, Sven; Pasler, Annika; Schedlowski, Manfred; Elsenbruch, Sigrid] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Psychol & Behav Immunobiol, Essen, Germany.
   [Hagen, Susanne; Pasler, Annika; Peters, Juergen; Frey, Ulrich H.] Univ Duisburg Essen, Univ Hosp Essen, Klin Anasthesiol & Intens Med, Essen, Germany.
   [Hoffmann, Oliver] Univ Duisburg Essen, Univ Hosp Essen, Clin Obstet & Gynecol, Essen, Germany.
   [Bingel, Ulrike] Univ Duisburg Essen, Univ Hosp Essen, Clin Neurol, Essen, Germany.
   [Frey, Ulrich H.] Ruhr Univ Bochum, Marienhosp Herne, Dept Anesthesiol, Bochum, Germany.
C3 University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; Ruhr University Bochum; St. Marien Hospital
RP Benson, S (corresponding author), Univ Hosp Essen, Inst Med Psychol & Behav Immunobiol, Hufelandstr 55, D-45122 Essen, Germany.
EM sven.benson@uk-essen.de
FU Stiftung Universitatsmedizin, Essen, Germany
CR Amanzio M, 2001, PAIN, V90, P205, DOI 10.1016/S0304-3959(00)00486-3
   Andersen KG, 2011, J PAIN, V12, P725, DOI 10.1016/j.jpain.2010.12.005
   Annoni M, 2018, INT REV NEUROBIOL, V139, P463, DOI 10.1016/bs.irn.2018.07.031
   Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E
   Atlas LY, 2012, J NEUROSCI, V32, P8053, DOI 10.1523/JNEUROSCI.0383-12.2012
   Barnett SF, 2013, ANESTHESIOLOGY, V119, P452, DOI 10.1097/ALN.0b013e3182976014
   Benedetti F, 2013, PHYSIOL REV, V93, P1207, DOI 10.1152/physrev.00043.2012
   Bingel U, 2014, JAMA-J AM MED ASSOC, V312, P693, DOI 10.1001/jama.2014.8342
   Bingel U, 2011, SCI TRANSL MED, V3, P0, DOI 10.1126/scitranslmed.3001244
   Brody H, 2011, JAMA-J AM MED ASSOC, V306, P2612, DOI 10.1001/jama.2011.1850
   Büchel C, 2014, NEURON, V81, P1223, DOI 10.1016/j.neuron.2014.02.042
   Chow A, 2009, SURGERY, V146, P435, DOI 10.1016/j.surg.2009.03.019
   Colloca L, 2018, INT REV NEUROBIOL, V138, P219, DOI 10.1016/bs.irn.2018.01.005
   Colloca L, 2013, PAIN, V154, P511, DOI 10.1016/j.pain.2013.02.002
   Diaz JJH, 2016, HAND SURG REHABIL, V35, P413, DOI 10.1016/j.hansur.2016.08.008
   Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Gärtner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568
   Joshi Girish P, 2005, ANESTHESIOL CLIN NORTH AM, V23, P21, DOI 10.1016/j.atc.2004.11.013
   Kam-Hansen S, 2014, SCI TRANSL MED, V6, P0, DOI 10.1126/scitranslmed.3006175
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Katz J, 2005, PAIN, V119, P16, DOI 10.1016/j.pain.2005.09.008
   Kaunisto MA, 2013, ANESTHESIOLOGY, V119, P1410, DOI 10.1097/ALN.0000000000000012
   Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X
   Kessner S, 2013, JAMA INTERN MED, V173, P1468, DOI 10.1001/jamainternmed.2013.6705
   Klinger R, 2014, PAIN, V155, P1055, DOI 10.1016/j.pain.2013.12.007
   Lehmann N, 2010, BRIT J ANAESTH, V105, P511, DOI 10.1093/bja/aeq186
   LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0
   Linde K, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-75
   Löwe B, 2010, J AFFECT DISORDERS, V122, P86, DOI 10.1016/j.jad.2009.06.019
   Luszczynska A, 2005, J PSYCHOL, V139, P439, DOI 10.3200/JRLP.139.5.439-457
   McNicol ED, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003348.pub3
   Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391
   Peerdeman KJ, 2016, PAIN, V157, P1179, DOI 10.1097/j.pain.0000000000000540
   Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176
   Pollo A, 2001, PAIN, V93, P77, DOI 10.1016/S0304-3959(01)00296-2
   Powell R, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008646.pub2
   Rehberg B, 2017, CLIN J PAIN, V33, P57, DOI 10.1097/AJP.0000000000000380
   Rief W, 2017, BMC MED, V15, P0, DOI 10.1186/s12916-016-0767-3
   Roderigo T, 2017, PAIN, V158, P1489, DOI 10.1097/j.pain.0000000000000940
   Schedlowski M, 2015, PHARMACOL REV, V67, P697, DOI 10.1124/pr.114.009423
   Schmid J, 2015, GUT, V64, P418, DOI 10.1136/gutjnl-2013-306648
   Sipilä RM, 2017, PAIN, V158, P922, DOI 10.1097/j.pain.0000000000000859
   Street RL, 2012, PATIENT EDUC COUNS, V89, P245, DOI 10.1016/j.pec.2012.06.032
   Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225
   Usichenko TI, 2005, PAIN, V114, P320, DOI 10.1016/j.pain.2004.08.021
   Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976
   Wang Y, 2018, INT J SURG, V52, P50, DOI 10.1016/j.ijsu.2018.02.032
   Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8
   Wiech K, 2016, SCIENCE, V354, P584, DOI 10.1126/science.aaf8934
   Zunhammer M, 2017, SCI TRANSL MED, V9, P0, DOI 10.1126/scitranslmed.aal2999
NR 52
TC 26
Z9 28
U1 0
U2 32
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304-3959
EI 1872-6623
J9 PAIN
JI Pain
PD JUL 15
PY 2019
VL 160
IS 7
BP 1562
EP 1571
DI 10.1097/j.pain.0000000000001546
PG 10
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA IQ5AO
UT WOS:000480763500010
PM 30839426
DA 2026-01-16
ER

PT J
AU Huang, W
   Yu, TY
   Long, WF
   Xiao, JB
   Zhao, GF
AF Huang Wei
   Yu Tingyu
   Long Wenfei
   Xiao Jianbin
   Zhao Gaofeng
TI Effect of electrically stimulating acupoint, Zusanli (ST 36), on patient's recovery after laparoscopic colorectal cancer resection: a randomized controlled trial
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE Colorectal neoplasms; Laparoscopes; Transcutaneous electric nerve stimulation; Recovery of function; Randomized controlled trial
ID enhanced recovery; surgery; acupuncture; pain; electroacupuncture; mechanisms; management; posterior; gases
AB OBJECTIVE: To investigate the effect of transcutaneous electrical acupoint stimulation (TEAS) on enhanced recovery after surgery (ERAS) in laparoscopic colorectal cancer resection and its clinical significance. METHODS: Sixty-four patients undergoing laparoscopic colorectal resection were randomly divided into two groups, the control group (group A) and the TEAS group (group B). Patients in the TEAS group received electroacupuncture stimulation of bilateral Zusanli (ST 36) at 30 min before anesthesia to the end of surgery. The patients in the control group were not given the stimulation. Perioperative anesthesia management of the two groups were performed according to the ERAS guidelines, and postoperative patient-controlled intravenous analgesia (PCIA) was used. The amount of remifentanil used in the two groups was observed and recorded, and the visual analogue scale (VAS) of the 4, 12, 24 and 48 h after surgery in the two groups was recorded. Moreover, postoperative anal ex-haust time, postoperative feeding time, postoperative first ambulation time and postoperative hospital stay length were compared between the two groups. RESULTS: Compared with group A, the VAS score of group B decreased significantly at 48 h after operation (P < 0.05). The postoperative anal exhaust time in group B was significantly shorter than that of group A (P < 0.05). There was no significant difference between the two groups with regards to remifentanil consumption, postoperative feeding time, postoperative first ambulation time and postoperative hospital stay (all P> 0.05). CONCLUSION: TEAS can promote the recovery of postoperative gastrointestinal function and reduce the pain intensity 48 h after surgery, thus satisfying the need of early postoperative analgesia. (C) 2019 JTCM. All rights reserved.
C1 [Huang Wei; Long Wenfei; Xiao Jianbin; Zhao Gaofeng] Guangdong Prov Hosp Chinese Med, Dept Anesthesiol, Guangzhou 510000, Guangdong, Peoples R China.
   [Yu Tingyu] Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou 510000, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Zhao, GF (corresponding author), Guangdong Prov Hosp Chinese Med, Dept Anesthesiol, Guangzhou 510000, Guangdong, Peoples R China.
EM zhaogaofeng97@163.com
CR Abdallah FW, 2013, BRIT J ANAESTH, V111, P721, DOI 10.1093/bja/aet214
   Abdikarim I, 2015, WORLD J GASTROENTERO, V21, P13339, DOI 10.3748/wjg.v21.i47.13339
   Deng G, 2013, ANN SURG ONCOL, V20, P1164, DOI 10.1245/s10434-012-2759-7
   Feldman LS, 2015, CAN J ANESTH, V62, P120, DOI 10.1007/s12630-014-0263-1
   Feng XZ, 2016, INT J SURG, V30, P104, DOI 10.1016/j.ijsu.2016.04.042
   Jiang WW, 2015, GENET MOL RES, V14, P16469, DOI 10.4238/2015.December.9.18
   Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Liu JS, 2012, AM J PHYSIOL-REG I, V303, PR209, DOI 10.1152/ajpregu.00301.2010
   Park C, 2015, ANAESTHESIA, V70, P434, DOI 10.1111/anae.12933
   Pavlidis T, 2002, MINERVA CHIR, V57, P17
   Reuben SS, 2007, J BONE JOINT SURG AM, V89A, P1343, DOI 10.2106/JBJS.F.00906
   Song J, 2013, NEUROGASTROENT MOTIL, V25, P807, DOI 10.1111/nmo.12183
   Su YS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/535742
   Sun K, 2017, CLIN J PAIN, V33, P340, DOI 10.1097/AJP.0000000000000400
   Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6
   Vather R, 2014, CLIN EXP PHARMACOL P, V41, P358, DOI 10.1111/1440-1681.12220
   Vather R, 2013, ANZ J SURG, V83, P319, DOI 10.1111/ans.12102
   Wang BG, 1997, ANESTH ANALG, V85, P406, DOI 10.1097/00000539-199708000-00029
   Wildbrett P, 2003, SURG ENDOSC, V17, P78, DOI 10.1007/s00464-002-9015-3
   Xie J, 2017, CHIN J CANCER, V36, P0, DOI 10.1186/s40880-016-0176-1
   Xiong JJ, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003497
   Xiong LZ, 2007, CHINESE MED J-PEKING, V120, P394, DOI 10.1097/00029330-200703010-00009
   Yang CX, 2012, ACUPUNCTURE ELECTRO, V37, P125, DOI 10.3727/036012912X13831831256249
   Yang Q, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-137
   Yang XY, 2015, BRIT J ANAESTH, V115, P883, DOI 10.1093/bja/aev352
   Yang ZK, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/276320
   Yin Xiu-qi, 2013, ZHEN CI YAN JIU, V38, P431
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
NR 29
TC 29
Z9 40
U1 2
U2 30
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD JUN 15
PY 2019
VL 39
IS 3
BP 433
EP 439
DI 
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA IF3OG
UT WOS:000472989500017
PM 32186016
DA 2026-01-16
ER

PT J
AU Qiu, JQ
   Liu, SR
   Lin, QL
   Li, MJ
   Zhuang, JX
   Wu, GW
AF Qiu, Jian-Qing
   Liu, Shu-Ru
   Lin, Qian-Lin
   Li, Ming-Jing
   Zhuang, Jing-Xiang
   Wu, Guang-Wen
TI [Acupuncture combined with cinesiotherapy cupping for knee osteoarthritis with qi
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; cinesiotherapy; cupping; knee osteoarthritis (KOA); randomized controlled trial (RCT)
AB OBJECTIVE: To compare the clinical efficacy between acupuncture combined with  cinesiotherapy cupping and acupuncture combined with conventional cupping for  knee osteoarthritis (KOA) with qi stagnation and blood stasis syndrome, and to  seek a better solution for KOA. METHODS: A total of 78 patients of KOA with qi  stagnation and blood stasis syndrome were randomly divided into an observation  group and a control group, 39 cases in each group (3 cases in the observation  group and 2 cases in the control group lost contact). Both groups were treated  with acupuncture at Neixiyan (EX-LE 4), Dubi (ST 35), Xuehai (SP 10), Liangqiu  (ST 34), Heding (EX-LE 2), Zusanli (ST 36), Yinlingquan (SP 9), Yanglingquan (GB  34) and Xuanzhong (GB 39). Based on the acupuncture treatment, the control group  was treated with conventional cupping. The No. 4 cupping glass was used for  Xuehai (SP 10), Liangqiu (ST 34) and Fengshi (GB 31), while the No. 3 cupping  glass was used for Yinlingquan (SP 9), while the cupping with appropriate size  was used for ashi points; the cupping glass was retained for 5 min. Based on the  acupuncture treatment, the observation group was treated with cinesiotherapy  cupping. The selection of acupoint and cupping glass was identical as the control  group. The patients were instructed to perform knee flexion-extension, hip  abduction-adduction, weight-bearing and other active exercise while cupping; the  treatment was given once a day, 10 times as a course of treatment; totally three  courses were given with an interval of 2 days between the courses. The patient's  symptom scores, pain scores and knee function scores were recorded before and  after treatment. The amount of joint effusion was measured by ultrasound; the  level of interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-α  (TNF-α) in joint effusion were measured by ELISA. RESULTS: After treatment, the  total effective rate in the observation group was 94.4% (34/36), which was  significantly higher than 86.5% (32/37) in the control group (P<0.05). Compared  before treatment, the symptom scores, pain scores, amount of joint effusion and  the levels of IL-1, IL-6, TNF-α in joint fluid in both groups all were decreased  after treatment, whereas the knee function scores were increased (P<0.05).  Compared with the control group, the symptom scores, pain scores, and the levels  of IL-1, TNF-α and the amount of joint effusion all were significantly decreased,  whereas the knee function scores were increased in the observation group  (P<0.05). The level of IL-6 in joint effusion was not significantly different  between the observation group and the control group (P>0.05). CONCLUSION: The  acupuncture combined with cinesiotherapy cupping could alleviate pain, improve  joint function and reduce joint effusion, which is superior to acupuncture  combined with conventional cupping.
C1 School of Acupuncture and Moxibustion, Fujian University of TCM, Fuzhou 350122, China.
   School of Acupuncture and Moxibustion, Fujian University of TCM, Fuzhou 350122, China.
   the Third People's Hospital Affiliated to Fujian University of TCM, Fuzhou 350000.
   the Third People's Hospital Affiliated to Fujian University of TCM, Fuzhou 350000.
   the Third People's Hospital Affiliated to Fujian University of TCM, Fuzhou 350000.
   the Third People's Hospital Affiliated to Fujian University of TCM, Fuzhou 350000
   Academy of Integrated Chinese and Western Medicine, Fujian University ofTCM, Fuzhou 350122
   Fujian Provincial Key Laboratory of Integrated Chinese andWestern Medicine on Geriatrics, Fuzhou 350122.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAY 18
PY 2019
VL 39
IS 5
BP 462
EP 6
DI 10.13703/j.0255-2930.2019.05.002
PG -456
WC Acupuncture Therapy; Humans; Knee Joint; Osteoarthritis, Knee; therapy; Qi; Treatment Outcome
UT PubMed:31099214
PM 31099214
DA 2019-05-18
ER

PT J
AU Grant, SJ
   Marthick, M
   Lacey, J
AF Grant, Suzanne J.
   Marthick, Michael
   Lacey, Judith
TI Establishing an integrative oncology service in the Australian healthcare settingthe Chris O'Brien Lifehouse Hospital experience
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Integrative oncology; Supportive care; Complementary therapy; Holistic care; Integrative medicine
ID alternative medicine; complementary therapy; cancer-patients; lung-cancer; pain; attitudes; outcm; anxiety
AB Comprehensive cancer centres are on the rise as patients seek a more holistic approach to maintaining their wellbeing when living with a cancer diagnosis. Many cancer centres worldwide now incorporate a selection of evidence-based complementary therapies and qualified therapists into their offerings. The Chris O'Brien Lifehouse, a comprehensive cancer centre in Sydney, Australia, provides integrative oncology services including acupuncture, massage, reflexology, dietetics and exercise physiology for individual patients, along with group programmes, and an integrative and supportive care medical specialist. The purpose of this paper is to reflect on one model of integrative oncology service and approach to integration and team and service development.
C1 [Grant, Suzanne J.; Marthick, Michael; Lacey, Judith] Chris OBrien Lifehouse, POB M33, Camperdown, NSW 2050, Australia.
   [Grant, Suzanne J.; Lacey, Judith] Western Sydney Univ, Natl Inst Complementary Med, Locked Bag 1797, Penrith, NSW 2751, Australia.
   [Lacey, Judith] Univ Sydney, Sch Med, Camperdown, NSW 2050, Australia.
C3 Chris O'Brien Lifehouse; Western Sydney University; University of Sydney
RP Grant, SJ (corresponding author), Chris OBrien Lifehouse, POB M33, Camperdown, NSW 2050, Australia.; Grant, SJ (corresponding author), Western Sydney Univ, Natl Inst Complementary Med, Locked Bag 1797, Penrith, NSW 2751, Australia.
EM suzanne.grant@lh.org.au
CR Amichai T, 2012, EUR J ONCOL NURS, V16, P520, DOI 10.1016/j.ejon.2012.01.004
   Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830
   Bell RM, 2010, CLIN J ONCOL NURS, V14, P365, DOI 10.1188/10.CJON.365-370
   Boon HS, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-32
   Buffart LM, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-559
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Coulter ID, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-191
   Deng G, 2008, CURR ONCOL, V15, P0
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Deng Gary E, 2009, J SOC INTEGR ONCOL, V7, P85
   Eisenberg DM, 2016, ACAD MED, V91, P1223, DOI 10.1097/ACM.0000000000001173
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Frenkel M, 2008, HEMATOL ONCOL CLIN N, V22, P727, DOI 10.1016/j.hoc.2008.04.002
   GIRGS A, 2015, CANC FORUM, V39, P2
   Grant S, 1900, V2, V0, P116
   Grant SJ, 2017, SUPPORT CARE CANCER, V0, P0
   Greenlee H, 2017, CANC J CLIN, V0, P0
   Herman PM, 2012, BMJ OPEN, V2, P0, DOI 10.1136/bmjopen-2012-001046
   Hibbard JH, 2013, HEALTH AFFAIR, V32, P216, DOI 10.1377/hlthaff.2012.1064
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Hunter J, 2013, COMPLEMENT THER CLIN, V19, P20, DOI 10.1016/j.ctcp.2012.10.002
   Hyodo I, 2003, CANCER, V97, P2861, DOI 10.1002/cncr.11402
   Johnson Jill R, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP330, DOI 10.1093/jncimonographs/lgu030
   Kerridge IH, 2004, MED J AUSTRALIA, V181, P164, DOI 10.5694/j.1326-5377.2004.tb06211.x
   King T, 2015, CL LYMPH MYELOM LEUK, V15, Pe317, DOI 10.1016/j.clml.2015.08.090
   Kligler B, 2011, AM J MANAG CARE, V17, P779
   Lacey JDH, 2017, MULT ASS SUPP CAR CA, V0, P25
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Mittring N, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/316950
   Oh B, 2010, ASIA-PAC J CLIN ONCO, V6, P342, DOI 10.1111/j.1743-7563.2010.01329.x
   Pérard M, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0696-2
   Phillips SM, 2014, CANCER EPIDEM BIOMAR, V23, P687, DOI 10.1158/1055-9965.EPI-13-1355
   Rademakers J, 2011, BMJ QUAL SAF, V20, P326, DOI 10.1136/bmjqs.2010.042358
   Risberg T, 2004, EUR J CANCER, V40, P529, DOI 10.1016/j.ejca.2003.11.011
   Robotin M, 2012, COMPLEMENT THER MED, V20, P345, DOI 10.1016/j.ctim.2012.04.001
   Robotin MC, 2006, MED J AUSTRALIA, V185, P377, DOI 10.5694/j.1326-5377.2006.tb00614.x
   Sagar SM, 2008, CURR ONCOL, V15, P0
   Seely DM, 2012, CURR ONCOL, V19, PE436, DOI 10.3747/co.19.1182
   Smith C, 2017, INTEGRATIVE ONCOLOGY, V0, P0
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
NR 41
TC 22
Z9 23
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUN 15
PY 2019
VL 27
IS 6
BP 2069
EP 2076
DI 10.1007/s00520-018-4460-2
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA HW8QK
UT WOS:000466954400014
PM 30225572
DA 2026-01-16
ER

PT J
AU Deng, XY
   Xu, TS
AF Deng, Xiao-Yue
   Xu, Tian-Shu
TI [Clinical observation of acupuncture combined with sertraline hydrochloride
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; depression; randomized controlled trial (RCT); sertraline hydrochloride tablets; tumor
AB OBJECTIVE: To compare the clinical effects of acupuncture combined with  sertraline hydrochloride and simple sertraline hydrochloride on tumor-related  depression. METHODS: Sixty patients with tumor-related depression who met the  inclusion criteria were randomly assigned to an observation group and a control  group, 30 patients in each group. The routine treatment in department of oncology  were given in both groups, oral sertraline hydrochloride (25 mg daily for the  first 5 days, then 50 mg daily) was given in the control group; on the basis of  the treatment in the control group, and acupuncture was applied at Hegu (LI 4),  Neiguan (PC 6), Taichong (LR 3), Shenmen (HT 7)，etc. in the observation  group，twice a week .The two groups were treated continuously for 4 weeks. The  Hamilton depression scale (HAMD) score and the quality of life score (QLQ-C30  questionnaire) were compared between the two groups before and after treatment.  RESULTS: After treatment, the HAMD scores in the two groups were significantly  lower than those before treatment (both P<0.05), and the HAMD scores in the  observation group were lower than those in the control group (P<0.05). In the  observation group, the symptom scores of fatigue, pain, nausea and vomiting,  dyspnea, insomnia, loss of appetite, constipation, and diarrhea were  significantly lower than those before treatment (all P<0.05), and the physical,  cognitive, emotional function, and the overall quality of life score were  significantly higher than those before treatment (all P<0.05); in the control  group, the symptom scores of insomnia decreased compared with that before  treatment (P<0.05), and the emotional function and overall quality of life score  were higher than those before treatment (both P<0.05); in addition to economic  difficulties, roles and social functions, the other scores after treatment in the  observation group were significantly improved than those in the control group  (all P<0.05). CONCLUSION: The combination of acupuncture and sertraline  hydrochloride tablets is better than simple sertraline hydrochloride in the  treatment of tumor-related depression, and it can improve the accompanying  symptoms and improve quality of life.
C1 Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of CM, Nanjing 210046, Jiangsu Province, China.
   Drum Tower Hospital of Nanjing, Nanjing 210008.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD APR 9
PY 2019
VL 39
IS 4
BP 379
EP 83
DI 10.13703/j.0255-2930.2019.04.009
PG -296
WC Acupuncture Therapy; Depression; therapy; Humans; Quality of Life; Sertraline; Tablets; Treatment Outcome
UT PubMed:30957448
PM 30957448
DA 2019-04-09
ER

PT J
AU Wang, J
   Lei, Y
   Bao, B
   Yu, X
   Dai, H
   Chen, F
   Li, H
   Wang, B
AF Wang, Jisheng
   Lei, Yi
   Bao, Binghao
   Yu, Xudong
   Dai, Hengheng
   Chen, Fei
   Li, Haisong
   Wang, Bin
TI Acupuncture for pain caused by prostate cancer: Protocol for a systematic review.
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Prostate cancer is a male malignant tumor disease with high  prevalence in recent years. Patients with advanced prostate cancer are more  likely to have bone metastasis and strong bone pain, and even lead to  pathological fracture, which has a serious impact on the quality of life of  patients. Acupuncture has good clinical efficacy in treating pain caused by  prostate cancer. This review hopes to adopt meta-analysis to evaluate the  efficacy and safety of acupuncture in the treatment of pain caused by prostate  cancer and provides evidence for its application in clinical practice. METHODS  AND ANALYSIS: We will search for PubMed, Cochrane Library, AMED, EMbase,  WorldSciNet, Nature, Science online and China Journal Full-text Database (CNKI),  China Biomedical Literature CD-ROM Database (CBM), and related randomized  controlled trials included in the China Resources Database. The time is limited  from the construction of the library to November 2018. We will use the criteria  provided by Cochrane 5.1.0 for quality assessment and risk assessment of the  included studies, and use the Revman 5.3 and Stata 13.0 software for  meta-analysis of the effectiveness, recurrence rate, and symptom scores of  epididymitis. ETHICS AND DISSEMINATION: This systematic review will evaluate the  efficacy and safety of acupuncture for pain caused by prostate cancer. Owing to  the fact that all of the data used in this systematic review and meta-analysis  have been published, this review does not require ethical approval. Furthermore,  all data will be anonymously analyzed during the review process trial. TRIAL  REGISTRATION NUMBER: PROSPERO CRD42018111550.
C1 Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese 
   Department of Andrology, The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Shaanxi, China.
   Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese 
   Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese 
   Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese 
   Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing.
   Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing.
   Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JAN 12
PY 2019
VL 98
IS 2
BP e13954
EP e13954
DI 10.1097/MD.0000000000013954
PG 1
WC Acupuncture Therapy; methods; Bone Neoplasms; complications; Cancer Pain; therapy; Humans; Male; Prostatic Neoplasms; complications; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Meta-Analysis as Topic; Systematic Reviews as Topic
UT PubMed:30633174
PM 30633174
DA 2019-01-12
ER

PT J
AU Tang, SK
   Tse, MMY
   Leung, SF
   Fotis, T
AF Tang, Shuk Kwan
   Tse, Mimi Mun Yee
   Leung, Sau Fong
   Fotis, Theofanis
TI The effectiveness, suitability, and sustainability of non-pharmacological methods of managing pain in community-dwelling older adults: a systematic review
SO BMC PUBLIC HEALTH
LA English
DT Review
DE Chronic pain; Aged; Older adults; Community-dwelling; Non-pharmacological interventions; Complementary therapy; Systematic review
ID elderly-people; knee osteoarthritis; tai-chi; management; efficacy; interventions; stimulation; population; prevalence; therapy
AB Background Pain is common in older adults. To maintain their quality of life and promote healthy ageing in the community, it is important to lower their pain levels. Pharmacological pain management has been shown to be effective in older adults. However, as drugs can have various side effects, non-pharmacological pain management is preferred for community-dwelling older adults. This systematic review evaluates the effectiveness, suitability, and sustainability of non-pharmacological pain management interventions for community-dwelling older adults. Methods Five databases, namely, CINHAL, Journals@Ovid, Medline, PsycInfo, and PubMed, were searched for articles. The criteria for inclusion were: full-text articles published in English from 2005 to February 2019 on randomized controlled trials, with chronic non-cancer pain as the primary outcome, in which pain was rated by intensity, using non-pharmacological interventions, and with participants over 65 years old, community-dwelling, and mentally competent. A quality appraisal using the Jadad Scale was conducted on the included articles. Results Ten articles were included. The mean age of the older adults was from 66.75 to 76. The interventions covered were acupressure, acupuncture, guided imagery, qigong, periosteal stimulation, and Tai Chi. The pain intensities of the participants decreased after the implementation of the intervention. The net changes in pain intensity ranged from - 3.13 to - 0.65 on a zero to ten numeric rating scale, in which zero indicates no pain and ten represents the worst pain. Conclusions Non-pharmacological methods of managing pain were effective in lowering pain levels in community-dwelling older adults, and can be promoted widely in the community.
C1 [Tang, Shuk Kwan; Tse, Mimi Mun Yee; Leung, Sau Fong] Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.
   [Fotis, Theofanis] Univ Brighton, Sch Hlth Sci, Westlain House,Village Way, Brighton BN1 9PH, E Sussex, England.
C3 Hong Kong Polytechnic University; University of Brighton
RP Tang, SK (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.
EM skangel.tang@connect.polyu.hk
CR Unknown -, 2006, INT J DISABILI HUM D, V0, P0, DOI DOI 10.1515/IJDHD.2006.5.1.9
   Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Unknown -, 2019, SUSTAINABILITY, V0, P0
   Baird CL, 2010, PAIN MANAG NURS, V11, P56, DOI 10.1016/j.pmn.2009.04.002
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Brismée JM, 2007, CLIN REHABIL, V21, P99, DOI 10.1177/0269215506070505
   Brochet B, 1998, AGE AGEING, V27, P279, DOI 10.1093/ageing/27.3.279
   Brown ST, 2011, PAIN MANAG NURS, V12, P190, DOI 10.1016/j.pmn.2010.05.004
   Bruckenthal P, 2016, J GERONTOL NURS, V42, P40, DOI 10.3928/00989134-20161110-08
   Cavalieri TA, 2005, J AM OSTEOPATH ASSOC, V105, P0
   Chung JWY, 2007, PAIN MED, V8, P235, DOI 10.1111/j.1526-4637.2006.00205.x
   Cusack Barry J, 2004, AM J GERIATR PHARMACOTHER, V2, P274, DOI 10.1016/j.amjopharm.2004.12.005
   De la Montana J, 2011, J NUTR HEALTH AGING, V15, P187, DOI 10.1007/s12603-010-0332-2
   Fine PG, 2009, J PAIN SYMPTOM MANAG, V38, PS4, DOI 10.1016/j.jpainsymman.2009.05.002
   Fouladbakhsh JM, 2011, PAIN MANAG NURS, V12, P70, DOI 10.1016/j.pmn.2010.08.005
   Fransen M, 2007, ARTHRIT RHEUM-ARTHR, V57, P407, DOI 10.1002/art.22621
   Hökkä M, 2014, J ADV NURS, V70, P1954, DOI 10.1111/jan.12424
   Hwang HF, 2003, AGE AGEING, V32, P593, DOI 10.1093/ageing/afg102
   International Association for the Study of Pain, 2012, CLASSIFICATION CHRON, V0, P0
   Itoh Kazunori, 2006, ACUPUNCT MED, V24, P5
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Li LW, 2018, ARTHRIT CARE RES, V70, P221, DOI 10.1002/acr.23262
   Lunde LH, 2009, J CLIN PSYCHOL MED S, V16, P254, DOI 10.1007/s10880-009-9162-y
   Ng KFJ, 2002, CLIN J PAIN, V18, P275, DOI 10.1097/00002508-200209000-00001
   Park J, 2012, J AM GERIATR SOC, V60, P555, DOI 10.1111/j.1532-5415.2011.03846.x
   PROHASKA TR, 1987, HEALTH PSYCHOL, V6, P495, DOI 10.1037/0278-6133.6.6.495
   Reid MC, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.h532
   Scheirer MA, 2005, AM J EVAL, V26, P320, DOI 10.1177/1098214005278752
   Schofield P, 2018, AGE AGEING, V47, P324, DOI 10.1093/ageing/afy018
   Schofield P, 2018, AGE AGEING, V47, Pi1, DOI 10.1093/ageing/afx192
   Sindhu F, 1996, J ADV NURS, V24, P1152, DOI 10.1111/j.1365-2648.1996.tb01020.x
   von Trott P, 2009, J PAIN, V10, P501, DOI 10.1016/j.jpain.2008.11.004
   Ward L, 2011, MUSCULOSKELET CARE, V9, P211, DOI 10.1002/msc.217
   Weiner DK, 2007, J AM GERIATR SOC, V55, P1541, DOI 10.1111/j.1532-5415.2007.01314.x
   Weiner DK, 2008, PAIN, V140, P344, DOI 10.1016/j.pain.2008.09.005
   White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007
   Yang KH, 2005, INT J NEUROSCI, V115, P949, DOI 10.1080/00207450590901378
NR 43
TC 30
Z9 40
U1 0
U2 22
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD NOV 8
PY 2019
VL 19
IS 1
BP 
EP 
DI 10.1186/s12889-019-7831-9
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA JM8AF
UT WOS:000496430300002
PM 31703654
DA 2026-01-16
ER

PT J
AU Gao, J
   Yuan, YS
   Lu, T
   Lv, HR
   Xu, HL
AF Gao, Jie
   Yuan, Yu-Song
   Lu, Ting
   Lv, Hao-Run
   Xu, Hai-Lin
TI Synovial sarcoma in the plantar region: A case report and literature review
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Review
DE Imaging examination; Pathological examination; Plantar; Synovial sarcoma; Case report
ID soft-tissue tumors; chemotherapy; metastasis
AB BACKGROUND Synovial sarcoma (SS), a rare malignant soft tissue tumor whose histological origin is still unknown, often occurs in limbs in young people and is easily misdiagnosed. CASE SUMMARY We report a 24-year-old man who sought treatment for plantar pain thought to be caused by a foot injury that occurred 4 years prior. Currently, he had been seen at another hospital for a 1-wk history of unexplained pain in the left plantar region and was treated with acupuncture, a kind of therapy of Chinese medicine, which partly relieved the pain. Because of this, the final diagnosis of biphasic SS was made after two subsequent treatments by pathological evaluation after the last operation. SS is rarely seen in the plantar area, and his history of a left plantar injury confused the original diagnosis. CONCLUSION This study shows that pathological and imaging examinations may play a vital role in the early diagnosis and treatment of SS.
C1 [Gao, Jie; Lu, Ting] Pingxiang Med Sch, Pingxiang Hlth Vocat Coll, Pingxiang 337000, Jiangxi, Peoples R China.
   [Yuan, Yu-Song; Lv, Hao-Run; Xu, Hai-Lin] Peking Univ, Dept Trauma & Orthoped, Peoples Hosp, 11 South Xizhimen St, Beijing 100044, Peoples R China.
C3 Peking University
RP Xu, HL (corresponding author), Peking Univ, Dept Trauma & Orthoped, Peoples Hosp, 11 South Xizhimen St, Beijing 100044, Peoples R China.
EM xuhailinfa@163.com
CR Alhazzani AR, 2010, UROL ANNALS, V2, P39, DOI 10.4103/0974-7796.62916
   Bakri A, 2012, AM J ROENTGENOL, V199, PW208, DOI 10.2214/AJR.11.8039
   Beck SE, 2011, INT J SURG ONCOL, V2011, P0, DOI 10.1155/2011/184891
   BERGER LOUIS, 1938, AMER JOUR CANCER, V34, P501
   Brisse HJ, 2010, PEDIATR RADIOL, V40, P1019, DOI 10.1007/s00247-010-1592-z
   Chen Y, 2012, J SURG ONCOL, V106, P162, DOI 10.1002/jso.23061
   Deraedt K, 2006, HISTOPATHOLOGY, V48, P473, DOI 10.1111/j.1365-2559.2005.02270.x
   Deshmukh R, 2004, CLIN ORTHOP RELAT R, V0, PP155, DOI 10.1097/01.blo.0000111887.82016.b0
   Egger JF, 2002, MODERN PATHOL, V15, P998, DOI 10.1097/01.MP.0000026616.41545.FF
   Eilber FC, 2007, ANN SURG, V246, P105, DOI 10.1097/01.sla.0000262787.88639.2b
   Fedors NH, 2010, ORTHOPEDICS, V33, P861, DOI 10.3928/01477447-20101021-35
   Frank GA, 2016, ARKHIV PATOLOGII, V78, P32, DOI 10.17116/patol201678432-42
   Haldar M, 2008, CLIN ORTHOP RELAT R, V466, P2156, DOI 10.1007/s11999-008-0340-2
   Jeganathan Reubendra, 2007, ULSTER MED J, V76, P109
   Jung SC, 2007, SKELETAL RADIOL, V36, P67, DOI 10.1007/s00256-006-0185-2
   Kadapa NPB, 2014, INDIA J SURG ONCOL, V5, P75, DOI 10.1007/s13193-013-0285-0
   Kanemitsu S, 2007, DIAGN MOL PATHOL, V16, P9, DOI 10.1097/PDM.0b013e318031f02f
   Kartha SS, 2002, LARYNGOSCOPE, V112, P1979, DOI 10.1097/00005537-200211000-00013
   Le Loarer F, 2014, GENE CHROMOSOME CANC, V53, P475, DOI 10.1002/gcc.22159
   Liang CH, 2015, ONCOL LETT, V9, P661, DOI 10.3892/ol.2014.2774
   Murphey MD, 2006, RADIOGRAPHICS, V26, P1543, DOI 10.1148/rg.265065084
   Ranchère-Vince D, 2010, ARCH PEDIATRIE, V17, P717, DOI 10.1016/S0929-693X(10)70075-0
   Romeo S, 2015, CLIN SARCOMA RES, V5, P0, DOI 10.1186/s13569-015-0021-3
   Scheer M, 2016, PEDIATR BLOOD CANCER, V63, P1198, DOI 10.1002/pbc.25973
   Scheithauer BW, 2007, NEURO-ONCOLOGY, V9, P454, DOI 10.1215/15228517-2007-029
   Shi WY, 2013, AM J CLIN ONCOL-CANC, V36, P83, DOI 10.1097/COC.0b013e31823fe450
   Tang YM, 2006, SKELETAL RADIOL, V35, P783, DOI 10.1007/s00256-005-0934-7
   Thway K, 2014, ANN DIAGN PATHOL, V18, P369, DOI 10.1016/j.anndiagpath.2014.09.002
   Vlenterie M, 2016, EUR J CANCER, V58, P62, DOI 10.1016/j.ejca.2016.02.002
   Yasui H, 2016, J CHEMOTHERAPY, V28, P417, DOI 10.1080/1120009X.2015.1133013
NR 30
TC 4
Z9 4
U1 0
U2 10
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 2307-8960
EI 
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD SEP 6
PY 2019
VL 7
IS 17
BP 2549
EP 2555
DI 10.12998/wjcc.v7.i17.2549
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA IW2NB
UT WOS:000484815000015
PM 31559291
DA 2026-01-16
ER

PT J
AU Calcagni, N
   Gana, K
   Quintard, B
AF Calcagni, Nicolas
   Gana, Kamel
   Quintard, Bruno
TI A systematic review of complementary and alternative medicine in oncology:
SO PloS one
LA English
DT Journal Article
AB BACKGROUND: Complementary and Alternative Medicines (CAM) are widely used by  cancer patients, despite limited evidence of efficacy. Manipulative and  body-based practices are some of the most commonly used CAM. This systematic  review evaluates their benefits in oncology. METHOD: A systematic literature  review was carried out with no restriction of language, time, cancer location or  type. PubMed, CENTRAL, PsycArticle, PsychInfo, Psychology and Behavioral Sciences  Collection and SOCindex were queried. Inclusion criteria were adult cancer  patients and randomized controlled trials (RCT) assessing manipulative and  body-based complementary practices on psychological and symptom outcomes. Effect  size was calculated when applicable. RESULTS: Of 1624 articles retrieved, 41  articles were included: massage (24), reflexology (11), acupressure (6). Overall,  25 studies showed positive and significant effects on symptom outcomes (versus 9  that did not), especially pain and fatigue. Mixed outcomes were found for quality  of life (8 papers finding a significant effect vs. 10 which did not) and mood (14  papers vs. 13). In most studies, there was a high risk of bias with a mean Jadad  score of 2, making interpretation of results difficult. CONCLUSION: These results  seem to indicate that manipulative CAM may be effective on symptom management in  cancer. However, more robust methodologies are needed. The methodological  requirements of randomized controlled trials are challenging, and more  informative results may be provided by more pragmatic study design.
C1 Laboratoire EA 4136 / INSERM UMR 1219, Team: Handicap Activity Cognition Health (HACH), Bordeaux, France.
   Univ. Bordeaux, Bordeaux, France.
   Univ. Bordeaux, Bordeaux, France.
   Laboratoire EA 4136 / INSERM UMR 1219, Team: Handicap Activity Cognition Health (HACH), Bordeaux, France.
   Univ. Bordeaux, Bordeaux, France.
NR 0
TC 0
SN 1932-620
EI 
J9 PLoS One
PD OCT 18
PY 2019
VL 14
IS 10
BP e0223564
EP e0223564
DI 10.1371/journal.pone.0223564
PG 1
WC Combined Modality Therapy; methods; Complementary Therapies; methods; Humans; Medical Oncology; methods; Neoplasms; diagnosis; Psychotherapy; methods; Treatment Outcome
UT PubMed:31622362
PM 31622362
DA 2019-10-18
ER

PT J
AU Chen, CT
   Lin, JG
   Huang, CP
   Lin, YW
AF Chen, Chao-Tsung
   Lin, Jaung-Geng
   Huang, Chun-Ping
   Lin, Yi-Wen
TI Electroacupuncture attenuates chronic fibromyalgia pain through the
SO Iranian journal of basic medical sciences
LA English
DT Journal Article
DE 3-kinase; Dorsal root ganglion; Electroacupuncture; Fibromyalgia; Phosphatidylinositol; Somatosensory cortex; Thalamus
AB OBJECTIVES: Fibromyalgia (FM) is a central nervous system disorder characterized  by widespread mechanical hyperalgesia due to unknown mechanisms. Several  inflammatory mediators, such as interleukin-1 (IL-1), IL-6, IL-8, and tumor  necrosis factor, are increased in the serum of FM patients. Although medications  including pregabalin, duloxetine, and milnacipran are used to treat FM, the  results are unsatisfying. In the present study we assessed whether  electroacupuncture (EA) can reduce chronic FM pain and then proposed an  underlying mechanism for this effect. MATERIALS AND METHODS: Chronic FM pain was  induced in mice by dual acid saline injection lasting up to 4 weeks. RESULTS:  Chronic FM pain was treated by EA manipulation, but not in the sham operated  group. Phosphorylated phosphatidylinositol 3-kinase (pPI3K), protein kinase B,  mechanistic target of rapamycin, and nuclear factor kappa-light-chain-enhancer of  activated B cells were unaltered in the mouse dorsal root ganglion (DRG) and  spinal cord (SC) after inducing FM and administering EA treatment. The  pPI3K-associated nociceptive signaling pathway was increased in the thalamus of  FM mice, but reversed by EA. Similar results were observed in the mouse  somatosensory cortex. CONCLUSION: These data suggest that EA has a significant  effect on a signaling pathway in brain areas of FM mice. These findings suggest  the value of EA for clinical practice.
C1 Center for General Education, Chung Yuan Christian University, Taoyuan 32023, Taiwan.
   College of Chinese Medicine, School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
   College of Chinese Medicine, Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan.
   College of Chinese Medicine, Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan.
NR 0
TC 0
SN 2008-387
EI 2008-386
J9 Iran J Basic Med Sci
PD DEC 7
PY 2019
VL 22
IS 9
BP 1085
EP 1090
DI 10.22038/ijbms.2019.35887.8547
PG 5
UT PubMed:31807253
PM 31807253
DA 2019-12-07
ER

PT J
AU Maindet, C
   Burnod, A
   Minello, C
   George, B
   Allano, G
   Lemaire, A
AF Maindet, Caroline
   Burnod, Alexis
   Minello, Christian
   George, Brigitte
   Allano, Gilles
   Lemaire, Antoine
TI Strategies of complementary and integrative therapies in cancer-related painattaining exhaustive cancer pain management
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Pain management; Personalized management; Multimorphic pain; Cancer pain; Mind-body therapy; Complementary therapies
ID quality-of-life; cognitive-behavioral therapy; randomized controlled-trial; breast-cancer; physical-activity; long-term; alternative medicine; stress reduction; virtual-reality; mindfulness meditation
AB PurposeComplementary integrative therapies (CITs) correspond to growing demand in patients with cancer-related pain. This demand needs to be considered alongside pharmaceutical and/or interventional therapies. CITs can be used to cover certain specific pain-related characteristics. The objective of this review is to present the options for CITs that could be used within dynamic, multidisciplinary, and personalized management, leading to an integrative oncology approach.MethodsCritical reflection based on literature analysis and clinical practice.ResultsMost CITs only showed trends in efficacy as cancer pain was mainly a secondary endpoint, or populations were restricted. Physical therapy has demonstrated efficacy in motion and pain, in some specific cancers (head and neck or breast cancers) or in treatments sequelae (lymphedema). In cancer survivors, higher levels of physical activity decrease pain intensity. Due to the multimorphism of cancer pain, certain mind-body therapies acting on anxiety, stress, depression, or mood disturbances (such as massage, acupuncture, healing touch, hypnosis, and music therapy) are efficient on cancer pain. Other mind-body therapies have shown trends in reducing the severity of cancer pain and improving other parameters, and they include education (with coping skills training), yoga, tai chi/qigong, guided imagery, virtual reality, and cognitive-behavioral therapy alone or combined. The outcome sustainability of most CITs is still questioned.ConclusionsHigh-quality clinical trials should be conducted with CITs, as their efficacy on pain is mainly based on efficacy trends in pain severity, professional judgment, and patient preferences. Finally, the implementation of CITs requires an interdisciplinary team approach to offer optimal, personalized, cancer pain management.
C1 [Maindet, Caroline] Grenoble Alpes Univ Hosp, Pain Management Ctr, Grenoble, France.
   [Burnod, Alexis] PSL Res Univ, Inst Curie, Dept Support Care, Paris, France.
   [Minello, Christian] Canc Ctr Georges Francois Leclerc, Anaesthesia Intens Care Dept, Dijon, France.
   [George, Brigitte] St Louis Hosp, Pain Management Unit, Paris, France.
   [Allano, Gilles] Mutualist Clin Porte de Orient, Pain Management Unit, Lorient, France.
   [Lemaire, Antoine] Valenciennes Gen Hosp, Oncol & Med Specialties Dept, Valenciennes, France.
C3 Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; UNICANCER; Universite PSL; Institut Curie; UNICANCER; Universite Bourgogne Europe; Centre Georges-Francois Leclerc; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Saint-Louis - APHP; CH de Valenciennes
RP Lemaire, A (corresponding author), Valenciennes Gen Hosp, Oncol & Med Specialties Dept, Valenciennes, France.
EM lemaire-a@ch-valenciennes.fr
FU Kyowa Kirin
CR Adam R, 2018, BMJ SUPPORT PALLIAT, V8, P204, DOI 10.1136/bmjspcare-2016-001232
   Adam R, 2017, BMJ SUPPORT PALLIAT, V7, P373, DOI 10.1136/bmjspcare-2016-001137
   Unknown -, 2016, TAI CHI QI GONG DEPT, V0, P0
   Unknown -, 2017, AN ASS ADV COMM GUID, V0, P0
   Unknown -, 2005, FROM CANCER PATIENT TO CANCER SURVIVOR: LOST IN TRANSITION, V0, P0
   Unknown -, 2016, EVID-BASED COMPL ALT, V0, P0, DOI DOI 10.1155/2016/7358918
   Unknown -, 2016, COMPL ALT INT HLTH W, V0, P0
   Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI 10.1093/clipsy/bpg015
   Ball EF, 2017, CURR OPIN OBSTET GYN, V29, P359, DOI 10.1097/GCO.0000000000000417
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Basen-Engquist K, 2006, PATIENT EDUC COUNS, V64, P225, DOI 10.1016/j.pec.2006.02.006
   Bennett MI, 2019, EUR J PAIN, V23, P660, DOI 10.1002/ejp.1346
   Bennett MI, 2009, PAIN, V143, P192, DOI 10.1016/j.pain.2009.01.016
   Binns-Turner Pamela G, 2011, AANA J, V79, P0
   Bosch F, 2002, CLIN PHARMACOL THER, V72, P107, DOI 10.1067/mcp.2002.126180
   Bouillet T, 2015, CRIT REV ONCOL HEMAT, V94, P74, DOI 10.1016/j.critrevonc.2014.12.012
   Bradt J, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911.pub3
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Breuer B, 2015, ONCOLOGIST, V20, P202, DOI 10.1634/theoncologist.2014-0276
   Brosse AL, 2002, SPORTS MED, V32, P741, DOI 10.2165/00007256-200232120-00001
   Buffart LM, 2014, CANCER TREAT REV, V40, P327, DOI 10.1016/j.ctrv.2013.06.007
   Buffart LM, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-559
   Butler LD, 2009, HEALTH PSYCHOL, V28, P579, DOI 10.1037/a0016124
   Campbell KL, 2012, BRIT J SPORT MED, V46, P909, DOI 10.1136/bjsports-2010-082719
   Campo RA, 2013, INTEGR CANCER THER, V12, P464, DOI 10.1177/1534735413485418
   Candido KD, 2017, CURR PAIN HEADACHE R, V21, P0, DOI 10.1007/s11916-017-0613-0
   Carson JW, 2009, SUPPORT CARE CANCER, V17, P1301, DOI 10.1007/s00520-009-0587-5
   Carver CS, 2005, HEALTH PSYCHOL, V24, P508, DOI 10.1037/0278-6133.24.5.508
   Cassell EJ, 2004, THE NATURE OF SUFFERING AND THE GOALS OF MEDICINE, V0, P0
   Chen CH, 2012, PALLIATIVE MED, V26, P206, DOI 10.1177/0269216311402711
   Chirico A, 2016, J CELL PHYSIOL, V231, P275, DOI 10.1002/jcp.25117
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chow R, 2017, SUPPORT CARE CANCER, V25, P3505, DOI 10.1007/s00520-017-3774-9
   Chwistek Marcin, 2017, F1000RES, V6, P945, DOI 10.12688/f1000research.10817.1
   Cleeland CS, 2011, J CLIN ONCOL, V29, P994, DOI 10.1200/JCO.2010.29.8315
   Corbin Lisa, 2005, CANCER CONTROL, V12, P158
   Crawford C, 2016, PAIN MED, V17, P1353, DOI 10.1093/pm/pnw099
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Davis MC, 2015, J CONSULT CLIN PSYCH, V83, P24, DOI 10.1037/a0038200
   Davis MC, 2013, ANN BEHAV MED, V46, P273, DOI 10.1007/s12160-013-9513-7
   Devine Elizabeth C, 2003, ONCOL NURS FORUM, V30, P75, DOI 10.1188/03.ONF.75-89
   Edwards RR, 2005, PAIN MED, V6, P88, DOI 10.1111/j.1526-4637.2005.05007.x
   Epstein RM, 2017, JAMA ONCOL, V3, P92, DOI 10.1001/jamaoncol.2016.4373
   Ernst E, 2010, INT J CLIN PRACT, V64, P1472, DOI 10.1111/j.1742-1241.2010.02425.x
   Ernst E, 2008, OXFORD HANDBOOK OF COMPLEMENTARY MEDICINE, V0, P0
   Ernst E, 2007, COMPLEMENTARY THERAPIES FOR PAIN MANAGEMENT, V0, P0
   Forsythe LP, 2013, BREAST CANCER RES TR, V137, P617, DOI 10.1007/s10549-012-2335-7
   Fuentes-Márquez P, 2019, PHYSIOTHER THEOR PR, V35, P1131, DOI 10.1080/09593985.2018.1472687
   Fulcrand J, 2018, J PAIN SYMPTOM MANAG, V56, PE101, DOI 10.1016/j.jpainsymman.2018.10.343
   Galantino ML, 2012, INTEGR CANCER THER, V11, P313, DOI 10.1177/1534735411413270
   Garssen B, 2013, PSYCHO-ONCOLOGY, V22, P572, DOI 10.1002/pon.3034
   Gershon J, 2004, J AM ACAD CHILD PSY, V43, P1243, DOI 10.1097/01.chi.0000135621.23145.05
   Gilpin HR, 2017, J PAIN, V18, P1153, DOI 10.1016/j.jpain.2017.04.003
   Goldstein MS, 2005, EVID-BASED COMPL ALT, V2, P557, DOI 10.1093/ecam/neh138
   Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Grant JA, 2011, PAIN, V152, P150, DOI 10.1016/j.pain.2010.10.006
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   Green CR, 2003, PAIN MED, V4, P277, DOI 10.1046/j.1526-4637.2003.03034.x
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7
   Gunnarsdottir S, 2017, SUPPORT CARE CANCER, V25, P3595, DOI 10.1007/s00520-017-3791-8
   Guo YC, 2014, J SPORT HEALTH SCI, V3, P3, DOI 10.1016/j.jshs.2013.10.004
   Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c
   Hilton L, 2017, ANN BEHAV MED, V51, P199, DOI 10.1007/s12160-016-9844-2
   House G, 2016, BRIT J PAIN, V10, P186, DOI 10.1177/2049463716664370
   Howell D, 2017, SUPPORT CARE CANCER, V25, P1323, DOI 10.1007/s00520-016-3500-z
   Hsieh RK, 2005, J FORMOS MED ASSOC, V104, P913
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Indovina P, 2018, CLIN J PAIN, V34, P858, DOI 10.1097/AJP.0000000000000599
   Institut national du Cancer (INCA), 2012, SYNTH ENQ NAT 2010 P, V0, P0
   Jahn P, 2014, PAIN, V155, P746, DOI 10.1016/j.pain.2014.01.006
   Jane SW, 2011, PAIN, V152, P2432, DOI 10.1016/j.pain.2011.06.021
   Johannsen M, 2013, BREAST CANCER RES TR, V138, P675, DOI 10.1007/s10549-013-2503-4
   Johannsen M, 2016, J CLIN ONCOL, V34, P3390, DOI 10.1200/JCO.2015.65.0770
   Kasasbeh MAM, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12625
   Kasasbeh MAM, 2017, J CLIN NURS, V26, P3430, DOI 10.1111/jocn.13709
   Knobf MT, 2014, CANCER NURS, V37, PE43, DOI 10.1097/NCC.0b013e318288d40e
   Kravitz RL, 2012, J PAIN SYMPTOM MANAG, V43, P874, DOI 10.1016/j.jpainsymman.2011.05.020
   Kroenke K, 2010, JAMA-J AM MED ASSOC, V304, P163, DOI 10.1001/jama.2010.944
   Kwekkeboom KL, 2010, J PAIN SYMPTOM MANAG, V39, P126, DOI 10.1016/j.jpainsymman.2009.05.022
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lee CE, 2017, HOLIST NURS PRACT, V31, P260, DOI 10.1097/HNP.0000000000000220
   Lee JH, 2016, J MUSIC THER, V53, P430, DOI 10.1093/jmt/thw012
   Lee R, 1999, ALTERNATIVE MED ALER, V2, P61
   Lee SC, 2016, EUR J ONCOL NURS, V21, P1, DOI 10.1016/j.ejon.2015.12.001
   Li A, 2011, PAIN MANAG, V1, P147, DOI 10.2217/PMT.10.15
   Li XM, 2012, J ADV NURS, V68, P1145, DOI 10.1111/j.1365-2648.2011.05824.x
   Luebbert K, 2001, PSYCHO-ONCOLOGY, V10, P490, DOI 10.1002/pon.537
   MacDonald N, 2002, J PAIN SYMPTOM MANAG, V23, P39, DOI 10.1016/S0885-3924(01)00374-8
   Mancuso P, 2016, IMMUNOTARGETS THER, V5, P47, DOI 10.2147/ITT.S73223
   Manzano A, 2014, J CLIN NURS, V23, P1877, DOI 10.1111/jocn.12447
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mayor S, 2000, BRIT MED J, V321, P1309, DOI 10.1136/bmj.321.7272.1309/b
   McCracken LM, 2014, AM PSYCHOL, V69, P178, DOI 10.1037/a0035623
   McNeely ML, 2008, CANCER, V113, P214, DOI 10.1002/cncr.23536
   McNeely ML, 2004, HEAD NECK-J SCI SPEC, V26, P518, DOI 10.1002/hed.20010
   Mendoza ME, 2017, PSYCHO-ONCOLOGY, V26, P1832, DOI 10.1002/pon.4232
   [Merskey HIASPIASP], 1994, IASP TASK FORCE ON TAXONOMY, VSecond, P0
   Mina DS, 2017, CURR ONCOL, V24, P284, DOI 10.3747/co.23.3585
   Moon JY, 2015, CLIN J PAIN, V31, P750, DOI 10.1097/AJP.0000000000000155
   Mustafa M, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004253.pub4
   Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI 10.1249/mss.0b013e3180616aa2
   Notaro P, 2016, SUPPORT CARE CANCER, V24, P1649, DOI 10.1007/s00520-015-2952-x
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Oldenmenger WH, 2011, PAIN, V152, P2632, DOI 10.1016/j.pain.2011.08.009
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Park CH, 2008, MED SCI SPORT EXER, V40, PS24, DOI 10.1249/01.mss.0000321549.50666.24
   Peacock Sue, 2008, REV PAIN, V1, P6, DOI 10.1177/204946370800100203
   Phillips KM, 2011, COGNITIVE THER RES, V35, P595, DOI 10.1007/s10608-011-9398-3
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Raffa RB, 2014, J CLIN PHARM THER, V39, P4, DOI 10.1111/jcpt.12110
   Rajotte EJ, 2012, J CANCER SURVIV, V6, P219, DOI 10.1007/s11764-011-0213-7
   Raphael J, 2010, PAIN MED, V11, P872, DOI 10.1111/j.1526-4637.2010.00841.x
   Reyes-Gibby CC, 2012, J WOMENS HEALTH, V21, P311, DOI 10.1089/jwh.2011.2852
   Robb KA, 2006, J PAIN, V7, P82, DOI 10.1016/j.jpain.2005.08.007
   Robb KA, 2007, J PAIN SYMPTOM MANAG, V33, P410, DOI 10.1016/j.jpainsymman.2006.09.020
   Rock CL, 2012, CA-CANCER J CLIN, V62, P243, DOI 10.3322/caac.21142
   Roffe L, 2005, PSYCHO-ONCOLOGY, V14, P607, DOI 10.1002/pon.889
   Rogers LQ, 2008, SUPPORT CARE CANCER, V16, P19, DOI 10.1007/s00520-007-0293-0
   Rogers LQ, 2006, SUPPORT CARE CANCER, V14, P1012, DOI 10.1007/s00520-006-0044-7
   Rosenzweig S, 2010, J PSYCHOSOM RES, V68, P29, DOI 10.1016/j.jpsychores.2009.03.010
   Roth AD, 2008, BEHAV COGN PSYCHOTH, V36, P129, DOI 10.1017/S1352465808004141
   Rustoen T, 2014, CANCER NURS, V37, P34, DOI 10.1097/NCC.0b013e3182948418
   Sander Wint Suzanne, 2002, ONCOL NURS FORUM, V29, P0
   Satija A, 2017, INDIAN J PALLIAT CAR, V23, P468, DOI 10.4103/IJPC.IJPC_100_17
   Schneider S M, 2000, PEDIATR NURS, V26, P593
   SPIEGEL D, 1983, PSYCHOSOM MED, V45, P333, DOI 10.1097/00006842-198308000-00007
   Stein KD, 2008, CANCER-AM CANCER SOC, V112, P2577, DOI 10.1002/cncr.23448
   Street RL, 2014, PSYCHO-ONCOLOGY, V23, P1111, DOI 10.1002/pon.3518
   Sundaramurthi T, 2017, CLIN J ONCOL NURS, V21, P13, DOI 10.1188/17.CJON.S3.13-30
   Syrjala KL, 2014, J CLIN ONCOL, V32, P1703, DOI 10.1200/JCO.2013.54.4825
   Tashjian VC, 2017, JMIR MENT HEALTH, V4, P0, DOI 10.2196/mental.7387
   Tatrow K, 2006, J BEHAV MED, V29, P17, DOI 10.1007/s10865-005-9036-1
   Trompetter HR, 2016, FRONT PSYCHOL, V7, P0, DOI 10.3389/fpsyg.2016.00353
   Turner JA, 2016, PAIN, V157, P2434, DOI 10.1097/j.pain.0000000000000635
   Valeberg BT, 2008, EUR J PAIN, V12, P582, DOI 10.1016/j.ejpain.2007.09.004
   Valeberg BT, 2016, CANCER NURS, V39, P328, DOI 10.1097/NCC.0000000000000319
   van Hecke O, 2013, BRIT J PAIN, V7, P209, DOI 10.1177/2049463713493264
   Wang YC, 2015, J ALTERN COMPLEM MED, V21, P667, DOI 10.1089/acm.2014.0310
   Wayne PM, 2018, J CANCER SURVIV, V12, P256, DOI 10.1007/s11764-017-0665-5
   Wetherell JL, 2016, INT J GERIATR PSYCH, V31, P302, DOI 10.1002/gps.4330
   Wilkie D, 2010, WESTERN J NURS RES, V32, P23, DOI 10.1177/0193945909348009
   Wolin Kathleen Y, 2012, J SUPPORT ONCOL, V10, P171, DOI 10.1016/j.suponc.2012.02.001
   Yan JH, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0061672
   Zautra AJ, 2008, J CONSULT CLIN PSYCH, V76, P408, DOI 10.1037/0022-006X.76.3.408
NR 158
TC 56
Z9 67
U1 1
U2 93
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD AUG 15
PY 2019
VL 27
IS 8
BP 3119
EP 3132
DI 10.1007/s00520-019-04829-7
PG 14
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA IF6QA
UT WOS:000473204000041
PM 31076901
DA 2026-01-16
ER

PT J
AU Mao, H
   Mao, JJ
   Chen, J
   Li, Q
   Chen, X
   Shen, X
   Zhao, L
   Wei, J
   Shen, X
AF Mao, Huijuan
   Mao, Jun J
   Chen, Junchao
   Li, Qing
   Chen, Xuefen
   Shen, Xubo
   Zhao, Ling
   Wei, Jianzi
   Shen, Xueyong
TI Effects of infrared laser moxibustion on cancer-related fatigue in breast cancer
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Cancer-related fatigue (CRF) is the most common and distressing  symptom associated with cancer treatment that breast cancer survivors (BCS)  experience. We previously found that laser moxibustion may be efficacious for  CRF. The primary aim of this study is to determine the specific efficacy of  10.6 μm infrared laser moxibustion on CRF. The secondary aim is to evaluate the  effect of infrared laser moxibustion on co-existing symptoms that BCS experience.  METHODS: We will conduct a randomized, sham-controlled, three-arm trial of  infrared laser moxibustion (ILM) against sham ILM (SILM) and waitlist control  (WLC) among BCS with moderate to severe fatigue. The two intervention groups will  receive either real or sham infrared laser moxibustion on four acupoints (i.e.,  ST36 [bilateral], CV4, and CV6) for 20 minutes each session for 6 weeks (twice  per week). The primary endpoint is the change in fatigue score from Baseline to  Week 6 as measured by the Chinese version of the Brief Fatigue Inventory (BFI-C).  Our secondary aim is to compare the severity of co-morbidities (e.g., depression,  insomnia, and pain) among the 3 groups. DISCUSSION: The results of our trial will  establish evidence for the efficacy of infrared laser moxibustion for CRF, a very  common and challenging symptom. TRIAL REGISTRATION NUMBER: NCT03553355.
C1 Shanghai University of Traditional Chinese Medicine, School of Acupuncture-Moxibustion and Tuina, Shanghai, China.
   Memorial Sloan Kettering Cancer Center, Bendheim Integrative Medicine Center, New York, NY.
   Shanghai University of Traditional Chinese Medicine, Institute of Disciplinary Science.
   Memorial Sloan Kettering Cancer Center, Bendheim Integrative Medicine Center, New York, NY.
   Shanghai University of Traditional Chinese Medicine, School of Public Health.
   Shanghai University of Traditional Chinese Medicine, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine.
   Shanghai University of Traditional Chinese Medicine, School of Acupuncture-Moxibustion and Tuina, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, School of Acupuncture-Moxibustion and Tuina, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, School of Acupuncture-Moxibustion and Tuina, Shanghai, China.
   Shanghai Research Center of Acupuncture and Meridian, Shanghai, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD AUG 24
PY 2019
VL 98
IS 34
BP e16882
EP e16882
DI 10.1097/MD.0000000000016882
PG 1
WC Breast Neoplasms; complications; Cancer Survivors; psychology; China; Fatigue; therapy; Female; Humans; Infrared Rays; therapeutic use; Moxibustion; methods; Quality of Life; Randomized Controlled Trials as Topic
UT PubMed:31441863
PM 31441863
DA 2019-08-24
ER

PT J
AU Santillan-Garcia, A
   Moran, JM
AF Santillan-Garcia, Azucena
   Moran, J M
TI Statistical Concerns About Acupressure on Pain in Cancer Patients With Bone
SO Integrative cancer therapies
LA English
DT Letter
C1 1 Hospital Universitario de Burgos, Burgos, Spain.
   2 Universidad Extremadura, Cáceres, Spain.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD FEB 23
PY 2019
VL 18
IS 
BP 1534735419827087
EP 1534735419827087
DI 10.1177/1534735419827087
PG 1
WC Acupressure; Bone Neoplasms; Cancer Pain; Humans; Pain; Pain Management
UT PubMed:30791737
PM 30791737
DA 2019-02-23
ER

PT J
AU Correia, JS
   Silva, M
   Castro, C
   Miranda, L
   Agrelo, A
AF Correia, Joana Sousa
   Silva, Manuel
   Castro, Clara
   Miranda, Lina
   Agrelo, Ana
TI The efficacy of the ganglion impar block in perineal and pelvic cancer pain
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Ganglion impar block; Walters' block; Pelvic cancer pain; Perineal cancer pain
ID management; anatomy
AB Background Visceral pain conducted by sympathetic fibers with pelvic and perineal origin can be treated using ganglion impar (GIB) or Walters' block in a simple and effective manner. This article aims to evaluate the effectiveness, security, and performance difficulty of GIB in patients with pelvic and perineal oncological pain. Methods A retrospective study between January 2016 and August 2017. Patients with poorly controlled pelvic oncological pain and patients experimenting opioid side effects in which GIB was performed ambulatory were included. Prognostic GIB was performed, under echographic and fluoroscopic control, with local anesthetic and corticoid. The neurolytic block was performed under fluoroscopic guidance. The technique was performed by the same anesthetist with pain management competence. For statistical analysis, Microsoft Excel 2013 (R) and IBM SPSS Statistics version 22.0 were used. Results Fifteen patients were included. One patient was excluded. A statistical significant basal pain score reduction was observed ((median of the verbal numerical scale (VNS) 7 (p25 = 7; p75 = 8)) compared with 72 h median VNS 4 ((p25 = 3; p75 = 5.3) p = 0.001, and 3 months (median VNS 4 (p25 = 3, p75 = 7)) p = 0.003 after the procedure. Regarding morphine consumption, a statistically significant reduction was observed 3 months after GIB performance (p = 0.012). Discussion/conclusion GIB is a safe and easy-to-perform technique achieving satisfactory and statistically significant results, regarding pain control improvement and opioid consumption reduction in patients which meet selection criteria. Prospective, randomized studies with more patients are needed for further conclusions.
C1 [Correia, Joana Sousa; Silva, Manuel; Miranda, Lina; Agrelo, Ana] Inst Portugues Oncol Porto Francisco Gentil, Dept Anesthesiol, Porto, Portugal.
   [Castro, Clara] Inst Portugues Oncol Porto Francisco Gentil, Dept Clin Epidemiol, Porto, Portugal.
   [Agrelo, Ana] Inst Portugues Oncol Porto Francisco Gentil, Pain Study & Treatment Dept, Porto, Portugal.
RP Correia, JS (corresponding author), Inst Portugues Oncol Porto Francisco Gentil, Dept Anesthesiol, Porto, Portugal.
EM joanassousacorreia@gmail.com
CR Agarwal-Kozlowski K, 2009, CLIN J PAIN, V25, P570, DOI 10.1097/AJP.0b013e3181a5f5c7
   Ahmed DG, 2015, PAIN PHYSICIAN, V18, PE49, DOI 10.36076/ppj/2015.18.e49
   Unknown -, 1996, CANCER PAIN RELIEF, V0, P0
   Bhatnagar S, 2012, PAIN PRACT, V12, P23, DOI 10.1111/j.1533-2500.2011.00467.x
   Datir A, 2010, CLIN RADIOL, V65, P21, DOI 10.1016/j.crad.2009.08.007
   de Leon-Casasola OA, 1997, TECH REG ANESTH PAIN, V1, P27
   Demircay E, 2010, TURK NEUROSURG, V20, P328, DOI 10.5137/1019-5149.JTN.2852-09.0
   Eker HE, 2008, REGION ANESTH PAIN M, V33, P381, DOI 10.1016/j.rapm.2008.01.006
   Foye PM, 2007, REGION ANESTH PAIN M, V32, P269, DOI 10.1016/j.rapm.2006.12.005
   Foye PM, 2006, AM J PHYS MED REHAB, V85, P783, DOI 10.1097/01.phm.0000233174.86070.63
   Gunduz OH, 2017, J PAIN RES, V10, P2815, DOI 10.2147/JPR.S134775
   Hong JH, 2006, REGION ANESTH PAIN M, V31, P583, DOI 10.1016/j.rapm.2006.09.001
   Johnston P J, 2012, PRAGUE MED REP, V113, P53
   Karaman H, 2011, J PAK MED ASSOC, V61, P879
   Lin CS, 2010, PAIN MED, V11, P390, DOI 10.1111/j.1526-4637.2010.00797.x
   Oh CS, 2004, ANESTHESIOLOGY, V101, P249, DOI 10.1097/00000542-200407000-00039
   Patijn J, 2010, PAIN PRACT, V10, P554, DOI 10.1111/j.1533-2500.2010.00404.x
   PLANCARTE R, 1990, ANESTHESIOLOGY, V73, P236, DOI 10.1097/00000542-199008000-00008
   Restrepo-Garces CE, 2013, REV. SOC. ESP. DOLOR, V20, P150
   Toshniwal Gokul R, 2007, PAIN PHYSICIAN, V10, P661
   WEMM K, 1995, REGION ANESTH, V20, P544, DOI 10.1136/rapm-00115550-199520060-00015
NR 21
TC 17
Z9 19
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD NOV 15
PY 2019
VL 27
IS 11
BP 4327
EP 4330
DI 10.1007/s00520-019-04738-9
PG 4
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA JF6CZ
UT WOS:000491476800035
PM 30880371
DA 2026-01-16
ER

PT J
AU Roth, I
   Highfield, L
   Cuccaro, P
   Wells, R
   Misra, S
   Engebretson, J
AF Roth, Isabel
   Highfield, Linda
   Cuccaro, Paula
   Wells, Rebecca
   Misra, Sanghamitra
   Engebretson, Joan
TI Employing Evidence in Evaluating Complementary Therapies: Findings from an Ethnography of Integrative Pain Management at a Large Urban Pediatric Hospital
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE complementary therapies; integrative medicine; pain management; ethnography; qualitative methods; pediatric
ID alternative medicine; united-states; children; acupuncture; cam; practitioners; challenges; experience; knowledge; cancer
AB Background: Complementary and Integrative Medicine (CIM) shows positive clinical benefit with minimal side effects, yet, challenges to effective integration of CIM providers in biomedical health care settings remain. This study aimed to better understand the role evidence played in the process of integration of complementary therapies into a large urban pediatric hospital from the perspective of patients, caregivers, providers, and administrators through applied medical ethnography. Methods: An ethnography was conducted over the course of 6 months in a large urban pediatric hospital in the Southern United States. At the time, the hospital was piloting an integrative medicine (IM) pain consult service. Purposive sampling was used to select providers, patients, administrators, and caregivers to follow as they engaged with both the preexisting pain service and pilot IM pain services. Field observation and interviews were conducted with 34 participants. Thematic content analysis was used to analyze field notes, interview transcripts, and documents collected. Findings: Analysis of the data revealed five themes regarding the role of evidence in the process of integration: Anecdotal Evidence and Personal Experience Effecting CIM Use, Open to Trying Whatever Works, Resistance to the Unfamiliar, Patients and Parents Trusting Doctors as Experts, and Importance of Scientific Evidence to Biomedicine. All themes address the role of evidence in relationship to acceptance of complementary therapies and correspond with three thought processes: critical thinking, relying on others for evidence, and reactionary thinking. Conclusion: Both scientific and anecdotal evidence informed CIM use in this context. Biomedical environments seeking to integrate CIM into pain treatment regimens will need to engage all relevant stakeholders in building education, clinical training, and research programs that are critically informed about the context and evidence for CIM.
C1 [Roth, Isabel] Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Program Integrat Med, Wing D,Rm 186, Chapel Hill, NC 27514 USA.
   [Highfield, Linda; Wells, Rebecca] Univ Texas Hlth Sci Ctr Sch Publ Hlth UTHlth, Dept Management Policy & Community Hlth, Houston, TX USA.
   [Cuccaro, Paula] Univ Texas Hlth Sci Ctr Sch Publ Hlth UTHlth, Dept Hlth Promot & Behav Sci, Houston, TX USA.
   [Misra, Sanghamitra] Baylor Coll Med, Dept Acad Gen Pediat, Houston, TX 77030 USA.
   [Engebretson, Joan] Univ Texas Hlth Sci Ctr Cizik Sch Nursing UTHlth, Dept Family Hlth, Houston, TX USA.
C3 University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Baylor College of Medicine
RP Roth, I (corresponding author), Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Program Integrat Med, Wing D,Rm 186, Chapel Hill, NC 27514 USA.
EM iroth@email.unc.edu
FU University of Texas Health Science Center at Houston School of Public Health (UTHealth); National Center for Complementary and Integrative Health [5T32AT00378-12]
CR Abrams DI, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-146
   Anheyer D, 2018, COMPLEMENT THER MED, V41, P186, DOI 10.1016/j.ctim.2018.09.025
   Unknown -, 2002, NATL. HEALTH STAT. REP, V0, P0
   Black Lindsey I, 2015, NATL HEALTH STAT REPORT, V0, P1
   Bradt J, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911
   Brooks MR, 2016, PEDIATR ANESTH, V26, P794, DOI 10.1111/pan.12948
   Coulter I, 2008, HEALTH SOCIOL REV, V17, P368, DOI 10.5172/hesr.451.17.4.368
   Crabtree BF, 1992, DOING QUALITATIVE RE, V3, P3
   Dusek Jeffery A, 2010, J PATIENT SAF, V6, P48, DOI 10.1097/PTS.0b013e3181d10ad5
   Eckert M, 2018, CHILDREN-BASEL, V5, P0, DOI 10.3390/children5090122
   Esparham A, 2018, CHILDREN-BASEL, V5, P0, DOI 10.3390/children5080111
   Frank L, 1900, V312, V0, P1513
   Frenkel M, 2007, J ALTERN COMPLEM MED, V13, P387, DOI 10.1089/acm.2006.6293
   Friedrichsdorf Stefan J, 2015, HOSP PEDIATR, V5, P18, DOI 10.1542/hpeds.2014-0084
   Gagnon EM, 2003, PSYCHO-ONCOLOGY, V12, P442, DOI 10.1002/pon.655
   Gale NK, 2013, BMC MED RES METHODOL, V13, P0, DOI 10.1186/1471-2288-13-117
   Gardiner P, 2017, CONTEMP CLIN TRIALS, V54, P25, DOI 10.1016/j.cct.2016.12.013
   Gilchrist Julie, 2012, MORBIDITY AND MORTALITY WEEKLY REPORT, V61, P270
   Golianu B, 2014, CHILDREN-BASEL, V1, P134, DOI 10.3390/children1020134
   Gray B, 2014, J ALTERN COMPLEM MED, V20, P342, DOI 10.1089/acm.2013.0167
   Groenewald CB, 2017, ACAD PEDIATR, V17, P785, DOI 10.1016/j.acap.2017.02.008
   Hechler T, 2015, PEDIATRICS, V136, P115, DOI 10.1542/peds.2014-3319
   Highfield ES, 2005, J ALTERN COMPLEM MED, V11, P373, DOI 10.1089/acm.2005.11.373
   Hollenberg D, 2010, HEALTH SOCIOL REV, V19, P34, DOI 10.5172/hesr.2010.19.1.034
   Johnny S, 2013, CODING MANUAL QUALIT, V2nd, P0
   Joseph-Williams N, 2014, PATIENT EDUC COUNS, V94, P291, DOI 10.1016/j.pec.2013.10.031
   Kemper KJ, 2008, PEDIATRICS, V122, P1374, DOI 10.1542/peds.2008-2173
   Kemper KJ, 2004, AMBUL PEDIATR, V4, P482, DOI 10.1367/A04-050R.1
   Knipper E, 2017, PEDIATR ANESTH, V27, P1070, DOI 10.1111/pan.13225
   Kuttner L, 2012, PEDIATR ANESTH, V22, P573, DOI 10.1111/j.1460-9592.2012.03860.x
   Mandel Susan E, 2014, HOSP TOP, V92, P28, DOI 10.1080/00185868.2014.906830
   McClafferty H, 2017, PEDIATRICS, V140, P0, DOI 10.1542/peds.2017-1961
   Mittring N, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/316950
   Paulozzi Leonard J, 2011, MORBIDITY AND MORTALITY WEEKLY REPORT, V60, P1487
   Robinson N, 1900, V1, V0, P43
   Roth I, 2017, ETHNOGRAPHY INTEGRAT, V0, P0
   Salkeld EJ, 2014, MED ANTHROPOL Q, V28, P44, DOI 10.1111/maq.12074
   Schensul J, 1999, ETHNOGRAPHERS TOOLKIT 3. ESSENTIAL ETHNOGRAPHIC METHODS: AUDIOVISUAL TECHNIQUES, V0, P0
   Sharf BF, 2012, PATIENT EDUC COUNS, V89, P434, DOI 10.1016/j.pec.2012.03.006
   Shuval JT, 2012, QUAL HEALTH RES, V22, P1317, DOI 10.1177/1049732312450326
   Smithson J, 2010, J HEALTH SERV RES PO, V15, P54, DOI 10.1258/jhsrp.2009.009104
   Spradley JP, 2016, THE ETHNOGRAPHIC INTERVIEW, V0, P0
   Taylor SL, 2018, MED ACUPUNCT, V30, P252, DOI 10.1089/acu.2018.1286
   Thompson MS, 2013, QUANT METH EDUC BEHA, V0, P163
   Thrane S, 2013, J PEDIATR ONCOL NURS, V30, P320, DOI 10.1177/1043454213511538
   Uman LS, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005179.pub3
   Vohra S, 2005, BMC HEALTH SERV RES, V5, P0, DOI 10.1186/1472-6963-5-78
   Weeks John, 2015, INTEGR MED (ENCINITAS), V14, P14
   Weeks J, 2016, J ALTERN COMPLEM MED, V22, P947, DOI 10.1089/acm.2016.29016.jjw
   Witt CM, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/652546
   Wolcott HF, 2008, ETHNOGRAPHY: A WAY OF SEEING, V2nd, P0
   Yang CS, 2015, PEDIATR RES, V78, P112, DOI 10.1038/pr.2015.91
   Yinger OS, 2015, J MUSIC THER, V52, P1, DOI 10.1093/jmt/thv004
NR 55
TC 11
Z9 13
U1 1
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAR 15
PY 2019
VL 25
IS 
BP S95
EP S105
DI 10.1089/acm.2018.0369
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA HP4RP
UT WOS:000461664000012
PM 30870018
DA 2026-01-16
ER

PT J
AU Ko, MM
   Jang, S
   Lee, JA
   Kang, BK
   Jung, J
AF Ko, Mi Mi
   Jang, Soobin
   Lee, Ju Ah
   Kang, Byung Kab
   Jung, Jeeyoun
TI Blood Stasis Therapy for Traumatic Injury: A Prospective, Single-Arm, Pre-Post Pilot Study
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE blood stasis; diagnosis; Traditional Korean Medicine; traumatic injury; pain; perfusion index
ID perfusion index; stimulation
AB Objectives: Blood stasis is an important pathophysiologic concept in Traditional East Asian Medicine. It has been considered to be a pathogenic factor in chronic and incurable conditions such as pain, infertility, cancer, coronary heart disease, and others. The aim of this study was to investigate the effects of pain reduction by blood stasis treatment for blood stasis syndromes with traumatic injury. Methods: A single-center prospective pretest-post-test pilot study included 73 patients with a trauma that occurred within the past 2 weeks who were admitted into Jaseng Hospital of Korean Medicine from August 2015 through December 2015. Of the 50 patients analyzed in this study, 42 were women (mean age, 33.52). Triple Energizer-reinforcing Saam acupuncture set, herbal medicine (Dangkwisoo-san), and wet cupping on tender point, which are Korean medical therapies generally executed to treat post-traumatic pain, were performed. The patients had to receive at least six sessions of treatment during the 2 weeks, with subsequent treatment being performed within 31 days after the previous treatment. Numeric rating scale (NRS) score and general pain severity indicator was measured as a primary outcome measure. The blood stasis questionnaire, oximetry, and patient's satisfaction were also measured. Results: The mean size of subcutaneous bleeding (width and length) and NRS score as a general pain indicator significantly decreased over the visits (all p<0.01, visit 1 vs. visit 6). Among the blood stasis symptoms in the questionnaire, 11 blood stasis indicators significantly decreased (all p<0.05). The patients showed significant improvement in the minimum and maximum value of peripheral perfusion index after the treatment (p=0.011 and p=0.15, respectively). Conclusions: This study reveals that blood stasis treatment may help improve the pain of patients with traumatic injury by enhancing the peripheral blood flow. The significant results observed in this study support some evidence of the theories of diagnosing blood stasis pattern and treatments of that pattern in Korean Medicine.
C1 [Ko, Mi Mi; Jang, Soobin; Kang, Byung Kab; Jung, Jeeyoun] Korea Inst Oriental Med, Clin Med Div, Daejeon 305811, South Korea.
   [Lee, Ju Ah] Gachon Univ, Coll Korean Med, Dept Korean Internal Med, Seongnam, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Gachon University
RP Jung, J (corresponding author), Korea Inst Oriental Med, Clin Med Div, Daejeon 305811, South Korea.
EM jjy0918@kiom.re.kr
FU Korea Institute of Oriental Medicine [K18191, K18192]
CR Unknown -, 2018, RAD 7 PULS COOX, V0, P0
   Unknown -, 2019, W PAC REG PARTN FOR, V0, P0
   김유진, 2008, JOURNAL OF KOREAN MEDICINE REHABILITATION 한방재활의학과학회지, V18, P119
   Choi TY, 2016, EUR J INTEGR MED, V8, P158, DOI 10.1016/j.eujim.2015.09.137
   De Felice C, 2002, EUR J PEDIATR, V161, P561, DOI 10.1007/s00431-002-1042-5
   신경민, 2010, JOURNAL OF ACUPUNCTURE RESEARCH, V27, P83
   Fang LY, 1991, ZHONG XI YI JIE HE Z, V11, P0
   Gunter RN, 2007, BLOOD STASISCHINAS C, V0, P0
   Hagar H, 2004, ANESTHESIOLOGY, V101, P0
   HALES JRS, 1989, CLIN EXP PHARMACOL P, V16, P403, DOI 10.1111/j.1440-1681.1989.tb01578.x
   Hasanin A, 2017, J CLIN MONIT COMPUT, V31, P961, DOI 10.1007/s10877-016-9936-3
   Hsiu H, 2011, MICROVASC RES, V81, P289, DOI 10.1016/j.mvr.2011.03.001
   Jeong Suhyeon, 2015, JOURNAL OF KOREAN MEDICINE REHABILITATION 한방재활의학과학회지, V25, P87, DOI 10.18325/jkmr.2015.25.1.087
   Jin XY, 2008, J ETHNOPHARMACOL, V117, P473, DOI 10.1016/j.jep.2008.02.033
   Jung J, 2018, CHIN J INTEGR MED, V24, P254, DOI 10.1007/s11655-017-2788-y
   Jung J, 2018, CHIN J INTEGR MED, V24, P752, DOI 10.1007/s11655-017-2813-1
   Kang BK, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/8049481
   Kim Ji Hyun, 2011, EVID BASED COMPLEMENT ALTERNAT MED, V2011, P718302, DOI 10.1155/2011/718302
   Knapp TR, 2016, CLIN NURS RES, V25, P467, DOI 10.1177/1054773816666280
   Korea Center for Disease Control and Prevention, 2015, CHRON DIS STAT ISS 2, V0, P0
   Lee JA, 2014, EUR J INTEGR MED, V7, P417
   Lee SMK, 2014, NUTR HEALTH SER, V0, PP423, DOI 10.1007/978-1-4939-0548-5_29
   Liao JQ, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000005533
   Liu H, 1993, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V13, P714
   MDSung Uk Cho，, 2011, JOURNAL OF THE KOREAN SOCIETY OF EMERGENCY MEDICINE 대한응급의학회지, V22, P59
   Moon S-K, 2005, THE JOURNAL OF KOREAN MEDICINE, V26, P115
   Nishimura T, 2014, J PAIN RES, V7, P91, DOI 10.2147/JPR.S57140
   Park B, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/316872
   Park B, 2014, AM J TRANSL RES, V6, P857
   김도형, 2014, THE JOURNAL OF KOREAN ORIENTAL INTERNAL MEDICINE 대한한방내과학회지, V35, P24
   Ryu SH, 2001, KOREAN J ORIENTAL IN, V22, P199
   Shi N, 2008, CHIN J INTEGR MED, V14, P303, DOI 10.1007/s11655-008-0303-1
   Terasawa K, 1983, JPN J ORIENT MED, V34, P1, DOI 10.3937/KAMPOMED.34.1
   Xu QY, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/490292
   Yang DH, 2006, J KOREA INST ORIENT MED DIAG, V10, P141
   Yu G, 2014, CHIN J INTEGR MED, V20, P300, DOI 10.1007/s11655-013-1332-3
   Zhang J Z, 1993, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V13, P397
NR 37
TC 7
Z9 8
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAR 15
PY 2019
VL 25
IS 3
BP 359
EP 365
DI 10.1089/acm.2018.0134
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA HR6SW
UT WOS:000463284500011
PM 30156424
DA 2026-01-16
ER

PT J
AU Serçe, S
   Ovayolu, Ö
   Pirbudak, L
   Ovayolu, N
AF Serçe, Sibel
   Ovayolu, Özlem
   Pirbudak, Lütfiye
   Ovayolu, Nimet
TI Response to "Statistical Concerns About Acupressure on Pain in Cancer Patients
SO Integrative cancer therapies
LA English
DT Letter
C1 1 Gaziantep University Hospital, Gaziantep, Turkey.
   2 Gaziantep University, Gaziantep, Turkey.
   2 Gaziantep University, Gaziantep, Turkey.
   2 Gaziantep University, Gaziantep, Turkey.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD MAR 19
PY 2019
VL 18
IS 
BP 1534735419834355
EP 1534735419834355
DI 10.1177/1534735419834355
PG 1
WC Acupressure; Bone Neoplasms; Cancer Pain; Humans; Pain
UT PubMed:30879342
PM 30879342
DA 2019-03-19
ER

PT J
AU Pan, SL
   Zheng, SL
   Zhou, XH
   Wang, QL
AF Pan, Sheng-Lian
   Zheng, Shi-Li
   Zhou, Xia-Hui
   Wang, Qing-Lai
TI [Acupuncture combined with Jingtong granule for nerve-root type cervical
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Jingtong granule; acupuncture; hemorheology; interleukin-1 beta (IL-1β); interleukin-6 (IL-6); nerve-root type cervical spondylosis; tumor necrosis factor-alpha (TNF-α)
AB OBJECTIVE: To explore the clinical efficacy of acupuncture combined with Jingtong  granule for nerve-root type cervical spondylosis and its effects on serum  interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta  (IL-1β) and hemorheological indexes. METHODS: A total of 114 patients with  nerve-root type cervical spondylosis were randomly divided into an observation  group and a control group, 57 cases in each group. The patients in both groups  were treated with traction. The patients in the control group were treated with  oral administration of Jingtong granule, 4 g each time, 3 times a day, while  based on the treatment of control group, the patients in the observation group  were treated with acupuncture at Dazhui (GV 14), Tianzhu (BL 10), Houxi (SI 3),  cervical Jiaji (EX-B 2), Quchi (LI 11), Hegu (LI 4) and Waiguan (TE 5), once a  day. Both groups were treated for 4 weeks. The simplified McGill pain  questionnaire (MPQ), neck disability index (NDI), numbness score, levels of IL-6,  TNF-α, IL-1β in serum and hemorheological indexes were observed before and after  treatment, and the clinical efficacy was compared between the two groups.  RESULTS: The total effective rate was 91.2% (52/57) in the observation group,  which was higher than 71.9% (41/57) in the control group (P<0.05). Compared  before treatment, the scores of MPQ, NDI and numbness in the two groups were  reduced after treatment (P<0.05). After treatment, the scores of MPQ, NDI and  numbness in the observation group were lower than those in the control group  (P<0.05). After treatment, the serum levels of IL-6, TNF-α and IL-1β in the two  groups were reduced (P<0.05), and those in the observation group were lower than  the control group (P<0.05). After treatment, the plasma viscosity, fibrinogen,  low shear rate of whole blood viscosity and high shear rate of whole blood  viscosity in the two groups were lower than before treatment (P<0.05), and those  in the observation group were lower than the control group (P<0.05). CONCLUSION:  Acupuncture combined with Jingtong granule have significant clinical efficacy for  nerve-root type cervical spondylosis, which could reduce the serum levels of  IL-6, TNF-α and IL-1β and improve hemorheology.
C1 Department of Acupuncture and Moxibustion, Wenzhou Hospital of TCM, Wenzhou 325000, Zhejiang Province, China.
   Department of Acupuncture and Moxibustion, Wenzhou Hospital of TCM, Wenzhou 325000, Zhejiang Province, China.
   Department of Acupuncture and Moxibustion, Wenzhou Hospital of TCM, Wenzhou 325000, Zhejiang Province, China.
   Department of Acupuncture and Moxibustion, Wenzhou Hospital of TCM, Wenzhou 325000, Zhejiang Province, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 11
PY 2019
VL 39
IS 12
BP 1274
EP 8
DI 10.13703/j.0255-2930.2019.12.005
PG -1266
WC Acupuncture Therapy; Humans; Interleukin-1beta; Interleukin-6; Spondylosis; therapy; Tumor Necrosis Factor-alpha
UT PubMed:31820601
PM 31820601
DA 2019-12-11
ER

PT J
AU Lown, EA
   Banerjee, A
   Vittinghoff, E
   Dvorak, CC
   Hartogensis, W
   Melton, A
   Mangurian, C
   Hu, H
   Shear, D
   Adcock, R
   Morgan, M
   Golden, C
   Hecht, FM
AF Lown, E Anne
   Banerjee, Anu
   Vittinghoff, Eric
   Dvorak, Christopher C
   Hartogensis, Wendy
   Melton, Alexis
   Mangurian, Christina
   Hu, Hiroe
   Shear, Deborah
   Adcock, Robyn
   Morgan, Michael
   Golden, Carla
   Hecht, Frederick M
TI Acupressure to Reduce Treatment-Related Symptoms for Children With Cancer and
SO Global advances in health and medicine
LA English
DT Journal Article
DE acupressure; acupuncture; childhood cancer; nausea; pain; symptom management; vomiting
AB BACKGROUND: We describe the study design and protocol of a pragmatic randomized  controlled trial (RCT) Acupressure for Children in Treatment for a Childhood  Cancer (ACT-CC). OBJECTIVE: To describe the feasibility and effectiveness of an  acupressure intervention to decrease treatment-related symptoms in children in  treatment for cancer or recipients of a chemotherapy-based hematopoietic stem  cell transplant (HSCT). DESIGN: Two-armed RCTs with enrollment of 5 to 30 study  days. SETTING: Two pediatric teaching hospitals. PATIENTS: Eighty-five children  receiving cancer treatment or a chemotherapy-based HSCT each with 1 parent or  caregiver. INTERVENTION: Patients are randomized 1:1 to receive either usual care  plus daily professional acupressure and caregiver delivered acupressure versus  usual care alone for symptom management. Participants receive up to 20  professional treatments. MAIN OUTCOME: A composite nausea/vomiting measure for  the child. SECONDARY OUTCOMES: Child's nausea, vomiting, pain, fatigue,  depression, anxiety, and positive affect. PARENT OUTCOMES: Depression, anxiety,  posttraumatic stress symptoms, caregiver self-efficacy, and positive affect.  Feasibility of delivering the semistandardized intervention will be described.  Linear mixed models will be used to compare outcomes between arms in children and  parents, allowing for variability in diagnosis, treatment, and age. DISCUSSION:  Trial results could help childhood cancer and HSCT treatment centers decide about  the regular inclusion of trained acupressure providers to support symptom  management.
C1 Social and Behavioral Sciences, School of Nursing, University of California, San Francisco, California.
   Department of Neurological Surgery, University of California, San Francisco, California.
   Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, California.
   Division of Pediatric Allergy, Immunology, & Blood and Marrow Transplantation, University of California, San Francisco, California.
   Osher Center for Integrative Medicine, University of California, San Francisco, California.
   Division of Pediatric Allergy, Immunology, & Blood and Marrow Transplantation, University of California, San Francisco, California.
   Department of Psychiatry, School of Medicine, University of California, San Francisco, California.
   Social and Behavioral Sciences, School of Nursing, University of California, San Francisco, California.
   Social and Behavioral Sciences, School of Nursing, University of California, San Francisco, California.
   Compass Care/Integrative Pediatric Pain and Palliative Care (IP3), UCSF Benioff Children's Hospital, San Francisco, California.
   Social and Behavioral Sciences, School of Nursing, University of California, San Francisco, California.
   Department of Pediatric Hematology-Oncology, UCSF Benioff Children's Hospital, Oakland, California.
   Osher Center for Integrative Medicine, University of California, San Francisco, California.
NR 0
TC 0
SN 2164-956
EI 2164-957
J9 Glob Adv Health Med
PD AUG 28
PY 2019
VL 8
IS 
BP 2164956119870444
EP 2164956119870444
DI 10.1177/2164956119870444
PG 1
UT PubMed:31453017
PM 31453017
DA 2019-08-28
ER

PT J
AU Yu, C
   Zhang, N
   Zhu, WK
   Zhang, YY
   Yang, J
   Wang, Y
   Song, XG
   Hu, L
   Wu, ZJ
   Liu, Q
   Tang, Y
   Wu, QF
   Yu, SG
AF Yu, Chang
   Zhang, Ning
   Zhu, Weikang
   Zhang, Yueyue
   Yang, Jiao
   Wang, Yong
   Song, Xiaoge
   Hu, Ling
   Wu, Zijian
   Liu, Qi
   Tang, Yong
   Wu, Qiaofeng
   Yu, Shuguang
TI Does Moxa Smoke Have Significant Effect on the Acupuncturist's Respiratory System? A Population-Based Study
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID moxibustion; health; exposure; symptoms; medicine; cancer; safety; pain
AB Objectives. To evaluate the safety of moxa smoke, especially to provide quantitative information and details for the occupational prevention of acupuncturists. Methods. We combined the questionnaire-based cross-sectional survey and lung function testing-based historical retrospective cohort research to investigate the safety of moxa smoke exposure (MSE) among acupuncturists. A mathematical regression model was established to quantitatively evaluate the relationship between moxa smoke exposure and the respiratory health of the acupuncturist. The smoke exposure time of the acupuncturist and the prevalence of abnormal respiratory symptoms or diseases were also evaluated. Results. (1) The cross-sectional research showed that the incidence of expectoration (18.7%) and rhinitis (22.7%) was the most common respiratory symptom and disease after MSE. No statistical difference was found between smoke exposure time of the acupuncturist and the prevalence of abnormal respiratory symptoms or diseases, except the prevalence of rhinitis and shortness of breath (P<0.01). Regression model for the incidence of first three symptoms (expectoration, shortness of breath, and wheezing) from the cross-sectional survey indicated that the weight coefficients of factors associated with moxa smoke were lower than those of factors unrelated to moxa smoke, such as gender and personal history of respiratory diseases. (2) Historical retrospective cohort research showed that there was no significant difference in the % predicted PEF. No statistic difference was found between the exposed and nonexposed group in large airway function indexes (% predicted FEV1, % predicted FVC, and % predicted FEV1/FVC) and small airway function indexes (% predicted FEF25, % predicted FEF50, % predicted FEF75, and % predicted MMEF), either. Especially, the % predicted MVV among males (106.23 +/- 2.92 vs. 95.56 +/- 1.92, P<0.01 and % predicted VC among females (100.70 +/- 1.59 vs. 95.91 +/- 1.61, P<0.05) between the two groups had statistical significance, but did not cause pulmonary ventilation dysfunction. Conclusions. MSE has no significant effect on the respiratory health of acupuncturists.
C1 [Yu, Chang; Zhang, Ning; Zhang, Yueyue; Yang, Jiao; Tang, Yong; Wu, Qiaofeng; Yu, Shuguang] Chengdu Univ Tradit Chinese Med, Acupuncture & Moxibust Coll, Chengdu 610075, Sichuan, Peoples R China.
   [Zhu, Weikang; Wang, Yong] Chinese Acad Sci, Acad Math & Syst Sci, MDIS, CEMS,NCMIS, Beijing 100080, Peoples R China.
   [Song, Xiaoge; Hu, Ling; Wu, Zijian] Anhui Univ Tradit Chinese Med, Acupuncture & Moxibust Coll, Hefei 230000, Anhui, Peoples R China.
   [Liu, Qi] Shaanxi Univ Tradit Chinese Med, Acupuncture & Moxibust Coll, Xian 712046, Shaanxi, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chinese Academy of Sciences; Anhui University of Chinese Medicine; Shaanxi University of Chinese Medicine
RP Wu, QF; Yu, SG (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Moxibust Coll, Chengdu 610075, Sichuan, Peoples R China.
EM 20052023@cdutcm.edu.cn; ysg@cdutcm.edu.cn
FU National Basic Research Program of China [2015CB554504]; National Natural Science Foundation of China [81873383, 81873386, 81330087, 81704160]; fund of Science and Technology Department of Sichuan Province, China [18YYJC0095]; fund of Sichuan Provincial Department of Education, China [18TD0018]; fund of Science and Technology Innovation and Cultivation Project of Sichuan Province, China [2019042]
CR Anastasi JK, 2009, GASTROENTEROL NURS, V32, P243, DOI 10.1097/SGA.0b013e3181b2c920
   Unknown -, 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   Unknown -, 2014, WORLD CHINESE MED, V0, P0
   BECKETT WS, 1994, OCCUP ENVIRON MED, V51, P14, DOI 10.1136/oem.51.1.14
   Cardini F, 1998, JAMA-J AM MED ASSOC, V280, P1580, DOI 10.1001/jama.280.18.1580
   Choi TY, 2017, MATURITAS, V100, P33, DOI 10.1016/j.maturitas.2017.03.314
   Cui YX, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/510318
   Duan Wen-Xiu, 2018, ZHEN CI YAN JIU, V43, P98, DOI 10.13702/j.1000-0607.170854
   Duan Wenxiu, 2016, ZHONGGUO ZHEN JIU, V36, P637, DOI 10.13703/j.0255-2930.2016.06.022
   Han Li, 2016, ZHONGGUO ZHEN JIU, V36, P499
   He R, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/9236742
   Huanfang X, 2013, EVID-BASED COMPL ALT, V2013, P6, DOI 10.1155/2013/178067
   Kwon OS, 2017, ACUPUNCT MED, V35, P93, DOI 10.1136/acupmed-2016-011105
   Lee MS, 2010, AM J CHINESE MED, V38, P829, DOI 10.1142/S0192415X10008275
   Li H, 2012, INVESTIGATION MED WO, V0, P0
   Lui KH, 2016, ENVIRON POLLUT, V213, P524, DOI 10.1016/j.envpol.2016.02.053
   Mao HJ, 2016, CANCER-AM CANCER SOC, V122, P3667, DOI 10.1002/cncr.30189
   Matsumoto T, 2016, EUR J INTEGR MED, V8, P414, DOI 10.1016/j.eujim.2016.03.005
   Peters J, 1996, INT J EPIDEMIOL, V25, P821, DOI 10.1093/ije/28.5.859
   Ping L, 2013, CHINESE ACUPUNCTURE, V33, P145
   Shu Q, 2016, AKUPUNKTUR AURIKULOM, V42, P11, DOI 10.1007/s15009-016-5429-1
   Stein DJ, 2017, GASTROENTEROL CLIN N, V46, P875, DOI 10.1016/j.gtc.2017.08.015
   STEVENS RG, 1984, AM J EPIDEMIOL, V119, P624, DOI 10.1093/oxfordjournals.aje.a113779
   Sun YJ, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1179-9
   Vas J, 2013, ACUPUNCT MED, V31, P31, DOI 10.1136/acupmed-2012-010261
   Wang JY, 2015, ARCH ENVIRON OCCUP H, V70, P225, DOI 10.1080/19338244.2013.872077
   Wang XM, 2015, ACSR ADV COMPUT, V34, P1055
   Wang X, 2018, J TRADIT CHIN MED, V38, P132
   Wheeler J, 2009, ACUPUNCT MED, V27, P16, DOI 10.1136/aim.2009.000422
   Wu HG, 2013, WORLD CHIN MED, V8, P845
   Xu DM, 2018, MED SCI MONITOR, V24, P2937, DOI 10.12659/MSM.909725
   Xu Ji, 2014, EVID BASED COMPLEMENT ALTERNAT MED, V2014, P783704, DOI 10.1155/2014/783704
   Yamaguchi Satoru, 2012, RINSHO SHINKEIGAKU, V52, P1287
   Yang MX, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0170952
   Yu Chang, 2018, ZHEN CI YAN JIU, V43, P103, DOI 10.13702/j.1000-0607.170840
   Zhao JM, 2014, WORLD J GASTROENTERO, V20, P13563, DOI 10.3748/wjg.v20.i37.13563
NR 37
TC 10
Z9 10
U1 0
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD SEP 16
PY 2019
VL 2019
IS 
BP 
EP 
DI 10.1155/2019/4873235
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA JB3LS
UT WOS:000488459400001
PM 31636685
DA 2026-01-16
ER

PT J
AU D'Alessandro, EG
   Nebuloni, Nagy DR
   de, Brito CMM
   Almeida, EPM
   Battistella, LR
   Cecatto, RB
AF D'Alessandro, Eduardo Guilherme
   Nebuloni Nagy, Daniela Ribeiro
   de Brito, Christina May Moran
   Almeida, Elisangela Pinto Marinho
   Battistella, Linamara Rizzo
   Cecatto, Rebeca Boltes
TI Acupuncture for chemotherapy-induced peripheral neuropathy: a randomised
SO BMJ supportive & palliative care
LA English
DT Journal Article
DE acupuncture; chemotherapy; neuropathy; quality of life; rehabilitation
AB Chemotherapy-induced peripheral neuropathy (CIPN) can cause loss of independence  and poor quality of life (QoL) due to severe disabilities, but in spite of its  importance there is still a lack of data for the management of CIPN. Acupuncture  has showed promising results and may be a cost-effective option for the  treatment. OBJECTIVES: To evaluate the effect of acupuncture treatment on  neurological symptoms of CIPN and QoL of oncological patients. METHODS: We  performed a clinical, single-centre, randomised and controlled pilot study that  involved 33 adult patients with cancer and CIPN randomised into two groups  (control and acupuncture treated with 10 sessions, two times per week). Both  groups were subjected to a complete physical examination and clinical assessment  with National Cancer Institute Common Terminology Criteria for Adverse Events  (NCI CTCAE) Scale V.2.0, FIM Scale, European Organisation for the Research and  Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Scale and  Visual Analogue Scale for pain before and 5 weeks after treatment. RESULTS: There  were no adverse events, and we found statistical differences in groups in  physical (p=0.03) and function (p=0.04) domains of EORTC QLQ-C30 when comparing  control and acupuncture groups. About NCI CTCAE Scale and neuropathy sensory  symptoms, we found better results in acupuncture group, comparing pretreatment  and post-treatment analyses (p=0.01). In control group, we have no differences  after 5 weeks (p=0.11). CONCLUSION: Although these results suggest an interesting  effect of acupuncture on this patient population, the clinical significance has  remained unclear. Given the tendency towards benefit and the lack of adverse  effects, the authors recommend a follow-up acupuncture trial using higher  follow-up time and better sample size. TRIAL REGISTRATION NUMBER: NCT02309164.
C1 Instituto do Cancer, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil.
   Instituto do Cancer, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil.
   Rehabilitation Department, Instituto do Cancer, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
   Rehabilitation Service, Hospital Sírio-Libanês, Sao Paulo, Brasil.
   Rehabilitation Department, Instituto do Cancer, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
   Department of Legal Medicine, Medical Ethics, Social and Work Medicine, Faculdade de Medicina, Universidade de São Paulo (USP), Sao Paulo, Brazil.
   Instituto de Medicina Física e de Reabilitação, Hospital das Clinicas 
   Rehabilitation Department, Instituto do Cancer, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazilrebeca.boltes@gmail.com.
   School of Medicine, Universidade Nove de Julho, Sao Paulo, Brazil.
NR 0
TC 0
SN 2045-436
EI 
J9 BMJ Support Palliat Care
PD JUL 1
PY 2019
VL 12
IS 1
BP 64
EP 72
DI 10.1136/bmjspcare-2018-001542
PG 8
WC Acupuncture Therapy; adverse effects; Adult; Antineoplastic Agents; adverse effects; Humans; Peripheral Nervous System Diseases; chemically induced; Pilot Projects; Quality of Life
UT PubMed:31256014
PM 31256014
DA 2019-07-01
ER

PT J
AU Liou, KT
   Hung, TKW
   Meghani, SH
   Epstein, AS
   Li, QS
   Romero, SAD
   Cohen, RB
   Mao, JJ
AF Liou, Kevin T
   Hung, Tony K W
   Meghani, Salimah H
   Epstein, Andrew S
   Li, Q Susan
   Romero, Sally A D
   Cohen, Roger B
   Mao, Jun J
TI What if Acupuncture Were Covered by Insurance for Pain Management? A
SO Pain medicine (Malden, Mass.)
LA English
DT Journal Article
DE Access; Acupuncture; Cancer; Disparities; Health Beliefs; Insurance; Pain
AB OBJECTIVE: In response to the national opioid crisis, governmental and medical  organizations have called for broader insurance coverage of acupuncture to  improve access to nonpharmacologic pain therapies, especially in cancer  populations, where undertreatment of pain is prevalent. We evaluated whether  cancer patients would be willing to use insurance-covered acupuncture for pain.  DESIGN AND SETTING: We conducted a cross-sectional survey of cancer patients with  pain at one academic center and 11 community hospitals. METHODS: We used logistic  regression models to examine factors associated with willingness to use  insurance-covered acupuncture for pain. RESULTS: Among 634 cancer patients, 304  (47.9%) reported willingness to use insurance-covered acupuncture for pain. In  univariate analyses, patients were more likely to report willingness if they had  severe pain (odds ratio [OR] = 1.59, 95% confidence interval [CI] = 1.03-2.45)  but were less likely if they were nonwhite (OR = 0.59, 95% CI = 0.39-0.90) or had  only received high school education or less (OR = 0.46, 95% CI = 0.32-0.65).  After adjusting for attitudes and beliefs in multivariable analyses, willingness  was no longer significantly associated with education (adjusted OR [aOR] = 0.78,  95% CI = 0.50-1.21) and was more negatively associated with nonwhite race (aOR =  0.49, 95% CI = 0.29-0.84). CONCLUSIONS: Approximately one in two cancer patients  was willing to use insurance-covered acupuncture for pain. Willingness was  influenced by patients' attitudes and beliefs, which are potentially modifiable  through counseling and education. Further research on racial disparities is  needed to close the gap in utilization as acupuncture is integrated into  insurance plans in response to the opioid crisis.
C1 Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Hematology-Oncology, Olive View-UCLA Medical Center, Sylmar, California.
   Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Medicine, Weill Cornell Medical College, New York, New York.
   Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, New York, New York.
   Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, New York, New York.
   Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
   Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Medicine, Weill Cornell Medical College, New York, New York.
NR 0
TC 0
SN 1526-463
EI 1526-237
J9 Pain Med
PD JUL 23
PY 2019
VL 20
IS 10
BP 2060
EP 2068
DI 10.1093/pm/pnz087
PG 8
WC Academic Medical Centers; statistics & numerical data; Acupuncture Therapy; Adult; Cancer Pain; economics; Cross-Sectional Studies; Educational Status; Ethnicity; Female; Hospitals, Community; statistics & numerical data; Humans; Insurance Coverage; economics; Male; Middle Aged; Pain Management; economics; Socioeconomic Factors; Surveys and Questionnaires
UT PubMed:31329938
PM 31329938
DA 2019-07-23
ER

PT J
AU Zhang, CH
   Ma, ZZ
   Huo, BB
   Lu, YC
   Wu, JJ
   Hua, XY
   Xu, JG
AF Zhang, Chen-hao
   Ma, Zhen-zhen
   Huo, Bei-bei
   Lu, Ye-chen
   Wu, Jia-jia
   Hua, Xu-yun
   Xu, Jian-guang
TI Diffusional plasticity induced by electroacupuncture intervention in rat model of peripheral nerve injury
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE Electroacupuncture; Peripheral nerve injury; Radial diffusivity; Brain plasticity
ID catwalk gait analysis; thalamic hyperexcitability; brain plasticity; central pain; acupuncture; stimulation; recovery; therapy; pathway; cancer
AB Electroacupuncture (EA) is an adjuvant therapy for peripheral nerve injury (PNI). Both peripheral and central alterations contribute to the rehabilitation process. We employed diffusion tensor imaging (DTI) to investigate the diffusion plasticity of afferent and efferent pathways caused by EA in model of peripheral nerve injury and reparation. Twenty-four rats were divided into three groups: normal group, model group and intervention group. Rats of the model group and the intervention group underwent sciatic nerve transection and anastomosis. EA intervention was performed on the intervention group at ST36 and GB-30 for three months. Gait assessment and DTI were conducted at days post-operative (DPO) 30, 60 and 90. We selected corticospinal tract, spinothalamic tract and internal capsule as regions of interest and analyzed diffusion metrics including fractional anisotropy (FA), axial diffusivity (AD) and radial diffusivity (RD). FA values and RD values displayed significant differences or obvious tendency while AD values maintained a stable level. RD values displayed better indicative performance than FA in internal capsule. The intervention group presented significant correlation between RD values and Regularity Index (RI) during the intervention period. The effect of EA on peripheral nerve injury repairing rats appeared to be accelerated recovery process of sensory and motor neural pathway. We proposed that RD was a potential in vivo indicator for structural plasticity caused by EA and PNI. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Chen-hao; Ma, Zhen-zhen; Lu, Ye-chen; Wu, Jia-jia; Xu, Jian-guang] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Ctr Rehabil, Shanghai, Peoples R China.
   [Zhang, Chen-hao; Xu, Jian-guang] Fudan Univ, Huashan Hosp, Dept Hand Surg, Shanghai, Peoples R China.
   [Hua, Xu-yun] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Dept Trauma & Orthoped, Shanghai, Peoples R China.
   [Ma, Zhen-zhen; Huo, Bei-bei; Lu, Ye-chen; Xu, Jian-guang] Shanghai Univ Tradit Chinese Med, Sch Rehabil Sci, 1200 Cailun Rd, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Fudan University; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Xu, JG (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Rehabil Sci, 1200 Cailun Rd, Shanghai, Peoples R China.
EM jianguangxu@fudan.edu.cn
FU Shanghai Key Laboratory of Peripheral Nerve and Microsurgery [17DZ2270500]
CR Andersson JLR, 2016, NEUROIMAGE, V125, P1063, DOI 10.1016/j.neuroimage.2015.10.019
   Asplund M, 2009, NEUROEPIDEMIOLOGY, V32, P217, DOI 10.1159/000197900
   Bozkurt A, 2008, J NEUROSCI METH, V173, P91, DOI 10.1016/j.jneumeth.2008.05.020
   Chen X, 2015, BRAIN RES, V1601, P64, DOI 10.1016/j.brainres.2015.01.011
   Cropley VL, 2017, AM J PSYCHIAT, V174, P286, DOI 10.1176/appi.ajp.2016.16050610
   Deumens R, 2007, J NEUROSCI METH, V164, P120, DOI 10.1016/j.jneumeth.2007.04.009
   Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011
   Flondell M, 2017, J PLAST SURG HAND SU, V51, P159, DOI 10.1080/2000656X.2016.1205503
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Goswami R, 2016, PAIN, V157, P729, DOI 10.1097/j.pain.0000000000000430
   Hao J, 1995, J TRADIT CHIN MED, V15, P114
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015
   Lee SH, 2013, CNS NEUROSCI THER, V19, P585, DOI 10.1111/cns.12108
   Li P, 1998, CIRCULATION, V97, P1186, DOI 10.1161/01.CIR.97.12.1186
   Liang SX, 2017, J STROKE CEREBROVASC, V26, P1953, DOI 10.1016/j.jstrokecerebrovasdis.2017.06.018
   Lin KL, 2010, J SURG RES, V161, P101, DOI 10.1016/j.jss.2008.10.020
   Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073
   Liu SS, 2017, INT SYM QUAL ELECT, V0, PP76, DOI 10.1109/ISQED.2017.7918296
   Lu CY, 2017, STROKE, V48, P1682, DOI 10.1161/STROKEAHA.117.016959
   Ma H, 2017, NEURAL PLAST, V2017, P0, DOI 10.1155/2017/5101925
   Maeda Y, 2017, BRAIN, V140, P914, DOI 10.1093/brain/awx015
   Matsumoto-Miyazaki J, 2016, J ALTERN COMPLEM MED, V22, P887, DOI 10.1089/acm.2014.0356
   Miki K, 2000, PAIN, V85, P263, DOI 10.1016/S0304-3959(99)00279-1
   Napadow V, 2013, HUM BRAIN MAPP, V34, P2592, DOI 10.1002/hbm.22091
   Napadow V, 2009, NEUROIMAGE, V47, P1055, DOI 10.1016/j.neuroimage.2009.05.079
   Pallarés V, 2015, COMPUT METH PROG BIO, V121, P66, DOI 10.1016/j.cmpb.2015.05.011
   Papp EA, 2014, NEUROIMAGE, V97, P374, DOI 10.1016/j.neuroimage.2014.04.001
   Ramu J, 2008, EXP NEUROL, V212, P100, DOI 10.1016/j.expneurol.2008.03.018
   Rusanescu G, 2017, J CELL MOL MED, V21, P299, DOI 10.1111/jcmm.12965
   Sullivan R, 2016, INT J MOL SCI, V17, P0, DOI 10.3390/ijms17122101
   Tambalo S, 2015, J NEUROSCI, V35, P10088, DOI 10.1523/JNEUROSCI.0540-15.2015
   Taylor KS, 2009, BRAIN, V132, P3122, DOI 10.1093/brain/awp231
   Wang GX, 2008, J NEUROSCI, V28, P11959, DOI 10.1523/JNEUROSCI.3296-08.2008
   Wasner G, 2008, BRAIN, V131, P2387, DOI 10.1093/brain/awn169
   Wu JJ, 2018, BRAIN RES, V1690, P61, DOI 10.1016/j.brainres.2018.04.009
   Wu Jia-Jia, 2018, WORLD NEUROSURG, V114, Pe267, DOI 10.1016/j.wneu.2018.02.173
   Yang Y, 2017, NEURAL PLAST, V2017, P0, DOI 10.1155/2017/4716792
   Zhang MX, 2018, ACUPUNCT MED, V36, P170, DOI 10.1136/acupmed-2017-011367
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhao N, 2018, J INTEGR NEUROSCI, V17, P61, DOI 10.31083/JIN-170043
NR 42
TC 11
Z9 14
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
EI 1532-2653
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD NOV 15
PY 2019
VL 69
IS 
BP 250
EP 256
DI 10.1016/j.jocn.2019.08.088
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA JP5SV
UT WOS:000498325100044
PM 31477463
DA 2026-01-16
ER

PT J
AU Wang, JS
   Lei, Y
   Bao, BH
   Yu, XD
   Dai, HH
   Chen, F
   Li, HS
   Wang, B
AF Wang, Jisheng
   Lei, Yi
   Bao, Binghao
   Yu, Xudong
   Dai, Hengheng
   Chen, Fei
   Li, Haisong
   Wang, Bin
TI Acupuncture for pain caused by prostate cancer Protocol for a systematic review
SO MEDICINE
LA English
DT Review
DE acupuncture; pain; protocol; prostate cancer; systematic review
ID analgesia
AB Background: Prostate cancer is a male malignant tumor disease with high prevalence in recent years. Patients with advanced prostate cancer are more likely to have bone metastasis and strong bone pain, and even lead to pathological fracture, which has a serious impact on the quality of life of patients. Acupuncture has good clinical efficacy in treating pain caused by prostate cancer. This review hopes to adopt meta-analysis to evaluate the efficacy and safety of acupuncture in the treatment of pain caused by prostate cancer and provides evidence for its application in clinical practice. Methods and analysis: We will search for PubMed, Cochrane Library, AMED, EMbase, WorldSciNet, Nature, Science online and China Journal Full-text Database (CNKI), China Biomedical Literature CD-ROM Database (CBM), and related randomized controlled trials included in the China Resources Database. The time is limited from the construction of the library to November 2018. We will use the criteria provided by Cochrane 5.1.0 for quality assessment and risk assessment of the included studies, and use the Revman 5.3 and Stata 13.0 software for meta-analysis of the effectiveness, recurrence rate, and symptom scores of epididymitis. Ethics and dissemination: This systematic review will evaluate the efficacy and safety of acupuncture for pain caused by prostate cancer. Owing to the fact that all of the data used in this systematic review and meta-analysis have been published, this review does not require ethical approval. Furthermore, all data will be anonymously analyzed during the review process trial.
C1 [Wang, Jisheng; Bao, Binghao; Yu, Xudong; Dai, Hengheng] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China.
   [Wang, Jisheng; Bao, Binghao; Yu, Xudong; Dai, Hengheng; Chen, Fei; Li, Haisong; Wang, Bin] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Androl, Beijing, Peoples R China.
   [Lei, Yi] Shaanxi Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Androl, Xianyang, Shaanxi, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Shaanxi University of Chinese Medicine
RP Li, HS; Wang, B (corresponding author), Dongzhimen Hosp, Dept Androl, Hai Yun Cang 5th ZIP, Beijing 100029, Peoples R China.
EM 1028bj@sina.com; dayiwangbin@sina.com
FU 2016 Beijing Chinese Medicine Salary Heritage 3+3 Project [2016-SZ-C-60]; Young Scientist Development Program 2016, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine [DZMYS-201609]
CR Unknown -, 2013, CHINA CANC, V0, P0
   Unknown -, 2017, CHINJ ONCOL PREVENT, V0, P0
   Unknown -, 2018, CHIN J MODER DRUG AP, V0, P0
   Unknown -, 2010, ACTA CHIN MED PHARM, V0, P0
   Unknown -, 2013, CANC PROGR, V0, P0
   Braunhut Beth L, 2018, SURG PATHOL CLIN, V11, P759, DOI 10.1016/j.path.2018.07.003
   Chao Y, 2015, J SHANGHAI U TRADIT, V29, P26
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P392
   Chien Tsu-Ming, 2016, ASIAN PAC J CANCER PREV, V17, P1187, DOI 10.7314/apjcp.2016.17.3.1187
   de Valois B, 2015, EUR J INTEGR MED, V7, P557
   de Freitas ATAG, 2016, J ACUPUNCT MERIDIAN, V9, P16, DOI 10.1016/j.jams.2015.08.002
   He YH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2017-018494
   Imanaka K, 2014, CLIN DRUG INVEST, V34, P501, DOI 10.1007/s40261-014-0204-3
   Lin LL, 2016, CELL TRANSPLANT, V25, P621, DOI 10.3727/096368916X690872
   Manzano A, 2014, J CLIN NURS, V23, P1877, DOI 10.1111/jocn.12447
   Nilsson S, 2005, J PAIN SYMPTOM MANAG, V29, P352, DOI 10.1016/j.jpainsymman.2004.07.008
   Patrick D, 2013, EUR UROL SUPPL, V12, P0
   Robinson DW, 2013, QUAL LIFE RES, V22, P2777, DOI 10.1007/s11136-013-0411-z
   Sauer CM, 2018, CRIT REV ONCOL HEMAT, V132, P66, DOI 10.1016/j.critrevonc.2018.09.013
   Shen XL, 2016, J UROLOGY, V195, P1397, DOI 10.1016/j.juro.2015.11.056
   Sheu SY, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0520-z
   Slavík H, 2014, NEW BIOTECHNOL, V31, PS106, DOI 10.1016/j.nbt.2014.05.1867
   Wei R, 2018, WORLD LATEST MED INF, V18, P32
   Xu JF, 2010, J UROLOGY, V183, PE836, DOI 10.1016/j.juro.2010.02.2253
   Zou Jian-Fei, 2010, XI BAO YU FEN ZI MIAN YI XUE ZA ZHI, V26, P1252
NR 26
TC 5
Z9 7
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN 15
PY 2019
VL 98
IS 2
BP 
EP 
DI 10.1097/MD.0000000000013954
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA HQ3CX
UT WOS:000462286300025
PM 30633174
DA 2026-01-16
ER

PT J
AU Liu, T
   Yu, J
   Kuang, W
   Wang, X
   Ye, J
   Qiu, X
   Xi, W
   Zeng, Y
   Zou, H
   Liu, Y
AF Liu, Tong
   Yu, Jiani
   Kuang, Weichuan
   Wang, Xiaoyin
   Ye, Jiang
   Qiu, Xiaojia
   Xi, Wen
   Zeng, Yao
   Zou, Hanhong
   Liu, Yue
TI Acupuncture for uterine fibroids: Protocol for a systematic review of randomized
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Uterine fibroids represent the most common gynecological benign  tumors in reproductive females. Acupuncture has been applied as a therapeutic  modality in China to treat uterine fibroids. However, currently, few critical  systematic reviews regarding the effect of acupuncture on uterine fibroids have  been published. Our proposed review aims to evaluate the current evidence on the  efficacy of acupuncture for uterine fibroids. METHODS: A total of 7 databases  were searched from their inception to December 2018, including PubMed, Medline,  Embase, the Cochrane Central Register of Controlled Trials, the Chinese National  Knowledge Infrastructure database, the Chinese Biomedical database, and the  Wanfang database. The primary outcomes will be reduction in uterine volume and  number of fibroids. Secondary outcomes are pelvic or low-back pain, assessed by  Visual Analog Scale (VAS); Irregular menstrual periods; Low-abdominal pressure  symptoms such as frequent or urgent urination, or constipation and adverse  events. Data synthesis will be computed by RevManV.5.3.5 software when a  data-analysis is allowed. Methodological quality will be evaluated with the risk  of bias according to Cochrane Handbook. RESULTS: This study will provide  high-quality evidence of acupuncture for uterine fibroids. CONCLUSION: The  conclusion of this systematic review will provide evidence to judge whether  acupuncture is an effective therapeutic intervention for patients with uterine  fibroids. TRIAL REGISTRATION NUMBER: PROSPERO CRD42019120484.
C1 Department of Acupuncture and Rehabilitation, GuangDong Second Hospital of Traditional Chinese Medicine.
   Department of Rehabilitation Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China.
   Department of Acupuncture and Rehabilitation, GuangDong Second Hospital of Traditional Chinese Medicine.
   Department of Acupuncture and Rehabilitation, GuangDong Second Hospital of Traditional Chinese Medicine.
   Department of Acupuncture and Rehabilitation, GuangDong Second Hospital of Traditional Chinese Medicine.
   Department of Acupuncture and Rehabilitation, GuangDong Second Hospital of Traditional Chinese Medicine.
   Department of Acupuncture and Rehabilitation, GuangDong Second Hospital of Traditional Chinese Medicine.
   Department of Acupuncture and Rehabilitation, GuangDong Second Hospital of Traditional Chinese Medicine.
   Department of Acupuncture and Rehabilitation, GuangDong Second Hospital of Traditional Chinese Medicine.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD MAR 1
PY 2019
VL 98
IS 8
BP e14631
EP e14631
DI 10.1097/MD.0000000000014631
PG 1
WC Acupuncture Therapy; adverse effects; Female; Humans; Leiomyoma; therapy; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Uterus; pathology; Systematic Reviews as Topic
UT PubMed:30813200
PM 30813200
DA 2019-03-01
ER

PT J
AU Zhang, K
   Tang, Q
AF Zhang, Kai
   Tang, Qilin
TI Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast
SO Breast (Edinburgh, Scotland)
LA English
DT Letter
C1 Department of Acupuncture and Moxibustion, Tianjin Gong An Hospital, Tianjin, China. 
   Tianjin University of Traditional Chinese Medicine, Tianjin, China.
EM coolzhangkai@163.com
NR 0
TC 0
SN 1532-308
EI 
J9 Breast
PD APR 29
PY 2019
VL 45
IS 
BP 119
EP 119
DI 10.1016/j.breast.2019.01.010
PG 0
WC Acupuncture Therapy; Aromatase; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Humans; Randomized Controlled Trials as Topic
UT PubMed:31029376
PM 31029376
DA 2019-04-29
ER

PT J
AU Shin, S
   Jang, BH
   Park, SH
   Lee, JW
   Chae, MS
   Kim, N
   Suh, HS
   Han, S
   Min, SY
   Baek, SK
   Lim, YJ
   Hwang, DS
AF Shin, Seungwon
   Jang, Bo-Hyoung
   Park, Seung-Hyeok
   Lee, Jin-Wook
   Chae, Min Soo
   Kim, Namhoon
   Suh, Hae Sun
   Han, Sola
   Min, Sun Young
   Baek, Sun Kyung
   Lim, Yu Jin
   Hwang, Deok-Sang
TI Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibitor-induced arthralgia of postmenopausal breast cancer stage I to III patients Study protocol for a prospective, randomized, assessor-blind, usual-care controlled, parallel-group, pilot clinical trial
SO MEDICINE
LA English
DT Article
DE aromatase inhibitors; arthralgia; breast neoplasms; moxibustion; randomized controlled trial; traditional Korean medicine
ID acupuncture; validation
AB Introduction: This study is a prospective, assessor-blinded, parallel-group, randomized controlled pilot trial to explore the effectiveness of 12-week adjuvant moxibustion therapy for arthralgia in menopausal females at stage I to III breast cancer on aromatase inhibitor (AI) administration, compared with those receiving usual care. Methods/design: Forty-six menopausal female patients with breast cancer who completed cancer therapy will be randomly allocated to either adjuvant moxibustion or usual care groups with a 1: 1 allocation ratio. The intervention group will undergo 24 sessions of adjuvant moxibustion therapy with usual care for 12 weeks, whereas the control group will receive only usual care during the same period. The usual care consists of acetaminophen administration on demand and self-directed exercise education to manage AI-related joint pain. The primary outcome is the mean change of the worst pain level according to the Brief Pain Inventory-Short Form between the initial visit and the endpoint. The mean changes in depression, fatigue, and quality of life will also be compared between groups. Safety and pharmacoeconomic evaluations will also be included. Discussion: Continuous variables will be compared by an independent t test or Wilcoxon rank-sum test between the adjuvant moxibustion and usual care groups. Adverse events will be analyzed using the chi-square or Fisher exact test. The statistical analysis will be performed by a 2-tailed test at a significance level of .05.
C1 [Shin, Seungwon] Kyung Hee Univ, Korean Med Hosp, Clin Trial Ctr, Seoul 02447, South Korea.
   [Jang, Bo-Hyoung] Kyung Hee Univ, Coll Korean Med, Dept Prevent Med, Seoul, South Korea.
   [Park, Seung-Hyeok; Lee, Jin-Wook; Chae, Min Soo; Kim, Namhoon] Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, Seoul, South Korea.
   [Suh, Hae Sun] Pusan Natl Univ, Pharmaceut Econ Outcomes Res & Policy, Busan, South Korea.
   [Han, Sola] Pusan Natl Univ, Coll Pharm, Busan, South Korea.
   [Min, Sun Young] Kyung Hee Univ, Coll Med, Dept Surg, Seoul, South Korea.
   [Baek, Sun Kyung] Kyung Hee Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Lim, Yu Jin] Kyung Hee Univ, Coll Med, Med Ctr, Dept Radiat Oncol, Seoul, South Korea.
   [Hwang, Deok-Sang] Kyung Hee Univ, Coll Korean Med, Dept Korean Obstet & Gynecol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Pusan National University; Pusan National University; Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Hwang, DS (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Korean Obstet & Gynecol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM soulhus@khu.ac.kr
FU Traditional Korean Medicine R&D Program - Ministry of Health and Welfare through the Korea Health Industry Development Institute (KHIDI) [HB16C0072]
CR Unknown -, 2008, PAC WROFTWWHO STAND, V0, P0
   Unknown -, 1995, KOR J PSYCHOPATHOL, V0, P0
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bouwmans C, 2015, VALUE HEALTH, V18, P753, DOI 10.1016/j.jval.2015.05.009
   Burstein HJ, 2007, BREAST, V16, P223, DOI 10.1016/j.breast.2007.01.011
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dai L, 2019, CHIN J INTEGR MED, V25, P71, DOI 10.1007/s11655-018-2999-x
   Deng H, 2013, EVID-BASED COMPL ALT, V2013, P7, DOI 10.1155/2013/379291
   Jeon JH, 2017, INTEGR CANCER THER, V16, P118, DOI 10.1177/1534735416654762
   Jun-Chen F, 2018, TMR INTEGR NURS, V2, P115, DOI 10.12032/tmrin20180720
   Kim TH, 2012, VALIDITY RELIABILITY, V0, P0
   Kim TH, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0101973
   Li A, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003244
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Ren Xiu-Mei, 2011, ZHONGGUO ZHEN JIU, V31, P1057
   Rhee MK, 1995, KOREAN J PSYCHOPATHOL, V4, P96
   Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1
   Stein KD, 2004, J PAIN SYMPTOM MANAG, V27, P14, DOI 10.1016/j.jpainsymman.2003.06.003
   Yoo HJ, 2005, QUAL LIFE RES, V14, P1627, DOI 10.1007/s11136-004-7712-1
   Yun YH, 2004, ONCOLOGY-BASEL, V66, P439, DOI 10.1159/000079497
   Zhao L, 2014, ARTHRITIS RES THER, V16, P0, DOI 10.1186/ar4590
NR 23
TC 1
Z9 2
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP 15
PY 2019
VL 98
IS 38
BP 
EP 
DI 10.1097/MD.0000000000017260
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA JB8AQ
UT WOS:000488788000070
PM 31568000
DA 2026-01-16
ER

PT J
AU Melo, RNR
   Francisco, SC
   Moura, CD
   Loudon, K
   Sawada, NO
   Chave, EDL
   Chianca, TCM
   Nogueira, DA
   Zhu, SJ
   Garcia, ACM
AF Rodrigues Melo, Ruan Nilton
   Francisco, Stephanie Carolina
   Moura, Caroline de Castro
   Loudon, Kirsty
   Sawada, Namie Okino
   Lopes Chave, Erika de Cassia
   Machado Chianca, Tania Couto
   Nogueira, Denismar Alves
   Zhu, Si Jia
   Mesquita Garcia, Ana Claudia
TI Auriculotherapy to control chemotherapy-induced nausea and vomiting in patients with cancer: protocol of a systematic review
SO SYSTEMATIC REVIEWS
LA English
DT Review
DE Nausea; Vomiting; Drug therapy; Neoplasms; Auricular acupuncture; Systematic review
ID acupressure; management; acupuncture; pain
AB Background Due to the worldwide rise in cancer incidence, and therefore the rise in the need for antineoplastic chemotherapy, it is important for both healthcare professionals and patients alike that the side effects of chemotherapy, such as chemotherapy-induced nausea and vomiting (CINV), are treated and prevented. Auriculotherapy is a type of acupuncture and may be a low-cost and safe antiemetic measure to control the side effects of chemotherapy. The goal of this systematic review is to synthesize the available evidence in the literature regarding the auriculotherapy effects to treat CINV in people with cancer. Methods The review will only include randomized controlled trials (RCTs) that compare the clinical effects of the auriculotherapy intervention (used alone or as an add-on), with sham auriculotherapy, routine treatment with antiemetic drugs, or other non-pharmacological interventions in patients with cancer with CINV who are undergoing chemotherapy. The outcomes to be evaluated are nausea and vomiting: in acute, delayed, or anticipated stages, when induced by chemotherapy. A comprehensive search for studies will be carried out in these databases: MEDLINE via PubMed, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, ICTRP, LILACS, CUMED, IBECS, BVS MTCI Americas, Web of Science, Scopus, PEDro, CNKI, and CBMdisc up until December 31, 2018. Only articles in English, Portuguese, and Spanish will be selected. Two independent reviewers will evaluate full texts, extract data, and assess the risk of bias of eligible articles. The quality of evidence will be assessed using Grading of Recommendations, Assessment, Development and Evaluation (GRADE). A meta-analysis will be undertaken to assess the interventions and outcomes' homogeneity, assessing statistical heterogeneity using the Cochran's Q test and quantified using Higgins' inconsistency index. If there is insufficient data for a meta-analysis, a narrative synthesis will be presented. This protocol has been prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines. Discussion The results of this systematic review will summarize the strength of evidence for the use of auriculotherapy in the control of CINV of patients with cancer and will be used to identify evidence gaps. Systematic review registration PROSPERO CRD42018117513
C1 [Rodrigues Melo, Ruan Nilton; Francisco, Stephanie Carolina; Lopes Chave, Erika de Cassia; Mesquita Garcia, Ana Claudia] Univ Fed Alfenas, Sch Nursing, Gabriel Monteiro Silva St,700 Ctr, BR-30130100 Alfenas, MG, Brazil.
   [Moura, Caroline de Castro; Machado Chianca, Tania Couto] Univ Fed Minas Gerais, Sch Nursing, Prof Alfredo Balena Ave 190, BR-37130001 Belo Horizonte, MG, Brazil.
   [Sawada, Namie Okino] Univ Sao Paulo, Ribeirao Preto Coll Nursing, Bandeirantes Ave 3900 Univ Campus Monte Alegre, BR-14040900 Ribeirao Preto, SP, Brazil.
   [Nogueira, Denismar Alves] Univ Fed Alfenas, Inst Exact Sci, Gabriel Monteiro Silva St 700 Ctr, BR-37130001 Alfenas, MG, Brazil.
   [Zhu, Si Jia] Beijing Univ Chinese Med BUCM China, Ctr Evidence Based Med, East Rd 11 North Third Ring Rd, Beijing 1000029, Peoples R China.
C3 Universidade Federal de Alfenas; Universidade Federal de Minas Gerais; Universidade de Sao Paulo; Universidade Federal de Alfenas
RP Garcia, ACM (corresponding author), Univ Fed Alfenas, Sch Nursing, Gabriel Monteiro Silva St,700 Ctr, BR-30130100 Alfenas, MG, Brazil.
EM ana.mesquita@unifal-mg.edu.br
CR Unknown -, 2018, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINESREG;): BREAST CANCER VERSION 2, V0, P0
   Unknown -, 2017, AM. J. MANAG. CARE, V0, P0
   Aslam Sadaf, 2010, INDIAN J SEX TRANSM DIS AIDS, V31, P47, DOI 10.4103/0253-7184.69003
   Booth A, 2012, SYST REV-LONDON, V1, P0, DOI 10.1186/2046-4053-1-2
   Booth A, 2011, LANCET, V377, P108, DOI 10.1016/S0140-6736(10)60903-8
   do Prado JM, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017030403334
   Eghbali M, 2016, COMPLEMENT THER CLIN, V24, P189, DOI 10.1016/j.ctcp.2016.06.006
   Fernández-Ortega P, 2012, SUPPORT CARE CANCER, V20, P3141, DOI 10.1007/s00520-012-1448-1
   Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Grunberg Steven M, 2004, J SUPPORT ONCOL, V2, P1
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins Julian P T, 2011, BMJ, V343, Pd5928, DOI 10.1136/bmj.d5928
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Inoue M, 2015, BMC PHARMACOL TOXICO, V16, P0, DOI 10.1186/s40360-015-0005-1
   Janelsins MC, 2013, EXPERT OPIN PHARMACO, V14, P757, DOI 10.1517/14656566.2013.776541
   Lee EJ, 2011, J PAIN SYMPTOM MANAG, V42, P589, DOI 10.1016/j.jpainsymman.2011.01.007
   Lewis S, 2001, BMJ-BRIT MED J, V322, P1479, DOI 10.1136/bmj.322.7300.1479
   Liau CT, 2005, SUPPORT CARE CANCER, V13, P277, DOI 10.1007/s00520-005-0788-5
   Macdonald G, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001930.pub3
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mafetoni RR, 2016, REV ESC ENFERM USP, V50, P726, DOI 10.1590/S0080-623420160000600003
   McGlinchey MP, 2018, SYST REV-LONDON, V7, P0, DOI 10.1186/s13643-018-0870-y
   Mercante B, 2018, MED ACUPUNCT, V30, P141, DOI 10.1089/acu.2017.1254
   Miao J, 2017, INT J NURS STUD, V70, P27, DOI 10.1016/j.ijnurstu.2017.02.014
   Minami M, 2003, PHARMACOL THERAPEUT, V99, P149, DOI 10.1016/S0163-7258(03)00057-3
   Moore CB, 2017, J PERIANESTH NURS, V32, P96, DOI 10.1016/j.jopan.2015.06.006
   Moradian S, 2015, INT J PALLIAT NURS, V21, P216, DOI 10.12968/ijpn.2015.21.5.216
   Moura CD, 2018, REV LAT-AM ENFERM, V26, P0, DOI 10.1590/1518-8345.2678.3050
   Mustian Karen M, 2011, US ONCOL HEMATOL, V7, P91
   Natale James J, 2015, HOSP PRACT (1995), V43, P226, DOI 10.1080/21548331.2015.1077095
   Ogilvie D, 2008, BMC MED RES METHODOL, V8, P0, DOI 10.1186/1471-2288-8-8
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Parsa-Yekta Z, 2012, RAZI JOURNAL OF MEDICAL SCIENCES, V18, P33
   Rabischong P, 2014, MED ACUPUNCT, V26, P84, DOI 10.1089/acu.2014.1038
   Ren RY, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000014621
   Round R, 2013, EVID-BASED COMPL ALT, V2013, P984763, DOI 10.1155/2013/984763
   Kurebayashi LFS, 2015, REV BRAS ENFERM, V68, P109, DOI 10.1590/0034-7167.2015680116p
   Schwarzer G, 2007, R NEWS, V7, P40
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Sommariva S, 2016, CRIT REV ONCOL HEMAT, V99, P13, DOI 10.1016/j.critrevonc.2015.12.001
   Taspinar A, 2010, EUR J ONCOL NURS, V14, P49, DOI 10.1016/j.ejon.2009.07.006
   Tipton Janelle M, 2007, CLIN J ONCOL NURS, V11, P69, DOI 10.1188/07.CJON.69-78
   Torres CH, 2015, SUPPORT CARE CANCER, V23, P3341, DOI 10.1007/s00520-015-2801-y
   Vidall C, 2011, ECANCERMEDICALSCIENC, V5, P0, DOI 10.3332/ecancer.2011.211
   Wood JM, 2011, CANCER NURS, V34, PE14, DOI 10.1097/NCC.0b013e3181e2cd79
   Yeh Chao Hsing, 2014, EVID BASED COMPLEMENT ALTERNAT MED, V2014, P375173, DOI 10.1155/2014/375173
   Zhao HJ, 2015, COMPLEMENT THER CLIN, V21, P68, DOI 10.1016/j.ctcp.2015.03.006
NR 48
TC 4
Z9 5
U1 2
U2 27
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2046-4053
J9 SYST REV-LONDON
JI Syst. Rev.
PD AUG 15
PY 2019
VL 8
IS 1
BP 
EP 
DI 10.1186/s13643-019-1124-3
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA IS0MJ
UT WOS:000481844200002
PM 31416474
DA 2026-01-16
ER

PT J
AU Ogawa-Ochiai, K
   Yoshimura, K
   Takebe, T
   Iwahashi, M
   Shirai, A
   Tsuda, M
   Ogawa, M
   Ishikawa, H
AF Ogawa-Ochiai, Keiko
   Yoshimura, Kenichi
   Takebe, Takae
   Iwahashi, Mako
   Shirai, Akiko
   Tsuda, Masaki
   Ogawa, Masao
   Ishikawa, Hideki
TI The effect of contact needle therapy on fatigue in patients with cancer in palliative care A study protocol for a randomized controlled trial
SO MEDICINE
LA English
DT Article
DE best supportive care; contact needle therapy; general fatigue; Japanese traditional (Kampo) medicine; randomized controlled trial
ID acupuncture
AB Introduction: Almost all patients with end-of-life cancer experience cancer-related fatigue; however, there are only a few known effective coping methods. Objectives : We will conduct a prospective, multi-center, single-blinded randomized controlled study to evaluate the efficacy of acupuncture for cancer-related fatigue in patients with end-of-life cancer. Methods: We will enroll 120 patients with cancer hospitalized in a palliative care unit or receiving consultation from a palliative care team in four hospitals. We will add acupuncture treatment; specifically, contact needle therapy (CNT), consisting of an intervention per week period to the usual care. The primary outcome measure will be the Cancer Fatigue Scale (CFS) score while the secondary outcome measures will be the Numerical Rating Scale (NRS) score for fatigue, pain, and salivary amylase levels. Conclusion: We will evaluate the possibility of using acupuncture therapy, that is, CNT, in relieving fatigue sensation in patients with advanced cancer.
C1 [Ogawa-Ochiai, Keiko; Iwahashi, Mako; Shirai, Akiko] Kanazawa Univ Hosp, Dept Japanese Tradit Kampo Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.
   [Yoshimura, Kenichi] Hiroshima Univ, Hiroshima Univ Hosp, Ctr Integrated Med Res, Hiroshima, Japan.
   [Yoshimura, Kenichi] Kanazawa Univ Hosp, Innovat Clin Res Ctr, Kanazawa, Ishikawa, Japan.
   [Takebe, Takae; Tsuda, Masaki] Mukeido Clin Acupuncture, Toyama, Japan.
   [Ogawa, Masao] Kanazawa Univ Hosp, Dept Anesthesiol, Kanazawa, Ishikawa, Japan.
   [Ishikawa, Hideki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Osaka, Japan.
C3 Kanazawa University; Hiroshima University; Kanazawa University; Kanazawa University; Kyoto Prefectural University of Medicine
RP Ogawa-Ochiai, K (corresponding author), Kanazawa Univ Hosp, Dept Japanese Tradit Kampo Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.
EM ikkandoo@gmail.com
CR Unknown -, 2013, TRADITIONAL MED STRA, V0, P0
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Hagelin CL, 2006, SUPPORT CARE CANCER, V14, P320, DOI 10.1007/s00520-005-0886-4
   Kimata-Kumagai Y, 2017, PALLIATIVE CARE RESEARCH, V12, P781, DOI 10.2512/jspm.12.781
   Leng G, 2013, ACUPUNCT MED, V31, P16, DOI 10.1136/acupmed-2012-010230
   Mucke M, 2015, COCHRANE DB SYST REV, V7, P23
   National Comprehensive Cancer Network (NCCN), 2019, CANC REL FAT, V0, P0
   Ogawa K, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/928129
   Okuyama T, 2000, J PAIN SYMPTOM MANAG, V19, P5, DOI 10.1016/S0885-3924(99)00138-4
   Yennurajalingam S, 2013, J CLIN ONCOL, V31, P3076, DOI 10.1200/JCO.2012.44.4661
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
NR 11
TC 0
Z9 0
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV 15
PY 2019
VL 98
IS 44
BP 
EP 
DI 10.1097/MD.0000000000017809
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA JO7BV
UT WOS:000497731800125
PM 31689865
DA 2026-01-16
ER

PT J
AU Wang, Y
   Zhang, HL
   Xia, LP
   Sun, ZL
   Xu, X
   Du, SZ
AF Wang Yang
   Zhang Huiling
   Xia Liping
   Sun Zhiling
   Xu Xiao
   Du Shizheng
TI Effectiveness and safety of moxibustion in treatment of lumbar disc herniation: a systematic review and Meta-analysis
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Review
DE Moxibustion; Intervertebral disc displacement; Review; Meta-analysis; Randomized controlled trial
ID cancer-related fatigue; pain; acupuncture; outcm
AB OBJECTIVE: To evaluate the effectiveness and safety of moxibustion therapy in the treatment of lumbar disc herniation (LDH). METHODS: Four Chinese databases and three English databases were searched from their inception to April 2018.Randomized controlled trials (RCTs) were included if moxibustion was used as the sole treatment or as a part of combination therapy with other treatments in patients with LDH. Two reviewers independently extracted the data and assessed the methodological quality using the Cochrane cri-teria for the risk of bias. The Meta-analysis was performed using Review Manager 5.3 software. RESULTS: In total, 16 RCTs including 1186 patients with LDH were analyzed. The Meta-analysis showed favorable effects of moxibustion in combination with massage therapy on the visual analog scale score compared with massage therapy alone [mean difference (MD) = -1.32, 95% confidence interval (CI) (-2.12, -0.51), P = 0.001]. The subgroup Meta-analysis failed to show favorable effects of electro-acupuncture plus moxibustion on the efficacy rate compared with electro-acupuncture alone [relative risk (RR) = 1.06, 95% CI (0.98, 1.14), P = 0.15]. However, acupuncture or massage therapy plus moxibustion improved the efficacy rates compared with acupuncture or massage therapy alone [RR = 1.33, 95% CI (1.18, 1.49), P < 0.000 01] [chi(2) = 2.76, P = 0.25, I-2 = 27%], [RR = 1.15, 95% CI (1.06, 1.25), P = 0.001] [chi(2) = 0.00, P = 0.95, I-2 = 0%]. With respect to the Japanese Orthopaedic Association (JOA) scores, acupuncture or massage therapy in addition to moxibustion produced results different from those of acupuncture or massage therapy alone [MD = 5.58, 95% CI (4.15, 7.00), P < 0.000 01] [chi(2) = 0.58, P = 0.45, I-2 = 0%], [MD = 3.61, 95% CI (3.01, 4.21), P < 0.000 01]. There were no significant differences in the JOA score for subjective symptoms, objective symptoms, daily living ability, and other parameters. In six RCTs, no adverse reactions occurred during moxibustion. CONCLUSION: Whether moxibustion is an effective intervention for LDH is unclear because of the small sample size of qualified RCTs and the high risk of bias. More high-quality RCTs that overcome the methodological shortcomings of the existing evidence are needed. (C) 2019 JTCM. All rights reserved.
C1 [Wang Yang; Xia Liping] Jiangsu Vocat Coll Med, Nursing Coll, Yancheng 224006, Peoples R China.
   [Zhang Huiling] Anhui Univ Chinese Med, Nursing Coll, Hefei 230012, Anhui, Peoples R China.
   [Sun Zhiling; Du Shizheng] Nanjing Univ Chinese Med, Nursing Coll, Nanjing 210046, Jiangsu, Peoples R China.
   [Xu Xiao] Changzhou Univ, Nursing Coll, Changzhou 213164, Peoples R China.
C3 Jiangsu Vocational College of Medicine; Anhui University of Chinese Medicine; Nanjing University of Chinese Medicine; Changzhou University
RP Xia, LP (corresponding author), Jiangsu Vocat Coll Med, Nursing Coll, Yancheng 224006, Peoples R China.
EM niggtgyx@163.com
FU National Natural Science Foundation of China: Exploring the multi-targeted regulatory mechanisms of moxibustion on rheumatoid arthritis based on lipid signaling pathway networks [81774383]; Outstanding Young Teachers' Overseas Training Program of Jiangsu Higher Education Institutions of China (2013); QingLan Project of Jiangsu Higher Education Institution of China (2014); Key Projects of Changzhou Municipal Health Committee:meridian flow theory based moxibustion intervention on ankylosing spondylitis [ZD201713]
CR Ahn SS, 2016, WORLD NEUROSURG, V86, P250, DOI 10.1016/J.WNEU.2015.09.047
   Unknown -, 2006, JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE, V0, P0, DOI DOI 10.1007/S11726-005-0257-1
   Unknown -, 2014, REV MAN REVMAN COMP, V0, P0
   Azimi P, 2012, J ORTHOP SCI, V17, P341, DOI 10.1007/s00776-012-0232-x
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Breivik H, 2016, SCAND J PAIN, V11, P150, DOI 10.1016/j.sjpain.2016.02.004
   Buchmann N, 2016, WORLD NEUROSURG, V89, P382, DOI 10.1016/j.wneu.2016.02.028
   Chen HD, 2013, ZHONG HUA ZHONG YI Y, V31, P2301
   Chen J, 2016, ASIAN PAC J ALLERGY, V34, P21, DOI 10.12932/ap0639.34.1.2016
   CHEN R, 2014, EVID-BASED COMPL ALT, V2014, P1
   Chen RX, 2012, J TRADIT CHIN MED, V32, P322, DOI 10.1016/S0254-6272(13)60032-1
   Cheng CW, 2013, J INTEGR MED-JIM, V11, P54, DOI 10.3736/jintegrmed2013009
   Chiu JH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/198584
   Choi TY, 2012, RHEUMATOL INT, V32, P2969, DOI 10.1007/s00296-012-2367-7
   Choi TY, 2011, CLIN RHEUMATOL, V30, P937, DOI 10.1007/s10067-011-1706-5
   Ehrler M, 2016, J MANIP PHYSIOL THER, V39, P192, DOI 10.1016/j.jmpt.2016.02.013
   Fardon DF, 2001, SPINE, V26, P461, DOI 10.1097/00007632-200103010-00007
   Fu Y, 2014, NANJING ZHONG YI YAO, V30, P120
   Geng H, 2006, EFFECT ELECTROACUPUN, V0, P6
   Geng H, 2017, JIANGSU ZHONG YI YAO, V49, P63
   Gherkin DC, 1995, SPINE, V20, P9
   He XR, 2013, ASIAN PAC J CANCER P, V14, P3067, DOI 10.7314/APJCP.2013.14.5.3067
   He Xing-Wei, 2007, ZHONGGUO ZHEN JIU, V27, P264
   Huang R, 2014, AN MO YU KANG FU YI, V5, P63
   Ji J, 2013, EVID-BASED COMPL ALT, V2013, P1
   Lee DH, 2010, BMC GASTROENTEROL, V10, P0, DOI 10.1186/1471-230X-10-36
   Lee MS, 2010, AM J CHINESE MED, V38, P829, DOI 10.1142/S0192415X10008275
   Lee MS, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-130
   Lee MS, 2010, STROKE, V41, P817, DOI 10.1161/STROKEAHA.109.566851
   Lee S, 2014, SUPPORT CARE CANCER, V22, P1429, DOI 10.1007/s00520-014-2161-z
   Li A, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003244
   Li H, 2011, IWGO NEWSLETTER, V32, P46
   MacPherson H, 2012, BMC GASTROENTEROL, V12, P1
   Manheimer E, 2012, AM J GASTROENTEROL, V107, P835, DOI 10.1038/ajg.2012.66
   Mao L, 2017, CLIN EFFICACY MOXIBU, V0, P17
   Moschetti W, 2009, SEMIN. SPINE SURG., V21, P223
   NACHEMSON AL, 1992, CLIN ORTHOP RELAT R, V0, P8
   Park JH, 2013, BMC PUBLIC HEALTH, V13, P0, DOI 10.1186/1471-2458-13-293
   Park JE, 2010, COMPLEMENT THER MED, V18, P215, DOI 10.1016/j.ctim.2010.07.001
   Peng Yan, 2014, ZHONGGUO ZHEN JIU, V34, P783
   Shiri R, 2007, EUR SPINE J, V16, P2043, DOI 10.1007/s00586-007-0362-6
   Song GM, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002790
   Sun ZL, 2014, EUR J INTEGR MED, V6, P621, DOI 10.1016/j.eujim.2014.08.002
   Tian X, 2013, SURG CLIN PREVENTION, V0, P259
   Tian X, 2014, ALTERN THER HEALTH M, V20, P33
   van Tulder M, 2002, BEST PRACT RES CL RH, V16, P761, DOI 10.1053/berh.2002.0267
   Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5
   Wang D, 2014, RES NURSING EFFECT M, V0, P28
   Wu S, 2016, FUJIAN ZHONG YI YAO, V47, P49
   Wu Z, 2010, CLIN OBSERVATION DIF, V0, P24
   Xu JF, 2012, GANSU ZHONG YI XUE Y, V29, P55
   Xu Z, 2018, SHI JIE ZHONG YI YAO, V13, P170
   Yang Dong-Lan, 2014, ZHONGGUO ZHEN JIU, V34, P341
   Yi G, 2012, GUANGXI ZHONG YI YAO, V35, P36
   Yoon C, 2016, BURNS, V42, P1588, DOI 10.1016/j.burns.2016.04.015
   Zhang Chuan-ying, 2015, ZHEN CI YAN JIU, V40, P205
NR 57
TC 13
Z9 16
U1 1
U2 17
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD OCT 15
PY 2019
VL 39
IS 5
BP 599
EP 608
DI 
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA JJ9WU
UT WOS:000494502900001
PM 32186109
DA 2026-01-16
ER

PT J
AU Eskander, JP
   Beakley, BD
   Zhang, S
   Paetzold, J
   Sharma, B
   Kaye, AD
   Sharma, S
AF Eskander, Jonathan P.
   Beakley, Burton D.
   Zhang, Si
   Paetzold, Jacquelyn
   Sharma, Bharat
   Kaye, Alan D.
   Sharma, Sanjay
TI A Multimodal Approach to Pain Management for Patients with Chronic Back Pain: Outcome Measures at 1Year
SO CURRENT PAIN AND HEADACHE REPORTS
LA English
DT Review
DE Interdisciplinary pain management; Chronic pain; Low back; Cervical; Pain; Interventional; Intervention; Physical therapy; Yoga; Acupuncture; Multimodal; Cognitive behavioral therapy; Nutrition
AB Purpose of ReviewThe purpose of this study is to evaluate the effectiveness of a multimodal approach to treating chronic low back pain.Recent FindingsChronic non-cancer-related back pain is often a frustrating and poorly managed problem for patients. It poses a significant public health issue worsened by the widespread use of narcotics. In 2016, the CDC released guidelines with noticeably more strict recommendations on prescription of narcotics for pain.SummaryVeterans at an interventional pain clinic presenting with chronic back pain refractory to medical and to surgical care were enrolled in an 8-week interdisciplinary pain management program. Pain scores were significantly reduced 1year after completion of the program. Patients in this study benefitted from lower and sustained pain scores, a reduction in emergency room, and urgent care clinic visits, as well as generally high satisfaction with the interdisciplinary program.
C1 [Eskander, Jonathan P.] Portsmouth Anesthesia Associates, Dept Anesthesiol, Portsmouth, VA 23703 USA.
   [Beakley, Burton D.] Ocshner Hlth Syst, Dept Anesthesiol, New Orleans, LA USA.
   [Zhang, Si] Stamford Hlth Med Grp, Dept Anesthesiol, Stamford, CT USA.
   [Paetzold, Jacquelyn] STAR Anesthesia PA, Dept Anesthesiol, San Antonio, TX USA.
   [Sharma, Bharat] Duke Univ, Dept Anesthesiol, Durham, NC USA.
   [Kaye, Alan D.] Louisiana State Univ, Dept Anesthesiol, Hlth Sci Ctr, New Orleans, LA USA.
   [Sharma, Sanjay] Southeast Louisiana Vet Hlth Care Syst, Dept Anesthesiol, New Orleans, LA USA.
C3 Duke University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans
RP Eskander, JP (corresponding author), Portsmouth Anesthesia Associates, Dept Anesthesiol, Portsmouth, VA 23703 USA.
EM jeskande@tulane.edu
CR Clark ME, 2003, J REHABIL RES DEV, V40, P381, DOI 10.1682/JRRD.2003.09.0381
   KAMES LD, 1990, PAIN, V41, P41, DOI 10.1016/0304-3959(90)91107-T
   Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656
   National Research Council (US) and Institute of Medicine (US) Panel on Musculoskeletal Disorders and the Workplace, 2001, MUSC DIS WORKPL LOW, V0, P0
   Sturgeon JA, 2015, PAIN, V156, P2627, DOI 10.1097/j.pain.0000000000000313
NR 5
TC 7
Z9 7
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1531-3433
EI 1534-3081
J9 CURR PAIN HEADACHE R
JI Curr. Pain Headache Rep.
PD AUG 15
PY 2019
VL 23
IS 8
BP 
EP 
DI 10.1007/s11916-019-0790-0
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA IJ0ST
UT WOS:000475610800002
PM 31286279
DA 2026-01-16
ER

PT J
AU Chien, TJ
   Liu, CY
   Fang, CJ
   Kuo, CY
AF Chien, Tsai-Ju
   Liu, Chia-Yu
   Fang, Ching-Ju
   Kuo, Chun-Yu
TI The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy:
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; cancer; chemotherapy; neuropathy; systematic review
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) has no cure, but  acupuncture may provide relief through its known neuromodulation or  neuroendocrine adjustment. This review aimed to assess the efficacy of  acupuncture in treating CIPN. Method: A literature review following the PRISMA  Statement was performed, searching 7 databases from inception through August  2019. All studies were clinical trials of the effect of acupuncture on CIPN. The  methodological quality of these trials was assessed using Cochrane criteria;  meta-analysis software (RevMan 5.2) was used to analyze the data. Data Sources:  The databases searched were the following: MEDLINE (Ovid), Embase, Cochrane  CENTRAL, Scopus, World Health Organization International Clinical Trials Registry  Platform, CNKI (China National Knowledge Infrastructure), and Wanfang Med Online.  Results: We examined 386 cancer patients from 6 randomized control trials, which  had high quality, based on the modified Jadad scale. Meta-analysis showed that  acupuncture led to significant improvements in pain scores (-1.21, 95% confidence  interval [CI] = -1.61 to -0.82, P < .00001) and nervous system symptoms based on  Functional Assessment of Cancer Therapy/Neurotoxicity questionnaire scores  (-2.02, 95% CI = -2.21 to -1.84, P < .00001). No significant change was noted in  nerve conduction velocity (1.58, 95% CI = -2.67 to 5.83, P = .47). Conclusion:  Acupuncture can effectively relieve CIPN pain and functional limitation. The  limited number of subjects warrants a larger scale study.
C1 Taipei City Hospital, Taipei.
   National Yang-Ming University, Taipei.
   National Yang-Ming University, Taipei.
   Chang Gung University, Taoyuan.
   China Medical University, Taichung.
   Flourish Traditional Chinese Medicine Clinic, Taipei.
   National Cheng Kung University, Tainan.
   National Cheng Kung University Hospital, Tainan.
   National Yang-Ming University, Taipei.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD DEC 14
PY 2019
VL 18
IS 
BP 1534735419886662
EP 1534735419886662
DI 10.1177/1534735419886662
PG 1
WC Acupuncture Therapy; methods; Antineoplastic Agents; adverse effects; China; Clinical Trials as Topic; Humans; Peripheral Nervous System Diseases; chemically induced; Randomized Controlled Trials as Topic; Surveys and Questionnaires
UT PubMed:31833790
PM 31833790
DA 2019-12-14
ER

PT J
AU Santos, WBR
   Melo, MAO
   Alves, RS
   de Brito, RG
   Rabelo, TK
   Prado, LD
   Silva, VKD
   Bezerra, DP
   de Menezes, JER
   Souza, DS
   de Vasconcelos, CML
   Scotti, L
   Scotti, MT
   Junior, WD
   Quintans, LJ
   Guimaraes, AG
AF Santos, Wagner B. R.
   Melo, Marlange A. O.
   Alves, Rafael S.
   de Brito, Renan G.
   Rabelo, Thallita K.
   Prado, Lindaura da S.
   Silva, Virginia K. dos S.
   Bezerra, Daniel P.
   de Menezes-Filho, Jose E. R.
   Souza, Diego S.
   de Vasconcelos, Carla M. L.
   Scotti, Luciana
   Scotti, Marcus Tullius
   Junior, Waldecy de Lucca
   Quintans-Junior, Lucindo J.
   Guimaraes, Adriana G.
TI p-Cymene attenuates cancer pain via inhibitory pathways and modulation of calcium currents
SO PHYTOMEDICINE
LA English
DT Article
DE Natural products; Monoterpenes; Antinociceptive; Hyperalgesia; Cancer pain
ID involvement; channels; pharmacology; carvacrol; bone
AB Background: Oncological pain is one of the most prevalent and difficult-to-treat symptoms in patients with cancer. p-Cymene (PC) is a monoterpene found in more than 100 different plant species, endowed with various pharmacological properties-particularly antinociceptive. Hypothesis/Purpose: PC has antinociceptive effect in a model of oncologic pain due to the activation of the descending inhibitory pathway of pain. Study Design: A pre-clinical, longitudinal, blind and randomized study. Methods: Male Swiss mice were induced with S180 cells in the right hind paw, then treated daily with PC (12.5, 25 and 50 mg/kg, s.c.) and screened for mechanical hyperalgesia, spontaneous nociception, nociception induced by non-noxious palpation, tumor growth, changes in the neuromuscular function and existence of bone degradation in the tumor area. The effect of PC on Ca2+ currents (electrophysiological records), histological and neurochemical changes (immunofluorescence for Fos) were also evaluated. Results: PC reduced (p < 0.05) the mechanical hyperalgesia, the spontaneous (p < 0.001) and non-noxious palpation (p < 0.001) nociceptions, not changing the tumor development, neuromuscular function or histopathological aspects of the paw affected. PC reduced Fos expression in the spinal cord (p < 0.001) and increased this expression in the PAG (p < 0.05) and in the NRM (p < 0.01). PC decreased the density of calcium channel currents (p < 0.05). Conclusion: These results suggest the antinociceptive effect of PC on oncologic pain, probably acting in both ascending and descending pain pathways, and modulating the calcium channel currents in order to exert its effects.
C1 [Santos, Wagner B. R.; Melo, Marlange A. O.; Alves, Rafael S.; de Brito, Renan G.; Rabelo, Thallita K.; de Menezes-Filho, Jose E. R.; Souza, Diego S.; de Vasconcelos, Carla M. L.; Quintans-Junior, Lucindo J.] Univ Fed Sergipe, Dept Physiol, Sao Cristovao, Sergipe, Brazil.
   [Prado, Lindaura da S.] Univ Fed Sergipe, Postgrad Program Sci Appl Hlth, Lagarto, Sergipe, Brazil.
   [Silva, Virginia K. dos S.] Univ Fed Sergipe, Dept Odontol, Lagarto, Sergipe, Brazil.
   [Bezerra, Daniel P.] Fundacao Oswaldo Cruz, Lab Tissue Engn & Immunopharmacol, Salvador, BA, Brazil.
   [Scotti, Luciana; Scotti, Marcus Tullius] Univ Fed Paraiba, Joao Pessoa, Paraiba, Brazil.
   [Junior, Waldecy de Lucca] Univ Fed Sergipe, Dept Morphol, Sao Cristovao, Sergipe, Brazil.
   [Guimaraes, Adriana G.] Univ Fed Sergipe, Dept Hlth Educ, Padre Alvares Pitangueira St 248, BR-49400000 Lagarto, Sergipe, Brazil.
C3 Universidade Federal de Sergipe; Universidade Federal de Sergipe; Universidade Federal de Sergipe; Fundacao Oswaldo Cruz; Universidade Federal da Paraiba; Universidade Federal de Sergipe; Universidade Federal de Sergipe
RP Guimaraes, AG (corresponding author), Univ Fed Sergipe, Dept Hlth Educ, Padre Alvares Pitangueira St 248, BR-49400000 Lagarto, Sergipe, Brazil.
EM adrianagibara@pq.cnpq.br
FU Foundation for Research and Technological Innovation Support of the State of Sergipe (Fundacao de Apoio a Pesquisa e Inovacao Tecnologica do Estado de Sergipe/FAPITEC/SE); National Council of Technological and Scientific Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/CNPq/Brazil) [449667/2014-6]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES/Brazil)
CR Unknown -, 2013, ISRN TOXICOL, V0, P0, DOI DOI 10.1155/2013/459530
   Bahmani M, 2014, ASIAN PAC J TROP MED, V7, PS43, DOI 10.1016/S1995-7645(14)60202-9
   Bonjardim LR, 2012, Z NATURFORSCH C, V67, P15, DOI 10.5560/ZNC.2012.67c0015
   Brito RG, 2013, BASIC CLIN PHARMACOL, V112, P215, DOI 10.1111/bcpt.12018
   Catterall WA, 2015, MOL PHARMACOL, V88, P141, DOI 10.1124/mol.114.097659
   de Oliveira TM, 2015, PHARM BIOL, V53, P423, DOI 10.3109/13880209.2014.923003
   de Santana MF, 2015, PHARM BIOL, V53, P1583, DOI 10.3109/13880209.2014.993040
   Du X, 2016, INT J MOL SCI, V17, P0, DOI 10.3390/ijms17020144
   Eisenberg E, 2014, CURR PAIN HEADACHE R, V18, P0, DOI 10.1007/s11916-014-0463-y
   Freitas ACN, 2018, TOXINS, V10, P0, DOI 10.3390/toxins10010043
   Gaertner J, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0328-9
   Gomathi R, 2015, IND CROP PROD, V73, P134, DOI 10.1016/j.indcrop.2015.03.090
   Gouveia DN, 2018, BIOMED PHARMACOTHER, V105, P652, DOI 10.1016/j.biopha.2018.06.027
   Guimaraes AG, 2014, LIFE SCI, V116, P8, DOI 10.1016/j.lfs.2014.08.020
   Guimaraes AG, 2014, EXPERT OPIN THER PAT, V24, P243, DOI 10.1517/13543776.2014.870154
   Guimaraes AG, 2013, PHYTOTHER RES, V27, P1, DOI 10.1002/ptr.4686
   Guimaraes AG, 2015, CHEM-BIOL INTERACT, V227, P69, DOI 10.1016/j.cbi.2014.12.020
   Gupta A, 2018, PERIOPERATIVE ASSESS, V0, PP359, DOI 10.1007/978-3-319-58868-1_26
   King T, 2007, PAIN, V132, P154, DOI 10.1016/j.pain.2007.06.026
   Lee S, 2013, CURR NEUROPHARMACOL, V11, P606, DOI 10.2174/1570159X11311060005
   Li JZ, 2016, BIOL PHARM BULL, V39, P1247, DOI 10.1248/bpb.b15-00827
   Ling CC, 2012, J ADV NURS, V68, P511, DOI 10.1111/j.1365-2648.2011.05841.x
   Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766
   Park JF, 2010, CHANNELS, V4, P510, DOI 10.4161/chan.4.6.12869
   Pathan H, 2012, BRIT J PAIN, V6, P11, DOI 10.1177/2049463712438493
   de Menezes JER, 2014, BASIC CLIN PHARMACOL, V115, P534, DOI 10.1111/bcpt.12274
   Sabino MAC, 2003, INT J CANCER, V104, P550, DOI 10.1002/ijc.10999
   Santana MF, 2011, REV BRAS FARMACOGN, V21, P1138, DOI 10.1590/S0102-695X2011005000156
   Santos PL, 2018, MOL NEUROBIOL, V55, P4560, DOI 10.1007/s12035-017-0658-4
   Selvaraj M, 2002, J MOL CATAL A-CHEM, V186, P173, DOI 10.1016/S1381-1169(02)00134-6
   Silva Martapolyana T M, 2015, SCIENTIFICWORLDJOURNAL, V2015, P458080, DOI 10.1155/2015/458080
   Quintans JDS, 2013, PHYTOMEDICINE, V20, P436, DOI 10.1016/j.phymed.2012.12.009
   Sivropoulou A, 1996, J AGR FOOD CHEM, V44, P1202, DOI 10.1021/jf950540t
   Sleigh James N, 2016, BMC RES NOTES, V9, P82, DOI 10.1186/s13104-016-1915-8
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   VANRIEZEN H, 1969, EUR J PHARMACOL, V6, P353, DOI 10.1016/0014-2999(69)90197-6
   Zamponi GW, 2009, BRAIN RES REV, V60, P84, DOI 10.1016/j.brainresrev.2008.12.021
   Zhong WT, 2013, INFLAMMATION, V36, P529, DOI 10.1007/s10753-012-9574-y
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 39
TC 27
Z9 30
U1 1
U2 12
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD AUG 15
PY 2019
VL 61
IS 
BP 
EP 
DI 10.1016/j.phymed.2019.152836
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA JH4HM
UT WOS:000492729600026
PM 31035053
DA 2026-01-16
ER

PT J
AU Hou, WZ
   Pei, LX
   Song, YF
   Wu, J
   Geng, H
   Chen, L
   Wang, YH
   Hu, Y
   Zhou, JY
   Sun, JH
AF Hou, Wenzhen
   Pei, Lixia
   Song, Yafang
   Wu, Jian
   Geng, Hao
   Chen, Lu
   Wang, Yuhang
   Hu, Yao
   Zhou, Jinyong
   Sun, Jianhua
TI Acupuncture therapy for breast cancer-related lymphedema: A systematic review and meta-analysis
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Review
DE acupuncture therapy; breast cancer-related lymphedema; meta-analysis
ID quality-of-life
AB This study aimed to conduct a comprehensive analysis of clinical studies on acupuncture treatment for breast cancer-related lymphedema (BCRL), so as to explore the efficacy and safety of acupuncture treatment and provide evidence for the clinical decision-making. Public databases, mainly including China Academic Journals Full-text Database, Database of Chinese Sci-Tech Journal, Wanfang, PubMed, Embase and the Cochrane Library, from the establishment of databases to December 2018 were searched for randomized controlled trials (RCT) of acupuncture for BCRL. Clinical RCT on the treatment of BCRL with acupuncture combined with drugs or functional exercise were enrolled for the analysis. Bias risk and quality were assessed by two investigators according to the Cochrane Handbook 5.1.0 standard, and the Revman 5.3 software was used for meta-analysis. A total of 13 studies were enrolled, comprising 747 patients (377 in the treatment group and 370 in the control group). The results of meta-analysis showed that acupuncture intervention could improve the total effective rate for the treatment of BCRL (odds ratio = 4.62; 95% confidence interval 2.61-8.17). Recent studies suggest that acupuncture therapy can alleviate the upper limb swelling and improve the subjective pain and discomfort in patients with BCRL, regardless of the control intervention used. However, the number of high-quality RCT is low. Moreover, most of the studies adopted inconsistent efficacy indicators. Hence, additional blinded, large-sample, randomized, well-controlled studies with objective and uniform efficacy indicators are needed, especially in China, to confirm the findings.
C1 [Hou, Wenzhen; Pei, Lixia; Geng, Hao; Chen, Lu; Sun, Jianhua] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Acupuncture, Nanjing, Jiangsu, Peoples R China.
   [Wu, Jian; Zhou, Jinyong] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Cent Lab, Nanjing, Jiangsu, Peoples R China.
   [Song, Yafang; Wang, Yuhang] Nanjing Univ Chinese Med, Dept Acupuncture & Manipulat, Nanjing, Jiangsu, Peoples R China.
   [Hu, Yao] WUXI Higher Hlth Vocat Technol Sch, Dept TCM, Wuxi, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Sun, JH (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp, Dept Acupuncture, Nanjing, Jiangsu, Peoples R China.; Zhou, JY (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp, Dept Cent Lab, Nanjing, Jiangsu, Peoples R China.
EM jinyongzhou@126.com; 377201634@qq.com
FU National Natural Science Foundation of China [81804193]; Youth Natural foundation of the Science and Technology Department of Jiangsu Province [BK20161083]; Leading Talents Project from Jiangsu Provincial Administration of TCM [SLJ0206]; peak talent project of Jiangsu Province Hospital of TCM [y2018rc05]
CR Unknown -, 2017, CHINESE JOURNAL OF WOMAN AND CHILD HEALTH RESEARCH, V0, P0
   Unknown -, 2012, CHIN J CLIN RES, V0, P0
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   CRUK, 2017, BREAST CANC INC, V0, P0
   DiSipio T, 2013, LANCET ONCOL, V14, P500, DOI 10.1016/S1470-2045(13)70076-7
   Feng L, 2018, MODERN JOURNAL OF INTEGRATED TRADITIONAL CHIN AND WESTERN MED, V27, P1870
   Jiang X, 2008, J NURS SCI, V23, P37
   Jiao HF, 2017, NEI MONGOL J TRADITI, V36, P130
   Lasinski BB, 2012, PM&R, V4, P580, DOI 10.1016/j.pmrj.2012.05.003
   Lee TS, 2008, BREAST CANCER RES TR, V110, P19, DOI 10.1007/s10549-007-9710-9
   段碧芳, 2007, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V48, P314
   Petrek JA, 2001, CANCER, V92, P1368, DOI 10.1002/1097-0142(20010915)92:6<1368::AID-CNCR1459>3.0.CO;2-9
   Ridner SH, 2005, SUPPORT CARE CANCER, V13, P904, DOI 10.1007/s00520-005-0810-y
   Smith CA, 2014, ACUPUNCT MED, V32, P387, DOI 10.1136/acupmed-2014-010593
   Taghian NR, 2014, CRIT REV ONCOL HEMAT, V92, P227, DOI 10.1016/j.critrevonc.2014.06.004
   Wu C, 2018, CHIN MED J METALL IND, V35, P324
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Zhang XY, 2019, ACUPUNCT MED, V37, P16, DOI 10.1136/acupmed-2018-011668
NR 22
TC 19
Z9 23
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD DEC 15
PY 2019
VL 45
IS 12
BP 2307
EP 2317
DI 10.1111/jog.14122
EA OCT 2019
PG 11
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA JR4UX
UT WOS:000489867000001
PM 31608558
DA 2026-01-16
ER

PT J
AU Gonzalez-Guerrero, JF
   Alcorta-Garza, AG
   Alcorta-Nuñez, F
   Melgoza-Alcorta, EM
   Gonzalez-Rodriguez, M
   Gonzalez-Alcorta, CB
   Alcorta-Garza, A
AF Francisco Gonzalez-Guerrero, Juan
   Gloria Alcorta-Garza, Antonia
   Alcorta-Nunez, Fernando
   Maria Melgoza-Alcorta, Emma
   Gonzalez-Rodriguez, Melany
   Beatriz Gonzalez-Alcorta, Celia
   Alcorta-Garza, Adelina
TI Association of the quality of psychosocial support and quality of life in patients with chronic oncological pain.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 UANL, Monterrey, NL, Mexico.
   UANL, San Pedro Garza Garcia, Mexico.
   Univ Hosp, Monterrey, Mexico.
C3 Universidad Autonoma de Nuevo Leon; Universidad Autonoma de Nuevo Leon
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2019
VL 37
IS 15
BP 
EP 
DI 10.1200/JCO.2019.37.15_suppl.e23113
PG 1
WC Oncology
SC Oncology
GA IZ8HT
UT WOS:000487345803152
DA 2026-01-16
ER

PT J
AU Genovese, TJ
   Mao, JJ
AF Genovese, Timothy J.
   Mao, Jun J.
TI Genetic Predictors of Response to Acupuncture for Aromatase InhibitorAssociated Arthralgia Among Breast Cancer Survivors
SO PAIN MEDICINE
LA English
DT Article
DE Acupuncture; Alternative Medicine; Joint; Musculoskeletal; Pain Management; Treatment Outcome
ID inhibitor-induced arthralgia; o-methyltransferase comt; clinical-efficacy; pain; morphine; women
AB Objective. To evaluate the associations between polymorphisms in two genes, catechol-O-methyltransferase and T-cell leukemia/lymphoma 1A, and acupuncture-mediated pain reduction among breast cancer survivors with aromatase inhibitorassociated arthralgia. Biospecimens were obtained from 38 patients enrolled in a clinical trial of acupuncture for aromatase inhibitorassociated arthralgia in postmenopausal hormone receptorpositive breast cancer survivors. We used polymerase chain reaction to genotype the rs4680 (Val158Met) and rs4633 (His62His) variants in the catechol-O-methyltransferase gene and rs2369049 (A > G) and rs7158782 (A > G) variants in the T-cell leukemia/lymphoma 1A gene. Response to acupuncture was defined by 30% reduction in end-of-treatment average pain, measured by the Brief Pain Inventory. We used Fisher exact tests to evaluate associations between genotype and treatment response. Among participants, all six (15.8%) subjects who expressed AA in locus rs4680 responded to acupuncture. In a combined analysis, the 18 (47.4%) subjects with the responder genotype at either rs4680 (AA) or rs2369049 (GG or AG) were significantly more likely to respond to acupuncture than those without (77.8% vs 45.0%, P=0.039). Specific genetic variations at loci rs4680 and rs2369049 are associated with response to acupuncture-type intervention for management of arthralgia. These results serve as a proof of concept for applying a precision medicine framework to the study of cancer pain management.
C1 [Genovese, Timothy J.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Integrat Med, 1275 York Ave, New York, NY 10021 USA.
C3 Brown University; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU National Institutes of Health/National Center for Complementary and Alternative Medicine [R21 AT004695]; National Cancer Institute [P30-CA008748]; National Cancer Institute of the National Institutes of Health [R25CA020449]; MSK Translational and Integrative Medicine Research Fund; National Cancer Institute [P30CA008748, R25CA020449] Funding Source: NIH RePORTER
CR Anderson JG, 2012, J ALTERN COMPLEM MED, V18, P235, DOI 10.1089/acm.2011.0022
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Boon Heather S, 2007, BMC WOMENS HEALTH, V7, P4, DOI 10.1186/1472-6874-7-4
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   De Gregori M, 2016, J PAIN, V17, P628, DOI 10.1016/j.jpain.2016.02.003
   Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013
   Donnellan PP, 2001, J CLIN ONCOL, V19, P2767
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Hickey OT, 2011, J CLIN ANESTH, V23, P482, DOI 10.1016/j.jclinane.2011.01.009
   Ho MF, 2016, MOL ENDOCRINOL, V30, P382, DOI 10.1210/me.2015-1267
   Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064
   Liu MH, 2012, BREAST CANCER RES, V14, P0, DOI 10.1186/bcr3137
   Männistö PT, 1999, PHARMACOL REV, V51, P593
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Morales L, 2008, J CLIN ONCOL, V26, P3147, DOI 10.1200/JCO.2007.15.4005
   Offit K, 2011, HUM GENET, V130, P3, DOI 10.1007/s00439-011-1028-3
   Park Ji-Yeun, 2013, EVID BASED COMPLEMENT ALTERNAT MED, V2013, P982095, DOI 10.1155/2013/982095
   Qin WY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/924541
   Rakvåg TT, 2005, PAIN, V116, P73, DOI 10.1016/j.pain.2005.03.032
   Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023
   Young EE, 2017, BIOL RES NURS, V19, P318, DOI 10.1177/1099800417692877
NR 23
TC 9
Z9 12
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JAN 15
PY 2019
VL 20
IS 1
BP 191
EP 194
DI 10.1093/pm/pny067
PG 4
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA HQ1QS
UT WOS:000462173900023
PM 29912452
DA 2026-01-16
ER

PT J
AU Deng, G
AF Deng, Gary
TI Integrative Medicine Therapies for Pain Management in Cancer Patients
SO CANCER JOURNAL
LA English
DT Review
DE Acupuncture; cancer pain; hypnosis; integrative medicine; massage therapy; mind-body therapies; mindfulness; music therapy; pain; pain management
ID clinical-practice guidelines; chronic noncancer pain; breast-cancer; massage therapy; reduce pain; acupuncture; metaanalysis; symptoms; music; interventions
AB Pain management for cancer patients should include pharmacologic and nonpharmacologic interventions. Integrative medicine therapies, such as mind-body practice, acupuncture, massage therapy, and music therapy, have been studied for their roles in pain management. Data from randomized controlled trials support the effect of hypnosis, acupuncture, and music therapy in reduction of pain. Mindfulness meditation, yoga, qigong, and massage therapy, although may not reduce pain per se, can relieve anxiety and mood changes, which are commonly associated with pain. In clinical practice, one should also consider burdens and risks to patients, patient preference, and the presence or absence of better alternatives when making decisions on whether an integrative medicine therapy is of clinical value.
C1 [Deng, Gary] Mem Sloan Kettering Canc Ctr, 1429 First Ave, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center
RP Deng, G (corresponding author), Mem Sloan Kettering Canc Ctr, 1429 First Ave, New York, NY 10021 USA.
EM dengg@mskcc.org
FU NIH/NCI Cancer Center Support Grant [P30 CA008748]; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2011, EVID BASED COMPLEMEN, V0, P0
   Baker DW, 2017, JAMA-J AM MED ASSOC, V317, P1117, DOI 10.1001/jama.2017.0935
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Bradt J, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911.pub3
   Bray FN, 2016, DERMATOLOGY THER, V6, P185, DOI 10.1007/s13555-016-0120-y
   Bro ML, 2018, PSYCHO-ONCOLOGY, V27, P386, DOI 10.1002/pon.4470
   Butler LD, 2009, HEALTH PSYCHOL, V28, P579, DOI 10.1037/a0016124
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Chan CLW, 2012, SUPPORT CARE CANCER, V20, P1121, DOI 10.1007/s00520-011-1378-3
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459
   CLEMENTJONES V, 1980, LANCET, V2, P946
   Couceiro Tania Cursino de Menezes, 2009, REV. BRAS. ANESTESIOL., V59, P358
   Cramer H, 2015, INTEGR CANCER THER, V14, P5, DOI 10.1177/1534735414550035
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dang W, 1998, J TRADIT CHIN MED, V18, P31
   Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021
   Fassoulaki A, 2008, ACTA ANAESTH BELG, V59, P241
   Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528
   Gewandter JS, 2017, NEUROLOGY, V89, P859, DOI 10.1212/WNL.0000000000004272
   Gil JA, 2019, AM J SPORT MED, V47, P1043, DOI 10.1177/0363546518819780
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Gramaglia C, 2019, CRIT REV ONCOL HEMAT, V138, P241, DOI 10.1016/j.critrevonc.2019.04.004
   Grealish L, 2000, CANCER NURS, V23, P237, DOI 10.1097/00002820-200006000-00012
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   Harb Ali H, 2014, CURR GASTROENTEROL REP, V16, P383, DOI 10.1007/s11894-014-0383-3
   Harbaugh CM, 2018, PEDIATRICS, V141, P0, DOI 10.1542/peds.2017-2439
   Helgason Chanel, 2013, CLIN SCHIZOPHR RELAT PSYCHOSES, V7, P138
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Lalla RV, 2014, CANCER-AM CANCER SOC, V120, P1453, DOI 10.1002/cncr.28592
   Lee JH, 2016, J MUSIC THER, V53, P430, DOI 10.1093/jmt/thw012
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Lu WD, 2012, MED ACUPUNCT, V24, P233, DOI 10.1089/acu.2012.0904
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Otti A, 2012, FORSCH KOMPLEMENTMED, V19, P197, DOI 10.1159/000341928
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paice JA, 2011, CA-CANCER J CLIN, V61, P157, DOI 10.3322/caac.20112
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Raiasekaran M, 2005, PALLIATIVE MED, V19, P418, DOI 10.1191/0269216305pm1030oa
   Saibil S, 2010, CURR ONCOL, V17, P168
   Salz T, 2019, J CLIN ONCOL, V37, P1001, DOI 10.1200/JCO.18.00938
   Sawynok J, 2016, NEUROSCIENCE, V338, P1, DOI 10.1016/j.neuroscience.2015.10.031
   Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1
   Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119
   SYRJALA KL, 1995, PAIN, V63, P189, DOI 10.1016/0304-3959(95)00039-U
   SYRJALA KL, 1992, PAIN, V48, P137, DOI 10.1016/0304-3959(92)90049-H
   Thaut MH, 2015, PROG BRAIN RES, V217, P143, DOI 10.1016/bs.pbr.2014.11.025
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Villars P, 2007, J PAIN SYMPTOM MANAG, V33, P67, DOI 10.1016/j.jpainsymman.2006.07.011
   Volpe U, 2018, PSYCHIATRY, V81, P218, DOI 10.1080/00332747.2018.1502559
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Weinrich S P, 1990, APPL NURS RES, V3, P140, DOI 10.1016/S0897-1897(05)80135-1
   Wilcock A, 2004, PALLIATIVE MED, V18, P287, DOI 10.1191/0269216304pm895oa
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wylde V, 2017, BJS-BRIT J SURG, V104, P1293, DOI 10.1002/bjs.10601
NR 70
TC 104
Z9 130
U1 1
U2 62
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-9117
EI 1540-336X
J9 CANCER J
JI Cancer J.
PD SEP-OCT 15
PY 2019
VL 25
IS 5
BP 343
EP 348
DI 10.1097/PPO.0000000000000399
PG 6
WC Oncology
SC Oncology
GA KB3LR
UT WOS:000506401800008
PM 31567462
DA 2026-01-16
ER

PT J
AU Li, K
   Giustini, D
   Seely, D
AF Li, K.
   Giustini, D.
   Seely, D.
TI A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy
SO CURRENT ONCOLOGY
LA English
DT Review
DE Acupuncture; systematic reviews; chemotherapy-induced peripheral neuropathy; CIPN; integrative oncology
ID quality-of-life; electroacupuncture; pain; xerostomia; management
AB Objectives In cancer patients, chemotherapy-induced peripheral neuropathy (CIPN) is a common complication, characterized by pain, loss of sensation, and numbness. Medical treatment for peripheral neuropathies has been shown to be ineffective for CIPN. Acupuncture has been shown to be safe and effective in treating cancer-related symptoms and other peripheral neuropathies. For the present review, we aimed to evaluate the efficacy of acupuncture for the treatment of CIPN. Design Comprehensive searches for relevant studies were conducted in Ovid EMBASE, the Web of Science, Ovid MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO Information Services, Ipswich, MA, U.S.A.), and the ClinicalTrials. gov Web site. References from previous systematic reviews were also searched. Additional trials were found in the reference lists of relevant papers and in searches of Google Scholar and acupuncture-specific Web sites. Included studies were randomized controlled trials (RCTS) of any type of acupuncture used to treat patients with CIPN. Results Three clinical trials (203 participants) were included. Two studies found acupuncture to be effective in alleviating CIPN pain and improving quality of life. One study found no benefit in improving neuropathic pain, symptoms, or quality of life. Study quality was variable and included a moderate overall risk of bias. Conclusions The evidence is insufficient to recommend acupuncture for the treatment or prevention of CIPN. Further research is needed to evaluate the effects of acupuncture in the treatment of CIPN. Given that acupuncture is considered safe and might provide relief for patients, it can be considered at the clinician's discretion.
C1 [Li, K.] Univ British Columbia, Fac Med, 317-2194 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.
   [Giustini, D.] Univ British Columbia, Biomed Branch Lib, Vancouver, BC, Canada.
   [Seely, D.] Ottawa Integrat Canc Ctr, Ottawa, ON, Canada.
C3 University of British Columbia; University of British Columbia
RP Li, K (corresponding author), Univ British Columbia, Fac Med, 317-2194 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.
EM kevin94li@alumni.ubc.ca
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2011, EVID-BASED COMPL ALT, V0, P0
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Dimitrova A, 2017, J ALTERN COMPLEM MED, V23, P164, DOI 10.1089/acm.2016.0155
   Dong ZQ, 2005, NEUROSCI LETT, V385, P189, DOI 10.1016/j.neulet.2005.05.051
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.03.010
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Gordon BS, 2018, J CLIN ONCOL, V36, P0, DOI 10.1200/JCO.2018.36.15_suppl.e22111
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Higgins JPT, 2011, BMJ, V343, P0
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Kleckner I, 2016, J CLIN ONCOL, V34, P0, DOI 10.1200/JCO.2016.34.15_suppl.10000
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lu W, 2017, CANC RES S, V77, P0
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   Mols F, 2014, SUPPORT CARE CANCER, V22, P2261, DOI 10.1007/s00520-014-2255-7
   Ouzzani M, 2016, SYST REV-LONDON, V5, P0, DOI 10.1186/s13643-016-0384-4
   Pachman DR, 2014, SUPPORT CARE CANCER, V22, P2281, DOI 10.1007/s00520-014-2289-x
   Pachman DR, 2014, J CLIN INVEST, V124, P72, DOI 10.1172/JCI73908
   Richardson PG, 2006, J CLIN ONCOL, V24, P3113, DOI 10.1200/JCO.2005.04.7779
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Starobova H, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00174
   Tofthagen C, 2013, SUPPORT CARE CANCER, V21, P3307, DOI 10.1007/s00520-013-1905-5
   Tsukaguchi M, 2013, J BLOOD MED, V4, P81, DOI 10.2147/JBM.S44127
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   2016, 1900, V156, V0, PP453, DOI 10.1007/S10549-016-3759-2
   2008, 1900, V155, V0, PP463, DOI 10.1016/J.NEUROSCIENCE.2008.06.016
   2003, 1900, V12, V0, PP59, DOI 10.1080/0962935031000114943
NR 37
TC 43
Z9 54
U1 0
U2 26
PU MULTIMED INC
PI TORONTO
PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA
SN 1198-0052
EI 
J9 CURR ONCOL
JI Curr. Oncol.
PD APR 15
PY 2019
VL 26
IS 2
BP E147
EP E154
DI 10.3747/co.26.4261
PG 8
WC Oncology
SC Oncology
GA HV7OU
UT WOS:000466171200004
PM 31043820
DA 2026-01-16
ER

PT J
AU Anand, K
   Niravath, P
AF Anand, Kartik
   Niravath, Polly
TI Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Acupuncture; Vitamin D; Aromatase inhibitor; Breast cancer; Arthralgia; Quality of life; Breast cancer survivors
ID stage breast-cancer; musculoskeletal symptoms; postmenopausal women; joint symptoms; inflammatory cytokines; randomized-trial; placebo; pain; multicenter; prevalence
AB Purpose of ReviewAromatase inhibitor-induced arthralgia (AIA) is a very common syndrome which significantly affects breast cancer survivors' quality of life, and it often leads to non-compliance with aromatase inhibitor (AI) therapy. However, the treatment of AIA remains a clinical challenge. Here, we will review the current data for acupuncture and vitamin D in the management of AIA.Recent FindingsAcupuncture has been shown to improve AIA symptoms, but it has not consistently been proven to offer significantly more clinical benefit than sham acupuncture. Similarly, while some vitamin D trials have shown benefit, the studies have not consistently shown improvement in AIA symptoms.SummaryNeither acupuncture nor vitamin D can be touted as standard treatments for AIA. However, many patients do experience subjective improvement of their symptoms with these therapies. When other treatments, such as exercise and duloxetine, are not feasible or not effective, it is reasonable to offer a trial of acupuncture or vitamin D to patients who are suffering from AIA, as the potential harms are very few, and they do offer possible relief from AIA symptoms.
C1 [Anand, Kartik; Niravath, Polly] Weill Cornell Med, Houston Methodist Canc Ctr, Outpatient Tower,Floor 24,6445 Main St, Houston, TX 77030 USA.
C3 Houston Methodist
RP Niravath, P (corresponding author), Weill Cornell Med, Houston Methodist Canc Ctr, Outpatient Tower,Floor 24,6445 Main St, Houston, TX 77030 USA.
EM paniravath@houstonmethodist.org
CR Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Boonstra A, 2013, CANCER NURS, V36, P52, DOI 10.1097/NCC.0b013e31824a7e18
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Chlebowski RT, 2011, MATURITAS, V68, P73, DOI 10.1016/j.maturitas.2010.10.006
   Coleman RE, 2012, CANCER RES, V72, P0, DOI 10.1158/0008-5472.SABCS12-S6-4
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Ezzo J, 2001, ARTHRITIS RHEUM, V44, P0, DOI 10.1002/1529-0131(200104)44:4
   Fenlon D, 2013, J PAIN SYMPTOM MANAG, V46, P523, DOI 10.1016/j.jpainsymman.2012.10.282
   GALLAGHER JC, 1980, J CLIN ENDOCR METAB, V51, P1359, DOI 10.1210/jcem-51-6-1359
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   Grossmann RE, 2012, EUR J CLIN NUTR, V66, P1072, DOI 10.1038/ejcn.2012.82
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Imtiaz Saba, 2012, INDIAN J ENDOCRINOL METAB, V16, P409, DOI 10.4103/2230-8210.95684
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Khan QJ, 2017, BREAST CANCER RES TR, V166, P491, DOI 10.1007/s10549-017-4429-8
   Khan QJ, 2010, BREAST CANCER RES TR, V119, P111, DOI 10.1007/s10549-009-0495-x
   Lim HD, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0151882
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Lonning PE, 2005, J CLIN ONCOL, V23, P5126, DOI 10.1200/JCO.2005.07.097
   MacPherson H, 2016, J ALTERN COMPLEM MED, V22, P101, DOI 10.1089/acm.2015.0184
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Miller WR, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00302-6
   Murphy CC, 2012, BREAST CANCER RES TR, V134, P459, DOI 10.1007/s10549-012-2114-5
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Niravath P, 2018, SAN ANT BREAST CANC, V0, P0
   Niravath P, 2018, CLIN BREAST CANCER, V18, P78, DOI 10.1016/j.clbc.2017.10.009
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Park JY, 2013, J KOREAN SURG SOC, V85, P205, DOI 10.4174/jkss.2013.85.5.205
   Plotnikoff GA, 2003, MAYO CLIN PROC, V78, P1463, DOI 10.4065/78.12.1463
   Prieto-Alhambra D, 2012, BREAST CANCER RES TR, V133, P1159, DOI 10.1007/s10549-012-2013-9
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549-011-1644-6
   Sandberg M, 2003, EUR J APPL PHYSIOL, V90, P114, DOI 10.1007/s00421-003-0825-3
   Sestak I, 2008, LANCET ONCOL, V9, P866, DOI 10.1016/S1470-2045(08)70182-7
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Sierpina VS, 2005, SOUTH MED J, V98, P330, DOI 10.1097/01.SMJ.0000140834.30654.0F
   Sims J, 1997, COMPLEMENTARY THERAPIES IN MEDICINE, V5, P102, DOI 10.1016/S0965-2299
   Singh S, 2012, BREAST CANCER RES TR, V132, P625, DOI 10.1007/s10549-011-1911-6
   Villaggio B, 2012, CLIN EXP RHEUMATOL, V30, P934
   Wu XK, 2017, JAMA-J AM MED ASSOC, V317, P2502, DOI 10.1001/jama.2017.7217
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/710750
NR 46
TC 10
Z9 11
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD JUN 15
PY 2019
VL 21
IS 6
BP 
EP 
DI 10.1007/s11912-019-0795-1
PG 8
WC Oncology
SC Oncology
GA HU0ZO
UT WOS:000465001400001
PM 30997616
DA 2026-01-16
ER

PT J
AU Bao, T
   Deng, G
   DeMarzo, LA
   Zhi, WI
   DeRito, JL
   Blinder, V
   Chen, C
   Li, QS
   Green, J
   Pendleton, E
   Mao, JJ
AF Bao, Ting
   Deng, Gary
   DeMarzo, Lauren A
   Zhi, W Iris
   DeRito, Janice L
   Blinder, Victoria
   Chen, Connie
   Li, Qing S
   Green, Jamie
   Pendleton, Eva
   Mao, Jun J
TI A Technology-Assisted, Brief Mind-Body Intervention to Improve the Waiting Room
SO JMIR cancer
LA English
DT Journal Article
DE acupressure; chemotherapy; meditation; mobile app; symptom relief
AB BACKGROUND: Patients waiting for chemotherapy can experience stress, anxiety,  nausea, and pain. Acupressure and meditation have been shown to control such  symptoms. OBJECTIVE: This study aimed to evaluate the feasibility and  effectiveness of an integrative medicine app to educate patients about these  self-care tools in chemotherapy waiting rooms. METHODS: We screened and enrolled  cancer patients in chemotherapy waiting rooms at two Memorial Sloan Kettering  Cancer Center locations. Patients were randomly assigned into an intervention arm  in which subjects watched acupressure and meditation instructional videos or a  control arm in which they watched a time- and attention-matched integrative  oncology lecture video. Before and after watching the videos, we asked the  patients to rate four key symptoms: stress, anxiety, nausea, and pain. We  performed the analysis of covariance to detect differences between the two arms  postintervention while controlling for baseline symptoms. RESULTS: A total of 223  patients were enrolled in the study: 113 patients were enrolled in the  intervention arm and 110 patients were enrolled in the control arm. In both  groups, patients showed significant reductions in stress and anxiety from  baseline (all P<.05), with the treatment arm reporting greater stress and anxiety  reduction than the control arm (1.64 vs 1.15 in stress reduction; P=.01 and 1.39  vs 0.78 in anxiety reduction; P=.002). The majority of patients reported that the  videos helped them pass time and that they would watch the videos again.  CONCLUSIONS: An integrative medicine self-care app in the waiting room improved  patients' experiences and reduced anxiety and stress. Future research could focus  on expanding this platform to other settings to improve patients' overall  treatment experiences.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
NR 0
TC 0
SN 2369-199
EI 2369-199
J9 JMIR Cancer
PD NOV 8
PY 2019
VL 5
IS 2
BP e13217
EP e13217
DI 10.2196/13217
PG 1
UT PubMed:31697238
PM 31697238
DA 2019-11-08
ER

PT J
AU Kim, TH
   Kang, JW
AF Kim, Tae-Hun
   Kang, Jung Won
TI Acupuncture for symptoms management in Korean breast cancer survivors: a
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE Korea; acupuncture; aromatase inhibitor–related arthralgia; breast cancer survivor; hot flushes; insomnia; post-mastectomy pain; sexual dysfunction
AB BACKGROUND: There is an unmet need for effective treatment of the various  treatment-related symptoms experienced by breast cancer survivors. These symptoms  could be alleviated by acupuncture. Although several lines of evidence in Western  countries suggest that acupuncture has a beneficial effect on symptoms in breast  cancer survivors, few relevant studies have been conducted in Korean patients.  This pilot study assessed the feasibility of acupuncture for a variety of  treatment-related symptoms in Korean breast cancer survivors. METHOD: From  October 2015 to March 2016, we recruited patients who had undergone treatment for  breast cancer and subsequently reported symptoms, including aromatase  inhibitor-related knee pain, vasomotor symptoms, insomnia, sexual dysfunction and  post-mastectomy pain in the chest wall or shoulder. The women received 4 weeks of  symptom-specific acupuncture followed by a further 4 weeks of follow-up to  evaluate the feasibility of acupuncture for this indication, and its impact on  common and symptom-specific outcome variables. RESULTS: Eight study participants  were recruited over a period of 6 months, six of whom completed the planned  acupuncture treatment and follow-up assessments. A total of 78 acupuncture  sessions were performed. We found that acupuncture was feasible, with only six  minor self-limiting acupuncture-related adverse events. Most of the women felt  that they had benefitted from participation in the study. The preliminary  analysis indicated improvement in common symptom-specific outcomes. CONCLUSION:  Our findings suggest that acupuncture is feasible, but low recruitment rates  should be considered when considering future acupuncture research in Korean  breast cancer survivors. Rigorous evaluation of this symptomatic treatment  strategy is now needed in the Korean population.
C1 1 Korean Medicine Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University, Seoul, South Korea.
   2 Department of Acupuncture & Moxibustion, College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD MAR 22
PY 2019
VL 37
IS 3
BP 164
EP 174
DI 10.1177/0964528419832610
PG 10
WC Acupuncture Therapy; Adult; Aged; Antineoplastic Agents; adverse effects; Breast Neoplasms; complications; Female; Humans; Mastectomy; adverse effects; Middle Aged; Neuralgia; etiology; Pilot Projects; Prospective Studies; Radiotherapy; adverse effects; Republic of Korea; Survivors; statistics & numerical data; Treatment Outcome
UT PubMed:30896247
PM 30896247
DA 2019-03-22
ER

PT J
AU Molassiotis, A
   Suen, LKP
   Cheng, HL
   Mok, TSK
   Lee, SCY
   Wang, CH
   Lee, P
   Leung, H
   Chan, V
   Lau, TKH
   Yeo, W
AF Molassiotis, Alexander
   Suen, Lorna K. P.
   Cheng, Hui Lin
   Mok, T. S. K.
   Lee, Sara C. Y.
   Wang, C. H.
   Lee, Paul
   Leung, Howan
   Chan, V.
   Lau, T. K. H.
   Yeo, Winnie
TI A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; chemotherapy-induced peripheral neuropathy; cancer; neurotoxicity; quality of life; pain
ID cancer; pain; prevention; common
AB Purpose: Chemotherapy-induced peripheral neuropathy is a complex side effect with few available treatment options. The aim of the study was to test the effectiveness of an 8-week course of acupuncture in the management of chemotherapy-induced peripheral neuropathy in cancer patients who were receiving or had received neurotoxic chemotherapy. Methods: Randomized assessor-blinded controlled trial with 2 arms; one arm received acupuncture twice weekly for 8 weeks, while the other arm was a wait-list control group receiving only standard care. Primary outcome was pain intensity and interference over the past week using the Brief Pain Inventory at the end of the intervention. Secondary outcomes included clinical assessment (CTCAE [Common Toxicity Criteria for Adverse Events] grading and Total Neuropathy Score-Clinical Version) and nerve conduction studies; and patient-reported outcome measures (Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity Quality of Life scale and Symptom Distress Scale) assessed at baseline, end of treatment (8 weeks), week 14, and week 20 from the beginning of treatment. Results: Eighty-seven patients were randomized to the experimental arm (n = 44) and to the standard care wait-list control arm (n = 43). Significant changes at 8 weeks were detected in relation to primary outcome (pain), the clinical neurological assessment, quality of life domains, and symptom distress (all P < .05). Improvements in pain interference, neurotoxicity-related symptoms, and functional aspects of quality of life were sustained in the 14-week assessment (P < .05), as were physical and functional well-being at the 20-week assessment (P < .05). Conclusions: Acupuncture is an effective intervention for treating chemotherapy-induced peripheral neuropathy and improving patients' quality of life and experience with neurotoxicity-related symptoms with longer term effects evident.
C1 [Molassiotis, Alexander; Suen, Lorna K. P.; Cheng, Hui Lin; Lee, Sara C. Y.; Lee, Paul] Hong Kong Polytech Univ, Kowloon, Hong Kong, Peoples R China.
   [Mok, T. S. K.; Wang, C. H.; Leung, Howan; Chan, V.; Lau, T. K. H.; Yeo, Winnie] Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University; Prince of Wales Hospital Hong Kong
RP Molassiotis, A (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hung Hom, 11 Yuk Choi Rd, Hong Kong, Peoples R China.
EM alex.molasiotis@polyu.edu.hk
FU Hong Kong's Health & Medical Research Fund [12131801]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Armstrong T, 2005, ONCOL NURS FORUM, V32, P305, DOI 10.1188/05.ONF.305-311
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Cavaletti G, 2010, EUR J CANCER, V46, P479, DOI 10.1016/j.ejca.2009.12.008
   CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Frigeni B, 2011, J PERIPHER NERV SYST, V16, P228, DOI 10.1111/j.1529-8027.2011.00351.x
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hoitsma E, 2004, J NEUROL SCI, V227, P119, DOI 10.1016/j.jns.2004.08.012
   Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x
   Kerckhove N, 2017, PAIN, V158, P180, DOI 10.1097/j.pain.0000000000000743
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mason S, 2002, BRIT MED J, V325, P832, DOI 10.1136/bmj.325.7368.832
   McCorkle R, 1998, USERS MANUAL SYMPTOM, V0, P0
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2013, J CLIN ONCOL, V31, P2058, DOI 10.1200/JCO.2013.49.2470
   Ocean AJ, 2004, SUPPORT CARE CANCER, V12, P619, DOI 10.1007/s00520-004-0657-7
   Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Pike Crystal T, 2012, CHEMOTHER RES PRACT, V2012, P913848, DOI 10.1155/2012/913848
   Postma TJ, 2000, ANN ONCOL, V11, P509, DOI 10.1023/A:1008345613594
   Raman S, 2018, QUAL LIFE RES, V27, P1089, DOI 10.1007/s11136-017-1745-8
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Shimozuma K, 2012, SUPPORT CARE CANCER, V20, P3355, DOI 10.1007/s00520-012-1492-x
   Wong K, 2013, SUPPORT CARE CANCER, V21, P1893, DOI 10.1007/s00520-013-1731-9
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wong R, 2016, INTEGR CANCER THER, V15, P153, DOI 10.1177/1534735415627926
   Xinnong C, 1999, CHINESE ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Yost KJ, 2005, EVAL HEALTH PROF, V28, P172, DOI 10.1177/0163278705275340
NR 32
TC 70
Z9 81
U1 6
U2 38
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD MAR 25
PY 2019
VL 18
IS 
BP 
EP 
DI 10.1177/1534735419836501
PG 12
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA HQ3HE
UT WOS:000462300700001
PM 30905173
DA 2026-01-16
ER

PT J
AU Saraswati, W
   Dahlan, EG
   Saputra, K
   Sutrisno, TC
AF Saraswati, Wita
   Dahlan, Erry Gumilar
   Saputra, Koosnadi
   Sutrisno, Thomas Cahyono
TI Effect of Electroacupuncture on Natural-Killer Cells and Tumor Size in Patients
SO Medical acupuncture
LA English
DT Journal Article
DE cervical squamous-cell carcinoma; electroacupuncture; natural-killer cells
AB Background: A natural-killer (NK) cell is a cytotoxic lymphocyte that responds to  tumor formation. Electroacupuncture (EA) in patients with cancer, who had  chemotherapy, enabled them to maintain their T-cell counts (CD3+, CD4+, and CD8+)  and NK-cell activity. Objective: To evaluate NK-cell levels and tumor sizes in  patients with cervical squamous-cell carcinoma (SCC) after EA on ST 36 (Zusanli).  Design: This study was a randomized, experimental clinical study with a  pre-post-test, control group design. Setting The study was performed in the  obstetrics and gynecology department, Gynecology Oncology Division of the Rumah  Sakit Dokter Soetomo General Hospital, in Surabaya, Jawa Timur, Indonesia,  conducted from February 2016 until May 2016. Subjects: Patients with cervical  SCC, stages IIb-IIIb (locally advanced)-determined clinically and  histopathologically-all of whom had 50 mg/m(2)/week of cisplatin chemotherapy.  The patients were divided, consecutively, into 2 groups by simple random  sampling. Intervention: The controls received only received the chemotherapy,  while treatment-group patients also had EA 1 day on bilateral ST 36 after each  chemotherapy cycle. Outcome Measures: Primary outcomes were percent of NK cells  and tumor size. Before the first treatment and after the fourth one, all patients  underwent peripheral blood examinations (complete blood counts, serum creatinine  and blood-urea-nitrogen levels, and flow-cytometry) to determine percentages of  NK cells, and pelvic magnetic resonance imaging to measure cervical tumor sizes.  Secondary outcomes were pain, nausea, vomiting, and appetite. Results: There was  a significant increase in number of NK cells (P = 0.00) and a significant  decrease in tumor sizes (P = 0.03) in the treatment group, compared to the  control group. There was a significant increase in appetite (P = 0.00) in the  treatment group, compared to baseline, but there were no significant differences  in pain (P = 0.061), nausea (P = 0.399), and vomiting (P = 0.854). Conclusions:  Patients with cervical SCC at stages IIb-IIIb, who received 4 cycles of  chemotherapy using 50 mg/m(2)/week of cisplatin and EA at ST 36, had increased  NK-cell percentages in their peripheral blood and had reductions in their  cervical tumors.
C1 Obstetrics and Gynecologic Department, Rumah Sakit Dokter Soetomo General Hospital, Surabaya, Jawa Timur, Indonesia.
   Faculty of Medicine, Universitas Airlangga, Surabaya, Jawa Timur, Indonesia.
   Obstetrics and Gynecologic Department, Rumah Sakit Dokter Soetomo General Hospital, Surabaya, Jawa Timur, Indonesia.
   Faculty of Medicine, Universitas Airlangga, Surabaya, Jawa Timur, Indonesia.
   Acupuncture Research Laboratory in Health Services, Ministry of Health of the Republic of Indonesia, Surabaya, Jawa Timur, Indonesia.
   Academy of Acupuncture Surabaya, Jawa Timur, Indonesia.
   Academy of Acupuncture Surabaya, Jawa Timur, Indonesia.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD FEB 26
PY 2019
VL 31
IS 1
BP 29
EP 36
DI 10.1089/acu.2018.1316
PG 7
UT PubMed:30805077
PM 30805077
DA 2019-02-26
ER

PT J
AU Benson, S
   Hagen, S
   Hoffmann, O
   Pasler, A
   Bingel, U
   Schedlowski, M
   Peters, J
   Elsenbruch, S
   Frey, UH
AF Benson, Sven
   Hagen, Susanne
   Hoffmann, Oliver
   Pasler, Annika
   Bingel, Ulrike
   Schedlowski, Manfred
   Peters, Jürgen
   Elsenbruch, Sigrid
   Frey, Ulrich H
TI Can a brief psychological expectancy intervention improve postoperative pain? A
SO Pain
LA English
DT Journal Article
AB Pain after surgery remains a major health problem, calling for optimized  treatment regimens to maximize the efficacy of pharmacological interventions. In  this randomized controlled trial, we tested in a routine surgical treatment  setting whether postoperative pain can be reduced by a brief preoperative  intervention, ie, positive verbal suggestions in combination with sham  acupuncture, designed to optimize treatment expectations. We hypothesized that  the expectancy intervention as add-on to patient-controlled intravenous analgesia  with morphine reduces patient-reported postoperative pain and improves  satisfaction with analgesia. Ninety-six women undergoing breast cancer surgery  were randomized at 2 stages: Before surgery, anesthesiologists delivered either  positive or neutral verbal suggestions regarding the benefits of acupuncture  needling on postoperative pain ("information condition"). Patients were then  randomized to receive sham acupuncture or no sham acupuncture during  postoperative care ("sham acupuncture condition"). Average pain during the  24-hour observation period after surgery as primary and satisfaction with  analgesia as secondary outcome was assessed with standardized measures and  analyzed with analysis of covariance accounting for morphine dose,  surgery-related, and psychological parameters. Postoperative pain ratings were  significantly reduced in patients who received positive treatment-related  suggestions (F = 4.45, P = 0.038, main effect of information). Moreover, patients  who received an intervention aimed at optimized treatment expectations reported  significantly greater satisfaction with analgesia (F = 4.89, P = 0.030,  interaction effect). Together, our proof-of-concept data support that optimizing  treatment expectations through verbal suggestions may offer a promising approach  to improve patient-reported outcomes. Future translational and clinical studies  are needed to test such psychological strategies in different surgical  interventions, patient groups, and pharmacological treatment regimens.
C1 Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Clinic for Obstetrics and Gynecology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, 
   Clinic for Neurology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
   Department of Anesthesiology, Marienhospital Herne, Ruhr University Bochum,
NR 0
TC 0
SN 1872-662
EI 
J9 Pain
PD MAR 7
PY 2019
VL 160
IS 7
BP 1562
EP 1571
DI 10.1097/j.pain.0000000000001546
PG 9
WC Acupuncture Therapy; Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; therapeutic use; Breast Neoplasms; surgery; Double-Blind Method; Female; Humans; Middle Aged; Morphine; therapeutic use; Pain Management; Pain Measurement; Pain, Postoperative; drug therapy; Patient Satisfaction; Psychotherapy, Brief; methods; Socioeconomic Factors; Treatment Outcome; Young Adult
UT PubMed:30839426
PM 30839426
DA 2019-03-07
ER

PT J
AU Yeh, CH
   Lukkahatai, N
   Campbell, C
   Sair, H
   Zhang, F
   Mensah, S
   Garry, C
   Zeng, J
   Chen, C
   Pinedo, M
   Khoshnoodi, M
   Smith, TJ
   Saligan, LN
AF Yeh, Chao Hsing
   Lukkahatai, Nada
   Campbell, Claudia
   Sair, Haris
   Zhang, Fengzhi
   Mensah, Sylvanus
   Garry, Courtney
   Zeng, Jing
   Chen, Changying
   Pinedo, Mariela
   Khoshnoodi, Mohammad
   Smith, Thomas J
   Saligan, Leorey N
TI Preliminary Effectiveness of Auricular Point Acupressure on Chemotherapy-Induced
SO Pain management nursing : official journal of the American Society of Pain
LA English
DT Journal Article
AB PURPOSE: To reduce chemotherapy-induced neuropathy (CIN)-a significant challenge  among cancer patients following chemotherapy-we explored the effects of auricular  point acupressure (APA), which involves needleless, acupuncture-like stimulation  on specific ear points. DESIGN/METHOD: This pilot study examined the effects of a  4-week APA intervention in the management of CIN. Descriptive analysis was used  to examine the changes in study outcomes. RESULTS: Fifteen participants were  enrolled. Two participants dropped out because they developed new medical  conditions. Thirteen participants completed the study (87% retention rate). Study  participants had more severe symptoms in their lower extremities (i.e., toes,  feet, soles) than in their upper extremities (i.e., fingers, wrists, elbows).  After the 4-week APA intervention, the mean percentage change scores ranged from  38% (tingling) to 49% (numbness); compared to pre-intervention, the therapeutic  effects of APA were sustained at the 1-month follow-up. Function in both upper  and lower extremities improved after the APA intervention (≥28%) and continued to  improve at the 1-month follow-up (≥36%). CONCLUSIONS: Preliminary results from  this small sample provide initial evidence of the effectiveness of APA on CIN.  Future studies should confirm these results using a larger sample, a comparative  sham control, and an examination of the underlying physiological mechanisms of  the anti-CIN effects of APA. CLINICAL IMPLICATIONS: APA may provide an  inexpensive and effective complementary approach for the self-management of CIN.  Once the seeds have been taped to the patient's ear by the provider, patients are  empowered to self-manage their CIN in their own environment.
C1 Johns Hopkins University School of Nursing, Baltimore, Maryland. 
   Johns Hopkins University School of Nursing, Baltimore, Maryland.
   Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
   Department of Radiology, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Phipps 455, Baltimore, Maryland.
   Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
   Johns Hopkins University School of Nursing, Baltimore, Maryland.
   Johns Hopkins University School of Nursing, Baltimore, Maryland.
   Chengdu Medical College School of Nursing, Chengdu, Sichuan, China.
   The Nursing College of Zhengzhou University, No. 100 Science Ave, Zhengzhou, Henan, China.
   Johns Hopkins University School of Nursing, Baltimore, Maryland.
   Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
   Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
   National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland.
EM cyeh13@jhu.edu
NR 0
TC 0
SN 1532-863
EI 
J9 Pain Manag Nurs
PD JUN 4
PY 2019
VL 20
IS 6
BP 614
EP 622
DI 10.1016/j.pmn.2019.04.005
PG 8
WC Acupressure; methods; Adult; Antineoplastic Agents; adverse effects; Drug Therapy; methods; Ear; innervation; Female; Humans; Male; Middle Aged; Neuralgia; etiology; Outcome Assessment, Health Care; standards; Self Report; Surveys and Questionnaires; Treatment Outcome
UT PubMed:31155279
PM 31155279
DA 2019-06-04
ER

PT J
AU Wang, CCF
   Tan, JY
   Williams, A
AF Wang, Carol Chunfeng
   Tan, Jing-Yu
   Williams, Anne
TI Safety and side effects of acupuncture therapy in Australia: A systematic review
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Review
DE Acupuncture; Adverse event; Side effect; Adverse effect; Safety; Risk; Systematic review
ID laser acupuncture; controlled-trial; adverse events; pain; depression; cancer
AB Introduction: The tremendous popularity of acupuncture in Australia demands continual safety assessment. This review aimed to determine the characteristics of acupuncture related adverse events, analyse their possible causes, and inform future research and practice. Methods: Across 8 databases, all types of clinical trials, surveys, and case reports from 2012 to 2018 reporting adverse events associated with the use of acupuncture in Australia on human subjects were systematically reviewed. Types of acupuncture including manual acupuncture, electro acupuncture and laser acupuncture. Incidence and form of acupuncture related adverse events were the key outcomes of this study. In addition, the quality of adverse events reporting and the likelihood of causality were examined by two reviewers and checked by two experts specialised in acupuncture. Results: The 17 analysed studies encompassed ten randomised controlled trials, two nonrandomised controlled trials, three uncontrolled clinical trials, and two case reports, with a total of 1160 participants receiving true acupuncture. Feelings of dizziness, fatigue and nausea were the most common adverse events identified in our review across all acupuncture modalities. Conclusions: Acupuncture is generally a safe modality and serious adverse events after treatment are uncommon when supported with well-established guidelines and practiced by licensed, qualified practitioners.
C1 [Wang, Carol Chunfeng] Edith Cowan Univ, Sch Nursing & Midwifery, Perth, WA 6027, Australia.
   [Tan, Jing-Yu] Charles Darwin Univ, Coll Nursing & Midwifery, Darwin, NT 0909, Australia.
   [Williams, Anne] Murdoch Univ, Sch Hlth Profess, Perth, WA, Australia.
C3 Edith Cowan University; Charles Darwin University; Murdoch University
RP Wang, CCF (corresponding author), Edith Cowan Univ, Sch Nursing & Midwifery, Perth, WA 6027, Australia.
EM c.wang@ecu.edu.au; benjamin.tan@cdu.edu.au; anne.williams@murdoch.edu.au
CR Abbate S, 2016, CHINESE AURICULAR AC, V0, P0
   Unknown -, 2013, EVIDENCE BASED NONPH, V0, P0
   Unknown -, 2016, STARRAG EVENT-A NEW MODEL IS LAUNCHED AND MACHINE RELIABILITY IS PRAISED, V0, P0
   Armour M, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180177
   Chen E, 2005, J ACCORD INTEGR MED, V1, P36
   Chia KL, 2015, J INTEGR MED-JIM, V13, P58, DOI 10.1016/S2095-4964(15)60150-9
   Cohen MM, 2017, MED J AUSTRALIA, V206, P494, DOI 10.5694/mja16.00771
   Easthope G, 2000, COMPLEMENT THER MED, V8, P226, DOI 10.1054/ctim.2000.0398
   Enblom A, 2017, ACUPUNCT MED, V35, P251, DOI 10.1136/acupmed-2015-011007
   Glazov G, 2014, ACUPUNCT MED, V32, P116, DOI 10.1136/acupmed-2013-010456
   Guan ZX, 2002, AURICULAR THERAPY TR, V0, P0
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009
   Lyons Zaza, 2012, COMPLEMENT THER CLIN PRACT, V18, P216, DOI 10.1016/j.ctcp.2012.06.003
   Maciocia Giovanni, 2015, THE FOUNDATIONS OF CHINESE MEDICINE: A COMPREHENSIVE TEXT, V3rd, P0
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Ni Maoshing, 1995, YELLOW EMPERORS CLAS, V0, P0
   Oh B, 2013, ACUPUNCT MED, V0, P0
   Ormsby SM, 2017, WOMEN BIRTH, V0, P0
   Peuker Elmar, 2004, ACUPUNCT MED, V22, P29
   Quah-Smith I, 2013, MED ACUPUNCT, V25, P124, DOI 10.1089/acu.2012.0901
   Quah-Smith I, 2012, MED ACUPUNCT, V24, P161, DOI 10.1089/acu.2011.0870
   Quah-Smith I, 2013, ACUPUNCT MED, V31, P282, DOI 10.1136/acupmed-2012-010297
   Quah-Smith I, 2013, J AFFECT DISORDERS, V148, P179, DOI 10.1016/j.jad.2012.11.058
   Quah-Smith I, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0012619
   Robinson A, 2016, ACUPUNCT MED, V34, P149, DOI 10.1136/acupmed-2015-212110rep
   Schroer S, 2011, CNS NEUROSCI THER, V17, P398, DOI 10.1111/j.1755-5949.2010.00159.x
   Smith C, 2014, J ALTERN COMPLEM MED, V20, P103, DOI 10.1089/acm.2013.0142
   Smith CA, 2014, ACUPUNCT MED, V32, P387, DOI 10.1136/acupmed-2014-010593
   Tan JY, 2014, EVID BASED COMPLEMEN, V14, P0
   Turner LA, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-67
   Wang CC, 2018, HOLIST NURS PRACT, V0, P0
   Wang R, 2017, ACUPUNCT MED, V35, P241, DOI 10.1136/acupmed-2016-011176
   Wang Y, 2015, EVID BASED COMPLEMEN, V2015, P0
   Wang ZJ, 2017, J PSYCHIATR RES, V84, P18, DOI 10.1016/j.jpsychires.2016.09.014
   White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   World Health Organization, 2005, THE USE OF THE WHO-UMC SYSTEM FOR STANDARDIZED CASE CAUSALITY ASSESSMENT, V0, P0
   Xu S, 2013, EVID BASED COMPLEMEN, V0, P0
   Xue CCL, 2008, BMC PUBLIC HEALTH, V8, P0, DOI 10.1186/1471-2458-8-105
   Xue CC, 2015, ANN ALLERG ASTHMA IM, V115, P317, DOI 10.1016/j.anai.2015.05.017
   Yamashita H, 1999, J ALTERN COMPLEM MED, V5, P229, DOI 10.1089/acm.1999.5.229
   Zhang AL, 2014, ACUPUNCT MED, V0, P0
   Zheng Z, 2014, INTEGR MED RES, V3, P103
   2017, 1900, V35, V0, PP284, DOI 10.1136/ACUPMED-2016-011152
NR 45
TC 10
Z9 11
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD APR 15
PY 2019
VL 27
IS 
BP 81
EP 89
DI 10.1016/j.eujim.2019.03.004
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA HW8JZ
UT WOS:000466937000012
DA 2026-01-16
ER

PT J
AU Kwan, YH
   Fong, W
   Ang, XL
   Tan, CS
   Tai, BC
   Huang, YY
   Bilger, M
   Phang, JK
   Tan, HC
   Lee, JV
   Sun, LM
   Tan, CT
   Dong, BQ
   Koh, HL
   Leung, YY
   Lui, NL
   Yeo, SI
   Ng, SC
   Fong, KY
   Thumboo, J
   Ostbye, T
AF Kwan, Yu Heng
   Fong, Warren
   Ang, Xiang Ling
   Tan, Chuen Seng
   Tai, Bee Choo
   Huang, Youyi
   Bilger, Marcel
   Phang, Jie Kie
   Tan, Hui Chin
   Lee, Jia Ven
   Sun, Limin
   Tan, Choy Tip
   Dong, Bao Qiang
   Koh, Hwee Ling
   Leung, Ying Ying
   Lui, Nai Lee
   Yeo, Siaw Ing
   Ng, Swee Cheng
   Fong, Kok Yong
   Thumboo, Julian
   Ostbye, Truls
TI Traditional Chinese medicine (TCM) collaborative care for patients with axial spondyloarthritis (AcuSpA): protocol for a pragmatic randomized controlled trial
SO TRIALS
LA English
DT Article
ID health-assessment questionnaire; ankylosing-spondylitis; disease-activity; alternative medicine; acupuncture; complementary; validation; management; efficacy; validity
AB BackgroundAxial spondyloarthritis (AxSpA) is a chronic disease which results in fatigue, pain, and reduced quality of life (QoL). Traditional Chinese medicine (TCM), especially acupuncture, has shown promise in managing pain. Although a TCM collaborative model of care (TCMCMC) has been studied in cancer, there are no randomized controlled trials investigating TCM in AxSpA. Therefore, we will conduct a pragmatic trial to determine the clinical effectiveness, safety, and cost-effectiveness of TCMCMC for patients with AxSpA. We define TCMCMC as standard TCM history taking and physical examination, acupuncture, and TCM non-pharmacological advice and communications with rheumatologists in addition to usual rheumatologic care. The purpose of this paper is to describe the rationale for and methodology of this trial.Methods/designThis pragmatic randomized controlled trial will recruit 160 patients who are diagnosed with AxSpA and have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs). Simple randomization to usual rheumatologic care or the intervention (TCMCMC) with a 1:1 allocation ratio will be used. Ten 30-min acupuncture sessions will be provided to patients assigned to the TCMCMC arm. All participants will continue to receive usual rheumatologic care. The primary endpoint spinal pain will be evaluated at week 6. Secondary endpoints include clinical, quality of life, and economic outcome measures. Patients will be followed up for up to 52weeks, and adverse events will be documented.DiscussionThis trial may provide evidence regarding the clinical effectiveness, safety, and cost-effectiveness of a TCMCMC for patients with AxSpA.Trial registrationClinicalTrials.gov, NCT03420404. Registered on 14 February 2018.
C1 [Kwan, Yu Heng; Bilger, Marcel; Thumboo, Julian; Ostbye, Truls] Duke NUS Med Sch, Program Hlth Serv & Syst Res, Singapore, Singapore.
   [Fong, Warren; Phang, Jie Kie; Leung, Ying Ying; Lui, Nai Lee; Yeo, Siaw Ing; Ng, Swee Cheng; Fong, Kok Yong; Thumboo, Julian] Singapore Gen Hosp, Dept Rheumatol & Immunol, Acad Bldg,Level 4,20 Coll Rd, Singapore 169856, Singapore.
   [Fong, Warren; Leung, Ying Ying] Duke NUS Med Sch, Singapore, Singapore.
   [Fong, Warren] Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Ang, Xiang Ling; Tan, Hui Chin; Lee, Jia Ven; Sun, Limin; Tan, Choy Tip] Singapore Thong Chai Med Inst, Singapore, Singapore.
   [Tan, Chuen Seng; Tai, Bee Choo] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Huang, Youyi] SingHealth, Internal Med Residency, Singapore, Singapore.
   [Dong, Bao Qiang] Liaoning Univ Tradit Chinese Med, Shenyang, Liaoning, Peoples R China.
   [Koh, Hwee Ling] Natl Univ Singapore, Dept Pharm, Singapore, Singapore.
C3 National University of Singapore; Singapore General Hospital; National University of Singapore; National University of Singapore; National University of Singapore; Liaoning University of Traditional Chinese Medicine; National University of Singapore
RP Thumboo, J (corresponding author), Duke NUS Med Sch, Program Hlth Serv & Syst Res, Singapore, Singapore.; Thumboo, J (corresponding author), Singapore Gen Hosp, Dept Rheumatol & Immunol, Acad Bldg,Level 4,20 Coll Rd, Singapore 169856, Singapore.
EM yuheng@u.duke.nus.edu; julian.thumboo@singhealth.com.sg
FU Singapore's Ministry of Health Traditional Chinese Medicine Research Grant [TCMRG/SGH310301]
CR Asquith M, 2016, CURR OPIN RHEUMATOL, V28, P405, DOI 10.1097/BOR.0000000000000299
   Braun J, 2015, EXPERT REV CLIN IMMU, V11, P935, DOI 10.1586/1744666X.2015.1052795
   Bruce B, 2003, J RHEUMATOL, V30, P167
   Bruce Bonnie, 2003, HEALTH QUAL LIFE OUTCOMES, V1, P20, DOI 10.1186/1477-7525-1-20
   Bullock M L, 1997, J ALTERN COMPLEMENT MED, V3, P31, DOI 10.1089/acm.1997.3.31
   Busija L, 2011, ARTHRIT CARE RES, V63, PS383, DOI 10.1002/acr.20541
   CALIN A, 1994, J RHEUMATOL, V21, P2281
   Camp A, 1998, MED ACUPUNCTURE W SC, V0, P60
   Chen FP, 2007, BMC HEALTH SERV RES, V7, P0, DOI 10.1186/1472-6963-7-26
   Cohen J, 1988, STAT POWER ANAL BEHA, V0, P0, DOI DOI 10.4324/9780203771587
   Cohen JD, 2006, J RHEUMATOL, V33, P79
   Dale J, 1997, COMPLEMENTARY THERAPIES IN MEDICINE, V5, P215, DOI 10.1016/S0965-2299(97)80032-5
   Efthimiou P, 2010, RHEUMATOL INT, V30, P571, DOI 10.1007/s00296-009-1206-y
   Elder WG, 2014, J AM BOARD FAM MED, V27, P846, DOI 10.3122/jabfm.2014.06.140042
   Ernst E, 2010, RHEUMATOLOGY, V49, P1957, DOI 10.1093/rheumatology/keq180
   Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005
   Galloway JB, 2013, ANN RHEUM DIS, V72, P229, DOI 10.1136/annrheumdis-2011-201108
   GARRETT S, 1994, J RHEUMATOL, V21, P2286
   Godwin Marshall, 2003, BMC MED RES METHODOL, V3, P28, DOI 10.1186/1471-2288-3-28
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089
   Johnson KE, 2016, TRIALS, V17, P0, DOI 10.1186/s13063-016-1158-y
   Jones SD, 1996, BRIT J RHEUMATOL, V35, P66
   Kiltz U, 2016, INTERNIST, V57, P1060, DOI 10.1007/s00108-016-0140-9
   Kwan YH, 2018, QUAL LIFE RES, V27, P2321, DOI 10.1007/s11136-018-1900-x
   Kwan YH, 2017, SEMIN ARTHRITIS RHEU, V47, P175, DOI 10.1016/j.semarthrit.2017.04.002
   Kwan YH, 2018, INT J RHEUM DIS, V21, P699, DOI 10.1111/1756-185X.12989
   Kwan Y, 2016, RHEUMATOL INT, V36, P1759, DOI 10.1007/s00296-016-3567-3
   Leung YY, 2017, BMC MUSCULOSKEL DIS, V18, P0, DOI 10.1186/s12891-017-1715-x
   Li JH, 2017, J MED ECON, V20, P91, DOI 10.1080/13696998.2016.1227829
   Liang Fei-fan, 2016, ZHONGGUO GU SHANG, V29, P449
   Lim MK, 2005, COMPLEMENT THER MED, V13, P16, DOI 10.1016/j.ctim.2004.11.002
   Luo N, 2012, MED CARE, V50, P627, DOI 10.1097/MLR.0b013e31824d7471
   MacPherson H, 2006, COMPLEMENT THER MED, V14, P20, DOI 10.1016/j.ctim.2005.07.006
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   MacPherson H, 2012, BMC GASTROENTEROL, V12, P0, DOI 10.1186/1471-230X-12-150
   Meng CF, 2003, RHEUMATOLOGY, V42, P1508, DOI 10.1093/rheumatology/keg405
   Nhan DT, 2016, RHEUM DIS CLIN N AM, V42, P285, DOI 10.1016/j.rdc.2016.01.011
   Phang JK, 2018, COMPLEMENT THER MED, V37, P143, DOI 10.1016/j.ctim.2018.03.003
   Png K, 2018, SEMIN ARTHRITIS RHEU, V48, P274, DOI 10.1016/j.semarthrit.2018.02.016
   Quinzanos I, 2015, CLIN EXP RHEUMATOL, V33, P146
   Ramiro S, 2014, ANN RHEUM DIS, V73, P529, DOI 10.1136/annrheumdis-2013-204575
   Ramonda R, 2016, ARTHRITIS RES THER, V18, P0, DOI 10.1186/s13075-016-0977-2
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233
   Sieper J, 2008, ANN RHEUM DIS, V67, P323, DOI 10.1136/ard.2007.075309
   Sieper J, 2009, ANN RHEUM DIS, V68, P1, DOI 10.1136/ard.2008.104018
   Sieper J, 2013, ANN RHEUM DIS, V72, P815, DOI 10.1136/annrheumdis-2012-201766
   Wee HL, 2004, CLIN THER, V26, P1137, DOI 10.1016/S0149-2918(04)90186-5
   Wong T W, 1995, ASIA PAC J PUBLIC HEALTH, V8, P167
   Zhang JH, 2010, B WORLD HEALTH ORGAN, V88, P915, DOI 10.2471/BLT.10.076737
   Zochling J, 2011, ARTHRIT CARE RES, V63, PS47, DOI 10.1002/acr.20575
   Zwarenstein M, 2008, BMJ-BRIT MED J, V337, P0, DOI 10.1136/bmj.a2390
NR 52
TC 3
Z9 3
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1745-6215
J9 TRIALS
JI Trials
PD JAN 14
PY 2019
VL 20
IS 
BP 
EP 
DI 10.1186/s13063-018-3117-2
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA HH4FD
UT WOS:000455676000001
PM 30642381
DA 2026-01-16
ER

PT J
AU Eskander, JP
   Beakley, BD
   Zhang, S
   Paetzold, J
   Sharma, B
   Kaye, AD
   Sharma, S
AF Eskander, Jonathan P
   Beakley, Burton D
   Zhang, Si
   Paetzold, Jacquelyn
   Sharma, Bharat
   Kaye, Alan D
   Sharma, Sanjay
TI A Multimodal Approach to Pain Management for Patients with Chronic Back Pain:
SO Current pain and headache reports
LA English
DT Journal Article
DE Acupuncture; Cervical; Chronic pain; Cognitive behavioral therapy; Interdisciplinary pain management; Intervention; Interventional; Low back; Multimodal; Nutrition; Pain; Physical therapy; Yoga
AB PURPOSE OF REVIEW: The purpose of this study is to evaluate the effectiveness of  a multimodal approach to treating chronic low back pain. RECENT FINDINGS: Chronic  non-cancer-related back pain is often a frustrating and poorly managed problem  for patients. It poses a significant public health issue worsened by the  widespread use of narcotics. In 2016, the CDC released guidelines with noticeably  more strict recommendations on prescription of narcotics for pain. Veterans at an  interventional pain clinic presenting with chronic back pain refractory to  medical and to surgical care were enrolled in an 8-week interdisciplinary pain  management program. Pain scores were significantly reduced 1 year after  completion of the program. Patients in this study benefitted from lower and  sustained pain scores, a reduction in emergency room, and urgent care clinic  visits, as well as generally high satisfaction with the interdisciplinary  program.
C1 Department of Anesthesiology, Portsmouth Anesthesia Associates, Portsmouth, VA, USA. jeskande@tulane.edu.
   Department of Anesthesiology, Ocshner Health System, New Orleans, LA, USA.
   Department of Anesthesiology, Stamford Health Medical Group, Stamford, CT, USA.
   Department of Anesthesiology, STAR Anesthesia, P.A., San Antonio, TX, USA.
   Department of Anesthesiology, Duke University, Durham, NC, USA.
   Department of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
   Department of Anesthesiology, Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA.
NR 0
TC 0
SN 1534-308
EI 
J9 Curr Pain Headache Rep
PD JUL 10
PY 2019
VL 23
IS 8
BP 54
EP 54
DI 10.1007/s11916-019-0790-0
PG 0
WC Adult; Aged; Chronic Pain; therapy; Cognitive Behavioral Therapy; Combined Modality Therapy; methods; Female; Humans; Low Back Pain; therapy; Male; Middle Aged; Pain Management; methods; Physical Therapy Modalities; Yoga
UT PubMed:31286279
PM 31286279
DA 2019-07-10
ER

PT J
AU Thottungal, A
   Kumar, P
   Bhaskar, A
AF Thottungal, Athmaja
   Kumar, Pranab
   Bhaskar, Arun
TI Interventions for myofascial pain syndrome in cancer pain: recent advances: why, when, where and how
SO CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE
LA English
DT Review
DE cancer pain; myofascial pain syndrome; myofascial trigger points; trigger point injection; ultrasound
ID guided trigger-point; breast-cancer; muscle; management; injection; acupuncture; prevalence; mechanisms; diagnosis; medicine
AB Purpose of review Pain is one of the most feared and most common symptoms of cancer, experienced by 38-85% of patients. Pain in terminally ill cancer patients is a multidimensional experience caused by a diverse array of factors - cancer itself, its treatment or other causes. Studies have shown a high incidence of myofascial pain syndrome (MPS) in patients with cancer and the knowledge of myofascial trigger points (MTrPs) is important to address and manage existing pain, and to prevent the recurrence of pain. This review aims to summarize recent advances in interventions for managing MPS in patients with cancer. Recent findings Database searches were conducted on MEDLINE, CINAHL, and Google Scholar to locate all studies published from inception until April 2019 using the keywords cancer pain, myofascial pain, TrPs with emphasis of any methodological quality that included interventions for MPS. MPS in advanced cancer patients are more commonly observed along with other cancer pains rather than independently with a prevalence of 11.9-48% in those patients diagnosed with cancer of head and neck and breast cancer. Summary Interventional therapies employing ultrasound guided injection of the MTrPs is gaining popularity in the management of MPS in cancer pain and may be a better alternative than the use of opioid analgesics in the multidisciplinary management.
C1 [Thottungal, Athmaja] East Kent Univ Hosp, Dept Anesthesia & Pain Management, Canterbury, Kent, England.
   [Kumar, Pranab] Toronto Western Hosp, Univ Hlth Network, Dept Anesthesia & Pain Management, Toronto, ON, Canada.
   [Bhaskar, Arun] Charing Cross Univ Hosp, Dept Anesthesia & Pain Management, London, England.
C3 University of Toronto; University Health Network Toronto
RP Bhaskar, A (corresponding author), Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Management Ctr, 2nd Floor South,Fulham Palace Rd, London W6 8RF, England.
EM akbhaskar@btinternet.com
CR Amichetti M, 2003, ONCOLOGY-BASEL, V65, P23, DOI 10.1159/000071201
   Baldry PE, 2005, ACUPUNCTURE, V0, P0, DOI 10.1016/B978-044306644-3.50010-3
   Baldry Peter, 2002, ACUPUNCT MED, V20, P2
   Barash IA, 2002, AM J PHYSIOL-REG I, V283, PR958, DOI 10.1152/ajpregu.00185.2002
   BATES MS, 1993, PAIN, V52, P101, DOI 10.1016/0304-3959(93)90120-E
   Borg-Stein Joanne, 2006, PHYS MED REHABIL CLIN N AM, V17, P491, DOI 10.1016/j.pmr.2005.12.003
   Brezinschek HP, 2008, Z RHEUMATOL, V67, P653, DOI 10.1007/s00393-008-0353-y
   Brinks A, 2010, BMC MUSCULOSKEL DIS, V11, P0, DOI 10.1186/1471-2474-11-206
   Bron C, 2012, CURR PAIN HEADACHE R, V16, P439, DOI 10.1007/s11916-012-0289-4
   Bubnov RV, 2013, MED ACUPUNCT, V25, P437, DOI 10.1089/acu.2013.0973
   Cheney FW, 1999, ANESTHESIOLOGY, V91, P552, DOI 10.1097/00000542-199908000-00030
   Chiarotto A, 2016, ARCH PHYS MED REHAB, V97, P316, DOI 10.1016/j.apmr.2015.09.021
   Chim D, 2009, TECH REG ANESTH PAIN, V13, P179
   Cho IT, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000006019
   Criscuolo C M, 2001, CURR PAIN HEADACHE REP, V5, P407, DOI 10.1007/s11916-001-0051-9
   Damous LL, 2014, J OVARIAN RES, V7, P0, DOI 10.1186/1757-2215-7-34
   Domingo T, 2011, CLIN J PAIN, V27, P297, DOI 10.1097/AJP.0b013e3182021612
   Drakonaki EE, 1900, V85, V0, P1435
   Fernández-de-las-Peñas C, 2018, PAIN MED, V19, P142, DOI 10.1093/pm/pnx207
   Fricton J R, 1996, NED TIJDSCHR TANDHEELKD, V103, P249
   Furlan AD, 2005, SPINE, V30, P944, DOI 10.1097/01.brs.0000158941.21571.01
   Gautam M, 2010, NEUROSCIENCE, V170, P893, DOI 10.1016/j.neuroscience.2010.08.003
   Gerwin R D, 2001, CURR PAIN HEADACHE REP, V5, P412, DOI 10.1007/s11916-001-0052-8
   Gerwin RD, 1997, PAIN, V69, P65, DOI 10.1016/S0304-3959(96)03248-4
   Gerwin R, 2018, PAIN MED, V19, P1, DOI 10.1093/pm/pnx219
   Gerwin RD, 2016, SEMIN NEUROL, V36, P469, DOI 10.1055/s-0036-1586262
   Gissel H, 2001, ACTA PHYSIOL SCAND, V171, P327, DOI 10.1046/j.1365-201x.2001.00835.x
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482
   Gulluoglu BM, 2006, INT J FERTIL WOMEN M, V51, P75
   Gunn CC, 1996, THE GUNN APPROACH TO THE TREATMENT OF CHRONIC PAIN: INTRAMUSCULAR STIMULATION FOR MYOFASCIAL PAIN OF RADICULOPATHIC ORIGIN, V2nd, P0
   Hasuo H, 2017, J PALLIAT MED, V20, P1085, DOI 10.1089/jpm.2016.0541
   Hasuo H, 2016, INDIAN J PALLIAT CAR, V22, P80, DOI 10.4103/0973-1075.173956
   Hocking MJL, 2010, J MUSCULOSKELET PAIN, V18, P186, DOI 10.3109/10582452.2010.483964
   Hong CZ, 1996, J FORMOS MED ASSOC, V95, P93
   HONG CZ, 1994, AM J PHYS MED REHAB, V73, P256, DOI 10.1097/00002060-199407000-00006
   Hsieh YL, 2007, AM J PHYS MED REHAB, V86, P397, DOI 10.1097/PHM.0b013e31804a554d
   Kalichman L, 2019, J BODYW MOV THER, V23, P311, DOI 10.1016/j.jbmt.2019.02.011
   Ko EJ, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12615
   Kumbhare D, 2017, REGION ANESTH PAIN M, V42, P407, DOI 10.1097/AAP.0000000000000572
   Kumbhare DA, 2016, AM J PHYS MED REHAB, V95, P72, DOI 10.1097/PHM.0000000000000376
   Lieber RL, 2002, CLIN ORTHOP RELAT R, V0, PPS90, DOI 10.1097/01.blo.0000031310.06353.9f
   Mayoral V, 2013, TECHNIQUES REGIONAL, V17, P150, DOI 10.1053/J.TRAP.2014.01.017
   MELZACK R, 1981, ARCH PHYS MED REHAB, V62, P114
   Morley-Forster Patricia K, 2003, PAIN RES MANAG, V8, P189
   Niraj G, 2011, BRIT J ANAESTH, V107, P474, DOI 10.1093/bja/aer247
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Raphael J, 2010, PAIN MED, V11, P872, DOI 10.1111/j.1526-4637.2010.00841.x
   Rivers WE, 2015, PAIN MED, V16, P1794, DOI 10.1111/pme.12780
   Saxena Anudeep, 2015, J PAIN PALLIAT CARE PHARMACOTHER, V29, P16, DOI 10.3109/15360288.2014.997853
   Sikdar S, 2010, C P IEEE ENG MED BIO, V302, P5305
   Sikdar S, 2009, ARCH PHYS MED REHAB, V90, P1829, DOI 10.1016/j.apmr.2009.04.015
   Simons DG, 1999, TRAVELL & SIMONS MYOFASCIAL PAIN AND DYSFUNCTION: THE TRIGGER POINT MANUAL, V2nd, P0
   SKOOTSKY SA, 1989, WESTERN J MED, V151, P157
   Syrjala KL, 2014, J CLIN ONCOL, V32, P1703, DOI 10.1200/JCO.2013.54.4825
   Thomas K, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0349-4
   Lacomba MT, 2010, CLIN J PAIN, V26, P320, DOI 10.1097/AJP.0b013e3181c4904a
   Tough EA, 2007, CLIN J PAIN, V23, P278, DOI 10.1097/AJP.0b013e31802fda7c
   Townsley P, 2011, ANAESTHESIA, V66, P386, DOI 10.1111/j.1365-2044.2011.06691.x
   Yap PRY, 2015, CURR PHARM DESIGN, V21, P5073, DOI 10.2174/1381612821666150915105738
NR 60
TC 15
Z9 18
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1751-4258
EI 1751-4266
J9 CURR OPIN SUPPORT PA
JI Curr. Opin Support Palliat. Car.
PD SEP 15
PY 2019
VL 13
IS 3
BP 262
EP 269
DI 10.1097/SPC.0000000000000446
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA JV0DK
UT WOS:000502036700018
PM 31348012
DA 2026-01-16
ER

PT J
AU Baeumler, PI
   Conzen, P
   Irnich, D
AF Baeumler, Petra Iris
   Conzen, Peter
   Irnich, Dominik
TI High Temporal Summation of Pain Predicts Immediate Analgesic Effect of Acupuncture in Chronic Pain Patients-A Prospective Cohort Study
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE quantitative sensory testing; wind-up ratio; vibration detection threshold; responder; sensitization
ID german research network; neuropathic pain; pressure pain; wind-up; differentiate subgroups; double-blind; cancer pain; back-pain; electroacupuncture; modulation
AB Objectives: This prospective cohort study explored whether two distinguished sensory parameters predicted acupuncture effects in chronic pain patients; namely high temporal summation of pain (TS) indicating spinal synaptic facilitation as well as a low vibration detection threshold (VDT) indicating a loss of A beta-fiber function. Methods: Pinprick induced TS and VDT were assessed by standardized, validated methods at the most painful body site and a pain free control site in 100 chronic pain patients receiving six acupuncture sessions as part of an interdisciplinary multimodal pain treatment (IMPT). Immediate change in pain intensity after the first acupuncture session (first treatment on the first day of IMPT) was assessed by the verbal rating scale (VRS, 0-100). After 4 weeks of treatment, patients indicated in a questionnaire whether acupuncture had relieved pain immediately and whether it had contributed to overall pain reduction and well-being after IMPT. Results: Logistic regression analysis revealed an association between high TS at the control site and a reduction in pain intensity of at least 30% (VRS) after the first acupuncture (OR [95%-CI] 4.3 [1.6-11.8]). Questionnaire ratings of immediate pain relief after acupuncture were associated with high TS at the control site (OR [95%-CI] 3.8 [1.4-10.2] any pain relief, OR [95%-CI] 5.5 [1.7-17.1] over 50% pain reduction) and at the pain site (OR [95%-CI] 3.2 [1.2-8.9] any pain relief). Appraisals of the contribution of acupuncture to overall pain reduction and well-being after IMPT were not associated with TS. The VDT was not associated with any outcome. Conclusion: This explorative study provides first-time evidence that high TS, especially at a pain free control site, but not VDT, might predict immediate analgesic response to acupuncture in chronic pain patients. Thus, highly centrally sensitized chronic pain patients might respond particularly well to acupuncture.
C1 [Baeumler, Petra Iris; Irnich, Dominik] Univ Hosp Ludwig Maximilians Univ, Multidisciplinary Pain Ctr, Dept Anaesthesiol, Munich, Germany.
   [Conzen, Peter] Univ Hosp Ludwig Maximilians Univ, Dept Anaesthesiol, Munich, Germany.
C3 University of Munich; University of Munich
RP Baeumler, PI (corresponding author), Univ Hosp Ludwig Maximilians Univ, Multidisciplinary Pain Ctr, Dept Anaesthesiol, Munich, Germany.
EM petra.baeumier@med.uni-muenchen.de
CR Altman DG, 1990, PRACTICAL STAT MED R, V0, P0, DOI DOI 10.1002/sim.4780101015
   Unknown -, 2014, R LANG ENV STAT COMP, V2014, P0
   Arendt-Nielsen L, 2015, HANDB EXP PHARMACOL, V227, P79, DOI 10.1007/978-3-662-46450-2_5
   Baeumler PI, 2015, PAIN, V156, P2245, DOI 10.1097/j.pain.0000000000000283
   Cha MH, 2010, NEUROL RES, V32, PS96, DOI 10.1179/016164109X12537002794363
   Clarke RW, 2002, NEUROSCIENCE, V112, P555, DOI 10.1016/S0306-4522(02)00093-3
   Cole SR, 2010, INT J EPIDEMIOL, V39, P417, DOI 10.1093/ije/dyp334
   Cramer H, 2015, COMPLEMENT THER MED, V23, P423, DOI 10.1016/j.ctim.2015.04.009
   Cribbie RA, 2000, EDUC PSYCHOL MEAS, V60, P893, DOI 10.1177/00131640021970970
   Cuignet O, 2015, BURNS, V41, P1298, DOI 10.1016/j.burns.2015.03.002
   Daenen L, 2014, PAIN PRACT, V14, P588, DOI 10.1111/papr.12113
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Edwards RR, 2011, SLEEP MED, V12, P603, DOI 10.1016/j.sleep.2010.09.018
   EIDE PK, 1994, PAIN, V58, P347, DOI 10.1016/0304-3959(94)90129-5
   Eide PK, 2000, EUR J PAIN, V4, P5, DOI 10.1053/eujp.1999.0154
   Eisenberg E, 2010, PAIN, V151, P104, DOI 10.1016/j.pain.2010.06.025
   Farrar JT, 2006, J PAIN SYMPTOM MANAG, V31, P369, DOI 10.1016/j.jpainsymman.2005.08.018
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   FURNHAM A, 1986, PERS INDIV DIFFER, V7, P385, DOI 10.1016/0191-8869(86)90014-0
   Gaskin, 2011, RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, V0, P0
   Geber C, 2008, PAIN, V139, P73, DOI 10.1016/j.pain.2008.03.006
   Geber C, 2011, PAIN, V152, P548, DOI 10.1016/j.pain.2010.11.013
   Gerhardt A, 2016, CLIN J PAIN, V32, P568, DOI 10.1097/AJP.0000000000000300
   Graven-Nielsen T, 2000, PAIN, V85, P483, DOI 10.1016/S0304-3959(99)00308-5
   Gruber S, 2016, STAT MED, V35, P3869, DOI 10.1002/sim.6936
   Harte SE, 2013, MED ACUPUNCT, V25, P154, DOI 10.1089/acu.2013.0965
   Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9
   Hsieh YL, 2014, BIOMED RES INT, V2014, P0, DOI 10.1155/2014/982121
   JANIG W, 1971, J PHYSIOL-LONDON, V214, P29
   Kim HN, 2012, BRAIN RES BULL, V87, P199, DOI 10.1016/j.brainresbull.2011.11.010
   Kong JT, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/187182
   Lang PM, 2010, ANESTH ANALG, V110, P1448, DOI 10.1213/ANE.0b013e3181d3e7ef
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Leite PMS, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/8586746
   Lev R, 2010, CEPHALALGIA, V30, P910, DOI 10.1177/0333102409357249
   Lin JG, 2016, BRAIN RES, V1649, P23, DOI 10.1016/j.brainres.2016.07.007
   List T, 2008, PAIN, V139, P333, DOI 10.1016/j.pain.2008.05.002
   Liu HP, 2017, J PHYSIOL SCI, V67, P197, DOI 10.1007/s12576-016-0456-1
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Maeda Y, 2017, BRAIN, V140, P914, DOI 10.1093/brain/awx015
   Magerl W, 2010, PAIN, V151, P598, DOI 10.1016/j.pain.2010.07.026
   Main CJ, 2008, PAIN MANAGEMENT. PRACTICAL APPLICATIONS OF THE BIOPSYCHOSOCIAL PERSPECTIVE IN CLINICAL AND OCCUPATIONAL SETTINGS, V0, P0
   Manni L, 2011, DIABETOLOGIA, V54, P1900, DOI 10.1007/s00125-011-2117-5
   Melin C, 2013, EUR J NEUROSCI, V37, P417, DOI 10.1111/ejn.12048
   MENDELL LM, 1966, EXP NEUROL, V16, P316, DOI 10.1016/0014-4886(66)90068-9
   Musial F, 2013, FORSCH KOMPLEMENTMED, V20, P219, DOI 10.1159/000353392
   Naugle KM, 2015, BEHAV BRAIN RES, V289, P61, DOI 10.1016/j.bbr.2015.04.014
   Nikolajsen L, 1996, PAIN, V67, P69, DOI 10.1016/0304-3959(96)03080-1
   Olesen SS, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0057963
   Patel CJ, 2014, J EPIDEMIOL COMMUN H, V68, P1096, DOI 10.1136/jech-2014-204195
   Petersen KK, 2017, CLIN J PAIN, V33, P1081, DOI 10.1097/AJP.0000000000000495
   Pfau DB, 2014, PAIN, V155, P1002, DOI 10.1016/j.pain.2014.02.004
   Pud D, 1998, PAIN, V75, P349, DOI 10.1016/S0304-3959(98)00014-1
   Puta C, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0058885
   Rabey M, 2015, PAIN, V156, P1874, DOI 10.1097/j.pain.0000000000000244
   Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041
   Sandkuhler J, 1996, PROG NEUROBIOL, V50, P49
   Staud R, 2001, PAIN, V91, P165, DOI 10.1016/S0304-3959(00)00432-2
   Staud R, 2008, PAIN, V139, P315, DOI 10.1016/j.pain.2008.04.024
   Tian SL, 2008, LIFE SCI, V83, P356, DOI 10.1016/j.lfs.2008.06.027
   Tobbackx Y, 2013, EUR J PAIN, V17, P279, DOI 10.1002/j.1532-2149.2012.00215.x
   Vaegter HB, 2016, PAIN, V157, P1480, DOI 10.1097/j.pain.0000000000000543
   Vickers A J, 2001, BMC MED RES METHODOL, V1, P6, DOI 10.1186/1471-2288-1-6
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478
   Wancura-Kampik I, 2012, SEGMENTAL ANATOMY: THE KEY TO MASTERING ACUPUNCTURE, V0, P0
   Westermann A, 2011, CLIN J PAIN, V27, P782, DOI 10.1097/AJP.0b013e31821d8fce
   Witt CM, 2011, CLIN J PAIN, V27, P550, DOI 10.1097/AJP.0b013e31820dfbf5
   Yarnitsky D, 2015, PAIN, V156, PS24, DOI 10.1097/01.j.pain.0000460343.46847.58
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang RX, 2005, NEUROSCI LETT, V384, P339, DOI 10.1016/j.neulet.2005.05.001
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zheng Z, 2010, EUR J PAIN, V14, P725, DOI 10.1016/j.ejpain.2009.11.006
   Zucker NA, 2017, PAIN MED, V18, P1582, DOI 10.1093/pm/pnx001
NR 80
TC 12
Z9 17
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JUL 11
PY 2019
VL 13
IS 
BP 
EP 
DI 10.3389/fnins.2019.00498
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA II8CZ
UT WOS:000475420300001
PM 31354400
DA 2026-01-16
ER

PT J
AU Gu, SH
   Lang, HB
   Gan, JH
   Zheng, ZW
   Zhao, F
   Tu, Q
AF Gu, Shuhan
   Lang, Hebin
   Gan, Jianhui
   Zheng, Zhiwen
   Zhao, Fang
   Tu, Qing
TI Effect of transcutaneous electrical acupoint stimulation on gastrointestinal function recovery after laparoscopic radical gastrectomy - A randomized controlled trial
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Transcutaneous electrical acupoint stimulation; Laparoscopic radical gastrectomy; Analgesia; Gastrointestinal function recovery; Enhanced recovery after surgery; Randomized controlled trial
ID enhanced recovery; postoperative nausea; acupuncture points; gastric-cancer; surgery; analgesia; electroacupuncture; pathway
AB Introduction: Acupuncture is widely used as perioperative analgesia and promotes postoperative physical recovery. Transcutaneous electrical acupoint stimulation (TEAS) is a acupuncture method that has many advantages. However, there has been little study on the application of TEAS in laparoscopic radical gastrectomy. This is a study exploring the effects of TEAS on gastrointestinal function recovery after laparoscopic radical gastrectomy in order to provide a stimulation model for clinical use. Methods: A total of 120 gastric cancer patients undergoing laparoscopic radical gastrectomy were randomly assigned into the long duration TEAS (L-TEAS) group, or the placebo-control (C-TEAS) group. All patients were routinely anesthetized. For the L-TEAS group TEAS was maintained from 30 min before anesthetic induction to 30 min after the operation, and TEAS was also performed for 30 min at 8 a.m., 1 p.m. and 6 p.m. within 2 d of the operation. But in the C-TEAS group, the output wires of the stimulator were broken. The stimulation sites included bilateral Zusanli (ST 36) and Neiguan (PC 6) acupoints. Postoperatively, the patients received patient-controlled intravenous analgesia (PCIA). The consumption of analgesics as well as the scores of the visual analogue scale (VAS) and Ramsay Sedation Scale (RSS) at 4 h (T1), 8 h (T2), 16 h (T3), 24 h (T4) and 36 h (T5) were observed and recorded after the operation in the 2 groups. The duration of first bowel sounds, flatus and defecation were recorded after the operation. The incidence of postoperative nausea and vomiting (PONV) as well as patient satisfaction was recorded. Results: Compared to the C-TEAS group, the VAS scores at 4 h (2.79 +/- 0.48 vs. 3.41 +/- 0.62), 8 h (2.65 +/- 0.42 vs. 3.17 +/- 0.49), and 24 h (1.98 +/- 0.39 vs. 2.72 +/- 0.73) were significantly decreased in the L-TEAS group (P < 0.05) after the operation. Compared to the C-TEAS group, analgesic consumption at 4 h (10.02 +/- 2.26 vs. 13.38 +/- 2.98), 8 h (20.55 +/- 4.59 vs. 24.63 +/- 3.94) and 36 h (72.64 +/- 9.74 vs. 76.01 +/- 10.43) was significantly decreased in the L-TEAS group (P < 0.05) after the operation. There was a significant difference in the incidence of PONV between the L-TEAS (12%) and C-TEAS (32.2%) groups (P < 0.05). No significant difference was observed with respect to RSS among the 2 groups (P > 0.05). The time intervals from surgery to the first bowel sounds as well as the passage of flatus and defecation were shorter in the L-TEAS group than in the C-TEAS group (19.69 +/- 7.61 h vs. 26.58 +/- 7.43 h, 36.58 +/- 10.75 h vs. 43.56 +/- 9.57 h and 71.48 +/- 20.62 h vs. 77.27 +/- 22.67 h, respectively) (P < 0.05). The rate of moderately satisfaction and above in the L-TEAS (67.3%) group was higher than for that in the C-TEAS group (42.4%), and for very satisfied, the LTEAS (55.2%) group was higher than that in the C-TEAS group (15.3%) (P < 0.05). Conclusions: Preoperative TEAS and sustained TEAS within 2 d of the operation can effectively reduce the early postoperative pain, reduce the early postoperative consumption of analgesics, the total consumption of anesthetics, and the incidence of PONV as well as shorten the duration of first bowel sounds, first flatus and first defecation after the operation, promoting the recovery of gastrointestinal function and improving the patient satisfaction rate.
C1 [Gu, Shuhan; Gan, Jianhui; Zheng, Zhiwen; Zhao, Fang; Tu, Qing] North China Univ Sci & Technol, Tangshan Peoples Hosp, Dept Anesthesiol, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China.
   [Lang, Hebin] North China Univ Sci & Technol, Tangshan Peoples Hosp, Dept Med Oncol, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China.
C3 North China University of Science & Technology; North China University of Science & Technology
RP Gan, JH (corresponding author), North China Univ Sci & Technol, Tangshan Peoples Hosp, Dept Anesthesiol, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China.
EM shuhangu@foxmail.com; 990320812@qq.com; ganjianhui888@126.com; zhiwen456@126.com; fangzhao668@163.com; qingtu1021@126.com
CR Abdikarim I, 2015, WORLD J GASTROENTERO, V21, P13339, DOI 10.3748/wjg.v21.i47.13339
   Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276
   Braga M, 2014, WORLD J SURG, V38, P2960, DOI 10.1007/s00268-014-2653-5
   Chang CS, 2001, DIGESTION, V64, P184, DOI 10.1159/000048860
   Chiu C, 2018, BMC ANESTHESIOL, V18, P0, DOI 10.1186/s12871-018-0505-9
   Ciardulli A, 2018, J MATERN-FETAL NEO M, V31, P1924, DOI 10.1080/14767058.2017.1330883
   Emmiler M, 2008, HEART SURG FORUM, V11, PE300, DOI 10.1532/HSF98.20081083
   Feldheiser A, 2016, ACTA ANAESTHESIOL SC, V0, P0
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Hughes MJ, 2015, BRIT J SURG, V102, P1619, DOI 10.1002/bjs.9949
   Kranke P, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009642.pub2
   Lee CH, 2012, J ACUPUNCT MERIDIAN, V5, P63, DOI 10.1016/j.jams.2012.01.002
   Lee S, 2018, J GASTRIC CANCER, V18, P152
   Lee S, 2013, CHIN J INTEGR MED, V19, P277, DOI 10.1007/s11655-013-1425-7
   Leung WW, 2013, WORLD J GASTROENTERO, V19, P381, DOI 10.3748/wjg.v19.i3.381
   Li JF, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000008036
   Lin XM, 1997, AM J GASTROENTEROL, V92, P1527
   Lu Z, 2015, BRIT J ANAESTH, V115, P183, DOI 10.1093/bja/aev227
   Lundeberg T, 2015, MECH ACUPUNCTURE PAI, V0, P0
   Lv JQ, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-153
   MacPherson H, 2002, J ALTERN COMPLEM MED, V8, P85, DOI 10.1089/107555302753507212
   Noroozinia Heydar, 2013, ACTA MED IRAN, V51, P163
   Park JY, 2018, TOXINS, V10, P0, DOI 10.3390/toxins10040163
   Praveena Seevaunnamtum S, 2016, ANESTHESIOLOGY PAIN, V6, P0, DOI 10.5812/aapm.40106
   Sun R, 2014, EVID-BASED COMPL ALT, V0, P0
   Susan M, 2017, J SURG ONCOL, V116, P0
   Tatic Milanka, 2003, MED PREGL, V56, P431, DOI 10.2298/MPNS0310431T
   Tu Q, 2019, UROLITHIASIS, V47, P279, DOI 10.1007/s00240-018-1056-8
   Wang LH, 2018, WORLD J GASTROENTERO, V24, P1562, DOI 10.3748/wjg.v24.i14.1562
   White PF, 2007, ANESTH ANALG, V104, P1380, DOI 10.1213/01.ane.0000263034.96885.e1
   Xue CCL, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-169
   Yeoh AH, 2016, TURK J MED SCI, V46, P620, DOI 10.3906/sag-1502-56
   Zhang ZD, 2014, ACUPUNCT MED, V32, P223, DOI 10.1136/acupmed-2013-010490
   Zhou DD, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/7341920
NR 34
TC 13
Z9 13
U1 7
U2 72
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD FEB 15
PY 2019
VL 26
IS 
BP 11
EP 17
DI 10.1016/j.eujim.2019.01.001
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA HP9XL
UT WOS:000462046300002
DA 2026-01-16
ER

PT J
AU Badel, T
   Zadravec, D
   Kes, VB
   Smoljan, M
   Lovko, SK
   Zavoreo, I
   Krapac, L
   Milosevic, SA
AF Badel, Tomislav
   Zadravec, Dijana
   Kes, Vanja Basic
   Smoljan, Mia
   Lovko, Sandra Kocijan
   Zavoreo, Iris
   Krapac, Ladislav
   Milosevic, Sandra Anic
TI OROFACIAL PAIN - DIAGNOSTIC AND THERAPEUTIC CHALLENGES
SO ACTA CLINICA CROATICA
LA English
DT Article
DE orofacial pain; temporomandibular joint; anxiety; trigeminal neuralgia
ID temporomandibular-joint
AB The concept of diagnostics and therapy of musculoskeletal and neuropathic diseases of the stomatognathic system, which are the subject of this paper, has been developing for decades. It can be said that in order to avoid misunderstanding, the orofacial pain as a clinical problem, in the narrower sense, involves non-odontogenic and non-malignant causes of orofacial region. In this study, the results of clinical diagnosis of the population of 557 consecutive patients with orofacial pain based on multidisciplinary diagnostics were evaluated. 15.6% of patients have given up on the participation in the study. It has been shown that the patients who dropped out of the study were significantly older (p=0.0411) than those who agreed to participate, but there was no difference in gender ratio (p=0.185) since the proportion of female patients prevailed. In an analysis of 84.4% of patients participating in the study, the elevated anxiety values were established (mean value on STAI 1 was 39.2 and STAI 2 was 41.1) and statistical significance was found in correlation between elevated anxiety and intensity of pain as shown on visual analogue scale on open mouth (p<0.0001). Compared to the age, the statistical significance was for STAI 1 (p=0.0097) but not for STAI 2 (p=0.5599). The most common form of therapy is Michigan stabilization splint: for disc displacement of temporomandibular joint (TMJ) in 38.9% of patients and in combination with physiotherapy in 18.7% of patients; for osteoarthritis of TMJ in 28.4% and in combination with physiotherapy in 26.4% of patients. The treatment with anticonvulsant drugs for trigeminal neuralgia predominates in 54.3% of patients, which is combined with acupuncture in 25.7% of patients and only acupuncture in 17.1% of patients. In this study, a multidisciplinary co-operation in initial diagnostics and differential was designed to develop subspecialist knowledge on orofacial pain.
C1 [Badel, Tomislav] Univ Zagreb, Sch Dent Med, Dept Removable Prosthodont, Zagreb, Croatia.
   [Zadravec, Dijana; Smoljan, Mia] Univ Zagreb, Sestre Milosrdnice Univ Hosp Ctr, Dept Diagnost & Intervent Radiol, Vinogradska Cesta 29, HR-10000 Zagreb, Croatia.
   [Kes, Vanja Basic; Zavoreo, Iris] Univ Zagreb, Sestre Milosrdnice Univ Hosp Ctr, Dept Neurol, Zagreb, Croatia.
   [Lovko, Sandra Kocijan] Psychiat Hosp Sv Ivan, Zagreb, Croatia.
   [Krapac, Ladislav] Acad Med Sci Croatia, Dept Publ Hlth, Zagreb, Croatia.
   [Milosevic, Sandra Anic] Univ Zagreb, Sch Dent Med, Dept Orthodont, Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb, School of Dental Medicine; University of Zagreb; University of Zagreb; University of Zagreb; University of Zagreb, School of Dental Medicine
RP Zadravec, D (corresponding author), Univ Zagreb, Sestre Milosrdnice Univ Hosp Ctr, Dept Diagnost & Intervent Radiol, Vinogradska Cesta 29, HR-10000 Zagreb, Croatia.
EM zadravec@sfzg.hr
CR Alanen P, 2018, J CRANIOMAND FUNC, V10, P103
   BADEL T, 2007, TEMPOROMANDIBULARNI, V0, P0
   Badel T, 2018, J. DENT. PROBL. SOLUT, V5, P029, DOI 10.17352/2394-8418.000060
   Badel T, 2017, ACTA CLIN CROAT, V56, P460, DOI 10.20471/acc.2017.56.03.13
   Badel T, 2014, ACTA CLIN CROAT, V53, P462
   Badel T, 2014, ACTA DERMATOVENER CR, V22, P114
   Badel T, 2013, PERIOD BIOL, V115, P185
   Bag AK, 2014, WORLD J RADIOL, V6, P567, DOI 10.4329/wjr.v6.i8.567
   BRAJKOVIC B, 2002, ACTA STOMATOL CROAT, V36, P213
   Canales GD, 2018, J ORAL REHABIL, V45, P881, DOI 10.1111/joor.12685
   Cesarik M, 2017, ACTA CLIN CROAT, V56, P44, DOI 10.20471/acc.2017.56.01.07
   Hladnik A, 2015, PERIOD BIOL, V117, P195
   Jerolimov V, 2009, MEDICAL SCIENCES, V0, P53
   Karibe H, 2011, CRANIO, V29, P138, DOI 10.1179/crn.2011.022
   Kes VB, 2017, ACTA CLIN CROAT, V56, P157, DOI 10.20471/acc.2017.56.01.21
   Krapac L, 2010, RAD HAZU MED ZNANOST, V34, P97
   Lajnert V, 2009, MEDICINA, V45, P56
   Learreta JA, 2009, CRANIO, V27, P125, DOI 10.1179/crn.2009.019
   Morovic-Vergles J, 2014, MEDIX, V20, P51
   Niemelä K, 2012, J ORAL REHABIL, V39, P799, DOI 10.1111/j.1365-2842.2012.02335.x
   Palla S, 2003, SCHMERZ, V17, P425, DOI 10.1007/s00482-003-0254-6
   Renton Tara, 2019, PRIM DENT J, V7, P71, DOI 10.1177/205016841800700414
   Shiloh AR, 2014, ANXIETY DISORDERS RI, V0, P93
   Sklebar D, 2015, PERIOD BIOL, V117, P231
   Spielberger CD, 2001, PRIRUCNIK UPITNIK AN, V0, P0
   Turp JC, 2017, J CRANIO MAND FUNC, V3, P197
   Turp JC, 2014, J CRANIOMANDIB FUNCT, V6, P231
   Yadav S, 2018, J AM GERIATR SOC, V66, P1213, DOI 10.1111/jgs.15354
NR 28
TC 31
Z9 39
U1 1
U2 22
PU SESTRE MILOSRDNICE UNIV HOSPITAL
PI ZAGREB
PA VINOGRADSKA C 29, ZAGREB, HR-10000, CROATIA
SN 0353-9466
EI 1333-9451
J9 ACTA CLIN CROAT
JI Acta Clin. Croat.
PD JUL 15
PY 2019
VL 58
IS 
BP 82
EP 89
DI 10.20471/acc.2019.58.s1.12
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA IU1PR
UT WOS:000483348700012
PM 31741564
DA 2026-01-16
ER

PT J
AU Lam, WC
   Zhong, L
   Liu, Y
   Shi, N
   Ng, B
   Ziea, E
   Bian, Z
   Lu, A
AF Lam, Wai Ching
   Zhong, Linda
   Liu, Yuqi
   Shi, Nannan
   Ng, Bacon
   Ziea, Eric
   Bian, Zhaoxiang
   Lu, Aiping
TI Hong Kong Chinese Medicine Clinical Practice Guideline for Cancer Palliative
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB It is common for patients with cancers in Hong Kong seeking Chinese Medicine (CM)  therapies as supportive care during cancer treatment and to manage  treatment-related side effects. This article provides clinical practice guideline  (CPG) on the use of CM for specific clinical indications caused by cancer and  during cancer treatment, including pain, constipation, and insomnia, and aims to  guide local licensed CM practitioners and provide beneficial reference for social  medical decision makers and patients. In this manuscript, we summarize the  clinical manifestation, CM pattern classification, and CM intervention including  herbal treatment, acupuncture treatment, regulating, and nursing based on pattern  differentiation.
C1 Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Kowloon 999077, Hong Kong.
   Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Kowloon 999077, Hong Kong.
   China Academy of Chinese Medical Science, Beijing 100700, China.
   China Academy of Chinese Medical Science, Beijing 100700, China.
   Department of Chinese Medicine, Hong Kong Hospital Authority, Kowloon 999077, Hong Kong.
   Department of Chinese Medicine, Hong Kong Hospital Authority, Kowloon 999077, Hong Kong.
   Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Kowloon 999077, Hong Kong.
   Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Kowloon 999077, Hong Kong.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD FEB 26
PY 2019
VL 2019
IS 
BP 1038206
EP 1038206
DI 10.1155/2019/1038206
PG 0
UT PubMed:30805017
PM 30805017
DA 2019-02-26
ER

PT J
AU Menéndez-Aponte, Y Guzmán RM
   Turcott, Chaparro JG
   De, la Piedra Gómez A
   Sandoval, Eslava VM
   Tarditi, Ruiz GC
   Tapia, Garduño IM
   De, la Torre Madrid I
   Figueroa, IG
   Mohar, Betancourt A
   Arrieta, O
AF Menéndez-Aponte Y Guzmán, Raquel María
   Turcott Chaparro, Jenny Georgina
   De la Piedra Gómez, Amanda
   Sandoval Eslava, Victoria Margarita
   Tarditi Ruiz, Gina Carolina
   Tapia Garduño, Ilse Merari
   De la Torre Madrid, Irma
   Figueroa, Irma Gallegos
   Mohar Betancourt, Alejandro
   Arrieta, Oscar
TI Effect of complementary Integrative Oncology on anxiety, depression and quality
SO Complementary therapies in clinical practice
LA English
DT Journal Article
DE Acupuncture; Cognitive behavior therapy; Integrative oncology; Lung cancer; Mindfulness; Thoracic cancer
AB PURPOSE: Thoracic-cancer (TC) patients have an extensive toll taken in terms of  health-related quality of life (HRQL). Integrative Oncology (IO) is recognized as  a valid complement to any Standard-Therapy treatment to improve outcomes in TC  patients. The objective of this pilot-study was to evaluate the effect of adding  IO (acupuncture, Cognitive-Behavior Therapy and mindfulness) in terms of  depression, anxiety and HRQL. METHODS: TC patients who attended the Thoracic  Oncology-Unit from July to September 2018 were invited to participate. A total of  16 patients were included in the study, 8 patients were required to attend 5  weekly sessions of IO and 8 patients were invited as controls. Anxiety,  depression and HRQL were measured at baseline and after completing 5 sessions of  IO or 5 weeks, using the HADS scale and the QLQ-C30 scale. RESULTS: A total of 8  patients in the IO group attended the 5 sessions and 8 patients were followed as  controls. Compliance with the therapies was high, none of the patients dropped  out from the study. A tendency for improvement in anxiety, fatigue, pain and  dyspnea was observed in patients attending IO, though not statistically  significant likely due to sample size. CONCLUSIONS: IO therapies are well  accepted among TC patients. Larger studies are necessary with robust sample sizes  to improve conclusions regarding outcome improvements.
C1 Integrative Oncology Center (CAAI), National Cancer Institute (INCan), Mexico. San Fernando, Num 22, sección 16, Tlalpan, CP, 14080, Ciudad de México, Mexico.
   Thoracic Oncology Unit and Laboratory of Personalized Medicine, National Cancer Institute (INCan), Mexico. San Fernando Num 22, sección 16, Tlalpan, CP, 14080,Ciudad de México, Mexico. 
   Integrative Oncology Center (CAAI), National Cancer Institute (INCan), Mexico. San Fernando, Num 22, sección 16, Tlalpan, CP, 14080, Ciudad de México, Mexico.
   Integrative Oncology Center (CAAI), National Cancer Institute (INCan), Mexico. San Fernando, Num 22, sección 16, Tlalpan, CP, 14080, Ciudad de México, Mexico.
   Integrative Oncology Center (CAAI), National Cancer Institute (INCan), Mexico. San Fernando, Num 22, sección 16, Tlalpan, CP, 14080, Ciudad de México, Mexico.
   Integrative Oncology Center (CAAI), National Cancer Institute (INCan), Mexico. San Fernando, Num 22, sección 16, Tlalpan, CP, 14080, Ciudad de México, Mexico.
   Integrative Oncology Center (CAAI), National Cancer Institute (INCan), Mexico. San Fernando, Num 22, sección 16, Tlalpan, CP, 14080, Ciudad de México, Mexico.
   Integrative Oncology Center (CAAI), National Cancer Institute (INCan), Mexico. San Fernando, Num 22, sección 16, Tlalpan, CP, 14080, Ciudad de México, Mexico.
   Integrative Oncology Center (CAAI), National Cancer Institute (INCan), Mexico. San Fernando, Num 22, sección 16, Tlalpan, CP, 14080, Ciudad de México, Mexico;Thoracic Oncology Unit and Laboratory of Personalized Medicine, National CancerInstitute (INCan), Mexico. San Fernando Num 22, sección 16, Tlalpan, CP, 14080,Ciudad de México, Mexico. 
   Thoracic Oncology Unit and Laboratory of Personalized Medicine, National Cancer Institute (INCan), Mexico. San Fernando Num 22, sección 16, Tlalpan, CP, 14080,Ciudad de México, Mexico.
EM ogar@unam.mx
NR 0
TC 0
SN 1873-694
EI 
J9 Complement Ther Clin Pract
PD AUG 7
PY 2019
VL 36
IS 
BP 56
EP 63
DI 10.1016/j.ctcp.2019.05.003
PG 7
WC Anxiety; therapy; Depression; therapy; Humans; Integrative Oncology; Pilot Projects; Quality of Life; psychology; Thoracic Neoplasms; psychology
UT PubMed:31383444
PM 31383444
DA 2019-08-07
ER

PT J
AU Lux, S
   Lobos, N
   Lespay-Rebolledo, C
   Salas-Huenuleo, E
   Kogan, MJ
   Flores, C
   Pinto, M
   Hernandez, A
   Pelissier, T
   Constandil, L
AF Lux, Sebastian
   Lobos, Nicolas
   Lespay-Rebolledo, Carolyne
   Salas-Huenuleo, Edison
   Kogan, Marcelo J.
   Flores, Christian
   Pinto, Mauricio
   Hernandez, Alejandro
   Pelissier, Teresa
   Constandil, Luis
TI The antinociceptive effect of resveratrol in bone cancer pain is inhibited by the Silent Information Regulator 1 inhibitor selisistat
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE cancer pain; mice; resveratrol; selisistat; Silent Information Regulator 1
ID suppresses neuroinflammation; skeletal destruction; neuropathic pain; murine model; spinal-cord; hyperalgesia; activation; management; tumor; reorganization
AB Objectives To study the antinociceptive effect of single and repeated doses of resveratrol in a bone cancer pain model, and whether this effect is prevented by the Silent Information Regulator 1 (SIRT1) inhibitor selisistat. Methods The femoral intercondylar bone of BALB/c mice was injected with 1 000 000 BJ3Z cancer cells. Bone resorption and tumour mass growth (measured by in vivo X-ray and fluorescence imaging), as well as mechanical nociceptive thresholds (von Frey device) and dynamic functionality (rotarod machine), were evaluated during the following 4 weeks. Acute resveratrol (100 mg/kg i.p.) and/or selisistat (10 mg/kg s.c.) were administered on day 14. Chronic resveratrol (100 mg/kg i.p., daily) and/or selisistat (0.5 mu g/h s.c., Alzet pump) were administered between days 14 and 20. Key findings Tumour growth gradually incremented until day 31, while mechanical hyperalgesia started on day 3 after cancer cell injection. Acute resveratrol increased the mechanical threshold of pain (peaking at 1.5 h), while the dynamic functionality decreased. Chronic resveratrol produced a sustained antinociceptive effect on mechanical hyperalgesia and improved the loss of dynamic functionality induced by the bone cancer tumour. Selisistat prevented all the effects of resveratrol. Conclusions Acute and chronic resveratrol induces antinociceptive effect in the model of metastatic osseous oncological pain, an effect that would be mediated by SIRT1 molecular signalling.
C1 [Lux, Sebastian; Lobos, Nicolas; Flores, Christian; Hernandez, Alejandro; Pelissier, Teresa; Constandil, Luis] Univ Santiago Chile, Fac Chem & Biol, Dept Biol, Lab Neurobiol, Santiago 9170022, Chile.
   [Lespay-Rebolledo, Carolyne; Pelissier, Teresa] Univ Chile, Program Mol & Clin Pharmacol, Fac Med, Inst Biomed Sci, Santiago, Chile.
   [Salas-Huenuleo, Edison; Kogan, Marcelo J.] Univ Chile, Fac Chem & Pharmaceut Sci, Dept Pharmacol & Toxicol Chem, Santiago, Chile.
   [Salas-Huenuleo, Edison; Kogan, Marcelo J.] Univ Santiago Chile, Fac Chem & Biol, Adv Ctr Chron Dis ACCDiS, Santiago, Chile.
   [Pinto, Mauricio] Univ Santiago Chile, Fac Chem & Biol, Dept Biol, Lab Immunol Reprod, Santiago, Chile.
   [Constandil, Luis] Ctr Dev Nanosci & Nanotechnol CEDENNA, Santiago, Chile.
C3 Universidad de Santiago de Chile; Universidad de Chile; Universidad de Chile; Universidad de Santiago de Chile; Universidad de Santiago de Chile
RP Constandil, L (corresponding author), Univ Santiago Chile, Fac Chem & Biol, Dept Biol, Lab Neurobiol, Santiago 9170022, Chile.
EM luis.constandil@usach.cl
FU Centers of Excellence with Basal/Conicyt financing, CEDENNA [FB0807]; Fondecyt [1181622]; Fondap [15130011]; Conicyt [21140171]
CR Unknown -, 1986, CANC PAIN REL, V0, P0
   Burton MD, 2017, NEUROSCIENCE, V359, P119, DOI 10.1016/j.neuroscience.2017.07.020
   Cain DM, 2001, PAIN MED, V2, P15, DOI 10.1046/j.1526-4637.2001.002001015.x
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Carbone L, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0155001
   Cheng W, 2016, PHARMACOGN MAG, V12, PS201, DOI 10.4103/0973-1296.182167
   Cheng W, 2014, FUND CLIN PHARMACOL, V28, P661, DOI 10.1111/fcp.12084
   Christo PJ, 2008, ANN NY ACAD SCI, V1138, P278, DOI 10.1196/annals.1414.033
   Colvin L, 2008, EUR J CANCER, V44, P1083, DOI 10.1016/j.ejca.2008.03.001
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gentilli M, 2001, LIFE SCI, V68, P1317, DOI 10.1016/S0024-3205(00)01018-3
   Gescher A, 2013, ANN NY ACAD SCI, V1290, P12, DOI 10.1111/nyas.12205
   Ghilardi JR, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-87
   Gui YL, 2015, EUR J PHARMACOL, V769, P234, DOI 10.1016/j.ejphar.2015.11.023
   Halvorson KG, 2008, J PAIN SYMPTOM MANAG, V36, P289, DOI 10.1016/j.jpainsymman.2007.10.005
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870
   Kulkarni SS, 2015, BBA-MOL BASIS DIS, V1852, P1114, DOI 10.1016/j.bbadis.2014.10.005
   Kumar A, 2007, LIFE SCI, V80, P1236, DOI 10.1016/j.lfs.2006.12.036
   Lee BH, 2011, BIOL PHARM BULL, V34, P523, DOI 10.1248/bpb.34.523
   Lucchesi M, 2017, CRIT REV ONCOL HEMAT, V119, P66, DOI 10.1016/j.critrevonc.2017.08.005
   Mantyh P, 2013, PAIN, V154, PS54, DOI 10.1016/j.pain.2013.07.044
   Mantyh PW, 2014, CURR OPIN SUPPORT PA, V8, P83, DOI 10.1097/SPC.0000000000000048
   Melemedjian OK, 2015, PROG MOL BIOL TRANSL, V131, P185, DOI 10.1016/bs.pmbts.2014.11.006
   National Research Council, 2011, GUIDE CARE USE LAB A, V0, P0
   Nencini S, 2016, FRONT PHYSIOL, V7, P0, DOI 10.3389/fphys.2016.00157
   Pham-Marcou TA, 2008, PAIN, V140, P274, DOI 10.1016/j.pain.2008.08.010
   Pinto MP, 2010, CANCER RES, V70, P2655, DOI 10.1158/0008-5472.CAN-09-4373
   Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19-24-10886.1999
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Shakibaei M, 2008, BIOCHEM PHARMACOL, V76, P1426, DOI 10.1016/j.bcp.2008.05.029
   Sharma Sameer, 2006, INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, V44, P566
   Sinclair DA, 2014, ANNU REV PHARMACOL, V54, P363, DOI 10.1146/annurev-pharmtox-010611-134657
   Singh AK, 2018, INFLAMM RES, V67, P633, DOI 10.1007/s00011-018-1156-5
   Singh AK, 2017, INFLAMM RES, V66, P911, DOI 10.1007/s00011-017-1072-0
   Singh CK, 2013, ANN NY ACAD SCI, V1290, P113, DOI 10.1111/nyas.12160
   Song HY, 2015, ANESTHESIOLOGY, V123, P1170, DOI 10.1097/ALN.0000000000000856
   Tao L, 2016, INT IMMUNOPHARMACOL, V34, P165, DOI 10.1016/j.intimp.2016.02.033
   Tillu DV, 2012, MOL PAIN, V8, P0, DOI 10.1186/1744-8069-8-5
   Torres-López JE, 2002, LIFE SCI, V70, P1669, DOI 10.1016/S0024-3205(02)01491-1
   Tsai RY, 2012, ANESTH ANALG, V115, P944, DOI 10.1213/ANE.0b013e31825da0fb
   Uhelski ML, 2013, NEUROSCIENCE, V247, P84, DOI 10.1016/j.neuroscience.2013.05.003
   Ungard RG, 2014, PAIN, V155, P28, DOI 10.1016/j.pain.2013.08.030
   Wang LL, 2016, MOL MED REP, V13, P4051, DOI 10.3892/mmr.2016.5027
   Wu B, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917707667
   Yan P, 2017, IRAN J BASIC MED SCI, V20, P1029, DOI 10.22038/IJBMS.2017.9272
   Yang YJ, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0550-6
   Yin Q, 2013, REGION ANESTH PAIN M, V38, P93, DOI 10.1097/AAP.0b013e3182795b23
   Yuasa T, 2012, ONCOTARGETS THER, V5, P221, DOI 10.2147/OTT.S30578
   Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022
   Zhao HS, 2017, NEUROSCIENCE, V348, P241, DOI 10.1016/j.neuroscience.2017.02.027
   Zhao X, 2014, NEUROPHARMACOLOGY, V85, P131, DOI 10.1016/j.neuropharm.2014.04.021
NR 54
TC 13
Z9 14
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD MAY 15
PY 2019
VL 71
IS 5
BP 816
EP 825
DI 10.1111/jphp.13064
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA HU1EL
UT WOS:000465015000010
PM 30592048
DA 2026-01-16
ER

PT J
AU Lee, SM
   Choi, HC
   Hyun, MK
AF Lee, Seong Min
   Choi, Ho Cheol
   Hyun, Min Kyung
TI An Overview of Systematic Reviews: Complementary Therapies for Cancer Patients
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE Complementary therapies; cancer; Assessing the Methodological Quality of Systematic Reviews 2; AMSTAR2
ID quality-of-life; traditional chinese medicine; compound kushen injection; breast-cancer; alternative medicine; herbal medicine; tai-chi; colorectal-cancer; adjunctive therapy; massage therapy
AB Introduction: This article critically examines the systematic reviews (SR) and meta-analysis (MA) of complementary therapies for cancer patients to appraise the evidence level, and offers suggestions for future research and practice. Methods: The Cochrane Library and MEDLINE were searched from their inception to January 2018, to identify SR and MA of complementary therapies available for cancer patients. Final selected SR and MA were methodologically evaluated for their quality by applying the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR2) instrument. Data extraction and risk of quality assessments were performed by 2 independent reviewers. Results: A total of 104 studies were included in the analysis. The majority of the individual clinical trials included in the SR and MA were performed in China (48%) and the United States (26.9%). Breast cancer was the most studied cancer type (25%), and acupuncture was the most studied intervention (21%). Side effects of cancer such as pain, depression, and fatigue were effectively managed with complementary therapies. The methodologically problematic items included not listing the excluded studies and lack of protocol or protocol registration. Conclusions: With increasing interest in research, complementary therapies appear to be beneficial in reducing side effects and raising the quality of life of cancer patients. Complementary therapies have generally been studied for all cancers, with acupuncture being the most researched, regardless of the cancer type. Since AMSTAR2 is a stricter assessment tool than before, future studies need to consider the risk of methodological bias with caution and discuss appropriate overall quality assessment tools.
C1 [Lee, Seong Min; Choi, Ho Cheol] Dongguk Univ, Coll Korean Med, Gyeongju, South Korea.
   [Hyun, Min Kyung] Dongguk Univ, Dept Prevent Med, Coll Korean Med, Gyeongju, South Korea.
C3 Dongguk University; Dongguk University
RP Hyun, MK (corresponding author), Dongguk Univ, Coll Korean Med, Dept Prevent Med, 123 Dongdae Ro, Gyeongju Si 38066, Gyeongsanbuk Do, South Korea.
EM mk3three@dongguk.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (Ministry of Science and ICT) [2016R1C1B3006806]
CR Archer S, 2015, PSYCHO-ONCOLOGY, V24, P1, DOI 10.1002/pon.3607
   Arthur K, 2012, INTEGR CANCER THER, V11, P232, DOI 10.1177/1534735411433832
   Bao YJ, 2014, SUPPORT CARE CANCER, V22, P825, DOI 10.1007/s00520-013-2063-5
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Bergenthal N, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009075.pub2
   Bradt J, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911.pub3
   Buckner CA, 2018, CURR ONCOL, V25, PE275, DOI 10.3747/co.25.3884
   Buffart LM, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-559
   Campbell CL, 2012, PATIENT EDUC COUNS, V89, P15, DOI 10.1016/j.pec.2012.06.019
   Cao HJ, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0160253
   Carayol M, 2015, PSYCHO-ONCOLOGY, V24, P737, DOI 10.1002/pon.3727
   Chan CLW, 2012, SUPPORT CARE CANCER, V20, P1121, DOI 10.1007/s00520-011-1378-3
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Chen MH, 2014, PHYTOTHER RES, V28, P976, DOI 10.1002/ptr.5092
   Chen X, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004520.pub7
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Choi TY, 2015, SUPPORT CARE CANCER, V23, P1819, DOI 10.1007/s00520-014-2530-7
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chung VCH, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002793
   Cramer H, 2012, CURR ONCOL, V19, PE343, DOI 10.3747/co.19.1016
   Cramer H, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010802.pub2
   Cramer H, 2015, INTEGR CANCER THER, V14, P5, DOI 10.1177/1534735414550035
   Cramer H, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-412
   Ernst E, 2003, INT J CANCER, V107, P262, DOI 10.1002/ijc.11386
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Ernst E, 2006, BREAST J, V12, P526, DOI 10.1111/j.1524-4741.2006.00340.x
   Ezzo J, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003475.pub2
   Felbel S, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010146.pub2
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Harder H, 2012, SUPPORT CARE CANCER, V20, P3055, DOI 10.1007/s00520-012-1611-8
   He WB, 2019, COMPLEMENT THER MED, V42, P407, DOI 10.1016/j.ctim.2018.12.020
   Hulett JM, 2016, INTEGR CANCER THER, V15, P405, DOI 10.1177/1534735416636222
   Kassab S, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004845.pub2
   Kim JI, 2010, INTEGR CANCER THER, V9, P326, DOI 10.1177/1534735410387423
   Kim KH, 2016, ACUPUNCT MED, V34, P248, DOI 10.1136/acupmed-2015-010941
   Kim W, 2015, COMPLEMENT THER MED, V23, P626, DOI 10.1016/j.ctim.2015.03.011
   Kim W, 2015, INTEGR CANCER THER, V14, P212, DOI 10.1177/1534735415572881
   Klein PJ, 2016, SUPPORT CARE CANCER, V24, P3209, DOI 10.1007/s00520-016-3201-7
   Koithan Mary, 2009, J NURSE PRACT, V5, P18
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee JW, 2015, COMPLEMENT THER MED, V23, P265, DOI 10.1016/j.ctim.2015.02.003
   Lee MS, 2007, ACTA ONCOL, V46, P717, DOI 10.1080/0284160701261584
   Lee MS, 2007, SUPPORT CARE CANCER, V15, P597, DOI 10.1007/s00520-007-0221-3
   Lee MS, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-130
   Lee MS, 2010, BREAST CANCER RES TR, V120, P309, DOI 10.1007/s10549-010-0741-2
   Lee PLT, 2016, COMPLEMENT THER MED, V27, P87, DOI 10.1016/j.ctim.2016.06.003
   Lee S, 2014, SUPPORT CARE CANCER, V22, P1429, DOI 10.1007/s00520-014-2161-z
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Mansky PJ, 2006, CANCER J, V12, P425, DOI 10.1097/00130404-200609000-00011
   McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392
   McCulloch M, 2016, INTEGR CANCER THER, V15, P285, DOI 10.1177/1534735416638738
   Milazzo S, 2006, EUR J CANCER, V42, P282, DOI 10.1016/j.ejca.2005.09.025
   Nie Yan-li, 2012, J EVID BASED MED, V5, P216, DOI 10.1111/jebm.12001
   Oh B, 2012, INTEGR CANCER THER, V11, P101, DOI 10.1177/1534735411413268
   Oh PJ, 2014, ONCOL NURS FORUM, V41, PE290, DOI 10.1188/14.ONF.E290-E301
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pan YQ, 2014, INT J CLIN ONCOL, V19, P829, DOI 10.1007/s10147-013-0635-5
   Pan YQ, 2017, ASIA-PAC J CLIN ONCO, V13, PE79, DOI 10.1111/ajco.12329
   Pearce A, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0184360
   Posadzki P, 2013, CLIN MED, V13, P126, DOI 10.7861/clinmedicine.13-2-126
   Puetz TW, 2013, JAMA INTERN MED, V173, P960, DOI 10.1001/jamainternmed.2013.836
   Roffe L, 2005, PSYCHO-ONCOLOGY, V14, P607, DOI 10.1002/pon.889
   Rossi E, 2015, SUPPORT CARE CANCER, V23, P1795, DOI 10.1007/s00520-014-2517-4
   Salhofer I, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011157.pub2
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Shin ES, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009873.pub3
   Shneerson C, 2013, COMPLEMENT THER MED, V21, P417, DOI 10.1016/j.ctim.2013.05.003
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Sun QZ, 2012, AFR J TRADIT COMPLEM, V9, P178, DOI 10.4314/ajtcam.v9i2.1
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Tao WW, 2015, ONCOTARGET, V6, P39725, DOI 10.18632/oncotarget.5388
   van Die MD, 2016, BJU INT, V117, P17, DOI 10.1111/bju.13361
   Walsh D, 2000, SUPPORT CARE CANCER, V8, P175, DOI 10.1007/s005200050281
   Wang SS, 2016, J CANCER RES THER, V12, P1298, DOI 10.4103/0973-1482.199538
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wu P, 2009, J EXP CLIN CANC RES, V28, P0, DOI 10.1186/1756-9966-28-112
   Xu M, 2009, J ALTERN COMPLEM MED, V15, P1347, DOI 10.1089/acm.2009.0202
   Yan JH, 2014, ASIAN PAC J CANCER P, V15, P3715, DOI 10.7314/APJCP.2014.15.8.3715
   Yan XY, 2016, SUPPORT CARE CANCER, V24, P11, DOI 10.1007/s00520-015-2737-2
   Yang S, 2012, CHIN J INTEGR MED, V18, P862, DOI 10.1007/s11655-012-1111-1
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
   Zeng YC, 2014, COMPLEMENT THER MED, V22, P173, DOI 10.1016/j.ctim.2013.11.010
   Zhang FR, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/8791538
   Zhang J, 2012, J ALTERN COMPLEM MED, V18, P994, DOI 10.1089/acm.2011.0514
   Zhang JM, 2012, SUPPORT CARE CANCER, V20, P3043, DOI 10.1007/s00520-012-1606-5
   Zhang M, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004921.pub2
   Zhong LLD, 2012, COMPLEMENT THER MED, V20, P240, DOI 10.1016/j.ctim.2012.02.004
NR 93
TC 35
Z9 41
U1 1
U2 21
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD DEC 15
PY 2019
VL 18
IS 
BP 
EP 
DI 10.1177/1534735419890029
PG 11
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA JY9HK
UT WOS:000504717000001
PM 31876212
DA 2026-01-16
ER

PT J
AU Sasaki, Y
   Cheon, C
   Motoo, Y
   Jang, S
   Park, S
   Ko, SG
   Jang, BH
   Hwang, DS
AF Sasaki, Yui
   Cheon, Chunhoo
   Motoo, Yoshiharu
   Jang, Soobin
   Park, Sunju
   Ko, Seong-Gyu
   Jang, Bo-Hyoung
   Hwang, Deok-Sang
TI [Complementary and Alternative Medicine for Breast Cancer Patients: An Overview
SO Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
LA jpn
DT Journal Article
DE breast cancer; complementary and alternative medicine; overview; systematic review
AB The application of systematic review (SR) has been increased rapidly in the field  of cancer treatment. Complementary and alternative medicine (CAM) for cancer is  no exception. The aim of this review is to evaluate and summarize systematic  reviews on the CAM use in breast cancer patients. Search sources were Centre for  Reviews and Dissemination (CRD), Cochrane Database of Systematic Reviews (CDSR),  and PubMed. In addition, we assessed the quality of SR with the Assessing the  Methodological Quality of Systematic Reviews (AMSTAR). This review did not  consider control groups and outcomes. Thirty-four SRs met a set of criteria.  According to interventions, there were twenty SRs which included yoga,  acupuncture, and herbal medicines. Meta-analysis of 19 out of 34 reviews showed  the followings: (1) acupuncture had a beneficial effect on the frequency of hot  flushes, (2) yoga had a beneficial effect on depression and health-related QOL,  (3) mindfulness-based stress reduction (MBSR) had a beneficial effect on anxiety  and depression, (4) combination of herbal medicine and chemotherapy  synergistically improved clinical outcomes, (5) acupuncture did not show  significant effect on the severity of hot flushes and cancer-related pain, (6)  yoga was unable to be confirmed as having an effect on cancer-related pain and  physical well-being. Given the results of AMSTAR, 9 out of 34 reviews were of  high quality and 3 reviews were deemed to be of low quality. In conclusion, since  most SRs were at moderate or high quality levels, CAM could be helpful for  treating specific symptoms related to breast cancer.
C1 Department of Applied Korean Medicine, Graduate School, Kyung Hee University.
   Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University.
   Department of Medical Oncology, Kanazawa Medical University.
   Clinical Medicine Division, Korea Institute of Oriental Medicine.
   Department of Preventive Medicine, College of Korean Medicine, Daejeon University.
   Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University.
   Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University.
   Department of Korean Gynecology, College of Korean Medicine, Kyung Hee University.
NR 0
TC 0
SN 1347-523
EI 
J9 Yakugaku Zasshi
PD JUL 2
PY 2019
VL 139
IS 7
BP 1027
EP 1046
DI 10.1248/yakushi.18-00215
PG 19
WC Acupuncture Therapy; Anxiety; Breast Neoplasms; psychology; Complementary Therapies; Databases, Bibliographic; Depression; Female; Herbal Medicine; Humans; Mindfulness; Palliative Care; Quality of Life; Yoga
UT PubMed:31257250
PM 31257250
DA 2019-07-02
ER

PT J
AU Bossi, P
   Ghiani, M
   Argenone, A
   Depenni, R
AF Bossi, Paolo
   Ghiani, Massimo
   Argenone, Angela
   Depenni, Roberta
TI Is pain part of a systemic syndrome in head and neck cancer?
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Review
DE Head and neck cancer; Multidisciplinary approach; Opioids; Pain; Pain management
AB Head and neck cancers (HNC) represent 5% of all malignancies worldwide with about  180,000 cancer deaths per year. Patients with HNC are characterized by a systemic  inflammatory state, generally associated with worse outcomes. Treatment-related  toxicity is common among HNC patients and causes systemic consequences such as  fatigue or cognitive dysfunction. The therapeutic treatments of HNC involve the  release in circulation of inflammatory systemic mediators, whose effects trigger  a vicious circle that may lead to functional and behavioral alterations. The  areas of the head and neck are highly sensitive to pain. Literature data confirm  that in HNC patients, pain is one of the most distressing symptoms across all the  phases of treatment. Pain is associated with worse general conditions,  depression, fatigue, impaired cognitive functions, and lower survival rate. The  treatment of advanced HNC cases is multimodal and requires a multidisciplinary  psycho-socio-pharmacological approach mediated by a team of experts. The  pharmacological approach in management of HNC patients with pain is fundamental  and involves the use of opioids, NSAIDs, steroids, or other drugs. Opioids in  pain management therapy in patients with HNC could allow the pain level to be  adequately monitored, thus improving quality of life. The integration of opioid  and non-opioid therapy as well as non-pharmacological interventions is essential  for the rehabilitation of physical, social, and psychological functions and to  achieve pain control in patients with HNC. Opioid treatment is the mainstay for  pain control, being used both for background and breakthrough cancer pain (BTcP)  episodes. Fentanyl, easily absorbed and generally well tolerated, appears to be a  possible choice due to its versatility. Non-pharmacological interventions, such  as tailored yoga, physical exercise, and acupuncture, may have a role in pain  management in patients with HNC.
C1 Medical Oncology, ASST Spedali Civili Brescia, Brescia, Italy. paolo.bossi@unibs.it.
   Department of Medical and Surgical Specialties, Radiological Sciences and Public 
   Oncology Department, A. Businco Hospital, Cagliari, Italy.
   Radiation Oncology Department, Istituto Nazionale Tumori-IRCCS-G. Pascale Foundation, Naples, Italy.
   Oncology and Haematology Department, University Hospital of Modena and Reggio Emilia, Modena, Italy.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD NOV 13
PY 2019
VL 28
IS 2
BP 451
EP 459
DI 10.1007/s00520-019-05147-8
PG 8
WC Analgesics, Opioid; administration & dosage; Breakthrough Pain; drug therapy; Cancer Pain; drug therapy; Depression; Exercise; Fatigue; chemically induced; Fentanyl; administration & dosage; Head and Neck Neoplasms; pathology; Humans; Pain Management; methods; Quality of Life; psychology
UT PubMed:31713692
PM 31713692
DA 2019-11-13
ER

PT J
AU Tam, KW
   Chen, L
   Lin, CC
   Huang, TW
   Kuan, YC
   Huang, YH
   Chen, HC
   Kao, CY
   Su, CM
AF Tam, Ka-Wai
   Chen, Lawrence
   Lin, Chao-Chun
   Huang, Tsai-Wei
   Kuan, Yi-Chun
   Huang, Yao-Hsien
   Chen, Hung-Chou
   Kao, Chun-Yu
   Su, Chih-Ming
TI Reply to correspondence concerning "Acupuncture on aromatase inhibitor-induced
SO Breast (Edinburgh, Scotland)
LA English
DT Letter
C1 Division of General Surgery, Department of General Surgery, Shuang Ho Hospital, Taipei Medical University, Taiwan
   Center for Evidence-Based Health Care, ShuangHo Hospital, Taipei Medical University, Taiwan. 
   Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, Taiwan.
   Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, Taiwan.
   School of Nursing, College of Nursing, Taipei Medical University, Taiwan.
   Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, Taiwan
   Department of Neurology, Shuang Ho Hospital, Taipei MedicalUniversity, Taiwan.
   Department of Neurology, Shuang Ho Hospital, Taipei Medical University, Taiwan.
   Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, Taiwan
   Department of Physical Medicine and Rehabilitation, Shuang HoHospital, Taipei Medical University, Taiwan.
   Division of General Surgery, Department of General Surgery, Shuang Ho Hospital, Taipei Medical University, Taiwan.
   Division of General Surgery, Department of General Surgery, Shuang Ho Hospital, Taipei Medical University, Taiwan.
EM elvintam@h.tmu.edu.tw
NR 0
TC 0
SN 1532-308
EI 
J9 Breast
PD MAR 13
PY 2019
VL 45
IS 
BP 119
EP 120
DI 10.1016/j.breast.2019.02.005
PG 1
WC Acupuncture Therapy; Aromatase; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Humans
UT PubMed:30857771
PM 30857771
DA 2019-03-13
ER

PT J
AU Ogawa-Ochiai, K
   Yoshimura, K
   Takebe, T
   Iwahashi, M
   Shirai, A
   Tsuda, M
   Ogawa, M
   Ishikawa, H
AF Ogawa-Ochiai, Keiko
   Yoshimura, Kenichi
   Takebe, Takae
   Iwahashi, Mako
   Shirai, Akiko
   Tsuda, Masaki
   Ogawa, Masao
   Ishikawa, Hideki
TI The effect of contact needle therapy on fatigue in patients with cancer in
SO Medicine
LA English
DT Journal Article
AB INTRODUCTION: Almost all patients with end-of-life cancer experience  cancer-related fatigue; however, there are only a few known effective coping  methods. OBJECTIVES: We will conduct a prospective, multi-center, single-blinded  randomized controlled study to evaluate the efficacy of acupuncture for  cancer-related fatigue in patients with end-of-life cancer. METHODS: We will  enroll 120 patients with cancer hospitalized in a palliative care unit or  receiving consultation from a palliative care team in four hospitals. We will add  acupuncture treatment; specifically, contact needle therapy (CNT), consisting of  an intervention per week period to the usual care. The primary outcome measure  will be the Cancer Fatigue Scale (CFS) score while the secondary outcome measures  will be the Numerical Rating Scale (NRS) score for fatigue, pain, and salivary  amylase levels. CONCLUSION: We will evaluate the possibility of using acupuncture  therapy, that is, CNT, in relieving fatigue sensation in patients with advanced  cancer. TRIAL REGISTRATION: UMIN000028304, registered on July 21st, 2017;  https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032401.
C1 Department of Japanese Traditional (Kampo) Medicine, Kanazawa University Hospital, Ishikawa.
   Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima University, Hiroshima.
   Innovative Clinical Research Center, Kanazawa University Hospital, Ishikawa.
   Mukeido Clinic of Acupuncture, Toyama.
   Department of Japanese Traditional (Kampo) Medicine, Kanazawa University Hospital, Ishikawa.
   Department of Japanese Traditional (Kampo) Medicine, Kanazawa University Hospital, Ishikawa.
   Mukeido Clinic of Acupuncture, Toyama.
   Department of Anesthesiology, Kanazawa University Hospital, Ishikawa.
   Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Osaka, Japan.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD NOV 7
PY 2019
VL 98
IS 44
BP e17809
EP e17809
DI 10.1097/MD.0000000000017809
PG 1
WC Adult; Humans; Acupuncture Therapy; methods; Fatigue; etiology; Medicine, Kampo; Neoplasms; complications; Palliative Care; Prospective Studies; Randomized Controlled Trials as Topic; Single-Blind Method; Terminal Care; Multicenter Studies as Topic
UT PubMed:31689865
PM 31689865
DA 2019-11-07
ER

PT J
AU Tsao, Y
   Creedy, DK
AF Tsao, Ying
   Creedy, Debra K.
TI Auricular acupressure: reducing side effects of chemotherapy in women with ovarian cancer
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Auricular acupressure; Chemotherapy; Ovarian cancer; Side effect management; Women
ID induced peripheral neuropathy; quality-of-life; symptom clusters; pain; acupuncture; management; acupoint; fatigue; impact
AB Purpose Many women with ovarian cancer may experience adverse effects from adjuvant chemotherapy after surgery. Non-pharmacological interventions can be used to reduce these side effects. We tested auricular acupressure to reduce treatment side effects in this population. Methods A prospective, quasi-randomized controlled trial was carried out at a publicly-funded hospital in southern Taiwan. Thirty-four women in the intervention group received auricular acupressure at four points (Shenmen, subcortex, endocrine, and heart), three times per day for 3 min per time, for 6 weeks. Thirty-one women in the control group received routine nursing care alone. The M. D. Anderson Symptom Inventory (MDASI) was completed at four time points. Results After receiving the third cycle of chemotherapy, side effect severity was elevated among both groups. Auricular acupressure reduced side effects such as disturbed sleep (t = - 11.99; p < .001, eta squared = 0.69), fatigue (t = - 2.57; p < .01, eta squared = 0.10), and lack of appetite (t = - 2.37; p = .024, eta squared = 0.08). Conclusion Auricular acupressure can reduce adverse side effects of chemotherapy in women with ovarian cancer. Future studies with a larger sample and using some laboratory-based tests (such as C-reactive protein, interleukin-6) are warranted to confirm the results.
C1 [Tsao, Ying] Tzu Chi Univ, Dept Nursing, 701,Zhongyang Rd,Sect 3, Hualien 97004, Taiwan.
   [Creedy, Debra K.] Griffith Univ, Sch Nursing & Midwifery, Brisbane, Qld, Australia.
C3 Tzu Chi University; Griffith University
RP Tsao, Y (corresponding author), Tzu Chi Univ, Dept Nursing, 701,Zhongyang Rd,Sect 3, Hualien 97004, Taiwan.
EM s2178593@mail.tcu.edu.tw; d.creedy@griffith.edu.au
CR Aktas A, 2013, CURR OPIN SUPPORT PA, V7, P38, DOI 10.1097/SPC.0b013e32835def5b
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Brewer JR, 2016, GYNECOL ONCOL, V140, P176, DOI 10.1016/j.ygyno.2015.11.011
   Burges A, 2011, DTSCH ARZTEBL INT, V108, P635, DOI 10.3238/arztebl.2011.0635
   Chen YW, 2014, PAIN MANAG NURS, V15, P539, DOI 10.1016/j.pmn.2012.12.005
   Chiang CJ, 2016, J FORMOS MED ASSOC, V115, P1076, DOI 10.1016/j.jfma.2015.10.011
   Chung YC, 2012, COMPLEMENT THER MED, V20, P353, DOI 10.1016/j.ctim.2012.02.008
   Cleeland CS, 2016, THE M.D. ANDERSON SYMPTOM INVENTORY USER GUIDE, V0, P0
   Coolbrandt A, 2014, INT J NURS STUD, V51, P495, DOI 10.1016/j.ijnurstu.2013.08.008
   Dong ST, 2016, J PAIN SYMPTOM MANAG, V51, P88, DOI 10.1016/j.jpainsymman.2015.07.013
   Ewertz M, 2015, ACTA ONCOL, V54, P587, DOI 10.3109/0284186X.2014.995775
   Goff B, 2012, CLIN OBSTET GYNECOL, V55, P36, DOI 10.1097/GRF.0b013e3182480523
   He WH, 2012, EURASIP J ADV SIG PR, V0, P0, DOI DOI 10.1186/1687-6180-2012-108
   Huang J, 2016, CANCER NURS, V39, P106, DOI 10.1097/NCC.0000000000000252
   Jiang QY, 2018, J CHIN MED ASSOC, V81, P358, DOI 10.1016/j.jcma.2018.01.005
   Kirkova J, 2006, J CLIN ONCOL, V24, P1459, DOI 10.1200/JCO.2005.02.8332
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Kwekkeboom KL, 2018, J PAIN SYMPTOM MANAG, V55, P1286, DOI 10.1016/j.jpainsymman.2018.01.008
   Lee EJ, 2011, J PAIN SYMPTOM MANAG, V42, P589, DOI 10.1016/j.jpainsymman.2011.01.007
   Li F, 2015, PAIN MED, V16, P1905, DOI 10.1111/pme.12761
   Lin CC, 2007, J PAIN SYMPTOM MANAG, V33, P180, DOI 10.1016/j.jpainsymman.2006.07.018
   Mendoza TR, 2013, CLIN BREAST CANCER, V13, P325, DOI 10.1016/j.clbc.2013.02.014
   Miltenburg NC, 2014, CANCER TREAT REV, V40, P872, DOI 10.1016/j.ctrv.2014.04.004
   Mücke M, 2016, J CACHEXIA SARCOPENI, V7, P23, DOI 10.1002/jcsm.12101
   Nho JH, 2017, EUR J ONCOL NURS, V30, P8, DOI 10.1016/j.ejon.2017.07.007
   Oldenmenger WH, 2013, J PAIN SYMPTOM MANAG, V45, P1083, DOI 10.1016/j.jpainsymman.2012.06.007
   Ovarian Cancer Research Fund Alliance, 2017, STATISTICS, V0, P0
   Round R, 2013, EVID-BASED COMPL ALT, V2013, P984763, DOI 10.1155/2013/984763
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Song HJ, 2015, COMPLEMENT THER MED, V23, P68, DOI 10.1016/j.ctim.2014.11.002
   Stanton G, 2017, J. ALTER. COMPLEMENT INTEGR. MED, V3, P1
   Thompson LMA, 2015, J ACUPUNCT MERIDIAN, V8, P127, DOI 10.1016/j.jams.2015.04.002
   Vanderbyl BL, 2017, SUPPORT CARE CANCER, V25, P1749, DOI 10.1007/s00520-017-3579-x
   Wang XS, 2010, JNCI-J NATL CANCER I, V102, P732, DOI 10.1093/jnci/djq097
   Woo A, 2015, ANN PALLIAT MED, V4, P176, DOI 10.3978/j.issn.2224-5820.2015.09.04
   Yeh CH, 2015, J PAIN RELIEF, V4, P1
   Yeh Chao Hsing, 2014, EVID BASED COMPLEMENT ALTERNAT MED, V2014, P375173, DOI 10.1155/2014/375173
   Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003
NR 38
TC 17
Z9 19
U1 2
U2 56
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD NOV 15
PY 2019
VL 27
IS 11
BP 4155
EP 4163
DI 10.1007/s00520-019-04682-8
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA JF6CZ
UT WOS:000491476800015
PM 30796521
DA 2026-01-16
ER

PT J
AU Zhang, K
   Gao, C
   Li, C
   Li, Y
   Wang, S
   Tang, Q
   Zhao, C
   Zhai, J
AF Zhang, Kai
   Gao, Chao
   Li, Chengyu
   Li, Yan
   Wang, Shenjun
   Tang, Qilin
   Zhao, Chen
   Zhai, Jingbo
TI Acupuncture for Acute Pancreatitis: A Systematic Review and Meta-analysis.
SO Pancreas
LA English
DT Journal Article
AB OBJECTIVE: The objective of this study was to assess the efficacy and safety of  acupuncture plus routine treatment (RT) for acute pancreatitis (AP). METHODS:  Literature searches were performed in 8 databases up to October 31, 2018.  Randomized controlled trials comparing acupuncture plus RT with RT alone for AP  were included. RESULTS: Twelve eligible studies were included finally. The  meta-analysis showed that acupuncture plus RT compared with RT alone could  significantly improve the total effective rate and gastrointestinal function and  reduce the Acute Physiology, Age, Chronic Health Evaluation II score, tumor  necrosis factor α count, the time of resuming to diets, and the length of  hospital stay. Only 3 of the studies reported adverse events or reactions.  CONCLUSIONS: This study suggested that acupuncture combined with RT may be  effective for AP. However, more rigorously designed randomized controlled trials  are warranted to confirm the current findings.
C1 From the Department of Acupuncture and Moxibustion, Tianjin Gong An Hospital.
   Tianjin Medical University General Hospital, Tianjin Institute of General Surgery, Tianjin.
   Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing.
   From the Department of Acupuncture and Moxibustion, Tianjin Gong An Hospital.
   Research Center of Experimental Acupuncture Science, School of Acumox and Tuina, Tianjin University of Traditional Chinese Medicine.
   Graduate College, Tianjin University of Traditional Chinese Medicine, Tianjin.
   Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing.
   Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
NR 0
TC 0
SN 1536-482
EI 
J9 Pancreas
PD OCT 9
PY 2019
VL 48
IS 9
BP 1136
EP 1147
DI 10.1097/MPA.0000000000001399
PG 11
WC Abdominal Pain; therapy; Acupuncture Therapy; methods; Acute Disease; Female; Humans; Male; Outcome Assessment, Health Care; methods; Pancreatitis; drug therapy; Randomized Controlled Trials as Topic; statistics & numerical data; Tumor Necrosis Factor-alpha; metabolism
UT PubMed:31593017
PM 31593017
DA 2019-10-09
ER

PT J
AU Li, SL
   Yan, ZK
   Huang, W
AF Li, Suli
   Yan, Zhongkai
   Huang, Wei
TI Effects of Huolong moxibustion on discogenic low back pain
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Huolong moxibustion; DLBP; curative effect; inflammatory factor
ID acupuncture; management
AB Objective: The goal of this study was to investigate the effect of Huolong moxibustion in the treatment of discogenic low back pain (DLBP) and its underlying mechanisms. Methods: One hundred and forty-eight patients with DLBP treated in the Orthopedics Department of Tangshan Gongren Hospital were selected and randomly divided into the observation group and control group. Patients in the control group were treated with regular treatment such as conventional traction and manual massage physiotherapy, while those in the observation group were treated with Huolong moxibustion based on the treatment in control group for 3 weeks. The two groups were compared in the treatment effect of DLBP, and visual analogue scale (VAS) score, Japanese Orthopedic Association (JOA) score, oswestry disability index (ODI) score, 36-Item Short-Form Health Survey (SF-36) score and serum inflammatory factors. Results: At 3 weeks after treatment, the total effective rate was 97.37% in observation group and 88.39% in control group, and there was a statistical difference between two groups (P=0.04). At 3 weeks after treatment, VAS score and ODI score in the observation group were remarkably lower than those in the control group (both P<0.001); JOA score and SF-36 score were also significantly increased (both P<0.001). Additionally, interleukin-2 (IL-2), IL-10, and tumor necrosis factor a (TNF-alpha) in the observation group was significantly lower than those in the control group (P<0.001). Conclusion: Huolong moxibustion shows efficacy in the treatment of DLBP, which is helpful to alleviate the symptoms of lumbago and improve the quality of life of patients. This might be associated with lower serum IL-6 and TNF-alpha expression levels.
C1 [Li, Suli; Yan, Zhongkai; Huang, Wei] Tangshan Gongren Hosp, Dept Tradit Chinese Med, 34 Longzenan Rd, Tangshan 063000, Hebei, Peoples R China.
RP Yan, ZK (corresponding author), Tangshan Gongren Hosp, Dept Tradit Chinese Med, 34 Longzenan Rd, Tangshan 063000, Hebei, Peoples R China.
EM yanzhongkai27j@163.com
CR Unknown -, 2000, COCHRANE DB SYST REV, V0, P0
   Birch S, 1999, J ALTERN COMPLEM MED, V5, P415, DOI 10.1089/acm.1999.5.415
   Chan AYP, 2017, PHYSIOTHERAPY, V103, P121, DOI 10.1016/j.physio.2016.08.001
   Cid J, 2015, PAIN PRACT, V15, P12, DOI 10.1111/papr.12135
   CROCK HV, 1970, MED J AUSTRALIA, V1, P983, DOI 10.5694/j.1326-5377.1970.tb116676.x
   Geurts JW, 2018, PAIN RES MANAG, V2018, P0, DOI 10.1155/2018/4696180
   Gorth DJ, 2015, DISCOV MED, V20, P177
   Helm S, 2017, PAIN PHYSICIAN, V20, P447, DOI 10.36076/ppj/447
   Huang Tao, 2014, ZHONGGUO ZHEN JIU, V34, P585
   Laidman J, 2017, AUST PRESCR, V40, P208, DOI 10.18773/austprescr.2017.077
   Lee JH, 2017, WORLD NEUROSURG, V105, P832, DOI 10.1016/j.wneu.2017.06.112
   Leem J, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2016-014936
   Li NH, 2016, SPINE J, V16, P1231, DOI 10.1016/j.spinee.2016.05.007
   Luo L, 2018, WORLD NEUROSURG, V111, PE185, DOI 10.1016/j.wneu.2017.12.022
   Mahmoudzadeh A, 2016, J RES MED SCI, V21, P0, DOI 10.4103/1735-1995.192502
   Mohammed Suja, 2018, J SPINE SURG, V4, P115, DOI 10.21037/jss.2018.03.04
   Molinos M, 2015, J R SOC INTERFACE, V12, P0, DOI 10.1098/rsif.2014.1191
   Namboothiri S, 2018, INT J SPINE SURG, V12, P388, DOI 10.14444/5045
   Ohtori S, 2015, SPINE J, V15, P1347, DOI 10.1016/j.spinee.2013.07.490
   Qin ZS, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2016-012821
   Sainoh T, 2016, PAIN MED, V17, P40, DOI 10.1111/pme.12892
   Selter A, 2018, JMIR MHEALTH UHEALTH, V6, P0, DOI 10.2196/mhealth.8256
   Sherman KJ, 2001, COMPLEMENT THER MED, V9, P146, DOI 10.1054/ctim.2001.0458
   Simon J, 2014, PHYS MED REH CLIN N, V25, P305, DOI 10.1016/j.pmr.2014.01.006
   Sun Hao-lin, 2011, BEIJING DA XUE XUE BAO YI XUE BAN, V43, P690
   Xi MA, 2016, CUREUS J MED SCIENCE, V8, P0, DOI 10.7759/cureus.514
   [闫仲凯 Yan Zhongkai], 2015, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V35, P1121
NR 27
TC 2
Z9 2
U1 1
U2 16
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
EI 
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PD JUN 15
PY 2019
VL 12
IS 7
BP 8936
EP 8942
DI 
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA IM4UR
UT WOS:000477991300115
DA 2026-01-16
ER

PT J
AU He, C
   Tang, QX
   Li, YX
   He, K
   Hou, ZL
AF He, Chi
   Tang, Qing-Xi
   Li, Ying-Xia
   He, Kai
   Hou, Zhi-Ling
TI Effectiveness of electroacupuncture for pain after osteosarcoma post surgery: A
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: This study will assess the effectiveness of electroacupuncture (EA)  for pain in patients with osteosarcoma post surgery (OSPS). METHODS: In this  study, we will comprehensively search the following electronic databases from  inception to the present without language restrictions: Cochrane Library, EMBASE,  MEDLINE, the Cumulative Index to Nursing and Allied Health Literature, the Allied  and Complementary Medicine Database, and Chinese Biomedical Literature Database.  Two authors will independently carry out study selection, data extraction, and  methodological assessments. RevMan 5.3 software will be used for statistical  analysis. RESULTS: The primary outcome is pain intensity. The secondary outcomes  consist of event-free survival, overall survival, quality of life, and adverse  events. CONCLUSION: The findings of this study will provide helpful evidence of  EA treatment for patients with OSPS. PROSPERO REGISTRATION NUMBER: PROSPERO  CRD42019146696.
C1 Department of Anesthesiology.
   Department of Emergency Surgery, First Affiliated Hospital of Jiamusi University, Jiamusi.
   Department of Emergency Surgery, First Affiliated Hospital of Jiamusi University, Jiamusi.
   Department of Orthopedis, Harbin Second Hospital, Harbin, China.
   Department of Anesthesiology.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD NOV 7
PY 2019
VL 98
IS 44
BP e17381
EP e17381
DI 10.1097/MD.0000000000017381
PG 1
WC Humans; Cancer Pain; therapy; Disease-Free Survival; Electroacupuncture; adverse effects; Osteosarcoma; surgery; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic
UT PubMed:31689744
PM 31689744
DA 2019-11-07
ER

PT J
AU Wang, JY
   Gao, YH
   Qiao, LN
   Zhang, JL
   Rong, PJ
   Liu, JL
AF Wang, Jun-Ying
   Gao, Yong-Hui
   Qiao, Li-Na
   Zhang, Jin-Ling
   Rong, Pei-Jing
   Liu, Jun-Ling
TI [Electroacupuncture alleviated incisional neck pain possibly by suppressing TNF-α
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Dorsal horns of cervical spinal cord; Electroacupuncture; Incisional neck pain; Inflammatory cytokines
AB OBJECTIVE: To observe the effect of electroacupuncture (EA) on incisional pain  and expression of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10) and  interleukin-4 (IL-4) of cervical dorsal part of spinal cord in rats with  incisional neck pain, so as to explore its analgesic mechanisms. METHODS:  Eighty-four male SD rats were randomly divided into normal control, model,  EA-Futu(LI18) and EA-Zusanli(ST36)-Yanglingquan(GB34, EA-ST36-GB34) groups (n=21  in each group). The incisional neck pain model was established by making a  longitudinal incision along the bilateral cervical thyroid regions and repeated  mechanical separation stimulation. For rats of the EA groups, EA (2 Hz/100 Hz, 1  mA) was applied to bilateral LI18 or ST36-GB34 for 30 min/ time during the  surgery, and 20 and 44 h after surgery, respectively. The thermal pain threshold  (TPT) of the incisional region was detected. The immunoactivity of TNF-α and  IL-10 of the dorsal portion of the cervical spinal cord (C2-C5) was detected by  immunofluorescence, and the expression of TNF-α, IL-10, IL-4 and IL-4 receptor  (IL-4R) mRNAs was determined by quantitative real-time PCR. RESULTS: Compared  with the normal group, the TPT of the incisional area was significantly decreased  at 4, 24 and 48 h after neck-incision (P<0.05), the levels of TNF-α mRNA, IL-10  mRNA and TNF-α IL-10 immunoactivity at 24 h were remarkably increased (P<0.05),  and the expression of IL-4R mRNA was considerably decreased at 24 h in the model  group (P<0.05). Following EA intervention, the TPT, and expression levels of IL-4  mRNA and IL-4R mRNA were significantly increased at 24 h after surgery in the  EA-LI18 group relevant to the model group (P<0.05), while the expression level of  TNF-α(coexpressed with microgliacytes) in the EA-LI18 group, and TNF-α mRNA  expression at 24 h in both EA-LI18 and EA-ST36-GB34 groups, as well as the  expression of IL-10 and IL-10 mRNA at 24 h in both EA-LI18 and EA-ST36-GB34  groups were significantly decreased (P<0.05). The effect of EA LI18 was  significantly superior to that of EA ST36-GB34 in up-regulating TPT and  expression of IL-4 mRNA and IL-4R mRNA at 24 h (P<0.05). CONCLUSION: EA of LI18  has an analgesic effect in incisional neck pain rats, which may be related to its  effect in down-regulating the expression of TNF-α, IL-10 and promoting IL-4  /IL-4R signaling in dorsal portions of the cervical spinal cord. The analgesic  effect of EA LI18 is better than that of EA ST36-GB34.
C1 Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD OCT 28
PY 2019
VL 44
IS 10
BP 703
EP 8
DI 10.13702/j.1000-0607.190355
PG -695
WC Acupuncture Points; Animals; Electroacupuncture; Interleukin-4; Male; Neck Pain; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-4; Spinal Cord; Tumor Necrosis Factor-alpha
UT PubMed:31657158
PM 31657158
DA 2019-10-28
ER

PT J
AU Deng, G
AF Deng, Gary
TI Integrative Medicine Therapies for Pain Management in Cancer Patients.
SO Cancer journal (Sudbury, Mass.)
LA English
DT Review
AB Pain management for cancer patients should include pharmacologic and  nonpharmacologic interventions. Integrative medicine therapies, such as mind-body  practice, acupuncture, massage therapy, and music therapy, have been studied for  their roles in pain management. Data from randomized controlled trials support  the effect of hypnosis, acupuncture, and music therapy in reduction of pain.  Mindfulness meditation, yoga, qigong, and massage therapy, although may not  reduce pain per se, can relieve anxiety and mood changes, which are commonly  associated with pain. In clinical practice, one should also consider burdens and  risks to patients, patient preference, and the presence or absence of better  alternatives when making decisions on whether an integrative medicine therapy is  of clinical value.
C1 From the Memorial Sloan Kettering Cancer Center, New York, NY.
NR 0
TC 0
SN 1540-336
EI 1528-911
J9 Cancer J
PD OCT 1
PY 2019
VL 25
IS 5
BP 343
EP 348
DI 10.1097/PPO.0000000000000399
PG 5
WC Acupuncture; Cancer Pain; etiology; Combined Modality Therapy; Complementary Therapies; Disease Management; Humans; Integrative Medicine; methods; Mind-Body Therapies; methods; Neoplasms; complications; Pain Management
UT PubMed:31567462
PM 31567462
DA 2019-10-01
ER

PT J
AU Jiang, X
   Tian, YH
   Xu, L
   Zhang, QL
   Wan, YX
   Qi, XW
   Li, B
   Guo, J
   Sun, WL
   Luo, AP
   Huang, JC
   Gu, XH
AF Jiang, Xin
   Tian, Yehong
   Xu, Lin
   Zhang, Qiaoli
   Wan, Yuxiang
   Qi, Xuewei
   Li, Bo
   Guo, Jing
   Sun, Weiliang
   Luo, Aiping
   Huang, Jinchang
   Gu, Xiaohong
TI Inhibition of Triple-Negative Breast Cancer Tumor Growth by Electroacupuncture with Encircled Needling and Its Mechanisms in a Mice Xenograft Model
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Triple-negative breast cancer; Electroacupuncture; Encircled needling; Tumor inhibition; Mechanisms
ID necrosis-factor; acupuncture; inflammation; prostate; fatigue; density; brain; alpha; cells; risk
AB Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer without effective targeted drugs. While breast cancer patients often use acupuncture for the relief of cancer-induced pain or the side effects of chemo- or radiation therapy, little information is known regarding the direct effects of electroacupuncture on TNBC tumor and its potential mechanisms. Here, we created a mice model of TNBC and electroacupuncture with encircled needling around the tumors was given to the animals daily for 3 weeks at 15-20 Hz (3 min, each time). For sham electroacupuncture control, the skin was punctured to a depth of 5 mm and then the needle was quickly withdrawn without electrical stimulation or manual needle manipulation. We found that electroacupuncture significantly inhibited TNBC tumor growth and the inhibitory rate increased gradually overtime. Mechanistic analysis showed that electroacupuncture inhibited tumor angiogenesis by reducing the expression of vascular endothelial growth factor A (VEGF-A), its receptor VEGF-R and neuropilin 1 (NRP-1). Electroacupuncture also led to a significant decrease of matrix metalloproteinase-2 (MMP-2) expression and an increase of tissue inhibitor of MMP (TIMP-2) expression. Additionally, the expression of semaphorin 3A (Sema3A) and nerve growth factor receptor (NGFR) p75 in TNBC tissue was significantly upregulated in response to electroacupuncture. Furthermore, tumor necrosis factor (TNF)-alpha level in the serum was dramatically reduced after electroacupuncture. These results showed that electroacupuncture could directly inhibit TNBC tumor growth through the inhibition of proteins related to tumor angiogenesis and extracellular matrix, the suppression of TNBC-induced inflammation and the upregulation of nerve growth factor receptors.
C1 [Jiang, Xin; Tian, Yehong; Xu, Lin; Zhang, Qiaoli; Wan, Yuxiang; Qi, Xuewei; Huang, Jinchang] Beijing Univ Chinese Med, Affiliated Hosp 3, Beijing 100029, Peoples R China.
   [Jiang, Xin; Gu, Xiaohong] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing 100029, Peoples R China.
   [Li, Bo] Capital Med Univ, Beijing Chest Hosp, Dept Tradit Chinese Med, Beijing 101149, Peoples R China.
   [Guo, Jing; Sun, Weiliang] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing 100029, Peoples R China.
   [Luo, Aiping] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Capital Medical University; China-Japan Friendship Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Cancer Institute & Hospital - CAMS
RP Gu, XH (corresponding author), Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing 100029, Peoples R China.; Huang, JC (corresponding author), Beijing Univ Chinese Med, Dept Acupuncture & Minimally Invas Oncol, Affiliated Hosp 3, Beijing 100029, Peoples R China.
EM C655@bucm.edu.cn; guxh1003@126.com
FU Beijing Municipal Natural Science Foundation [7172128]; National Natural Science Foundation for Young Scientists of China [81804177]
CR Anagnostopoulou V, 2013, ENDOCRINOLOGY, V154, P2446, DOI 10.1210/en.2012-2249
   Bao Fei, 2011, ZHONGGUO ZHEN JIU, V31, P241
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Bianchi-Smiraglia A, 2013, ONCOGENE, V32, P3049, DOI 10.1038/onc.2012.320
   Cayir Y, 2014, ACUPUNCT MED, V32, P376, DOI 10.1136/acupmed-2014-010612
   Chen JH, 2019, CANCER MANAG RES, V11, P1453, DOI 10.2147/CMAR.S188251
   Chen Yun-Fei, 2008, ZHONGGUO ZHEN JIU, V28, P675
   Chen ZX, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep40837
   Cook MT, 2017, BREAST CANCER-TARGET, V9, P9, DOI 10.2147/BCTT.S124860
   Fu SP, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0094604
   Goda M, 2010, J PHARMACOL SCI, V112, P463, DOI 10.1254/jphs.09354SC
   Haase G, 2008, CURR OPIN NEUROBIOL, V18, P284, DOI 10.1016/j.conb.2008.07.013
   Han J, 2018, CURR PHARM DESIGN, V24, P2530, DOI 10.2174/1381612824666180727114134
   Huang Guo-Fu, 2012, ZHEN CI YAN JIU, V37, P403
   Jiang X, 2019, CURR PHARM DESIGN, V25, P862, DOI 10.2174/1381612825666190306164157
   Kämmerer U, 2001, J HISTOCHEM CYTOCHEM, V49, P623, DOI 10.1177/002215540104900509
   Kather JN, 2015, ONCOTARGET, V6, P19163, DOI 10.18632/oncotarget.4383
   Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041
   Lampropoulou A, 2014, BIOCHEM SOC T, V42, P1623, DOI 10.1042/BST20140244
   Langevin HM, 2015, J ALTERN COMPLEM MED, V21, P113, DOI 10.1089/acm.2014.0186
   Lebrec H, 2015, CURR MED RES OPIN, V31, P557, DOI 10.1185/03007995.2015.1011778
   Liao GS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/437948
   [Liu Yanan 刘雅楠], 2015, JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE 针灸推拿医学, V13, P67, DOI 10.1007/s11726-015-0826-x
   Liu Y, 2019, NEUROGASTROENT MOTIL, V31, P0, DOI 10.1111/nmo.13474
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Luo D, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5302049
   Manni L, 2005, REPROD BIOL ENDOCRIN, V3, P0, DOI 10.1186/1477-7827-3-21
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molloy Niamh H, 2011, CANCERS (BASEL), V3, P510, DOI 10.3390/cancers3010510
   Naim A, 2017, J CLIN EXP HEPATOL, V7, P367, DOI 10.1016/j.jceh.2017.09.004
   Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081
   Navarro SL, 2012, CANCER EPIDEM BIOMAR, V21, P1167, DOI 10.1158/1055-9965.EPI-12-0110
   Nishida N, 2006, VASC HEALTH RISK MAN, V2, P213, DOI 10.2147/vhrm.2006.2.3.213
   Ondicova K, 2010, LANCET ONCOL, V11, P596, DOI 10.1016/S1470-2045(09)70337-7
   Ouyang BS, 2011, CHIN J INTEGR MED, V17, P505, DOI 10.1007/s11655-011-0783-2
   Ran QQ, 2015, NEURAL REGEN RES, V10, P1069, DOI 10.4103/1673-5374.160095
   Robotin M, 2012, COMPLEMENT THER MED, V20, P345, DOI 10.1016/j.ctim.2012.04.001
   Sanyal A, 2017, CELL REP, V18, P225, DOI 10.1016/j.celrep.2016.12.028
   Schmadeka R, 2014, AM J CLIN PATHOL, V141, P462, DOI 10.1309/AJCPQN8GZ8SILKGN
   Shimelis H, 2018, JNCI-J NATL CANCER I, V110, P855, DOI 10.1093/jnci/djy106
   Smeester BA, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/387169
   Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334
   Tam Lai-Shan, 2007, BMC COMPLEMENT ALTERN MED, V7, P35, DOI 10.1186/1472-6882-7-35
   Yang GY, 2017, FRONT PLANT SCI, V8, P0, DOI 10.3389/fpls.2017.00513
   Yang Ji-Jun, 2012, ZHEN CI YAN JIU, V37, P173
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
NR 46
TC 16
Z9 22
U1 7
U2 29
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
EI 
J9 INT J MED SCI
JI Int. J. Med. Sci.
PD JUN 15
PY 2019
VL 16
IS 12
BP 1642
EP 1651
DI 10.7150/ijms.38521
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA JO0TE
UT WOS:000497298800013
PM 31839752
DA 2026-01-16
ER

PT J
AU Li, K
   Giustini, D
   Seely, D
AF Li, K
   Giustini, D
   Seely, D
TI A systematic review of acupuncture for chemotherapy-induced peripheral
SO Current oncology (Toronto, Ont.)
LA English
DT Journal Article
DE Acupuncture; chemotherapy-induced peripheral neuropathy; cipn; integrative oncology; systematic reviews
AB OBJECTIVES: In cancer patients, chemotherapy-induced peripheral neuropathy (cipn)  is a common complication, characterized by pain, loss of sensation, and numbness.  Medical treatment for peripheral neuropathies has been shown to be ineffective  for cipn. Acupuncture has been shown to be safe and effective in treating  cancer-related symptoms and other peripheral neuropathies. For the present  review, we aimed to evaluate the efficacy of acupuncture for the treatment of  cipn. DESIGN: Comprehensive searches for relevant studies were conducted in Ovid  embase, the Web of Science, Ovid medline, the Cochrane Central Register of  Controlled Trials (central), cinahl (ebsco Information Services, Ipswich, MA,  U.S.A.), and the ClinicalTrials.gov Web site. References from previous systematic  reviews were also searched. Additional trials were found in the reference lists  of relevant papers and in searches of Google Scholar and acupuncture-specific Web  sites. Included studies were randomized controlled trials (rcts) of any type of  acupuncture used to treat patients with cipn. RESULTS: Three clinical trials (203  participants) were included. Two studies found acupuncture to be effective in  alleviating cipn pain and improving quality of life. One study found no benefit  in improving neuropathic pain, symptoms, or quality of life. Study quality was  variable and included a moderate overall risk of bias. CONCLUSIONS: The evidence  is insufficient to recommend acupuncture for the treatment or prevention of cipn.  Further research is needed to evaluate the effects of acupuncture in the  treatment of cipn. Given that acupuncture is considered safe and might provide  relief for patients, it can be considered at the clinician's discretion.
C1 Faculty of Medicine, University of British Columbia, Vancouver, BC.
   Biomedical Branch Library, University of British Columbia, Vancouver, BC.
   Ottawa Integrative Cancer Centre, Ottawa, ON.
NR 0
TC 0
SN 1718-772
EI 1198-005
J9 Curr Oncol
PD MAY 3
PY 2019
VL 26
IS 2
BP e147
EP e154
DI 10.3747/co.26.4261
PG 1
WC Acupuncture Therapy; Antineoplastic Agents; adverse effects; Humans; Peripheral Nervous System Diseases; chemically induced; Randomized Controlled Trials as Topic
UT PubMed:31043820
PM 31043820
DA 2019-05-03
ER

PT J
AU Zick, SM
   Sen, A
   Hassett, AL
   Schrepf, A
   Wyatt, GK
   Murphy, SL
   Arnedt, JT
   Harris, RE
AF Zick, Suzanna Maria
   Sen, Ananda
   Hassett, Afton Luevano
   Schrepf, Andrew
   Wyatt, Gwen Karilyn
   Murphy, Susan Lynn
   Arnedt, John Todd
   Harris, Richard Edmund
TI Impact of Self-Acupressure on Co-Occurring Symptoms in Cancer Survivors.
SO JNCI cancer spectrum
LA English
DT Journal Article
AB BACKGROUND: Cancer survivors with fatigue often experience depressive symptoms,  anxiety, and pain. Previously, we reported that self-acupressure improved  fatigue; however, its impact on other co-occurring symptoms and their involvement  in treatment action has not been explored. METHODS: Changes in depressive  symptoms, anxiety, and pain were examined prior to and following two formulas of  self-acupressure and usual care using linear mixed models in 288 women from a  previously reported clinical trial. Participants were categorized by random  assignment into one of three groups: 1) relaxing acupressure, 2) stimulating  acupressure, or 3) usual care. Moderators investigated were body mass index, age,  depressive symptoms, anxiety, sleep and pain, and mediators were change in these  symptoms. RESULTS: Following treatment, depressive symptoms improved  statistically significantly for the relaxing acupressure group (41.5%) compared  with stimulating acupressure (25%) and usual care (7.7%). Both acupressure groups  were associated with greater improvements in anxiety than usual care, but only  relaxing acupressure was associated with greater reductions in pain severity, and  only stimulating acupressure was associated with greater reductions in pain  interference. There were no statistically significant moderators of sleep  quality, anxiety, or depressive symptoms. Fatigue statistically significantly  moderated pain, and age statistically significantly modified fatigue. Changes in  depressive symptoms and sleep quality statistically significantly mediated the  relationship between relaxing acupressure and usual care on fatigue; however, the  effect was small. CONCLUSIONS: Acupressure was associated with greater  improvements than usual care in anxiety, pain, and symptoms of depression in  breast cancer survivors with troublesome fatigue. These findings warrant further  evaluation in suitably controlled randomized trials.
C1 Department of Family Medicine.
   Department of Nutritional Sciences, University of Michigan, Ann Arbor, MI.
   Department of Family Medicine.
   Department of Biostatistics, University of Michigan, Ann Arbor, MI.
   Department of Anesthesiology, University of Michigan, Ann Arbor, MI.
   Department of Anesthesiology, University of Michigan, Ann Arbor, MI.
   College of Nursing, Michigan State University, East Lansing, MI.
   Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI.
   Physical Medicine and Rehabilitation, VA Ann Arbor Health Care System, GRECC, Ann 
   Sleep and Circadian Research Laboratory.
   Departments of Psychiatry and Neurology, University of Michigan, Ann Arbor, MI.
   Department of Anesthesiology, University of Michigan, Ann Arbor, MI.
NR 0
TC 0
SN 2515-509
EI 
J9 JNCI Cancer Spectr
PD JAN 29
PY 2019
VL 2
IS 4
BP pky064
EP pky064
DI 10.1093/jncics/pky064
PG 1
UT PubMed:30687806
PM 30687806
DA 2019-01-29
ER

PT J
AU Tang, SK
   Tse, MMY
   Leung, SF
   Fotis, T
AF Tang, Shuk Kwan
   Tse, Mimi Mun Yee
   Leung, Sau Fong
   Fotis, Theofanis
TI The effectiveness, suitability, and sustainability of non-pharmacological methods
SO BMC public health
LA English
DT Journal Article
DE Aged; Chronic pain; Community-dwelling; Complementary therapy; Non-pharmacological interventions; Older adults; Systematic review
AB BACKGROUND: Pain is common in older adults. To maintain their quality of life and  promote healthy ageing in the community, it is important to lower their pain  levels. Pharmacological pain management has been shown to be effective in older  adults. However, as drugs can have various side effects, non-pharmacological pain  management is preferred for community-dwelling older adults. This systematic  review evaluates the effectiveness, suitability, and sustainability of  non-pharmacological pain management interventions for community-dwelling older  adults. METHODS: Five databases, namely, CINHAL, Journals@Ovid, Medline,  PsycInfo, and PubMed, were searched for articles. The criteria for inclusion  were: full-text articles published in English from 2005 to February 2019 on  randomized controlled trials, with chronic non-cancer pain as the primary  outcome, in which pain was rated by intensity, using non-pharmacological  interventions, and with participants over 65 years old, community-dwelling, and  mentally competent. A quality appraisal using the Jadad Scale was conducted on  the included articles. RESULTS: Ten articles were included. The mean age of the  older adults was from 66.75 to 76. The interventions covered were acupressure,  acupuncture, guided imagery, qigong, periosteal stimulation, and Tai Chi. The  pain intensities of the participants decreased after the implementation of the  intervention. The net changes in pain intensity ranged from - 3.13 to - 0.65 on a  zero to ten numeric rating scale, in which zero indicates no pain and ten  represents the worst pain. CONCLUSIONS: Non-pharmacological methods of managing  pain were effective in lowering pain levels in community-dwelling older adults,  and can be promoted widely in the community.
C1 School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong. skangel.tang@connect.polyu.hk.
   School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong.
   School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong.
   School of Health Sciences, University of Brighton, Westlain House, Village Way, Brighton, BN1 9PH, UK.
NR 0
TC 0
SN 1471-245
EI 
J9 BMC Public Health
PD NOV 11
PY 2019
VL 19
IS 1
BP 1488
EP 1488
DI 10.1186/s12889-019-7831-9
PG 0
WC Aged; Analgesics, Opioid; therapeutic use; Chronic Pain; therapy; Complementary Therapies; methods; Female; Humans; Independent Living; statistics & numerical data; Male; Pain Management; methods; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:31703654
PM 31703654
DA 2019-11-11
ER

PT J
AU Wu, QL
   Cao, W
   Wang, W
   Jiang, ZY
   Chen, L
   Li, LL
AF Wu, Qiu-Lan
   Cao, Wen
   Wang, Wei
   Jiang, Zi-Yu
   Chen, Li
   Li, Li-Li
TI [Wrist-ankle needle combined with opioid drugs on refractory cancer pain: a
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE analgesia; opioid drugs; randomized controlled trial (RCT); refractory cancer pain; wrist-ankle needle
AB OBJECTIVE: To compare the clinical effect of wrist-ankle needle combined with  opioid drugs and opioid drugs alone in treating refractory cancer pain. METHODS:  Sixty patients were randomly divided into an observation group and a control  group, 30 cases in each one. The opioid drugs in accordance with the three-step  analgesic principle and other auxiliary drugs were treated in the control group.  On the basis of the treatment in the control group, wrist-ankle needle was added  in the observation group, and acupoints were selected according to the pain site  and the primary focus, the treatment was given once a day for 10 days. The visual  analogue scale (VAS) score, the times of pain outbreaks and the incidence of  adverse reactions were compared at the 2nd, 4th, 6th, 8th and 10th days of  treatment and the 3rd and 7th days after treatment. The therapeutic effect in the  two groups were compared after treatment. RESULTS: Compared with the control  group, the VAS scores in the observation group were significantly reduced from  the 2nd day of wrist-ankle needle treatment, and continued to the 3rd day after  the end of the treatment (P<0.05), but there was no statistically significant  difference between the two groups on the 7th day after the end of the treatment  (P>0.05); compared with the control group, the times of pain outbreaks in the  observation group decreased from the 2nd day to the 10th day of treatment (all  P<0.05); the incidence of nausea, vomiting and constipation in the observation  group was significantly reduced compared with the control group (P<0.05); the  total effective rate in the observation group was 86.7% (26/30), which was higher  than 76.7% (23/30) in the control group (P<0.05). CONCLUSION: Wrist-ankle needle  combined with opioid drugs can increase the efficacy of the refractory cancer  pain and reduce the adverse reactions of opioid drugs.
C1 Department of Oncology, Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Nanjing University of CM, Nanjing 210028, JiangsuProvince, China.
   Department of Oncology, Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Nanjing University of CM, Nanjing 210028, JiangsuProvince, China.
   Department of Oncology, Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Nanjing University of CM, Nanjing 210028, JiangsuProvince, China.
   Department of Oncology, Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Nanjing University of CM, Nanjing 210028, JiangsuProvince, China.
   Department of Oncology, Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Nanjing University of CM, Nanjing 210028, JiangsuProvince, China.
   Department of Oncology, Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Nanjing University of CM, Nanjing 210028, JiangsuProvince, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD OCT 18
PY 2019
VL 39
IS 10
BP 1051
EP 4
DI 10.13703/j.0255-2930.2019.10.005
PG -1047
WC Acupuncture Analgesia; methods; Analgesics, Opioid; therapeutic use; Ankle; Cancer Pain; therapy; Humans; Treatment Outcome; Wrist
UT PubMed:31621255
PM 31621255
DA 2019-10-18
ER

PT J
AU Chen, LS
   Li, YY
   Chen, H
   Liu, BW
   Wang, DW
   Zhao, YH
AF Chen, Li-Shu
   Li, Yue-Ying
   Chen, Hao
   Liu, Bo-Wen
   Wang, Da-Wei
   Zhao, Yong-Hua
TI Polyglycolic acid sutures embedded in abdominal acupoints for treatment of simple obesity in adults: a randomized control trial
SO CHINESE MEDICINE
LA English
DT Article
DE Polyglycolic acid sutures embedding therapy; Simple obesity; Therapeutic effects; Regulation of inflammatory response
ID physical-activity; weight-loss; inflammation; life; interleukin-18; acupuncture; quality; risk; diet
AB Background: Acupoint catgut embedding therapy characterized by acupoint, needle and catgut are superior to traditional acupuncture, due to exerting more comprehensive therapeutic efficacy. However, it is still deficient in clinical evidence for polyglycolic acid sutures, a novel biodegradable material instead of catgut, embedded for the treatment of simple obesity. In our study, we investigate the efficacy and related mechanism of polyglycolic acid sutures embedded in abdominal acupoints on simple obese persons by a randomized control trial. Methods: A total of 51 eligible participators were randomly allocated to a polyglycolic acid sutures embedding therapy (PASET) group (n = 28) or control group (n = 23). Participators in PASET group received polyglycolic acid sutures alternatively embedded in abdominal I group and II group acupoints in odd and even number therapeutic courses, and participators in control group were required to perform lifestyle modification. The duration of the study was 10 weeks. Results: It suggested that PASET significantly reduced weight, body mass index, hip circumference, waist circumference, waist/hip ratio, waist-to-height ratio and thickness of abdominal subcutaneous fat tissue compared with those before treatment (p < 0.01), but lifestyle modification only illustrated downward trend of weight (p < 0.05). Moreover, PASET group also improved the evaluated scores in aspects of physical function, self-esteem, public distress and sexual life, as well as decreased blood pressure, glycemia, low density lipoprotein, uric acid and the levels of tumor necrosis factor-alpha, interleukin-1 beta, and increased high density lipoprotein in comparison with those before treatment (p < 0.05), whose efficacies are superior to control group. Additionally, our results also indicate PASET is relative safe and its pain and discomfort can be tolerable. Conclusions: PASET distinctly ameliorates anthropometric data and quality of life in obese population, which associates with improvements of metabolic profile and inflammatory response. Based on the advantageous actions, we think PASET is an effective therapeutic approach to simple obesity treatment.
C1 [Chen, Li-Shu] Ningbo Coll Hlth Sci, Ningbo 315100, Zhejiang, Peoples R China.
   [Li, Yue-Ying] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr, Key Lab Canc Prevent & Therapy,Tianjins Clin Res, Tianjin 300060, Peoples R China.
   [Chen, Hao] Nanjing Univ Chinese Med, Nanjing 210046, Jiangsu, Peoples R China.
   [Liu, Bo-Wen] Nanjing Univ Chinese Med, Dept Neurol, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, Nanjing 210008, Peoples R China.
   [Wang, Da-Wei] Guangzhou Univ Chinese Med, Shunde Hosp, Shunde 528333, Peoples R China.
   [Zhao, Yong-Hua] Univ Macau, State Key Lab Qual Res Chinese Med, Inst Chinese Med Sci, Taipa 999078, Macao, Peoples R China.
C3 Tianjin Medical University; Nanjing University of Chinese Medicine; Nanjing University; Nanjing University of Chinese Medicine; Guangzhou University of Chinese Medicine; Southern Medical University - China; University of Macau
RP Zhao, YH (corresponding author), Univ Macau, State Key Lab Qual Res Chinese Med, Inst Chinese Med Sci, Taipa 999078, Macao, Peoples R China.
EM yonghuazhao@um.edu.mo
FU Science and Technology Development Fund, Macau SAR [106/2014/A3]
CR Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4
   Brestoff JR, 2015, CELL, V161, P146, DOI 10.1016/j.cell.2015.02.022
   Chen Lishu, 2018, ZHONGGUO ZHEN JIU, V38, P319, DOI 10.13703/j.0255-2930.2018.03.025
   Chuang YT, 2011, ACUPUNCT MED, V29, P307, DOI 10.1136/acupmed.2011.010084
   Cox AJ, 2015, LANCET DIABETES ENDO, V3, P207, DOI 10.1016/S2213-8587(14)70134-2
   Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X
   Esfahani SB, 2018, HEALTH PSYCHOL OPEN, V5, P0, DOI 10.1177/2055102918786867
   Esposito K, 2002, J CLIN ENDOCR METAB, V87, P3864, DOI 10.1210/jc.87.8.3864
   Fan XL, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5459326
   Guo TP, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/401914
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Jung UJ, 2014, INT J MOL SCI, V15, P6184, DOI 10.3390/ijms15046184
   Kolotkin RL, 2002, QUAL LIFE RES, V11, P157, DOI 10.1023/A:1015081805439
   Kolotkin RL, 2001, OBES RES, V9, P102, DOI 10.1038/oby.2001.13
   Leahy S, 2012, ULTRASOUND MED BIOL, V38, P28, DOI 10.1016/j.ultrasmedbio.2011.10.011
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Melnikova I, 2006, NAT REV DRUG DISCOV, V5, P369, DOI 10.1038/nrd2037
   Mraz M, 2014, J ENDOCRINOL, V222, PR113, DOI 10.1530/JOE-14-0283
   Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415
   Ng AWT, 2017, SCI TRANSL MED, V9, P0, DOI 10.1126/scitranslmed.aan6446
   Ning HH, 2018, ENDOCRINE, V62, P528, DOI 10.1007/s12020-018-1717-y
   OHNHAUS EE, 1975, PAIN, V1, P379, DOI 10.1016/0304-3959(75)90075-5
   Qi L, 2008, NUTR REV, V66, P684, DOI 10.1111/j.1753-4887.2008.00128.x
   Rizzo M, 2009, CLIN ENDOCRINOL, V70, P870, DOI 10.1111/j.1365-2265.2008.03407.x
   Rodgers RJ, 2012, DIS MODEL MECH, V5, P621, DOI 10.1242/dmm.009621
   Schofield W N, 1985, HUM NUTR CLIN NUTR, V39 Suppl 1, P5
   Seravalle G, 2017, PHARMACOL RES, V122, P1, DOI 10.1016/j.phrs.2017.05.013
   Tan HW, 2010, ATHEROSCLEROSIS, V208, P350, DOI 10.1016/j.atherosclerosis.2009.07.053
   Tantawy SA, 2017, DIABET METAB SYND OB, V10, P513, DOI 10.2147/DMSO.S140250
   Wadden TA, 2012, CIRCULATION, V125, P1157, DOI 10.1161/CIRCULATIONAHA.111.039453
   Wang LH, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5796381
   Wu XM, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000014610
   Ye JP, 2013, AM J PHYSIOL-ENDOC M, V304, PE466, DOI 10.1152/ajpendo.00266.2012
   Zhang KP, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/6409389
   Zhang RQ, 2017, POSTGRAD MED J, V93, P743, DOI 10.1136/postgradmedj-2017-134969
   Zheng RJ, 2017, CLIN LAB, V63, P1581, DOI 10.7754/Clin.Lab.2017.170311
NR 37
TC 16
Z9 17
U1 3
U2 29
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
EI 
J9 CHIN MED-UK
JI Chin. Med.
PD SEP 18
PY 2019
VL 14
IS 1
BP 
EP 
DI 10.1186/s13020-019-0258-5
PG 9
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA JD5KV
UT WOS:000490022800001
PM 31548850
DA 2026-01-16
ER

PT J
AU Shi, RY
   Fu, TF
   Cai, YQ
   Du, JY
   Fang, JF
   Fang, JQ
   Liang, Y
AF Shi, Ren-Yi
   Fu, Tao-Fang
   Cai, Yang-Qian
   Du, Jun-Ying
   Fang, Jun-Fan
   Fang, Jian-Qiao
   Liang, Yi
TI [Electroacupuncture intervention relieves pain possibly by promoting MOR
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Bone cancer pain; Electroacupuncture; Endocytosis of receptor; Locus coeruleus (LC); Morphine tolerance; µ-opioid receptor
AB OBJECTIVE: To observe the effect of electroacupuncture (EA) on pain behavior and  expression of µ-opioid receptor (MOR) and Rab5 (an important protein molecule for  internalization of MOR) in the locus coeruleus (LC) region in bone cancer pain  (BCP) rats with morphine tolerance (MT), so as to explore its mechanisms  underlying improvement of BCP and MT. METHODS: The present study included two  parts. In the first part, 23 female SD rats were randomized into sham BCP (n＝6),  BCP (n＝9) and BCP＋MT (n＝8) groups, and in the second part, 61 female SD rats were  randomized into 5 groups: sham BCP (n＝11), BCP (n＝11), BCP＋MT (n＝13), BCP＋MT＋EA  (n＝13) and BCP＋MT＋sham EA (n＝13). The BCP morphine tolerance (BCP＋MT) model was  established by injection of 10 µL of human Walker 256 breast cancer cells (MRMT-1  breast cancer cells, 1 x10(4) cells/µL) into the bone marrow cavity at the upper  part of the left tibia and intraperitoneal injection of morphine hydrochloride  (10 mg/kg, once per 12 h, for 11 successive days). On day 21 after inoculation,  EA (2 Hz/100 Hz, 0.5－1.5 mA, increasing 0.5 mA every 10 min) was began to applied  to bilateral "Zusanli" (ST30) and "Kunlun" (BL60) immediately after the first  intraperitoneal injection of morphine. The treatment was performed for 30 min  every time, once daily for 7 successive days. The paw withdrawal threshold (PWT)  was detected before and 10, 11, 21, 22, 24, 26 and 28 days after inoculation. The  immunoactivity of MOR and Rab5 proteins in the LC region was detected by  immunofluorescence histochemistry. RESULTS: In the first part of the study, at  the 10(th) day after inoculation of cancer cells, the PWT of the BCP and BCP＋MT  groups was significantly lower than that of the sham BCP group (P<0.05),  suggesting a success of BCP model. From day 11 to 19 after inoculation (during  injection of morphine), the PWTs of the BCP＋MT group were significantly higher  than those of the BCP group (P<0.01), and on day 21, the PWT of the BCP＋MT group  was similar to that of the BCP group (P>0.05) but significantly lower than that  of the sham BCP group (P<0.01), suggesting a success of MT. H．E. staining showed  a large quantity of MRMT-1 cancer cells in the bone marrow cavity in both BCP and  BCP＋MT groups. In the second part of the study, the decreased PWTs from 10(th) to  28(th) day after inoculation were significantly increased on day 22, 24, 26 and  28 in the BCP＋MT＋EA group relevant to the BCP, BCP＋MT and BCP＋MT＋sham EA groups  (P<0.01). The ratios of MOR and Rab5 positive ((＋)) cells and MOR(＋)/Rab5(＋) of  the left LC region were significantly lower in the BCP and BCP＋MT groups than  those of the sham BCP group (P<0.01), but were considerably higher in the  BCP＋MT＋EA group than those in the BCP, BCP＋MT and BCP＋MT＋sham EA groups (P<0.01).  The ratios of Rab5(＋) and MOR(＋)/Rab5(＋) cells of the BCP＋MT group were  significantly lower than those of the BCP group (P<0.05). No significant changes  were found in the ratios of MOR(＋) and Rab5(＋) cells and MOR(＋)/Rab5(＋) cells  after BCP＋MT＋sham EA in comparison with the BCP＋MT group (P>0.05). CONCLUSION: EA  intervention can relieve pain and MT in bone cancer pain rats with MT, which may  be related to its effects in increasing MOR expression and promoting endocytosis  of MOR in LC region.
C1 Laboratory of Neuro-biology and Acupuncture Research, the Third Clinical Medical College, Zhejiang University of Chinese Medicine, Hangzhou 310053, China.
   Laboratory of Neuro-biology and Acupuncture Research, the Third Clinical Medical College, Zhejiang University of Chinese Medicine, Hangzhou 310053, China.
   Laboratory of Neuro-biology and Acupuncture Research, the Third Clinical Medical College, Zhejiang University of Chinese Medicine, Hangzhou 310053, China.
   Laboratory of Neuro-biology and Acupuncture Research, the Third Clinical Medical College, Zhejiang University of Chinese Medicine, Hangzhou 310053, China.
   Laboratory of Neuro-biology and Acupuncture Research, the Third Clinical Medical College, Zhejiang University of Chinese Medicine, Hangzhou 310053, China.
   Laboratory of Neuro-biology and Acupuncture Research, the Third Clinical Medical College, Zhejiang University of Chinese Medicine, Hangzhou 310053, China.
   Laboratory of Neuro-biology and Acupuncture Research, the Third Clinical Medical College, Zhejiang University of Chinese Medicine, Hangzhou 310053, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD APR 5
PY 2019
VL 44
IS 3
BP 161
EP 9
DI 10.13702/j.1000-0607.180635
PG -152
WC Animals; Cancer Pain; Cell Line, Tumor; Electroacupuncture; Endocytosis; Female; Humans; Locus Coeruleus; Morphine; Rats; Rats, Sprague-Dawley
UT PubMed:30945497
PM 30945497
DA 2019-04-05
ER

PT J
AU Guzmán, RMMAY
   Chaparro, JGT
   Gómez, AD
   Eslava, VMS
   Ruiz, GCT
   Garduño, IMT
   Madrid, ID
   Figueroa, IG
   Betancourt, AM
   Arrieta, O
AF Menendez-Aponte y Guzman, Raquel Maria
   Turcott Chaparro, Jenny Georgina
   De la Piedra Gomez, Amanda
   Sandoval Eslava, Victoria Margarita
   Tarditi Ruiz, Gina Carolina
   Tapia Garduno, Ilse Merari
   Madrid, Irma De la Torre
   Figueroa, Irma Gallegos
   Betancourt, Alejandro Mohar
   Arrieta, Oscar
TI Effect of complementary Integrative Oncology on anxiety, depression and quality of life in thoracic cancer patients: A pilot study
SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
LA English
DT Article
DE Integrative oncology; Acupuncture; Mindfulness; Cognitive behavior therapy; Thoracic cancer; Lung cancer
ID cell lung-cancer; eortc qlq-lc13; association; prognosis; medicine; acupuncture
AB Purpose: Thoracic-cancer (TC) patients have an extensive toll taken in terms of health-related quality of life (HRQL). Integrative Oncology (IO) is recognized as a valid complement to any Standard-Therapy treatment to improve outcomes in TC patients. The objective of this pilot-study was to evaluate the effect of adding IO (acupuncture, Cognitive-Behavior Therapy and mindfulness) in terms of depression, anxiety and HRQL. Methods: TC patients who attended the Thoracic Oncology-Unit from July to September 2018 were invited to participate. A total of 16 patients were included in the study, 8 patients were required to attend 5 weekly sessions of IO and 8 patients were invited as controls. Anxiety, depression and HRQL were measured at baseline and after completing 5 sessions of IO or 5 weeks, using the HADS scale and the QLQ-C30 scale. Results: A total of 8 patients in the IO group attended the 5 sessions and 8 patients were followed as controls. Compliance with the therapies was high, none of the patients dropped out from the study. A tendency for improvement in anxiety, fatigue, pain and dyspnea was observed in patients attending IO, though not statistically significant likely due to sample size. Conclusions: IO therapies are well accepted among TC patients. Larger studies are necessary with robust sample sizes to improve conclusions regarding outcome improvements.
C1 [Menendez-Aponte y Guzman, Raquel Maria; De la Piedra Gomez, Amanda; Sandoval Eslava, Victoria Margarita; Tarditi Ruiz, Gina Carolina; Tapia Garduno, Ilse Merari; Madrid, Irma De la Torre; Figueroa, Irma Gallegos; Betancourt, Alejandro Mohar] Natl Canc Inst INCan, Integrat Oncol Ctr CAAI, Num 22,Sect 16, Tlalpan 14080, Ciudad De Mexic, Mexico.
   [Turcott Chaparro, Jenny Georgina; Betancourt, Alejandro Mohar; Arrieta, Oscar] Natl Canc Inst INCan, Thorac Oncol Unit, Num 22,Sect 16, Tlalpan 14080, Ciudad De Mexic, Mexico.
   [Turcott Chaparro, Jenny Georgina; Betancourt, Alejandro Mohar; Arrieta, Oscar] Natl Canc Inst INCan, Lab Personalized Med, Num 22,Sect 16, Tlalpan 14080, Ciudad De Mexic, Mexico.
C3 Instituto Nacional de Cancerologia (INCAN); Instituto Nacional de Cancerologia (INCAN); Instituto Nacional de Cancerologia (INCAN)
RP Arrieta, O (corresponding author), Natl Canc Inst INCan, Thorac Oncol Unit, Num 22,Sect 16, Tlalpan 14080, Ciudad De Mexic, Mexico.; Arrieta, O (corresponding author), Natl Canc Inst INCan, Lab Personalized Med, Num 22,Sect 16, Tlalpan 14080, Ciudad De Mexic, Mexico.
EM ccraquel@hotmail.com; jennyturcott@gmail.com; amandadpg@hotmail.com; dravsandovale@gmail.com; gtarditi@prodigy.net.mx; mera2306@gmail.com; idelatorre44@gmail.com; igallegosf@yahoo.com.mx; alejandromohar@gmail.com; ogar@unam.mx
FU AstraZeneca [NCR-18-13933]
CR Armstrong K, 2018, SUPPORT CARE CANCER, V26, P2267, DOI 10.1007/s00520-017-4007-y
   Arrieta O, 2018, QUAL LIFE RES, V27, P2709, DOI 10.1007/s11136-018-1930-4
   Arrieta O, 2013, ANN SURG ONCOL, V20, P1941, DOI 10.1245/s10434-012-2793-5
   Arrieta O, 2012, J THORAC ONCOL, V7, P1228, DOI 10.1097/JTO.0b013e3182582a93
   Arrieta O, 2012, LUNG CANCER, V77, P205, DOI 10.1016/j.lungcan.2012.02.005
   BERGMAN B, 1994, EUR J CANCER, V30A, P635, DOI 10.1016/0959-8049(94)90535-5
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Daniels Sheena, 2015, J ADV PRACT ONCOL, V6, P54, DOI 10.6004/jadpro.2015.6.1.5
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Frenkel M, 2018, J ALTERN COMPLEM MED, V24, P862, DOI 10.1089/acm.2018.0175
   Galindo Vázquez Oscar, 2015, SALUD MENT, V38, P253
   Turcott JG, 2019, NUTR CANCER, V71, P409, DOI 10.1080/01635581.2018.1506488
   Hofmann SG, 2017, PSYCHIAT CLIN N AM, V40, P739, DOI 10.1016/j.psc.2017.08.008
   Hulbert-Williams NJ, 2018, CURR OPIN SUPPORT PA, V12, P276, DOI 10.1097/SPC.0000000000000360
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Minchom A, 2016, EUR J CANCER, V61, P102, DOI 10.1016/j.ejca.2016.03.078
   Nipp RD, 2017, J CLIN ONCOL, V35, P2551, DOI 10.1200/JCO.2016.71.3404
   Sánchez-Lara K, 2012, NUTR CANCER, V64, P526, DOI 10.1080/01635581.2012.668744
   Schellekens MPJ, 2014, BMC CANCER, V14, P0, DOI 10.1186/1471-2407-14-3
   Turcott JG, 2018, SUPPORT CARE CANCER, V26, P3029, DOI 10.1007/s00520-018-4154-9
NR 21
TC 5
Z9 8
U1 1
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744-3881
EI 1873-6947
J9 COMPLEMENT THER CLIN
JI Complement. Ther. Clin. Pract.
PD AUG 15
PY 2019
VL 36
IS 
BP 56
EP 63
DI 10.1016/j.ctcp.2019.05.003
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA IN6CJ
UT WOS:000478763500010
PM 31383444
DA 2026-01-16
ER

PT J
AU Li, HP
   Su, W
   Shu, Y
   Yuan, XC
   Lin, LX
   Hou, TF
   Xiang, HC
   Zhu, H
   Hu, XF
   Pan, L
   Wu, JN
   Meng, XF
   Pan, HL
   Wu, CH
   Li, M
AF Li, Hong-Ping
   Su, Wen
   Shu, Yang
   Yuan, Xiao-Cui
   Lin, Li-Xue
   Hou, Teng-Fei
   Xiang, Hong-Chun
   Zhu, He
   Hu, Xue-Fei
   Pan, Li
   Wu, Jing-Nan
   Meng, Xian-Fang
   Pan, Hui-Lin
   Wu, Cai-Hua
   Li, Man
TI Electroacupuncture decreases Netrin-1-induced myelinated afferent fiber sprouting and neuropathic pain through μ-opioid receptors
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE postherpetic neuralgia; analgesia; mechanical hyperalgesia; rat; mu-opioid receptors
ID colorectal-cancer; sensory neurons; spinal-cord; mechanical sensitivity; axon guidance; mice lacking; rat-brain; expression; mouse; dcc
AB Purpose: We determined whether electroacupuncture (EA) reduces Netrin-1-induced myelinated primary afferent nerve fiber sprouting in the spinal cord and pain hypersensitivity associated with postherpetic neuralgia (PHN) through activation of mu-opioid receptors. Methods: PHN was induced by systemic injection of resiniferatoxin (RTX) in rats. Thirty-six days after RTX injection, a mu-opioid receptor antagonist, beta-funaltrexamine (beta-FNA) or a kappa-opioid receptor antagonist, nor Binaltorphimine (nor-BNI), was injected intrathecally 30 mins before EA, once every other day for 4 times. Mechanical allodynia was tested with von Frey filaments. The protein expression level of Netrin-1 and its receptors (DCC and UNC5H2) were quantified by using western blotting. The myelinated primary afferent nerve fiber sprouting was mapped with the transganglionic tracer cholera toxin B-subunit (CTB). Results: Treatment with 2 Hz EA at "Huantiao" (GB30) and "Yanglingquan" (GB34) decreased the mechanical allodynia at 22 days and the myelinated primary afferent nerve fiber preternatural sprouting into the lamina II of the spinal dorsal horn at 42 days after RTX injection. Also, treatment with 2 Hz EA reduced the protein levels of DCC and Netrin-1 and promoted the expression of UNC5H2 in the spinal dorsal horn 42 days after RTX injection. Furthermore, the mu-opioid receptor antagonist beta-FNA, but not the kappa-opioid receptor antagonist nor-BNI, reversed the effect of EA on neuropathic pain caused by RTX. In addition, morphine inhibited the Netrin-1 protein level induced by RTX in SH-SY5Y cells. Conclusions: Through activation of mu-opioid receptors, treatment with EA reduces the expression level of DCC and Netrin-1 and changes a growth-permissive environment in spinal dorsal horn into an inhibitory environment by increasing UNC5H2, thus decreasing RTX-caused primary afferent nerve sprouting in the spinal dorsal horn and neuropathic pain.
C1 [Li, Hong-Ping; Yuan, Xiao-Cui; Lin, Li-Xue; Hou, Teng-Fei; Xiang, Hong-Chun; Zhu, He; Hu, Xue-Fei; Pan, Li; Wu, Jing-Nan; Meng, Xian-Fang; Wu, Cai-Hua; Li, Man] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Neurobiol, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.
   [Su, Wen; Wu, Cai-Hua] Wuhan First Hosp, Dept Acupuncture, 215 Zhongshan Ave, Wuhan 430030, Hubei, Peoples R China.
   [Shu, Yang] Jiangsu Univ, Dept Cent Lab, Affiliated Hosp, Zhenjiang 212000, Jiangsu, Peoples R China.
   [Pan, Hui-Lin] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA.
C3 Huazhong University of Science & Technology; Jiangsu University; University of Texas System; UTMD Anderson Cancer Center
RP Wu, CH; Li, M (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Neurobiol, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.; Wu, CH (corresponding author), Wuhan First Hosp, Dept Acupuncture, 215 Zhongshan Ave, Wuhan 430030, Hubei, Peoples R China.
EM wch0007@126.com; liman73@mails.tjmu.edu.cn
FU National Natural Science Foundation of China [81804187]; Natural Science Foundation of Jiangsu Province [BK20160548]; Major Social Development Project of Zhenjiang city [SH2016032]; Doctor startup Fund Program [JDFYRC-2015005]
CR Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0
   Bakkum BW, 2007, J MANIP PHYSIOL THER, V30, P336, DOI 10.1016/j.jmpt.2007.04.007
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen L, 2009, J PAIN, V10, P732, DOI 10.1016/j.jpain.2008.12.012
   Chen SR, 2006, J NEUROPHYSIOL, V95, P3086, DOI 10.1152/jn.01343.2005
   Engelkamp D, 2002, MECH DEVELOP, V118, P191, DOI 10.1016/S0925-4773(02)00248-4
   Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0
   FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591
   Grachev YV, 1998, ZH NEVROPATOL PSIKH, V98, P4
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225
   KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7
   Khan GM, 2002, NEUROSCIENCE, V114, P291, DOI 10.1016/S0306-4522(02)00372-X
   Kieffer BL, 2009, NEUROPHARMACOLOGY, V56, P205, DOI 10.1016/j.neuropharm.2008.07.033
   Kim HY, 2009, PAIN, V145, P332, DOI 10.1016/j.pain.2009.06.035
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Komatsuzaki K, 2002, BIOCHEM BIOPH RES CO, V297, P898, DOI 10.1016/S0006-291X(02)02277-5
   Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0
   Liu H, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/848603
   Liu N, 2011, NEUROSCIENCE, V194, P349, DOI 10.1016/j.neuroscience.2011.07.037
   Manitt C, 2001, J NEUROSCI, V21, P3911, DOI 10.1523/JNEUROSCI.21-11-03911.2001
   Manitt C, 2004, J NEUROSCI RES, V77, P690, DOI 10.1002/jnr.20199
   Manitt C, 2006, J NEUROSCI RES, V84, P1808, DOI 10.1002/jnr.21070
   Mao-Ying QL, 2006, EUR J PAIN, V10, P689, DOI 10.1016/j.ejpain.2005.11.001
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   Mehlen P, 2004, J CLIN ONCOL, V22, P3420, DOI 10.1200/JCO.2004.02.019
   Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935
   Mintz CD, 2013, ANESTHESIOLOGY, V118, P825, DOI 10.1097/ALN.0b013e318287b850
   Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766
   Pan HL, 2003, J NEUROSCI, V23, P2911
   Philip A, 2011, J PALLIAT MED, V14, P765, DOI 10.1089/jpm.2011.9685
   Richards LJ, 1997, J NEUROSCI, V17, P2445
   Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X
   Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544
   Stein C, 2011, PHARMACOL REV, V63, P860, DOI 10.1124/pr.110.003145
   Thiébault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100
   Ugur M, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.01240
   VANCANEGHEM P, 1975, CR SOC BIOL, V169, P242
   Wang Chen-Yao, 2012, ZHEN CI YAN JIU, V37, P64
   Wang LN, 2006, BRAIN RES, V1120, P46, DOI 10.1016/j.brainres.2006.08.077
   Wang XD, 2013, NEURAL REGEN RES, V8, P64, DOI 10.3969/j.issn.1673-5374.2013.01.008
   WARD SJ, 1982, J PHARMACOL EXP THER, V220, P494
   WARD SJ, 1985, EUR J PHARMACOL, V107, P323, DOI 10.1016/0014-2999(85)90257-2
   Wehrle R, 2005, EUR J NEUROSCI, V22, P2134, DOI 10.1111/j.1460-9568.2005.04419.x
   Williams ME, 2003, J NEUROSCI, V23, P11279
   Wu CH, 2016, MOL NEUROBIOL, V53, P5640, DOI 10.1007/s12035-015-9482-x
   Wu CH, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-18
   Yuan XY, 2017, APPL SPECTROSC, V71, P2325, DOI 10.1177/0003702817721527
   Zhang RX, 2005, BRAIN RES, V1048, P235, DOI 10.1016/j.brainres.2005.05.008
   Zhang RX, 2004, BRAIN RES, V1020, P12, DOI 10.1016/j.brainres.2004.05.067
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
   2011, 1900, V138, V0, PP2153, DOI 10.1242/DEV.044529
NR 52
TC 27
Z9 37
U1 2
U2 14
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2019
VL 12
IS 
BP 1259
EP 1268
DI 10.2147/JPR.S191900
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA HU8ME
UT WOS:000465541900001
PM 31118749
DA 2026-01-16
ER

PT J
AU Carannante, F
   Caricato, M
   Ripetti, V
AF Carannante, F
   Caricato, M
   Ripetti, V
TI The valdoni technique for bowel anastomosis. A rare complication.
SO Annals of medicine and surgery (2012)
LA English
DT Journal Article
DE Colon cancer; Ileocolic anastomose; Right emicolectomy; Surgery complications; Valdoni technique
AB BACKGROUND: Valdoni technique involves leaving the mucosa layer, between the two  anastomosed bowel tract intact, providing for a subsequent breakage of the  intestine. It is a technique that allows you to keep the operating field  clean.Surgical technique and Case Report: We describe the Valdoni technique. We  also report a case of 75 years old man affected by an ascending colon cancer with  no metastasis. The patient underwent right hemicolectomy. Making the anastomose,  the surgeon did the Valdoni technique, with no intraoperative complications.The  postoperative course was characterized by an abdominal pain with swollen abdomen,  no flatus and vomit. A computed tomography (CT) revealed a sub-stenosis of the  anastomose. We decided to do an urgent colonoscopy, with a resection of the  mucosa layer not totally opened, using a Needle-knife Precut. The post procedure  course was uneventful. The patient was discharged three days later. CONCLUSION:  Valdoni technique allows the surgeon to keep the operating field clean. It is a  valid alternative when the surgeons have to make a colonic anastomosis, doing  open surgery.
C1 Department of General Surgery, Università Campus Bio-Medico, Via Alvaro del Portillo 21, 00128, Rome, Italy.
   Department of General Surgery, Università Campus Bio-Medico, Via Alvaro del Portillo 21, 00128, Rome, Italy.
   Department of General Surgery, Università Campus Bio-Medico, Via Alvaro del Portillo 21, 00128, Rome, Italy.
NR 0
TC 0
SN 2049-080
EI 2049-080
J9 Ann Med Surg (Lond)
PD JUL 19
PY 2019
VL 44
IS 
BP 68
EP 71
DI 10.1016/j.amsu.2019.06.006
PG 3
UT PubMed:31316770
PM 31316770
DA 2019-07-19
ER

PT J
AU Jeon, E
   Kwak, M
   Shin, I
   Kang, S
   Shon, H
   Jung, E
AF Jeon, Eonju
   Kwak, Minah
   Shin, Imhee
   Kang, Seokbong
   Shon, Hosang
   Jung, Euidal
TI Acupuncture for the Treatment of Fatigue after Total Thyroidectomy in Women with Papillary Thyroid Cancer: A Pilot Study
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article
DE Acupuncture; Fatigue; Quality of life; Papillary thyroid cancer; Total thyroidectomy; Weight gain
ID quality-of-life; persistent posttreatment fatigue; management; breast
AB Objectives: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer and the most common endocrine malignancy. Although it has a good prognosis, patients experience weight gain, fatigue, and neck pain after total thyroidectomy, and quality of life (QOL) can also decline. There is no effective treatment for these symptoms. This study evaluated the feasibility and safety of acupuncture for treating of fatigue in patients with PTC after total thyroidectomy. Methods: This is a prospective randomized controlled study using before and after measurements. The subjects included 25 patients with thyroid cancer who had undergone total thyroidectomy and were experiencing fatigue. Twelve patients underwent Saam (or Sa-Ahm) acupuncture treatment and thirteen subjects did not. Saam acupuncture, which is one of the original therapeutic modalities representing traditional Korean medicine, is a unique treatment method that has a different origin than the modalities from China and Japan. The basic characteristic of combining five shu points in Saam acupuncture is the selection of the tonification and sedation points along the self-meridian and other meridians based on creation and governor relationships. Acupuncture treatment was delivered two times a week for 6 weeks, in 25 to 30 minutes at each session. Acupoints were individually tailored according to the individual pattern of each patient. Fatigue severity and QOL were evaluated using the fatigue scale score and Short Form-36 (SF-36), respectively. Fatigue severity scale is a 9-item self-report questionnaire scale developed by Krupp et al. in 1989. SF-36 is a 36-item, patient-reported survey of patient health. Body weight, body mass index, fatigue scale score, and SF-36 score were evaluated pre- and post-treatment, and laboratory tests for biochemical variables were also performed. Results: Fatigue scale score (FSS) significantly improved in the acupuncture group (FSS; 29.92 to 19.50, decrease; 91.7%) compared to the control group (FSS; 29.92 to 31.15, decrease; 46.2%) at post-treatment compared to baseline (p=0.011). SF-36 scores were 74.12 in the acupuncture group and 69.02 in the control group, with no statistically significant difference (p=0.085). Weight change did not differ between the two groups. Liver enzymes such as aspartate aminotransferase were lower in the acupuncture group (27.67 to 24.33 IU/L) than in the control group (20.77 to 24.08 IU/L) (p=0.01). No other biochemical markers differed between the two groups. Conclusions: Acupuncture such as ST-36, CV-4, KI-10, and HT-8 may relieve fatigue and improve QOL in patients PTC who experience fatigue, and reduced QOL after total thyroidectomy without biochemical changes. A larger prospective study is required to confirm these effects.
C1 [Jeon, Eonju; Shon, Hosang; Jung, Euidal] Catholic Univ Daegu, Sch Med, Dept Internal Med, 33 Duryugongwon Ro,17 Gil, Daegu, South Korea.
   [Kwak, Minah; Kang, Seokbong] Daegu Haany Univ, Coll Korean Med, Dept Internal Med, Daegu, South Korea.
   [Shin, Imhee] Catholic Univ Daegu, Sch Med, Dept Med Stat, Daegu, South Korea.
C3 Catholic University of Daegu; Daegu Haany University; Catholic University of Daegu
RP Jung, E (corresponding author), Catholic Univ Daegu, Sch Med, Dept Internal Med, 33 Duryugongwon Ro,17 Gil, Daegu, South Korea.
EM jed15@cu.ac.kr
FU Ministry of Health & Welfare, Republic of Korea [090-091-3000-3033-340-320-01]
CR Ahn CB, 2009, J ACUPUNCT MERIDIAN, V2, P309, DOI 10.1016/S2005-2901(09)60074-1
   Unknown -, 2010, SHANGHAI J ACU MOX, V0, P0
   Aytac B, 2005, SAUDI MED J, V26, P1746
   Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110
   Debry C, 1995, ANN OTOLARYNGOL CHIR CERVICOFAC, V112, P211
   Dong Jia-Zi, 2018, ZHEN CI YAN JIU, V43, P335, DOI 10.13702/j.1000-0607.171010
   Gamper EM, 2015, EUR J NUCL MED MOL I, V42, P1179, DOI 10.1007/s00259-015-3022-9
   Gonçalves J, 2005, OTOLARYNG HEAD NECK, V132, P490, DOI 10.1016/j.otohns.2004.09.028
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
   Hegyi G, 2013, ACUPUNCTURE ELECTRO, V38, P161, DOI 10.3727/036012913X13831832269243
   Huang SM, 2004, J ADV NURS, V47, P492, DOI 10.1111/j.1365-2648.2004.03128.x
   Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126
   Jeong YJ, 2015, MED ACUPUNCT, V27, P206, DOI 10.1089/acu.2014.1071
   Kim KW, 2010, SAAM ACUPUNCTURE MET, V0, P0
   Kwon HJ, 2015, OPEN JOURNAL OF IMMUNOLOGY, V05, P90, DOI 10.4236/oji.2015.53010
   Lee MH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/130324
   Mendoza A, 2004, THYROID, V14, P133, DOI 10.1089/105072504322880373
   Omura Y, 2013, ACUPUNCTURE ELECTRO, V38, P37, DOI 10.3727/036012913X13831831849484
   Osmolski Antoni, 2006, OTOLARYNGOL POL, V60, P165
   Park M, 2015, EVID-BASED COMPL ALT, V2015, P0
   Pellegriti G, 2013, J CANCER EPIDEMIOL, V2013, P0, DOI 10.1155/2013/965212
   Rogers P A, 1992, PROBL VET MED, V4, P162
   Sawka AM, 2014, ENDOCRIN METAB CLIN, V43, P475, DOI 10.1016/j.ecl.2014.02.007
   Stone P, 2001, J PAIN SYMPTOM MANAG, V22, P1007, DOI 10.1016/S0885-3924(01)00361-X
   Sun GX, 2015, J CLIN ACUPUNCT MOXI, V31, P23
   To J, 2015, THYROID, V25, P198, DOI 10.1089/thy.2014.0418
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Yim YK, 2006, WORLD J GASTROENTERO, V12, P2245, DOI 10.3748/wjg.v12.i14.2245
   Yin CS, 2007, NEUROL RES, V29, PS10, DOI 10.1179/016164107X172301
   ANN ONCOLOGY, 1900, P561, V0, P0
   2011, 1900, V21, V0, PP1339, DOI 10.1089/THY.2010.0393
   2016, 1900, V55, V0, PP365, DOI 10.3109/0284186X.2015.1102965
   2013, 1900, V23, V0, PP1247, DOI 10.1089/THY.2013.0015
   2013, 1900, V52, V0, PP249, DOI 10.3109/0284186X.2012.741326
NR 34
TC 3
Z9 3
U1 3
U2 36
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PD JUN 15
PY 2019
VL 44
IS 1
BP 23
EP 38
DI 10.3727/036012919X15549226100464
PG 16
WC Integrative & Complementary Medicine; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA HY1VV
UT WOS:000467906200003
DA 2026-01-16
ER

PT J
AU Liu, T
   Yu, JN
   Kuang, WC
   Wang, XY
   Ye, J
   Qiu, XJ
   Xi, W
   Zeng, Y
   Zou, HH
   Liu, Y
AF Liu, Tong
   Yu, Jiani
   Kuang, Weichuan
   Wang, Xiaoyin
   Ye, Jiang
   Qiu, Xiaojia
   Xi, Wen
   Zeng, Yao
   Zou, Hanhong
   Liu, Yue
TI Acupuncture for uterine fibroids Protocol for a systematic review of randomized controlled trials
SO MEDICINE
LA English
DT Review
DE acupuncture; protocol; systematic review; uterine fibroids
AB Background: Uterine fibroids represent the most common gynecological benign tumors in reproductive females. Acupuncture has been applied as a therapeutic modality in China to treat uterine fibroids. However, currently, few critical systematic reviews regarding the effect of acupuncture on uterine fibroids have been published. Our proposed review aims to evaluate the current evidence on the efficacy of acupuncture for uterine fibroids. Methods: A total of 7 databases were searched from their inception to December 2018, including PubMed, Medline, Embase, the Cochrane Central Register of Controlled Trials, the Chinese National Knowledge Infrastructure database, the Chinese Biomedical database, and the Wanfang database. The primary outcomes will be reduction in uterine volume and number of fibroids. Secondary outcomes are pelvic or low- back pain, assessed by Visual Analog Scale ( VAS); Irregular menstrual periods; Low- abdominal pressure symptoms such as frequent or urgent urination, or constipation and adverse events. Data synthesis will be computed by RevManV. 5.3.5 software when a data- analysis is allowed. Methodological quality will be evaluated with the risk of bias according to Cochrane Handbook. Results: This study will provide high- quality evidence of acupuncture for uterine fibroids. Conclusion: The conclusion of this systematic review will provide evidence to judge whether acupuncture is an effective therapeutic intervention for patients with uterine fibroids.
C1 [Liu, Tong; Kuang, Weichuan; Wang, Xiaoyin; Ye, Jiang; Qiu, Xiaojia; Xi, Wen; Zeng, Yao; Liu, Yue] GuangDong Second Hosp Tradit Chinese Med, Dept Acupuncture & Rehabil, Guangzhou, Guangdong, Peoples R China.
   [Yu, Jiani] Guangdong Prov Hosp Tradit Chinese Med, Dept Rehabil Med, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine
RP Liu, T; Liu, Y (corresponding author), GuangDong Second Hosp Tradit Chinese Med, Dept Acupuncture & Rehabil, Guangzhou, Guangdong, Peoples R China.
EM liutongmama@163.com; liuyue2288@163.com
FU National Science Foundation for Young Scientists of China [81704179]
CR AAGL Advancing Minimally Invasive, 2012, J MINIM INVAS GYN, V19, P3, DOI 10.1016/j.jmig.2011.09.003
   Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Chabbert-Buffet N, 2014, FERTIL STERIL, V102, P630, DOI 10.1016/j.fertnstert.2014.07.1238
   Donnez J, 2016, HUM REPROD UPDATE, V22, P665, DOI 10.1093/humupd/dmw023
   Friend DR, 2017, DRUG DELIV TRANSL RE, V7, P829, DOI 10.1007/s13346-017-0423-2
   Higgins J, 2011, COCHRANE HDB SYSTEMA, V0, P0
   Jacoby VL, 2014, EUR J OBSTET GYN R B, V182, P220, DOI 10.1016/j.ejogrb.2014.09.004
   Kang HS, 2011, MATURITAS, V68, P346, DOI 10.1016/j.maturitas.2011.02.001
   Liu T, 2017, ALTERN THER HLTH MED, V0, P0
   Rong Z, 2017, PLOS ONE, V12, P0
   Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9
   Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063
   Wallach EE, 2004, OBSTET GYNECOL, V104, P393, DOI 10.1097/01.AOG.0000136079.62513.39
   Wang Y, 2018, KOREAN J RADIOL, V19, P724, DOI 10.3348/kjr.2018.19.4.724
   Zhang Y, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007221.pub2
NR 16
TC 9
Z9 9
U1 2
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD FEB 15
PY 2019
VL 98
IS 8
BP 
EP 
DI 10.1097/MD.0000000000014631
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA HQ3SP
UT WOS:000462331100080
PM 30813200
DA 2026-01-16
ER

PT J
AU Liu, SR
   Qiu, JQ
   Zhang, LY
   Lin, QL
   Ye, GP
   Zhu, DY
AF Liu, Shu-Ru
   Qiu, Jian-Qing
   Zhang, Lin-Yun
   Lin, Qian-Lin
   Ye, Guo-Ping
   Zhu, Ding-Yu
TI [Warming acupuncture combined with moxibustion at Yongquan (KI 1) for knee
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Point KI 1 (Yongquan); kidney-marrow deficiency; knee osteoarthritis; moxibustion; randomized controlled trial (RCT); warming acupuncture
AB OBJECTIVE: To compare the clinical effect between warming acupuncture combined  with moxibustion at Yongquan (KI 1) and simple warming acupuncture for knee  osteoarthritis with kidney-marrow deficiency. METHODS: A total of 66 patients of  knee osteoarthritis with kidney-marrow deficiency were randomized into an  observation group and a control group, 33 cases in each one. Warming acupuncture  was applied at Neixiyan (EX-LE 4), Dubi (ST 35), Zusanli (ST 36) and Xuanzhong  (GB 39) on the affected side in both of the groups. In the observation group,  mild moxibustion at bilateral Yongquan (KI 1) was adopted additionally. Each  treatment lasted for 30 min, 3 times a week (once every other day), and the  consecutive 6 weeks of treatment were required. The Western Ontario and McMaster  Universities Osteoarthritis Index (WOMAC) score (such as joint pain, stiffness  and physical function), the amount of joint effusion and the serum contents of  interleukin-1β(IL-1β), tumor necrosis factor-α (TNF-α) and high-sensitivity  C-reactive protein (hs-CRP) were observed before and after treatment in the two  groups. RESULTS: The total effective rate in the observation group was 93.3%  (28/30), which was superior to 87.1% (27/30) in the control group (P<0.05).  Compared before treatment, the pain scores, stiffness scores, physical function  scores, the amount of joint effusion and the contents of IL-1β, TNF-α and hs-CRP  after treatment were significantly reduced in the two groups (P<0.05), and the  improvements of these indices in the observation group were superior to the  control group (P<0.05). CONCLUSION: Warming acupuncture combined with moxibustion  at Yongquan (KI 1) can improve joint function, reduce the amount of joint  effusion and the contents of inflammatory response indices for knee  osteoarthritis with kidney-marrow deficiency. The therapeutic effect of warming  acupuncture combined with moxibustion at Yongquan (KI 1) is better than simple  warming acupuncture.
C1 School of Acupuncture and Moxibustion, Fujian University of CM, Fuzhou 350122, China.
   School of Acupuncture and Moxibustion, Fujian University of CM, Fuzhou 350122, China.
   Department of Acupuncture and Moxibustion, Second People's Hospital Affilated to Fujian University of CM, Fuzhou 350003.
   Department of Acupuncture and Moxibustion, Second People's Hospital Affilated to Fujian University of CM, Fuzhou 350003.
   School of Acupuncture and Moxibustion, Fujian University of CM, Fuzhou 350122, China.
   Department of Acupuncture and Moxibustion, Second People's Hospital Affilated to Fujian University of CM, Fuzhou 350003.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD AUG 10
PY 2019
VL 39
IS 8
BP 799
EP 803
DI 10.13703/j.0255-2930.2019.08.001
PG 4
WC Acupuncture Points; Acupuncture Therapy; Bone Marrow; Humans; Moxibustion; Osteoarthritis, Knee; therapy; Treatment Outcome
UT PubMed:31397121
PM 31397121
DA 2019-08-10
ER

PT J
AU Garland, SN
   Xie, SX
   DuHamel, K
   Bao, T
   Li, Q
   Barg, FK
   Song, S
   Kantoff, P
   Gehrman, P
   Mao, JJ
AF Garland, Sheila N.
   Xie, Sharon X.
   DuHamel, Kate
   Bao, Ting
   Li, Qing
   Barg, Frances K.
   Song, Sarah
   Kantoff, Philip
   Gehrman, Philip
   Mao, Jun J.
TI Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID severity index; management; validation; disorder; fatigue
AB Background: Insomnia is a common and debilitating disorder experienced by cancer survivors. Although cancer survivors express a preference for using nonpharmacological treatment to manage insomnia, the comparative effectiveness between acupuncture and Cognitive Behavioral Therapy for Insomnia (CBT-I) for this disorder is unknown. Methods: This randomized trial compared 8 weeks of acupuncture (n = 80) and CBT-I (n = 80) in cancer survivors. Acupuncture involved stimulating specific points on the body with needles. CBT-I included sleep restriction, stimulus control, cognitive restructuring, relaxation training, and education. We measured insomnia severity (primary outcome), pain, fatigue, mood, and quality of life posttreatment (8 weeks) with follow-up until 20 weeks. We used linear mixed-effects models for analyses. All statistical tests were two-sided. Results: The mean age was 61.5 years and 56.9% were women. CBT-I was more effective than acupuncture posttreatment (P<.001); however, both acupuncture and CBT-I produced clinically meaningful reductions in insomnia severity (acupuncture: -8.31 points, 95% confidence interval = -9.36 to -7.26; CBT-I: -10.91 points, 95% confidence interval = -11.97 to -9.85) and maintained improvements up to 20 weeks. Acupuncture was more effective for pain at the end of treatment; both groups had similar improvements in fatigue, mood, and quality of life and reduced prescription hypnotic medication use. CBT-I was more effective for those who were male (P<.001), white (P = .003), highly educated (P<.001), and had no pain at baseline (P<.001). Conclusions: Although both treatments producedmeaningful and durable improvements, CBT-I was more effective and should be the first line of therapy. The relative differences in the comparative effectiveness between the two interventions for specific groups should be confirmed in future adequately powered trials to guide more tailored interventions for insomnia.
C1 [Garland, Sheila N.] Mem Univ Newfoundland, Dept Psychol, St John, NF, Canada.
   [Garland, Sheila N.] Mem Univ Newfoundland, Dept Oncol, St John, NF, Canada.
   [Xie, Sharon X.] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA.
   [DuHamel, Kate] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 1275 York Ave, New York, NY 10021 USA.
   [Bao, Ting; Li, Qing; Kantoff, Philip; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.
   [Barg, Frances K.; Song, Sarah] Penn Presbyterian Med Ctr, Dept Family Med & Community Hlth, Andrew Mutch Bldg, Philadelphia, PA USA.
   [Gehrman, Philip] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
C3 Memorial University Newfoundland; Memorial University Newfoundland; University of Pennsylvania; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Presbyterian Medical Center; University of Pennsylvania
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU Patient-Centered Outcomes Research Institute (PCORI) award [CER-1403-14292]; National Institutes of Health/National Cancer Institute Cancer Center grant [P30 CA008748]; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Berger AM, 2017, ONCOLOGY-NY, V31, P610
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Carney CE, 2012, SLEEP, V35, P287, DOI 10.5665/sleep.1642
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Fleming L, 2015, CURR SLEEP MED REP, V1, P177, DOI 10.1007/s40675-015-0021-0
   Fu C, 2017, SLEEP, V0, P40
   Garland SN, 2018, SUPPORT CARE CANCER, V26, P2407, DOI 10.1007/s00520-018-4086-4
   Garland SN, 2016, CONTEMP CLIN TRIALS, V47, P349, DOI 10.1016/j.cct.2016.02.010
   Garland SN, 2014, J CLIN ONCOL, V32, P449, DOI 10.1200/JCO.2012.47.7265
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   Johnson JA, 2016, SLEEP MED REV, V27, P20, DOI 10.1016/j.smrv.2015.07.001
   Kripke Daniel F, 2016, F1000RES, V5, P918, DOI 10.12688/f1000research.8729.1
   MacLeod Jodi, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP46, DOI 10.1093/jncimonographs/lgx008
   Manni L, 2010, AUTON NEUROSCI-BASIC, V157, P9, DOI 10.1016/j.autneu.2010.03.020
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Matthews EE, 2012, BEHAV SLEEP MED, V10, P217, DOI 10.1080/15402002.2012.666220
   McCarthy MS, 2018, ONCOL NURS FORUM, V45, P607, DOI 10.1188/18.ONF.607-618
   Medalie L, 2017, JAMA-J AM MED ASSOC, V317, P762, DOI 10.1001/jama.2016.19004
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175
   Savard J, 2011, J CLIN ONCOL, V29, P3580, DOI 10.1200/JCO.2010.33.2247
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487
   Sedgwick P, 2014, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g6694
   Soligo M, 2013, INT REV NEUROBIOL, V111, P91, DOI 10.1016/B978-0-12-411545-3.00005-5
   Stein KD, 2004, J PAIN SYMPTOM MANAG, V27, P14, DOI 10.1016/j.jpainsymman.2003.06.003
   Stepanski EJ, 2009, J CLIN SLEEP MED, V5, P132
   Yin X, 2017, SLEEP MED, V37, P193, DOI 10.1016/j.sleep.2017.02.012
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zachariae R, 2018, JNCI-J NATL CANCER I, V110, P880, DOI 10.1093/jnci/djx293
   Zhou ES, 2017, J CANCER SURVIV, V11, P74, DOI 10.1007/s11764-016-0564-1
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 36
TC 128
Z9 154
U1 1
U2 65
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD DEC 15
PY 2019
VL 111
IS 12
BP 1323
EP 1331
DI 10.1093/jnci/djz050
PG 9
WC Oncology
SC Oncology
GA KF9HG
UT WOS:000509549100010
PM 31081899
DA 2026-01-16
ER

